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Abstract 
Maintaining cellular homeostasis involves a repertoire of intricate systems being able to 
respond to internal changes and environmental stimuli. Co-ordinating the process of post-
transcriptional gene regulation is a number of ribonucleases, including polynucleotide 
phosphorylase (PNPase). PNPase controls steady-state transcript levels and thus regulates the 
production of various proteins, including enzymes involved in central metabolism. A feedback 
mechanism between central metabolism and RNA turnover has been previously suggested for 
the bacterium Escherichia coli. The Krebs cycle metabolite citrate was observed to modulate 
the activity of E. coli PNPase in vitro and in vivo. To discover whether such interactions are 
conserved across evolution, PNPase homologs from bacteria, eukarya and archaea were 
studied. Notably, citrate co-crystallises within the active site of Homo sapiens PNPase, 
suggesting that the citrate-PNPase communicative link may be conserved in eukaryotes.  
 
In the current study, a combination of bioinformatics and in silico molecular docking 
approaches, show that citrate is predicted to bind PNPase and related exoribonucleolytic 
proteins, from diverse bacterial species, eukaryotic organelles and archaea. Furthermore, in 
vitro results suggested that PNPase, from another bacterial species Synechocystis sp, may also 
be susceptible to inhibition/attenuation by citrate, and that this attenuation may therefore be 
commonplace amongst prokaryotes. Moreover, both eukaryotic PNPase from human 
mitochondria and the archaeal exosome complex from Sulfolobus solfataricus, is similarly 
inhibited/attenuated by citrate. The recurring interaction between citrate and PNPase homologs 
across all three domains, may represent an ancient and evolutionarily conserved mechanism of 
regulating RNA turnover. 
 
Using the same in silico and in vitro approaches, the tricarboxylic acid (TCA) metabolites 
acetyl-CoA and succinyl-CoA were also shown to affect hPNPase and EcPNPase 3’-5’ 
phosphorolytic activity. Results indicated that the nucleotide component of CoA in these 
metabolites, may bind and occlude the active site in a similar way to citrate. Accordingly, other 
nucleotide-based metabolites were investigated; phosphate-rich nucleotides and signalling 
molecules (GTP, ppppG, ppGpp) were predicted to bind to the active site of hPNPase. The 
results from gel-based assays then demonstrated that GTP, ppppG and ppGpp could affect the 
activity of both hPNPase and EcPNPase. It was also observed that the activity of hPNPase was 
more affected by these metabolites than EcPNPase and this was supported by previous 
research that suggested that PNPase homologs, across evolutionarily diverse organisms, have 
different phosphate preferences. Whether other PNPases can similarly interact with phosphate-
rich nucleotides needs to be investigated. Likewise, the in vivo effects and physiological 
relevance of these metabolite-PNPase interactions remain to be discovered. 
[ii] 
 
In summary, this study demonstrates that a metabolite-PNPase regulatory mechanism has the 
capacity to be conserved amongst all three domains of life and proposes that metabolite-
mediated, post-transcriptional mechanisms are widespread. A system where central 
metabolism can influence RNA stability in a feedback loop, provides another tier of added 
complexity to the current hierarchal process governing the cellular flow of information. This 
mechanism potentially facilitates the fine-tuned response that is required to modify cellular 
functioning for adaptation and or survival. A greater understanding of the intricate network of 
interactions, occurring in cells, is invaluable for developing novel medical and 
biotechnological applications.  
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1 Introduction 
 
1.1 Cellular Information Flow and Gene Regulation  
It is well established that the cellular information flow in all domains of life, involves 
deoxyribonucleic acid (DNA) being transcribed into ribonucleic acid (RNA) before being 
translated into proteins (Figure 1.1 (a-c)). As synthesised proteins can include the enzymes 
responsible for creating metabolites, the central dogma can be further expanded to include central 
metabolism (Figure 1.1 (c-d)). These metabolites are also known to regulate gene expression and 
therefore the system can be seen to be comprised of a complex and dynamic feedback loop. 
 
 
Figure 1.1 Cellular Information Flow: A Complex Regulatory System  
The flow of cellular information shows that (a) DNA genes can be transcribed into (b) transcripts including 
messenger RNA (mRNA), small non-coding RNAs (sRNAs), long non-coding RNAs and riboswitches. The 
latter two can post-transcriptionally control gene expression (side arrow) thus regulating the translation of the 
transcript into protein. (c) Furthermore, synthesised proteins can include transcription factors and 
ribonucleases (RNases-blue), which can regulate gene expression of the DNA and RNA level, respectively. 
The collection of proteins in the cell (proteome) controls (d) central metabolism, generating metabolites 
which can then relay back and control transcription factors and riboswitches (dotted lines). Image adapted 
from Prof. Anastasia Callaghan.  
 
Since the discovery of DNA, there has been a plethora of research published which demonstrates 
that at each stage of cellular information flow, shown in Figure 1.1, tight regulation occurs. There 
have also been reports of detrimental effects on cellular function when information is not 
transferred in an efficient and correct manner. This has revealed the importance of regulating gene 
expression, not only for normal cellular growth and differentiation, but also cellular senescence.  
 
Precise control of transcript levels relies on both transcription and degradation rates. Specifically, 
controlling the level of RNA turnover is vital for normal cellular homeostasis, since the pool of 
RNA available effectively dictates both the cellular pool of proteins and metabolites, termed the 
proteome and metabolome respectively (Figure 1.1 (c)-(d) respectively). Therefore, by altering 
[2] 
RNA turnover, a cell is able to respond to temporal cellular requirements and or environmental 
changes. Acting together with DNA transcription control, RNA turnover regulation facilitates the 
essential adaptions that the cell needs to survive (Clements et al., 2002; Ibrahim, Wilusz, & Wilusz, 
2008; Nurmohamed et al., 2011; Witharana, Roppelt, Lochnit, Klug, & Evguenieva-Hackenberg, 
2012). Extensive research has revealed that ribonuclease enzymes (RNases) have an important and 
broad role in regulating gene expression at the RNA level and this is highlighted Figure 1.1 (blue 
RNase) and reviewed subsequently in Section 1.2.  
 
1.2 Ribonucleases  
RNases are ubiquitous enzymes that play central roles in RNA metabolism and control turnover 
across all domains of life. They are required for the control of gene expression, primarily through 
the degradation of mRNAs, the processing and degradation of regulatory RNAs, and for the 
maturation and quality control of stable RNAs (reviewed in Arraiano et al., 2010). However, they 
also have the potential to be incredibly destructive and consequently their activity is carefully 
regulated (reviewed in Deutscher, 2015).  
 
Across evolutionarily divergent organisms, in all domains of life, there are a wide variety of RNA 
substrates. As a result, there are also a number of different degradation mechanisms available and 
this is reflected by the large size and functional diversity of the RNase enzyme group (Ibrahim et 
al., 2008; Nurmohamed et al., 2011; Zuo & Deutscher, 2001). Nevertheless, the general ways in 
which RNases work are highly conserved. Collectively, RNases either degrade RNA by 
endoribonuclease or exoribonuclease activity; essentially breaking phosphodiester bonds within the 
RNA molecule internally, or by removing nucleotides from the 5’ or 3’ ends respectively (Figure 
1.2) (Deutscher, 1993). These RNA degradation processes result in the overall destruction of 
transcripts and release of nucleotide diphosphates for phosphorolytic mechanism (NDPs, red 
segments (Figure 1.2)) or monophosphate for hydrolytic mechanisms, from RNA that is no longer 
needed or damaged, thus providing more nucleotides that can be reutilised for RNA synthesis 
(Deutscher, 1993).  
 
[3] 
 
Figure 1.2 RNase-Mediated RNA Degradation 
The process of RNase-mediated RNA degradation is shown in this schematic. Endoribonucleases (grey) 
break internal phosphodiester bonds within the RNA molecule (red). Whereas exoribonucleases remove 
nucleotides from the 5’ end (black) or 3’ end (blue). This process releases nucleotide diphosphates (NDPs, 
red segments) from RNA degraded by phosphorolytic enzymes and nucleotide monophosphates from 
hydrolytic enzymes. Image generated in GIMP (Version 2)(GIMP, n.d.).  
 
RNases can degrade RNA independently or as part of multi-protein complexes. However, the net 
result, the regulation of cellular RNA levels and thus protein production within the cell, is the same 
(Zuo & Deutscher, 2001). For example, in bacteria, the main RNA degrading machine is the 
degradosome, whereas in archaea and eukaryotes it is the exosome (Carpousis, 2007; Raijmakers, 
Schilders, & Pruijn, 2004; Sarkar & Fisher, 2006). Prior to discussing these RNase complexes in 
more detail, the processes by which each domain of life, including prokaryotes, eukaryotes and 
archaea, can regulate RNA turnover are briefly reviewed in Sections 1.3.1-1.3.3 respectively. 
 
1.3 RNA Turnover 
1.3.1 RNA Turnover in Prokaryotes 
The rate of turnover dictates RNA stability, this can vary considerably between organisms and even 
individual transcripts within a cell.  Escherichia coli is the best studied prokaryote model, so much 
of the research on RNA turnover has been conducted using this organism. In E. coli, RNAs which 
are known to be stable include transfer and ribosomal RNAs (tRNAs and rRNAs), conversely, 
messenger RNAs (mRNAs) are typically unstable with an average half-live ranging from 2-25 
minutes (Janga & Babu, 2009). The 5’ end of mRNAs are also reported to be less stable than the 3’ 
end, producing a model where a net 5’-3’ directionality of degradation is suggested (Selinger, 
2003).  Additionally, the existence of structural features or biochemical factors, that target specific 
classes of mRNA for decay, have been suggested to affect stability. This was following the 
observation that some E. coli mRNAs are degraded by individual RNases, while others are targeted 
by multi-protein complexes in vivo (Bernstein, Lin, Cohen, & Lin-Chao, 2004).  
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The length of the poly adenosine (poly(A)) tail at the 3’ end of a mRNA has also been linked to 
prokaryotic transcript stability. Previous data found that in a wild type E. coli strain, poly(A) tails 
ranged between 10-50 nts and in strains where the poly(A) polymerase (PAP) enzyme which 
synthesises these tails was absent, mRNA transcripts were found to be more stable (O’Hara et al., 
1995). This research indicated that the post-transcriptional modification of polyadenylation in E. 
coli, decreases stability by signalling transcripts for degradation (Sarkar, 1997). It was suggested 
that these poly (A) tails, produced from polyadenylation enzymes, help prokaryotic RNases to 
turnover RNA by clearing the barrier of secondary structures and providing a platform for RNase 
binding (Mohanty & Kushner, 2000a). Interestingly, polyadenylation is highly indiscriminate; 
essentially targeting virtually all unprotected mRNA 3’ ends for efficient control of gene 
expression (Sarkar, 1997). 
 
Rapid mRNA turnover is thought to be essential for an organism’s survival in environments subject 
to rapid changes (Wilusz, Wormington, & Peltz, 2001). As such, the RNA of the cyanobacteria 
Prochlorococcus has been discovered to have a short median half-life of 2.4 minutes, which is 
suggested to allow rapid recycling of nucleotides that would be advantageous in nutrient poor 
oceans (Steglich et al., 2010). 
 
1.3.2 RNA Turnover in Eukaryotes 
The average half-life of eukaryotic mRNA is longer when compared with that of transcripts from 
prokaryotes (Rauhut & Klug, 1999). This is likely due to several factors, for example unlike 
unicellular prokaryotic organisms, which are highly exposed to variations in the surrounding 
environment; multi-cellular eukaryotic organisms are typically more protected from their 
environment. Hence the rapid RNA turnover required for prokaryotes to survive in harsh conditions 
is less crucial for eukaryote survival. Additionally, eukaryotes have evolved a more complex gene 
expression system, where mRNA is transcribed within the nucleus and transported to the cytoplasm 
for translation into proteins. Therefore, post-transcriptional modifications, which are not required 
for prokaryote mRNA stability, are required for eukaryote transcript stability. This increased level 
of eukaryote transcript processing, through the addition of protective entities, likely explains why 
differences in mRNA stability control exist between the RNA turnover systems of complex 
eukaryotic and simpler prokaryotic organisms.  
 
Eukaryotic mRNA processing involves the addition of a long poly(A) tail and covalently linked 5’-
methylguanosine-cap structure. In contrast to prokaryotes, the long 3’ Poly(A) tail does not target 
the mRNA for degradation, instead these modifications promote transcript stabilisation and are 
crucial for efficient processing, nuclear export and translation (Schmid & Jensen, 2008; Wilusz et 
al., 2001). As a result, the length of mRNA Poly(A) tails and efficiency of polyadenylation is 
significantly higher in eukaryotes than prokaryotes, with tails on eukaryotic transcripts ranging 
from 80-200 nt in length (Steege, 2000).  However, the precise mechanism in eukaryotes for 
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mRNA decay, can vary significantly across eukaryotes. For example, in the yeast Saccharomyces 
cerevisiae, polyadenylation of aberrant transcripts can lead to degradation rather than stabilisation 
(Ibrahim et al., 2008).  Interestingly, the addition of a poly(A) tail can even have opposite functions 
within the same cell (Borowski, Szczesny, Brzezniak, & Stepien, 2010).  
 
Evidently, with added mRNA processing there is added complexity in eukaryotic mRNA 
degradation pathways. RNases which cleave RNA internally can leave it susceptible to further 
external degradation by other RNases. However, due to their additional modifications, degradation 
of eukaryotic transcripts usually occurs following the deadenylation and decapping events shown in 
Figure 1.3 (Wilusz et al., 2001).  
 
 
Figure 1.3 Eukaryotic mRNA Decay 
Processed eukaryotic mRNA containing a 5’cap structure (7-meGpppG) and a 3’ poly(A) tail is deadenylated 
by deadenylase (blue), decapped by decapping enzymes (yellow bolt) and then subject to decay at the 5’ 
and/or 3’ ends by exoribonucleases (exo, green and pink respectively). Image taken directly from (Wilusz et 
al., 2001). 
 
As it is in prokaryotes, effective RNA turnover is an essential process in eukaryotes; abnormal 
mRNA stability has been implicated in disease states, including cancer, chronic inflammatory 
responses and coronary disease (Wilusz et al., 2001). As a result, processes including nonsense-
mediated decay, which remove mutated transcripts with premature termination codons, exist to 
prevent erroneous gene expression. Also, processes commonly termed no-go decay and non-stop 
decay are also in place to remove transcripts with defective transcription and termination elements 
respectively (Belasco, 2010; Shoemaker & Green, 2012). This effective turnover of harmful 
defective transcripts is crucial, as it prevents gene expression which can result in genetic diseases 
such as cystic fibrosis and Duchenne muscular dystrophy (Wilusz et al., 2001). 
 
To add more complications, in addition to nuclear-encoded transcripts, eukaryotes also transcribe 
genes within their mitochondria and disturbance of mitochondrial gene expression has been linked 
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to aging, cancer and neurodegenerative diseases in humans (Borowski et al., 2010). Furthermore, 
the RNA degradation process within mitochondria has been reported to be different to the 
processes occurring within the cytoplasm and this is most likely due to the mitochondria’s 
evolutionary roots. For example, plant and algae chloroplasts were found to have a poly(A)-
mediated RNA degradation mechanism very similar to that of prokaryotes (Hayes, Kudla, & 
Gruissem, 1999). Since mRNA degradation occurring in organelles can also involve nuclear-
encoded proteins, there must be fundamental differences between this system and that existing in 
bacteria (Hayes et al., 1999). 
 
1.3.3 RNA Turnover in Archaea 
The process of RNA turnover in archaea is still not fully understood. For example, the presence of 
polyadenylation enzymes and the role of polyadenylation within archaea appears to be conflicting; 
neither PAP nor polynucleotide phosphorylase (PNPase) homologs have been identified in any 
archaeal class. However, a multi-protein complex similar to PNPases, termed the archaeal 
exosome, has been found in some classes. Additionally, different members of the archaea have 
been discovered to have very different RNA turnover machinery. For example, the halophilic 
archaeal organism Haloferax volcanii is not known to contain homologs of the eukaryotic 
degrading exosome complex, although the hyperthermophile Sulfolobus solfataricus possesses an 
archaeal exosome. In addition, no polyadenylation was detected in H. volcanii, whereas 
polyadenylation was discovered to occur in S. solfataricus by the archaeal exosome complex 
(Portnoy et al., 2005).   
 
1.3.4  RNA Turnover Summary 
In summary, although the mechanisms of RNA turnover have diversified over evolution, leading to 
fundamental differences between the kingdoms, there are many basic features in common, 
including the use of ribonucleases to mediate mRNA degradation. The subsequent Sections 1.4.1-
1.4.2 review the plethora of RNase complexes that exist and how they degrade transcripts, to 
control gene expression, across evolutionarily distinct organisms. It focuses on how the RNA 
degradosome and exosome complexes control RNA turnover across prokaryotes, eukaryotes and 
archaea. 
 
1.4 RNase Complexes 
1.4.1 RNA Degradosome 
In prokaryotes, a complex of RNases termed the degradosome is known to effectively couple 
exoribonucleases and endoribonucleases together with other proteins, to produce a degrading 
machine that can efficiently coordinate RNA turnover. The most well studied degradosome 
complex is that of E. coli and this is reported to control global gene expression post-
transcriptionally (Callaghan et al., 2005; Marcaida, DePristo, Chandran, Carpousis, & Luisi, 2006).  
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The E. coli degradosome is assembled upon the endoribonuclease RNase E (EC 3.1.26.12), which 
has two distinct domains; a structured catalytic N-terminal domain (NTD) and a mostly natively 
unstructured RNA and protein binding C-terminal domain (CTD) (Callaghan et al., 2004; Marcaida 
et al., 2006) (Figure 1.4 )(a)). It is within this extensive scaffolding CTD that the other principal 
components of the degradosome including, the exoribonuclease PNPase (EC 2.7.7.8), a DEAD-box 
RNA-dependent ATPase/helicase called RhlB (EC 3.6.4.13), and the glycolytic enzyme Enolase 
(EC 4.2.1.11) are assembled (Figure 1.4) (Carpousis, Vanhouwe, Ehretsmann, & Krisch, 1994; Py, 
Causton, Mudd, & Higgins, 1994; Py, Higgins, Krisch, & Carpousis, 1996; Vanzo et al., 1998). 
Remarkably the RNase E protein does not need to exhibit RNase activity to act as the essential 
scaffold in the reconstitution process; indicating that the enzyme is bifunctional (Coburn, Miao, 
Briant, & Mackie, 1999).  
 
 
Figure 1.4 RNA Degradosome Complex  
(a) A schematic of the domain organisation of the RNA degradosome is provided, showing the RNase E N-
terminal domain (NTD, 1-510) and its C-terminal domain (CTD, 511-1061). The RhlB (698-762), Enolase 
(833-850) and PNPase (1021-1061) RNase E microdomains, within which these proteins assemble, are 
indicated (coloured orange, pink and blue respectively). (b) The organisation of these proteins upon the CTD 
of RNase E is shown as a schematic, with one RNase E monomer highlighted in red. The other monomers of 
the tetrameric protein are shown in grey for clarity. Figure kindly provided by Dr Heather Bruce and adapted. 
 
The main enzyme of the degradosome, RNase E, has an evolutionarily conserved NTD; however 
its CTD exhibits sequence divergence and researchers have suggested that the two halves are thus 
evolving at different rates (Erce, Low, March, Wilkins, & Takayama, 2009). The CTD has been 
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observed to exhibit weak conservation even in closely related phyla (Hardwick, Chan, Broadhurst, 
& Luisi, 2011; Marcaida et al., 2006). This sequence diversity, and the natively unstructured 
characteristics of the CTD, are thought to help modulate the interactions of proteins assembled 
within the degradosome. Although degradosomes and degradosome-like assemblies are conserved 
throughout proteobacteria, the composition of assembled proteins is variable and it is thought that 
the CTD provides the capacity for rapid adaptations. A summary of RNA degradosome evolution is 
provided in Figure 1.5 and the diversity of proteins which associate with the CTD are shown 
(Hardwick et al., 2011).  
 
 
[9] 
 
Figure 1.5 RNA Degradosome Evolution 
A phylogenetic tree for bacterial RNase E which shows the degradosome as an assembly that varies greatly 
in the course of evolution. RNase E homologs with a helicase, enolase and PNPase associated at the C-
terminal domain, similar to E. coli (red star/cartoon), are colour-coded as the red branches in the 
phylogenetic tree (Type A). The characteristic microdomains for the branches that are not well conserved are 
labelled in black. The branches coloured green are also γ-proteobacteria (Type B), like E. coli, however the 
3’-5’ exoribonuclease RNase R is instead present within this degradosome. The Rhodobacter capsulatus 
RNase E (blue star/cartoon) sequence is not available but its homologs are indicated within the blue branch. 
The α-proteobacteria (Type C) and gram-positive bacteria (Type D) are most divergent from E. coli with 
either no PNPase, or PNPase at the N-terminal domain respectively. Image taken directly from (Marcaida et 
al., 2006).  
 
The compositional variability of the degradosome may explain how individual prokaryotic 
organisms differentially regulate RNA metabolism. It may also suggest how these bacteria are able 
[10] 
to adapt and survive when exposed to different environmental and cellular metabolic fluxes 
(Carpousis, 2007; Marcaida et al., 2006). This is especially important, since bacteria are known to 
inhabit a wide variety of environmental niches, which can be extreme in nature and/or rapidly 
changing. For example, alternative assemblies of the E. coli degradosome have been suggested to 
form in different growth conditions; under cold shock, RNA helicase CsdA co-purifies with the 
degradosome in place of RhlB (Prud’homme-Géńreux et al., 2004). Other minor components of the 
degradosome have been discovered including the protein chaperones Dnak and GroEl. Interestingly 
these proteins have been linked not only to the heat shock survival of E. coli (Miczak, Kaberdin, 
Wei, & Lin-Chao, 1996), but also to the heat and antibiotic shock survival of the opportunistic 
human pathogen Acinetobacter baumannii (Cardoso et al., 2010). This information further 
indicates that RNA degradosomes are adjustable and capable of adapting to different environmental 
conditions. 
 
Although many variations are available, in E. coli, a minimal degradosome of RNase E, PNPase, 
and RhlB is suggested to form spontaneously in vitro in the absence of all other cellular 
components (Coburn et al., 1999). This minimal RNA degradosome is therefore capable of both 
endoribonuclease and exoribonuclease activity through the presence of RNase E and PNPase 
respectively. Additionally, the presence of RhlB in the minimal degradosome has been shown to 
facilitate PNPase-mediated degradation in vitro, presumably by helping unwind RNA stem loops 
(Py et al., 1996). As mentioned previously, enolase was originally discovered as a RNA 
degradosome component, however the observation that only 5-10% of the total cellular enolase co-
purified with the degradosome, led to questions about its role (Py et al. 1996). Indeed, later a 
minimal degradosome was shown to assemble and exhibit activity without enolase; suggesting 
enolase was not crucial in vitro (Coburn et al., 1999). Although a potential role in regulating 
response to growth conditions has been suggested for enolase (Vanzo et al., 1998), the activity this 
enzyme has on RNA metabolism is poorly understood and the relevance/importance of this 
metabolic enzyme on RNA turnover still requires understanding (Hardwick et al., 2011). 
 
In addition to the presence of the ATP-sensing RNA helicase and the metabolic enzyme enolase 
within the E. coli degradosome, the discovery of the Krebs enzyme aconitase within the 
Caulobactor crescentus degradosome indicated another link between RNA degradation and 
metabolism and environmental sensing (Carpousis et al., 2007; Hardwick et al., 2011; Liou et al., 
2001; Nurmohamed et al., 2009; Nurmohamed et al., 2011). Furthermore, although Bacillus 
subtilis lacks an RNase E homolog, it possesses a degradosome-like assembly with a functionally 
analogous endoribonuclease RNase Y, which can also recruit two glycolytic enzymes, namely 
enolase and phosphofructokinase (Commichau et al., 2009). From these observations, researchers 
have suggested that the conserved association of metabolic enzymes with RNases in bacteria 
further indicates that the interaction has functional consequence (Hardwick et al., 2011). This is 
reviewed in more detail later in Section 1.6. However, it is important to note the reoccurrence of 
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the interactions between enzymes involved in central metabolism and the main machinery 
controlling post-transcriptional gene regulation in bacteria.  
 
In summary, the overall composition of the degradosome complex is diverse across prokaryotes, 
however the enzymes involved in this complex are highly conserved. The equivalent RNA 
degrading complex in eukaryotes is called the exosome and its role in regulating post-
transcriptional gene expression is briefly introduced below in Section 1.4.2 before more detailed 
structural information is provided in Section 1.5. 
 
1.4.2 RNA Exosome 
All eukaryotic and archaeal exosomes identified to date contain proven or predicted RNase and 
RNA binding subunits. These exosome subunits associate with a range of cofactors, not only in a 
species-dependent manner, but also dependent on their cellular localisation (Ng, Waterman, 
Antson, & Ortiz-Lombardia, 2010). The exosome core assembly itself has a remarkable 
resemblance to the bacterial RNase and polyadenylation enzyme PNPase (Hardwick et al., 2011). 
The archaeal exosome is most similar to PNPase both structurally and functionally. In contrast, 
although the eukaryotic exosome has structural homology to PNPase and the archaeal exosome, it 
has lost its phosphorolytic catalytic activity and requires additional domains to mediate its 
hydrolytic activity (Lykke-Andersen et al., 2009). The structural and functional conservation of the 
RNA exosome and PNPase is discussed in Section 1.5.4 in more detail.  
 
The presence of PNPase in the prokaryote RNA degradosome, and its homology to the eukaryotic 
and archaeal exosome structures, highlights the importance of this ribonuclease in RNA turnover. 
Hence the subsequent Section 1.5 describes the activity, structure, evolution and role of PNPase in 
regulating gene expression. 
 
1.5 Polynucleotide Phosphorylase  
Polynucleotide Phosphorylase (PNPase, also known as polyribonucleotide nucleotidyltransferase) 
and RNase PH are two enzymes within the phosphate dependent exoribonuclease (PDX) super-
family. The PDX family use inorganic phosphate (PO43-) to degrade RNA, in contrast to the other 6 
super-families: RBN, DEDDM, RNR, RRP4 and 5PX, which are known to use hydrolytic cleavage 
for this process (as reviewed in Zuo & Deutscher, 2001). 
 
1.5.1 PNPase Activity 
PNPase is an important processive 3’-5’ bacterial exoribonuclease, which can act both 
independently within the cell cytoplasm, and as part of the bacterial degradosome complex 
(Bernstein et al., 2004). The activity of PNPase in E. coli (EcPNPase) is well-studied and its mode 
of activity is shown in Figure 1.6. This enzyme has an interesting role in that it can reversibly act as 
either a metal-dependent phosphorolytic nuclease (degrading RNA) or a template-independent 
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polymerase (synthesising RNA) (Littauer & Soreq, 1982; Mohanty & Kushner, 2000b). In the 
presence of excess inorganic phosphate (PO43-) and either of the metal cofactors; magnesium 
(Mg2+) or manganese (Mn2+), PNPase can progressively degrade single stranded RNA in a 3’ to 5’ 
direction, releasing NDPs in the process (Figure 1.6, forward arrow) (Nurmohamed et al., 2009). 
More specifically, the metal ion in EcPNPase is thought to be coordinated by two conserved 
aspartate residues, and these residues may act in conjunction with the bound metal to support 
general acid/base catalysis (Nurmohamed et al., 2009). However, in the presence of excess NDPs 
the enzyme can reverse its function (Figure 1.6, reverse arrow) and systematically add NDPs onto 
the 3’ end of RNA, releasing inorganic phosphate in the process (Mohanty & Kushner, 2000a; 
Nurmohamed et al., 2011).  
 
 
Figure 1.6 PNPase Activity 
(a) PNPase can act to either degrade RNA substrate at the 3’ end using inorganic phosphate (PO43-) and metal 
ions such as Mg2+ or (b) in the presence of NDPs it can synthesise RNA from the 3’ end in the reverse 
reaction. Figure adapted from (Nurmohamed et al., 2011) using GIMP (v2)(GIMP, n.d.). 
 
1.5.2 PNPase Structure 
Structural studies of PNPase from E. coli (EcPNPase; (Nurmohamed et al., 2009; Shi, Yang, Lin-
Chao, Chak, & Yuan, 2008)), Streptomyces antibioticus (SanPNPase; (Symmons, Jones, & Luisi, 
2000)), C. crescentus (Hardwick, Gubbey, Hug, Jenal, & Luisi, 2012), Coxiella burnetii (Franklin 
et al., 2015) and Homo sapiens (hPNPase; (Lin et al., 2012)) have revealed a ring-shaped 
homotrimeric complex, with a core hexamer of PH domains that form a central channel that is able 
to accommodate single-stranded RNA. The RNA-binding domains are positioned on one side of 
the PH ring where they can guide RNA into the channel towards the active site (Franklin et al., 
2015; Hardwick et al., 2012; Lin et al., 2012; Shi et al., 2008; Symmons et al., 2000). 
 
Focusing on EcPNPase, a schematic of the full-length domain organisation and solved core enzyme 
structure is shown in Figure 1.7 (a) and (b) respectively. The domain schematic in Figure 1.7 (a) 
shows the full length protein, with the catalytically inactive phosphorolysis or RNase PH-like 
domain (PH-1), a linking α helical domain (H), a catalytically active RNase PH-like domain 2 (PH-
2), followed by two RNA binding domains; a K-homology domain (KH) and an S1 domain (S1) 
(Leszczyniecka, DeSalle, Kang, & Fisher, 2004; Symmons et al., 2000). The 3D structure of 
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EcPNPase is highlighted Figure 1.7 (b); only the core enzyme (ΔKH/S1; KH and S1 domains 
truncated) could be determined by X-ray crystallography. This may be a result of flexibility within 
the KH and S1 domains (3GCM) (Nurmohamed et al., 2009). EcPNPase is a homotrimeric protein 
and interactions between each monomer (coloured dark blue, blue and cyan respectively) 
collectively form a central pore. The domains which contribute to a single ‘core’ monomer are 
highlighted with dotted lines; this includes the PH-1 and 2 domains and a linking α helical domain 
(Figure 1.7 (b)). 
 
 
Figure 1.7 PNPase Domain Organisation and Crystal Structure  
(a) PNPase domain architecture is shown with the RNase PH-like domain (PH-1) domain, an α helical 
domain (H), PH-2 domain and the KH and S1 RNA binding regions. (b) The PNPase crystal structure from 
E. coli (PDB: 3GCM) with individual monomers coloured in dark blue, blue and cyan. The domains in (a) 
which constitute one monomer in (b) are indicated with dotted lines (Nurmohamed et al., 2009). Image 
created using GIMP (v2) (GIMP, n.d.). 
 
The catalytic activity of EcPNPase resides in the PH-2 domain only; however it has been shown 
that both PH domains are required for full catalytic activity (Briani et al., 2007; Jarrige et al., 
2002). Interestingly, both domains are also required for maintaining the enzyme’s activity in 
response to cold temperatures, affecting E. coli stress survival (Awano et al., 2008). Due to 
difficulty determining the crystal structure of full-length EcPNPase, the KH and S1 RNA binding 
domains are proposed to assemble on the top of the core protein in a similar manner to C. 
crescentus PNPase (Hardwick et al., 2012). Moreover, the proposed mechanism of how the KH 
and S1 domains help feed RNA substrates into the active site for cleavage, is provided by the 
crystal structures of RNA-bound and apo C. crescentus PNPase. The RNA-free form suggests that 
RNA capture is facilitated by a ‘splayed’ conformation of S1 domains. The RNA bound form of C. 
crescentus PNPase suggests that the three KH domains collectively close upon the substrate RNA 
and direct the 3’ end towards the constricted aperture at the entrance of the central channel. It is 
proposed that upon RNA binding, the substrate is channeled to the active site through mechanical 
ratcheting (Hardwick et al., 2012). The KH pore of hPNPase is also proposed to trap long RNA 
tails and feed them into the central channel for the degradation process in a similar manner to C. 
crescentus PNPase (Lin et al., 2012).   
[14] 
 
The enzyme EcPNPase shown in Figure 1.7 is highly conserved. It shares a similar structure across 
all PNPase homologs and its evolution is described below in Section 1.5.3. 
 
1.5.3 Origin of the PNPase Domains 
Through extensive phylogenetic comparison, which highlighted the similarities between PNPase 
RNase PH-like domains and the domains in the RNase PH protein itself, a model of PNPase 
domain evolution has been proposed (Figure 1.8) (Leszczyniecka et al., 2004). Leszczyniecka and 
colleagues conducted phylogenetic analysis to provide the model which suggested that a common 
ancestral RNase PH-like domain (Figure 1.8, red) underwent an initial duplication event (Figure 
1.8 (a) black arrow), which gave rise to the physically linked RNase PH-like domains 1 and 2. A 
later divergence event of the RNase PH-like domain 2 was suggested (Figure 1.8 (b), blue), 
followed by a second duplication event (Figure 1.8 (c) arrow), thus creating two copies of the gene. 
It has been hypothesised that for one of these duplicates, a stop codon was introduced within the 5’ 
untranslated region (UTR) of the RNase PH-like domain 1; causing this domain to be silenced 
(Figure 1.8 (d) black circle). Following separate evolutionary changes; a gene transfer event 
relocated one gene to a different location of the genome, now called RNase PH (green), and the 
other gene, now called PNPase (red and blue), acquired KH and S1 domains (orange and yellow 
respectively). Although two different proteins resulted, similarities still exist; the RNase PH and 
PNPase RNase PH-like 2 domains are most similar (Figure 1.8 (e)). Functionally, both these 
enzymes belong to the same PDX family of 3’-5’ phosphorolytic exoribonucleases. 
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Figure 1.8 PNPase Domain Evolution 
The domain evolution of PNPase and RNase PH proteins is proposed within this schematic from the 
extensive phylogenetic analysis conducted by Leszczyniecka et al., 2004. (a) The model suggests an initial 
gene duplication event, (b) followed by a divergent event gave rise to the physically linked RNase PH-like 
domains 1 and 2 (red and blue). (c) A second duplication event, (d) a subsequent gene silencing event (black 
circle) and divergent event (green), then gave rise to the (e) two separate PNPase and RNase PH genes. The 
PNPase gene also acquired the additional KH and S1 domains (orange and yellow respectively). Image 
adapted from (Leszczyniecka et al., 2004) using GIMP (v2)(GIMP, n.d.). 
 
In summary, over evolution the RNase PH domain has been retained and has even evolved to form 
the ribonuclease PNPase. This is important to understand, as RNase PH-like proteins form not only 
the basis of PNPase in prokaryotes, such as E. coli, and eukaryotes, such as H. sapiens, but they are 
also the main component of exosome complexes. The structural conservation of PNPase and 
exosome complexes are discussed in more detail in the following Section 1.5.4. 
 
1.5.4 PNPase Structural Conservation 
The PNPase enzyme itself is evolutionarily conserved, it is found in both prokaryotes and 
eukaryotes and can be located within the cytoplasm, chloroplasts and mitochondria; an N-terminal 
signal peptide targets PNPases to these organelles (Schuster & Stern, 2009; Yehudai-resheff, Hirsh, 
& Schuster, 2001). Whilst archaea do not possess PNPase (Leszczyniecka., 2004), their exosome 
consists of RNase PH-like proteins called Rrp, which are thought to originate from a common 
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ancestor of PNPase (Evguenieva-Hackenberg, Hou, Glaeser, & Klug, 2014; Liu, Greimann, & 
Lima, 2006). Furthermore, the domains of the eukaryotic exosome also consist of Rrp proteins and 
so it is no surprise that the overall organisation of RNase PH, PNPase, archaeal and eukaryotic 
exosomes are all very similar, as shown in Figure 1.9 (Slomovic et al., 2008). Thus the structure, 
and possibly the function, of RNA degrading machines are seen to be evolutionarily linked across 
the three domains of life.  
 
 
Figure 1.9 PNPase and Exosome Structural Homology  
The crystal structures of (a) E. coli (3GCM), (b) H. sapiens (3U1K) PNPase, (c) S. solfataricus (3L7Z) and 
(d) H. sapiens (2NN6) exosomes. RNase PH-like domains (PH) of PNPases and homologous domains (Rrp) 
of exosome are indicated. Two PH domains (PH-1 and PH-2) collectively form one PNPase monomer in (a) 
E. coli (light pink and purple respectively) and (b) H. sapiens PNPase (light and dark blue respectively). Two 
Rrp domains (Rrp41 and Rrp42) form an equivalent exosome monomer in (c) S. solfataricus (blue and green 
respectively). The individual domains which make up (d) H. sapiens exosomes are Rrp41 (green), Rrp42 
(cyan), Rrp43 (red), Rrp45 (blue), Rrp46 (yellow) and Mtr3 (pink)). (Lin et al., 2012; Liu et al., 2006; Lu, 
Ding, & Ke, 2010; Nurmohamed et al., 2009). Adapted from an image provided by Dr Louise Butt.  
 
The overall crystal structures of PNPase and exosome homologs is shown in Figure 1.9 and since 
no crystallography data are available for EcPNPase S1 and KH domains, the RNA binding domains 
of the other enzymes are not shown. Comparison of the structures for EcPNPase and hPNPase 
show that both enzymes consists of two different PH-1 and 2 domains (coloured light pink and 
purple and light blue and dark blue respectively), which collectively form one protomer (Figure 1.9 
(a-b)). For both EcPNPase and hPNPase, three protomers collectively form a homotrimeric protein 
with a pseudo-hexameric ring-like structure, which is very similar to the archaeal S. solfataricus 
exosome and eukaryotic H. sapiens exosomes (Figure 1.9 (c-d)). The RNase PH protein is not 
shown within this figure, but is also known to form a hexameric ring of six identical RNase PH 
domains. 
[17] 
 
The archaeal exosome complex contains five different proteins: Rrp42 and Rrp41 (equivalent to 
PH-1 and PH-2 respectively) and three RNA-binding proteins Rrp4 (contains S1 and KH domains), 
Csl4 (contains S1 and Zn-finger domains) and DnaG (binds polyA) (Evguenieva-Hackenberg, 
Walter, Hochleitner, Lottspeich, & Klug, 2003). Structural studies of exosomes from S. solfataricus 
(SsoExosome; Lorentzen et al., 2005a; Lorentzen, Dziembowski, Lindner, Seraphin, & Conti, 
2007a; Lorentzen & Conti, 2005, 2012; Lu, Ding, & Ke, 2010), Archaeoglobus fulgidus (Büttner, 
Wenig, & Hopfner, 2005; Hartung, Niederberger, Hartung, Tresch, & Hopfner, 2010), Pyrococcus 
abyssi (Navarro, Oliveira, Zanchin, & Guimarães, 2008), and Methanothermobacter 
thermautotrophicus (Ng et al., 2010) have revealed a similar architecture to PNPase. A trimer of 
Rrp41/Rrp42 dimers assemble to form the ring-shaped PH-domain hexamer of the archaeal 
exosome core (Figure 1.9 (c)). Three RNA-binding proteins, Rrp4 and/or Csl4-DnaG can then 
assemble on one face of the ring where they channel RNA towards the active site (not shown) 
(Büttner et al., 2005; Lee, Hartung, Hopfner, & Ha, 2010; Lorentzen & Conti, 2012; Lorentzen et 
al., 2007; Lu et al., 2010). The eukaryotic core exosome has a hexameric ring structure that is 
similar, except it consists of six different RNase PH-like proteins (Rrp41 (green), Rrp42 (light 
blue), Rrp43 (red), Rrp45 (blue), Rrp46 (yellow) and Mtr3 (pink), Figure 1.9 (d)) (Liu et al., 2006).  
 
Whilst the PNPase and exosome proteins are seen to be structurally similar, functionally only the 
archaeal exosome exhibits similar enzymatic activity to PNPase. The eukaryotic exosome core has 
lost its RNA phosphorolytic degradation activity and requires additional accessory protein 
domains, Rrp6 and Rrp44, to hydrolytically cleave the RNA (Dziembowski, Lorentzen, Conti, & 
Séraphin, 2007; Januszyk & Lima, 2014; Liu et al., 2006; Lykke-Andersen et al., 2009; Wasmuth, 
Januszyk, & Lima, 2014). Despite this, the possibility of a 3’-5’ RNA feeding mechanism through 
the central pore of the eukaryotic exosome is suggested to be similar to PNPase and the archaeal 
exosome (Wasmuth et al., 2014). Nevertheless, the eukaryotic exosome was not the focus of this 
PhD research and PNPase homologs and the homologous archaeal exosome were only considered 
as examples of 3’-5’ phosphorolytically active enzymes. In order to appreciate the importance of 
studying PNPase, its cellular roles are outlined below in Section 1.5.5. 
 
1.5.5 PNPase Roles 
EcPNPase can function independently but it is also a component of the multiprotein degradosome 
complex. About 10-20% of PNPase is found in the canonical degradosome along with RNase E, 
the RNA helicase RhlB and the glycolytic enzyme enolase (Aït-Bara & Carpousis, 2015; Bandyra, 
Bouvier, Carpousis, & Luisi, 2013; Sarkar & Fisher, 2006). This association with another 
ribonuclease and a helicase is likely to assist EcPNPase in its degradative capacity. However, 
localisation to the cytoplasmic membrane as part of the degradosome, is thought to restrict its 
activity (Aït-Bara & Carpousis, 2015; Bandyra et al., 2013). 
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In terms of physiological function, the most studied PNPase is that from E. coli. In this bacterium 
PNPase is required for growth at low temperatures (Awano et al., 2008) and its activity has been 
implicated in all aspects of RNA metabolism including; mRNA turnover (Donovan & Kushner, 
1986; Mohanty & Kushner, 2003), degradation of small regulatory RNAs (sRNAs; (Andrade & 
Arraiano, 2008; Andrade, Pobre, Matos, & Arraiano, 2012) and the quality control of stable RNAs  
(Cheng & Deutscher, 2003; Li, Reimers, Pandit, & Deutscher, 2002). In bacterial species, PNPase 
also affects complex processes, such as the tissue-invasive virulence of Salmonella enterica 
(Clements et al., 2002) and virulence factor secretion in Yersinia (reviewed in Matos, Bárria, 
Pobre, Andrade, & Arraiano, 2012). 
 
As mentioned previously, PNPase in eukaryotes can be localised to the chloroplast and 
mitochondria. The exact role of hPNPase in the mitochondria remains to be fully understood and 
there is some controversy over its activity within this organelle. This is mainly due to its presence 
in the intermembrane space (IMS), where it is not thought to be involved in regulating 
mitochondrial RNA levels (Chen et al., 2006), but it may instead play a role in RNA import (Wang 
et al., 2010). Interestingly, a mutation in PNPT1, which encodes hPNPase, is reported to impair 
RNA import into mitochondria and cause respiratory-chain deficiency and hereditary hearing loss 
(Alodaib et al., 2016). PNPase is clearly involved in many essential processes and although its 
activity within the mitochondria still requires much more research, it’s important to understand the 
roles it plays in both RNA turnover and metabolism.  
 
Not surprisingly, given these diverse roles, PNPase activity is tightly controlled at both post-
transcriptional and post-translational levels. In E. coli, the stability of the pnp mRNA transcript and 
therefore expression of the pnp gene is auto-regulated by PNPase in a mechanism involving the 
endoribonucleases RNase III and RNase E (Carzaniga et al., 2009; Jarrige et al., 2001). Not only 
does PNPase regulate itself, but other cellular components have been shown to interact with the 
enzyme and control its activity. The next Section 1.6 reviews in more detail how cellular 
metabolism may regulate PNPase activity, and thus RNA turnover. 
  
1.6 Regulating RNA Turnover in Response to Cellular 
Metabolism 
The initial discovery that the glycolytic enzyme enolase and the Krebs cycle aconitase, can also 
form part of the degradosome in E. coli and C. crescentus respectively, hinted at a connection 
between RNA degradosome activity and central metabolism (Hardwick et al., 2011; Miczak et al., 
1996; Nurmohamed et al., 2011; Vanzo et al., 1998). Also suggestive of a link between RNA 
degradation and metabolism is the finding that PNPase activity can be regulated by nucleotides and 
secondary signalling molecules. For example, EcPNPase is inhibited by ATP nucleotides (Del 
Favero et al., 2008) and cyclic di-GMP secondary messenger molecules in vitro (c-di-GMP; 
Tuckerman et al., 2011), and its homologues from Nonomuraea sp. and Streptomyces are inhibited 
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by stringent response alarmone signalling molecules (Gatewood & Jones, 2010; Siculella et al., 
2010). More specifically, PNPase in S. antibioticus was found to respond and coordinate its 
function in accordance to the stringent response alarmone guanosine tetraphosphate (ppGpp) and 
its precursor guanosine pentaphosphate (pppGpp) (Bralley & Jones, 2003), collectively termed 
(p)ppGpp (Hauryliuk, Atkinson, Murakami, Tenson, & Gerdes, 2015). This is interesting since 
(p)ppGpp has been linked to antibiotic production in response to amino acid and energy starvation, 
and suggests a link between environmental sensing and PNPase activity (Bralley & Jones, 2003; 
Mechold, Cashel, Steiner, Gentry, & Malke, 1996). Although PNPase from S. antibioticus and E. 
coli have significant structural conservation (Nurmohamed et al., 2009; Symmons et al., 2000), 
remarkably (p)ppGpp was not found to inhibit EcPNPase (Gatewood & Jones, 2010) and the 
significance of this alarmone’s effect on other PNPase homologs is unknown.  
 
Although the observations described previously may indicate a communicative link between RNA 
degradative machines and central metabolism, direct evidence of such a link was missing. This was 
true until research studying the structural and functional roles of PNPase in E.coli, independent of 
the degradosome, discovered that the Krebs cycle metabolite citrate could modulate its RNase 
activity both in vitro and in vivo (Nurmohamed et al., 2011). Cellular metabolism was also 
discovered to be dependent upon EcPNPase activity (Nurmohamed et al., 2011).  The findings 
presented within this publication by our group and collaborators in Cambridge, laid the foundations 
for this PhD project. Hence the details of the citrate-PNPase interaction, discovered in bacteria, are 
described initially below and then the question of whether the citrate-PNPase interaction is a 
conserved communication mechanism in other organisms is addressed. 
 
1.6.1 PNPase Activity May Be Modulated by Citrate in E. coli 
The initial suggestion of a citrate-PNPase interaction in E. coli occurred upon solving the crystal 
structure of EcPNPase (3GCM). It was in this publication that Nurmohamed and colleagues 
observed that, like the S. antibioticus homologue (SanPNPase), EcPNPase forms a homotrimer 
with a ring-like architecture and a central channel, as shown in Figure 1.10 (a) (Nurmohamed et al., 
2009; Symmons et al., 2000). Interestingly, they also noticed two citrate molecules co-crystallised 
within each of the EcPNPase three active sites and within one of three ‘vestigial’ active sites, 
which were not previously seen for SanPNPase (Figure 1.10). They also noted that, although these 
active and vestigial sites are related through approximate molecular symmetry, only the former 
possessed catalytic activity (Nurmohamed et al., 2009).  
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Figure 1.10 EcPNPase Crystal Structure  
(a) EcPNPase homotrimer with each monomer coloured black, dark grey and light grey respectively. 
Highlighted within the structure are Mg2+ ions (purple sphere) and citrate molecules (at active and vestigial 
sites; orange and red sticks respectively). (b) The individual monomer and (c) a zoomed in image of the 
active site (dark grey ribbons) are shown. This image was created in MOE (Molecular Operating 
Environment, 2013) using the 3GCM structure deposited within the PDB (Nurmohamed et al., 2009) and 
prepared in GIMP (v2)(GIMP, n.d.).  
 
Upon discovery, the question of whether citrate was just an artefact of the crystallisation buffer, 
which contained 20 mM sodium citrate, or if it represented a physiologically relevant interaction 
was examined further by our research group. Accordingly, the subsequent study suggested that 
EcPNPase activity was indeed modulated in vitro and in vivo by physiologically relevant 
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concentrations of citrate (Nurmohamed et al., 2011). More specifically, experiments in vivo found 
that E. coli cell strains (RNase II-/R-), which are known to be dependent on PNPase for viability 
(Cheng & Deutscher, 2003; Donovan & Kushner, 1986), exhibited suppressed growth in the 
presence of increased intracellular citrate concentrations. Doubling times of the untreated PNPase 
dependant strain (RNase II-/R-) increased from 49.0 (+/- 2.2) to 59.4 (+/- 3.2) minutes in the 
presence of 50 mM Mg2+ citrate. Contrastingly, there was no effect measured for WT and PNPase 
null strains when the same concentration of Mg2+ citrate was applied. It is understood that both 
RNases II and R, which are present in the WT and PNPase null strains, are able to compensate for 
loss in PNPase activity. Hence the negligible effect of citrate on these strains was unsurprising, and 
suggested that the negative effect observed specifically in the RNase II-/R- strain, was likely a result 
of citrate impact on PNPase function (Cheng & Deutscher, 2003; Nurmohamed et al., 2011). 
 
Utilisation of these strains for subsequent microarray analysis of mRNA levels revealed a PNPase-
mediated response to citrate, when comparing a PNPase null mutant +/- citrate, against a WT strain 
+/- citrate. Genes generally affected by PNPase and those displaying a PNPase-mediated response 
to citrate were compared. Individual genes were assigned to gene ontology terms and from this it 
was clear that a PNPase-mediated citrate response broadly affected genes involved in cellular 
metabolic processes. More specifically, genes which were affected by citrate in a PNPase-
dependent manner included those involved in cellular amino acid and derivative metabolic 
processes, and cellular biosynthetic and organic acid metabolic processes (Nurmohamed et al., 
2011). Transcripts cirA and fkpA, encode an outer membrane receptor and heat shock chaperone 
protein respectively and have been previously reported to be regulated by PNPase, were 
upregulated in a PNPase-mediated response to citrate in microarray analysis (Nurmohamed et al., 
2011). To complement the microarray analysis, RT-PCR was conducted to validate the relative 
abundance of mRNAs known to be regulated by PNPase. The levels of these transcripts, including 
cirA and fkpA, were also found to be upregulated in the presence of Mg2+ citrate, in a PNPase-
dependant manner. Collectively, results from RT-PCR and microarray analysis showed that not 
only were specific transcripts affected in a PNPase-dependent response to citrate, but RNA 
metabolism was also broadly altered in vivo (Nurmohamed et al., 2011).  
 
Additionally, cellular metabolism was also observed to be affected widely by PNPase activity; the 
impact of PNPase on the metabolome was examined using 1H NMR spectroscopy and gas 
chromatography mass spectrometry. The results of which suggested many metabolites were 
affected by PNPase loss, when comparing the null strain with the WT. The Krebs cycle metabolite 
succinate was found to decrease whereas citrate increased. It is important to recapitulate that a 
metabolite, in this case citrate, can affect PNPase activity and that PNPase itself can in turn affect 
metabolite levels. This potentially suggests that these interactions represent a novel feedback loop, 
where RNases may sense the metabolic status of the cell and modify it accordingly (Nurmohamed 
et al., 2011). 
[22] 
  
Following in vivo work, the effect of citrate on PNPase activity was also investigated in vitro. It is 
known that PNPase requires metal ions for activity and that it can use either Mg2+ or Mn2+ for 
catalysis. The effect of both Mg2+ citrate and Mn2+ citrate on EcPNPase activity were therefore 
investigated and compared in vitro. Interestingly, only Mg2+ citrate was found to inhibit PNPase 
degradation activity; even in conditions of a 2-fold excess of Mg2+ to citrate. These findings 
indicate that citrate does not simply chelate active site metal ions and the inhibition seen actually 
requires specific ligand geometry.  
 
It is important to acknowledge that citrate is also found ‘free’ within the cell and this ‘free’ citrate 
can also bind EcPNPase, yet unlike Mg2+ citrate, the free form was discovered to stimulate 
EcPNPase activity. The authors investigated the binding affinity of these interactions further and 
established that ‘free’ citrate bound EcPNPase with a weaker affinity than Mg2+ citrate; ~25 and ~3 
mM respectively. Additionally, rather than binding in the active site, like Mg2+ citrate, free citrate 
was found to bind the ‘vestigial’ active site, potentially acting allosterically. It is well established 
that a metal ion is required for catalytic activity at the active site, hence the effect of the Mg2+ 
citrate was the focus of this PhD work and the effects of free citrate were not investigated.  
 
In summary, the results described by Nurmohamed et al clearly revealed a communicative link 
between PNPase and metabolism in E. coli; whether this represents a mechanism that is conserved 
in other prokaryotes and/or higher organisms, remains to be identified and was one of the main 
research questions of this thesis.  
 
1.6.2 Is Citrate Binding Conserved in PNPases Homologs?  
As discussed previously in Section 1.5.4, PNPase is present in prokaryotic and eukaryotic domains 
and, although PNPase is absent in archaea, a homologous protein, termed the archaeal exosome, is 
known to exist. The structure and function of these PNPase homologs are highly conserved, all 
forming ring like structures, with similar domain architecture and phosphorolytic activity. It is 
important to note that these archaeal exosomes described are distinct from the eukaryotic 
exosomes, which have lost their phosphorolytic activity and instead utilises hydrolytic activity to 
degrade their RNA substrates. 
  
The protein sequences and crystal structures of a number of PNPase homologs across the three 
domains of life are available, allowing easy comparison of their overall structure and proposals of 
their evolution. Upon examination of the solved eukaryotic hPNPase structure (PDB: 3U1K), 
citrate was also found to co-crystallise within the active site, similar to EcPNPase (Lin et al., 2012). 
When the two enzymes are compared, they both possess a similar homotrimeric shape and citrate 
binds similarly within the active sites. However, unlike EcPNPase, the role of citrate within the 
hPNPase active site was not examined by Lin et al; they simply stated that co-crystallisation of 
[23] 
citrate was a result of its presence in the crystallisation buffer. Following the understanding that 
citrate has a physiological role within EcPNPase, it would be interesting to see if the same physical 
association of citrate with hPNPase has analogous effects on its activity. Furthermore, the 
localisation of PNPase to the mitochondria, the site of general metabolic activities in humans 
including the tricarboxylic acid (TCA) cycle and thus citrate synthesis, suggests that citrate could 
be available for hPNPase to mediate a regulatory role (Piwowarski et al., 2003). The intracellular 
citrate concentration in E. coli has been described to range between 2-20 mM when grown on 
glucose/glycerol or acetate respectively (Bennett et al., 2009). Although the level of inhibition of 
EcPNPase by citrate observed in vitro correlates with citrate concentration in this range 
(Nurmohamed et al., 2011), the intracellular concentration of citrate in human cells is not clear. 
The human metabolome online database resource suggests that citrate is found in all cell types. It is 
present in both the mitochondria and cytoplasm and also in extracellular biofluids including blood, 
urine and saliva (Wishart et al., 2013) and this may explain why it is difficult to determine cellular 
concentration of citrate. Although there has been some controversy over the intracellular citrate 
concentration, alongside the localisation of hPNPase to the mitochondria, and its role within this 
organelle (Chen, Koehler, & Teitell, 2007), there is not enough evidence to exclude the existence 
of a citrate-hPNPase regulatory interaction and as a result hPNPase was selected as a eukaryotic 
model to study within this work. 
 
In contrast to EcPNPase and hPNPase, which were co-crystallised with citrate, the structure of 
PNPase from gram-positive S. antibioticus (SanPNPase) was solved in the free form as citrate 
wasn’t present in the crystallisation buffer (PDB: 1E3P, Symmons et al., 2000). Like hPNPase, 
SanPNPase also has a similar structure to PNPase from the gram-negative bacterium E. coli. It 
therefore represented a bacterial PNPase homolog that could be used for in silico investigations 
comparing citrate-PNPase structural conservation across structurally diverse prokaryotes. 
Additionally, recombinant PNPase protein, from Synechocystis sp (cyanobacteria), was 
commercially available and therefore could be used for in vitro experimental studies, comparing 
citrate-PNPase communication across evolutionarily diverse prokaryotes.  
 
The crystal structure of the archaeal homolog SsoExosome was also solved in the free form (PDB: 
4BA1, Lorentzen & Conti, 2012). Whether citrate can bind to the SsoExosome and regulate 
activity is currently unknown. There is evidence that S. solfataricus possess a TCA cycle, and 
citrate synthase is encoded within the genome, suggesting the presence of citrate within this 
organism (She et al., 2001; Ulas, Riemer, Zaparty, Siebers, & Schomburg, 2012). The SsoExosome 
also has a similar structure and active site to EcPNPase and hPNPase, so it may potentially interact 
with citrate. For these reasons, all three enzymes were utilised for in silico and in vitro 
experimental studies within this thesis, as they represent well characterised models, spanning 
across evolution. 
 
[24] 
In summary, the structures of several PNPases are available, including EcPNPase, hPNPase and 
SsoExosome, which are representatives that span across the three domains of life including 
prokaryotes, eukaryotes and archaea respectively. Furthermore, there is evidence for each of these 
organisms, that citrate synthesis occurs in the same location that these enzymes are found and thus 
it is potentially available for binding/regulation. Whether the citrate-PNPase communication in E. 
coli represents an important regulatory effect, that is conserved across evolution, is an unresolved 
question. Accordingly, the following Section 1.6.3 reviews bioinformatic techniques that have 
previously been used to study PNPase sequence conservation and that can be applied to investigate 
the conservation of citrate-binding residues. 
 
1.6.3 Conservation of Citrate Binding Residues in PNPase Homologs 
Bioinformatics can provide insights into the structure and function of macromolecules such as 
proteins and nucleic acids (Xiong, 2006). The ability to compare individual residues in proteins, 
which may be involved in ligand binding or enzymatic catalysis, across a variety of evolutionarily 
distinct species, is invaluable. For instance, comparing individual amino acid sequences of a 
protein of interest and a previously characterised protein through basic alignments and/or more 
complex bioinformatics can shed light on possible domains, motifs and even functions which are 
conserved. Most multiple sequence alignment (MSA) tools use a hierarchical or tree-based method, 
including the publicly accessible and popular Clustal web server systems (Higgins & Sharp, 1988). 
These types of systems build an MSA using pairwise comparison; starting with the most similar 
sequence pair and progressing to more distantly related sequences. This progressive algorithm can 
be problematic, as errors, in any stage, are propagated during the growing MSA. An alternative 
method, which is less efficient but improves the accuracy of MSA, involves an iterative process of 
pairwise alignments. Iterative MSA reduce the errors inherent in progressive methods, by 
repeatedly realigning the initial sequence, as the MSA grows (Hirosawa, Totoki, Hoshida, & 
Ishikawa, 1995).  
 
Protein sequence alignments, using the techniques described above and structural comparisons 
previously published in the literature, have revealed that hPNPase, EcPNPase and SsoExosome all 
have similar domain architecture and overall structure (Figure 1.11). As mentioned previously in 
Section 1.5.4, PNPases contain five different protein domains; the PH-1 domain (equivalent to 
archaeal Rrp42), the PH-2 domain (equivalent to archaeal Rrp41), a PNPase unique helical domain 
(H), and a KH and S1 RNA binding domain (equivalent to archaeal Rrp4), and this is summarised 
in Figure 1.11 (a). Archaeal exosomes can also have a Csl4-DnaG RNA binding domain; however, 
this contains a S1 and Zn-finger domain that is not equivalent to the PNPase homologs. Moreover, 
structural studies, summarised in Figure 1.11 (b), highlight the similar architecture of PNPases to 
the archaeal exosome; PNPase forms a hexamer ring-like structure from a homotrimer of PH-1/PH-
2 domains, whereas the archaeal exosome forms a similar hexameric structure with a trimer of 
Rrp41/Rrp42 dimers. Additionally, like the KH and S1 RNA binding domains, which form their 
[25] 
own ring on the top face of the PH-domain hexamer in PNPase, a heterotrimer of Rrp4/Csl4-DnaG 
RNA-binding proteins form a flexible ring on one face of the archaeal exosome (not shown) 
(SsoExosome; Lorentzen & Conti, 2005, 2012; Lorentzen et al., 2005; Lorentzen, Dziembowski, 
Lindner, Seraphin, & Conti, 2007; Lu, Ding, & Ke, 2010).  
[26] 
 
Figure 1.11 Structural Conservation of 3'-5’ PNPase Homologs 
(a) PNPase and Archaeal Exosome protein domains are illustrated in the schematic. The RNA Binding Region (RBRI) in PNPase PH-1 domain and its homologous archaeal exosome 
protein Rrp42 are indicated. A helical domain is shown to link the PH-1 and PH-2 domains in PNPase only. A second RNA Binding Region (RBRII), a Phosphate and Metal Ion Binding 
Region (PBR and MBR, respectively) are indicated within the PNPase PH-2 domain and its homologous archaeal exosome protein Rrp41. The KH and S1 domains in PNPase and 
corresponding archaeal exosome protein homolog Rrp4 are also shown. These proteins form a trimeric ring; (b) the solved crystal structures of EcPNPase (3GCM), hPNPase (3U1K) and 
SsoExosome (4BA1) are shown, with individual monomers, in each protein, coloured different shades of blue, red and green respectively. Structural imaged were generated in MOE 
(Molecular Operating Environment, 2013) and prepared using GIMP (v2)(GIMP, n.d.). 
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Although the domain architecture and structural similarity of enzyme homologs are a good early 
indication of a functional similarity, a more detailed sequence alignment is required to evaluate the 
level of sequence conservation. Previous publications, utilising both structural and mutagenesis 
approaches, have helped define the architecture of the PNPase active site. This research has shown 
that the active sites of EcPNPase, hPNPase and SsoExosome are all composed of four sub-sites: 
two RNA Binding Regions (RBRI and RBRII), an inorganic Phosphate Binding Region (PBR) and 
a divalent Metal ion Binding Region (MBR), which are highlighted within Figure 1.11 (a) 
(Portnoy, Palnizky, Yehudai-Resheff, Glaser, & Schuster, 2007). The catalytic centre is located 
entirely within the PH-2 domain and comprises the MBR and PBR. This alignment and the 
information gained from the study conducted by Portnoy and co-workers was valuable, however, in 
order to compare the other PNPase species utilised within this work, another alignment was 
required.   
 
By comparing the conservation of important active site residues, which are known through 
previous mutagenesis and crystallography experiments to interact with key ligands, deductions can 
be made about PNPase homologs for which functional information is limited or not available. In 
theory this may help predict if the characterised citrate interaction in the prokaryote E. coli PNPase, 
and thus its regulatory effects, are conserved in eukaryotes and/or archaeal homologs.  
 
1.6.4 Use of Techniques, Including Molecular Docking, in Ligand-Protein 
Interaction Research  
The previous Section 1.6.3 described how initial protein sequence alignments using bioinformatics 
tools can help provide information about a protein of interest. If structural data are available, even 
more information may be acquired; potentially domains, or even individual residues of a protein 
can be discovered which may be of interest to study further.  
 
As mentioned previously, in terms of PNPase a variety of structures are available, however unlike 
hPNPase and EcPNPase, the SsoExosome was not co-crystallised with citrate bound. In order to 
see if citrate does interact with this enzyme, sophisticated molecular characterisation techniques 
such as X-ray crystallography or NMR spectroscopy could be used. In terms of NMR, the 
SsoExosome is above the typical molecular weight limits of solving its overall 3D structure, 
although ligand binding may be examined through observing chemical shift perturbations in the 
presence of citrate. To examine citrate binding to SsoExosome, X-ray crystallography can also be 
conducted. If citrate is present in the crystallisation buffer or soaked in after SsoExosome crystals 
have formed, the resulting crystals may produce more information about where citrate binds and 
what residues are involved. 
 
Alternatively, if a structure is already solved, an alternative approach can be used to predict ligand 
binding in silico. This is much easier to conduct compared to crystallography, as getting crystals 
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can sometimes be difficult. For example, if a structure is already solved, in silico ligand binding 
can be predicted using molecular docking calculations relatively quickly. Alternatively, if the 
structure is not available and only the protein sequence is known, a model can be predicted based 
on a homologous protein using molecular modelling tools.  
 
Once a structure is solved experimentally by one of the various sophisticated techniques mentioned 
above i.e. NMR or X-ray crystallography, the information is deposited within the RCSB protein 
data bank (PDB), which is a repository of atomic coordinates and other information describing 
proteins and other important biological macromolecules (Berman et al., 2000). Important, detailed 
information about the location of every atom in a molecule relative to one another is recorded in a 
text file and is accessible for further use. More specifically, pdb.txt files contain a list, including the 
type of atom (ATOM standard residues: amino acid/nucleic acid and HETATM nonstandard 
residues: water, inhibitors, cofactors, ions, and solvent respectively), the atom’s serial number and 
its name (i.e. carbon (C), nitrogen (N)). Details of the residue type, chain identifier, residue 
number, and X, Y, Z orthogonal Å coordinates are also provided, along with structural features 
such as the presence of α-helices, β-sheets and disulphide bond linkages. Collectively, molecular 
visualisation programs (e.g. PyMOL) use all this information to generate 3D structures from input 
data and create images like those shown in Figure 1.11 (b). This process is incredibly valuable; 
picturing 3D structural information may not only provide insight into how a molecule such as a 
protein may function, just by its overall shape and size, but comparison to other similar structures 
previously determined, may also shed light on its role. For example, comparison of the full-length 
H. sapiens and C. crescentus PNPase structures with the core E. coli PNPase structure (KH 
truncation), suggested that the RNA-binding KH domain in PNPase regulates the size of the central 
pore channel. This work also proposed that a more constructed central pore is more efficient for 
RNA binding and cleavage; highlighting the use of comparative studies for revealing potential 
mechanisms of enzyme activity. In addition, the appearance of well-defined, ligand accessible 
pockets within a protein can suggest a possible means of functional regulation, especially if 
ligands/inhibitors are known. 
 
Molecular modelling and docking programs, for example the Molecular Operating Environment 
(MOE) program, can utilise PDB.txt file information to generate the same 3D structures seen in 
visualisation programs such as PyMOL (Molecular Operating Environment, 2013). However, they 
possess the added prospect of creating in silico 3D models from protein sequences (with an 
unknown structure) using the solved structure as a template. These sophisticated programs (e.g. 
MOE) can also dock individual molecules or databases containing large libraries of molecules into 
the structure, using a number docking algorithms. These small molecule databases are easily 
accessible for virtual screening from public resources such as the Zinc database (Sterling & Irwin, 
2015) and commercial websites such as Sigma-Aldrich. Utilisation of these kinds of databases 
allows a variety of commercially available ligands to be docked into the pockets of a receptor 
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protein. It is the docking algorithms which then allow docking of these ligands to be conducted, 
and they use various ligand orientations, to predict if there is a ligand conformation which 
favourably binds to the target site. Strengths of association (binding affinities) between a ligand 
and a receptor can be predicted using scoring functions, which suggest if the interaction will likely 
form a stable complex. There are a variety of different programs and algorithms available to 
conduct in-silico structural molecular modelling and docking and MOE is an example of a well-
accepted program with a broad range of features and free online resources (Molecular Operating 
Environment, 2013). Other researchers have used MOE for molecular docking to study enzyme-
metabolite interactions in evolutionarily distinct organisms; specifically to investigate the 
interactions of endocrine active substances (EASs) and their metabolites towards the ligand binding 
domain (LBD) of the androgen receptor (AR) in three distantly related vertebrate species (Galli et 
al., 2014). In summary, MOE is an accepted approach to study the conservation of protein-ligand 
interactions, which is applicable to the studies investigating citrate-binding studies in evolutionarily 
distinct organisms.  
 
1.6.5 Exploring PNPase Activity  
The 3’-5’ degradation activity of PNPase has been well established and the methods of these assays 
can be applied to study metabolite-RNase interactions. For example, the inhibition of the TCA 
metabolite citrate on canonical PNPase degradation activity in E. coli has been documented 
(Nurmohamed et al., 2011). Although the effect of other TCA metabolites hasn’t been examined, 
the energy containing molecules ATP and GTP, have been shown to inhibit PNPase (Del Favero et 
al., 2008). Also this inhibition appears to be specific to purine nucleoside triphosphates; the 
pyrimidine nucleotides CTP and UTP did not exert any appreciable effect (Del Favero et al., 2008).  
 
Despite the high structural conservation of PNPase (Section 1.6.3), other studies have published 
results which suggest differences exist between homologs from different organisms. For example, 
nucleoside diphosphates (a mixture of 20 µM ADP, CDP, GDP and UDP) were observed to effect 
the activity of Streptomyces coelicolor PNPase but not EcPNPase (Chang, Cozad, Mackie, & 
Jones, 2008), and alarmones have been suggested to regulate PNPases in some prokaryotic species 
but not others (Gatewood & Jones, 2010). The study by Chang and colleagues also reported 
differences in RNA substrate preference; PNPase from E. coli was 2-fold more effective at 
degrading the single stranded 3’ tail of a substrate derived from the rpsO-pnp operon of S. 
coelicolor than PNPase from either S. coelicolor or S. antibioticus. Although the S. coelicolor 
PNPase was more effective than EcPNPase in degrading a substrate with a 3’ stem-loop structure 
(Chang et al., 2008). Other factors which regulate PNPase activity have also been described to vary 
over evolution. For example, EcPNPase displays optimal activity at phosphate concentrations 
exceeding 10 mM, whereas the optimal activity of hPNPase was found at 0.1 mM, and is inhibited 
at higher concentrations (Portnoy et al., 2007). It is thought that the localisation of these two 
enzymes may play a role in their different preferences for inorganic phosphate; EcPNPase may 
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have evolved to function in the presence of high concentrations of phosphate (10-20 mM) in 
bacteria and organelle matrices, and although the concentration of phosphate in the IMS in human 
cells is unknown, hPNPase may have acquired a low phosphate preference for its function within 
this location (Portnoy et al., 2007).  
 
1.6.6 TCA Metabolites Affecting PNPase  
The information provided so far within this Section 1.6 has mainly focused on the various factors 
effecting PNPase activity and whether the citrate-PNPase interaction observed in E. coli is 
conserved. The following section now focuses on the TCA cycle and whether other TCA 
metabolites, similar to citrate, may also regulate RNA turnover.  
 
1.6.6.1 The TCA Cycle  
Citrate was established by Hans Krebs to be an intermediate of the aerobic process which yields the 
energy required for living organisms (reviewed in Kornberg, 2000). Named after its discoverer, the 
Krebs Cycle, also commonly referred to as the citric acid or TCA cycle contains a number of 
metabolite intermediates, as shown in Figure 1.12.  
 
The TCA cycle is the second of three stages which utilise organic fuel molecules in a series of 
chemical reactions leading to the overall generation of energy. More specifically, in aerobic 
organisms, carbohydrates, proteins and fats can be oxidised to yield CO2 and H2O via glycolysis, 
followed by the TCA cycle and finally the respiratory chain (also termed the electron transport 
chain). In summary, pyruvate derived from glucose and other sugars by glycolysis, is initially 
converted to acetyl-CoA in an irreversible oxidation process, where the carboxyl group is removed 
as CO2 and the acetyl group moiety is linked to CoA (Figure 1.12). This two carbon acetyl group 
can now be fed into the TCA cycle and is donated from acetyl-CoA to the four carbon compound 
oxaloacetate, to form the six carbon citrate molecule (Figure 1.12). The multiple chemical 
reactions, within each turn of the cycle, utilise one acetyl group and generate two molecules of 
CO2. Furthermore, the energy released is conserved in nucleoside triphosphate (ATP or GTP) and 
in the reduced electron carriers NADH (3x) and FADH2 (1x), which are subsequently oxidised, 
giving up protons (H+) and electrons that are used in the respiratory chain to generate ATP. Not 
only does this process result in the overall generation of energy required for the cell, some 
intermediates of the process are utilised as precursors for a wide variety of products (as reviewed in 
Lehninger, Nelson, & Cox, 2000).  
 
[31] 
 
Figure 1.12 TCA Cycle 
The main stages of the TCA cycle. The multiple chemical reactions, within each turn of the cycle, utilise one 
acetyl group and generate two molecules of CO2. The energy released is conserved in nucleoside 
triphosphates (ATP or GTP), NADH (3x) and FADH2 (1x), which are subsequently used in the respiratory 
chain to generate more ATP and thus energy. 2D representations of metabolites were generated in MOE 
(Molecular Operating Environment, 2013) and the figure was prepared in GIMP (v2)(GIMP, n.d.). 
 
1.6.6.2 Evolution of The TCA Cycle 
The discovery of the TCA cycle explained how microorganisms could oxidise acetate to CO2 and 
H2O, but failed to explain how these organisms also survived on acetate as a sole carbon source 
(Kornberg, 2000). This was until a bypass step was discovered in which acetyl-CoA reacted with 
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another TCA metabolite, isocitrate, to generate two further TCA metabolites, malate and succinate. 
The sequence was thus: 1) isocitrate → succinate + glyoxylate and then 2) glyoxylate + acetyl-CoA 
→ malate + CoA. Effectively this ‘glyoxylate bypass/shunt’ reaction meant carbon was not lost as 
CO2  and the two cycles could be combined and termed the ‘glyoxylate cycle’ (Kornberg, 2000).  
 
The evolution of the ‘complete’ TCA cycle was studied in detail by Huynen, Dandekar, & Bork in 
1999. In this study, Huynen and colleagues utilised the availability of completely sequenced 
genomes and compared the presence of genes, encoding the enzymes that catalyse the series of 
TCA reactions, over evolutionarily distinct organisms. The genomes of four archaea, fourteen 
bacteria and one eukaryote were examined and variations such as the reductive and branched TCA 
cycle, the glyoxylate shunt and the pathways connecting the TCA cycle to pyruvate and 
phosphoenolpyruvate were examined. A graphical display of the reaction steps provided within this 
publication, is shown in Figure 1.13. It is obvious that the reactions of the TCA cycle in each 
species are diverse and have evolved with varying degrees of ‘completeness’ (Figure 1.13). For 
example, only the four largest genomes, including E. coli, Bacillus subtilis, Mycobacterium 
tuberculosis and S. cerevisiae and the smaller genome from Rickettsia prowazekii contain a 
complete TCA cycle, while others contain gaps or the TCA cycle is completely absent. Within the 
genomes lacking a complete cycle, there seems to be more conservation between steps 6-8 (Figure 
1.13); from succinate to oxaloacetate (oxidative cycle) and less conservation in steps 1-3, from 
acetyl-CoA to 2-ketoglutarate (Figure 1.13). The research noted that although incomplete, the 
metabolites usually generated in the reactions which are missing, are instead produced in other 
ways. This means that metabolites such as 2-ketoglutarate, oxaloacetate and succinyl-CoA, which 
are starting points for other pathways including the synthesis of glutamate, aspartate and porphyrin 
respectively, are still produced from pyruvate. They observed that autotrophic bacteria generated 
these metabolites via the right branch of the TCA (oxidative direction, clockwise Figure 1.13(a)), 
whereas the methanogenic archaea and Archaeoglobus fulgidus generate them via the left branch 
(reductive direction, anti-clockwise Figure 1.13(a)). 
 
The variations of the TCA cycle presented within Figure 1.13 provide an indication of its 
evolutionary origins (Huynen, Dandekar, & Bork in 1999). It is thought that the TCA cycle 
originally evolved as two separate pathways, stemming from pyruvate to either 2-ketoglutarate as 
an oxidative branch, or succinyl-CoA in a reductive branch. Huynen and colleagues also comment 
that alternative potential intermediate stages, are present in other pathways. Particularly two 
archaeal species Methanococcus jannaschii and Methanobacterium thermoautotrophicum have 
homologs of isocitrate dehydrogenase and aconitase in the leucine biosynthesis pathway. They 
noted that the methanogenic lifestyle of these organisms is presumably very old; as reflected by its 
presence throughout the euryarchaeal phylogeny. The only archaeal isocitrate dehydrogenase found 
in A. fulgidus probably arose through horizontal gene transfer from the bacteria. In the bacteria the 
[33] 
TCA cycle is reported to have been complete by the time of the proteobacteria emergence, and the 
incomplete TCA in pathogens is likely due to a secondary loss of genes. 
 
Since the publication by Huynen and colleagues, more evidence has suggested our understanding 
of TCA cycles, in individual species, still remains to be improved. Previously it was generally 
accepted that cyanobacteria, including Synechocystis sp. PCC 6803 had an incomplete TCA cycle, 
however the discovery of novel genes has changed this view (Zhang & Bryant, 2011). 
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Figure 1.13 TCA Cycle Evolution 
(a) TCA cycle reactions. When there are two enzymes that are not homologous but catalyse the same reaction 
(non-homologous gene displacement), one is marked with a solid line and the other with a dashed line. The 
oxidative direction is clockwise. The enzymes with their EC numbers are as follows: 1, citrate synthase 
(4.1.3.7); 2, aconitase (4.2.1.3); 3, isocitrate dehydrogenase (1.1.1.42); 4, 2-ketoglutarate dehydrogenase 
(solid line; 1.2.4.2 and 2.3.1.61) and 2-ketoglutarate ferredoxin oxidoreductase (dashed line; 1.2.7.3); 5, 
succinyl-CoA synthetase (solid line; 6.2.1.5) or succinyl-CoA–acetoacetate-CoA transferase (dashed line; 
2.8.3.5); 6, succinate dehydrogenase or fumarate reductase (1.3.99.1); 7, fumarase (4.2.1.2) class I (dashed 
line) and class II (solid line); 8, bacterial-type malate dehydrogenase (solid line) or archaeal-type malate 
dehydrogenase (dashed line) 3 (1.1.1.37); 9, isocitrate lyase (4.1.3.1); 10, malate synthase (4.1.3.2); 11, 
phosphoenolpyruvate carboxykinase (4.1.1.49) or phosphoenolpyruvate carboxylase (4.1.1.32); 12, malic 
enzyme (1.1.1.40 or 1.1.1.38); 13, pyruvate carboxylase or oxaloacetate decarboxylase (6.4.1.1); 14, pyruvate 
dehydrogenase (solid line; 1.2.4.1 and 2.3.1.12) and pyruvate ferredoxin oxidoreductase (dashed line; 
1.2.7.1). (b) TCA cycles of individual species, together with the phylogeny of the species. The major 
kingdoms of life are indicated in red (Archaea), blue (Bacteria) and yellow (Eukarya). Question marks 
represent reactions for which there is biochemical evidence in the species itself or in a related species but for 
which no genes could be found. Genes that lie in a single operon are shown in the same colour (black, red or 
green). Figure and legend taken directly from (Huynen et al., 1999). 
 
As reviewed in Lehninger et al., 2000, the location of the TCA cycle varies over evolution; in 
prokaryotes the TCA cycle occurs in the cytosol, with the proton gradient for ATP production 
(electron transport pathway) occurring across the plasma membrane. Contrastingly, in eukaryotes, 
[35] 
the TCA cycle is present in the matrix of the mitochondria and ATP production occurs in the inner 
membrane.  
 
In summary, although over evolution the exact location, the diversity of reaction steps and the 
completeness of the TCA cycle is varied, there seems to be a tendency, for a wide range of 
organisms, to converge to this method of energy production (Huynen et al., 1999). Thus, the 
mechanisms regulating the TCA cycle and in turn, the downstream processes affected by this 
metabolic pathway, are clearly important to understand. The exact enzymes involved in the TCA 
cycle, and thus the pool of metabolites available to an organism, appear to vary between different 
species (Figure 1.13 (b)). Whether RNases can sense the pool of available metabolites and 
coordinate their activity accordingly, remains to be discovered. The TCA cycle in E. coli and H. 
sapiens is well characterised and they are examples of excellent prokaryote and eukaryote model 
systems with a full TCA cycle. However, the completeness of the TCA cycle in archaea is less 
understood and so the effects of TCA metabolites on PNPase was the main focus of this work.  
 
1.6.7 Regulating RNA Turnover in Response to Cellular Metabolism 
Summary 
In summary, the information provided within this Section 1.6 highlights the recurrent evolution of 
physical associations between the enzymes of RNA degradation and central metabolism and 
suggests a possible conserved metabolite-RNase communicative link. The impact of a 
communicative link between RNases and central metabolism is now discussed in Section 1.7, so 
that the importance of studying these interactions in more detail can be identified.  
 
1.7 Thesis Focus: Exploring the Impact of a Metabolite-
PNPase Conserved Link 
The proposed work will not only provide new information and scientific advancement in the field 
of post-transcriptional gene regulation research, its potential impact could also be to improve the 
development of biotechnology applications.  
 
In terms of advancing our understanding of RNase regulation, if a conserved metabolite-RNase 
communication link truly exists it would add key information to the post-transcriptional gene 
regulation network shown in Figure 1.14. If a cell were able to sense the pool of metabolites 
available and control gene expression accordingly, it would add another tier, and feedback loop, to 
the hierarchal process which regulates the flow of cellular information. It would also provide the 
basis for further research; although this study aims to determine if a conserved communication link 
exists in vitro, undeniably the field would also benefit from a more detailed in vivo 
characterisation. 
 
[36] 
 
Figure 1.14 Cellular Information Flow: Metabolite-RNase Communication  
The flow of cellular information. Whether central metabolism can control RNases (blue arrow/question 
mark) remains to be discovered. Image adapted from Prof. Anastasia Callaghan.  
 
The general field of systems biology may also be impacted; with important in silico validation and 
data generated, computational modelling specialists in universities and research institutes, may be 
able to use the methods of metabolite docking into PNPase homologs for similar studies. 
Potentially revealing inhibitory ligands, that were not testing within this work, and could 
subsequently be tested experimentally. If metabolite-PNPase and metabolite-archaeal exosome 
communicative links are conserved, it may infer an ancient and important communication 
mechanism. In which case, other RNases could be investigated; possibly including elements of the 
bacterial degradosome.  
 
A greater understanding of the factors effecting metabolic changes within a cell, potentially can be 
utilised with both therapeutic and industrial benefits in mind. A wide variety of industries thrive on 
exploiting cellular systems to produce products, including drugs, biofuels and food. Understanding 
these cellular systems not only allows improvements of current processes but also the development 
of novel technologies. For example, by targeting and artificially manipulating the metabolome of 
host systems in the process of manufacturing drugs, the amount of starting culture materials may be 
reduced and as a result of increased product yields, profits may be increased. Furthermore, a deeper 
understanding of global regulatory mechanisms controlling gene expression may also provide 
invaluable insight into how disease states arise. For example, the role of PNPase in cancer, chronic 
inflammatory responses and coronary disease (Wilusz et al., 2001) may be revealed. This could 
help towards the development of medical countermeasures against the plethora of disease states 
associated with faulty gene expression and metabolism. 
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With wide-spread impact on scientific understanding, biotechnology engineering and advancement 
of medical therapeutics, the role of metabolites in ribonuclease activity regulation was the subject 
of this thesis; the aims of which are provided in the subsequent Section 1.7.1. 
 
1.7.1 Thesis Aims 
Regulation of post-transcriptional gene expression is essential for maintaining cellular homeostasis 
and co-ordinating the process of RNA turnover is a number of ribonucleases, including 
polynucleotide phosphorylase (PNPase). Following the observation that the TCA cycle metabolite 
citrate was observed to modulate the activity of E. coli PNPase in vitro and in vivo, Nurmohamed 
and colleagues proposed that a feedback mechanism may exist between central metabolism and 
RNA turnover. This is further substantiated by the studies reviewed in this chapter, that identify 
nucleotides (ATP and GTP), a secondary signalling molecule (c-di-GMP) and a stringent response 
alarmone signalling molecules (ppGpp) interacting with proteins involved in post-transcriptional 
gene regulation (Del Favero et al., 2008; Gatewood & Jones, 2010; Tuckerman, Gonzalez, & 
Gilles-Gonzalez, 2011). Therefore, the primary purpose of this study is to both explore the 
conservation of citrate-PNPase interactions across evolution and to examine whether other 
metabolites may also play a role in affecting RNA turnover. This study will provide evidence that 
citrate regulation may be conserved in all three domains of life, across prokaryotes, eukaryotes and 
archaea. Furthermore, by primarily focusing on metabolites of central metabolism and looking at 
the key functional groups/features that may be important in PNPase regulation; this study will also 
propose that a metabolite-PNPase interaction may be particularly maintained in complex 
multicellular organisms such as H. sapiens. 
 
Details of all the materials and methods required for this study, including the reagents and general 
biochemical/microbiology techniques utilised for preparing and analysing the synthesis of various 
biological samples, will be provided in Chapter 2. Initially, this study involves cloning, expression 
and purification of recombinant PNPase homolog representatives across the three domains of life, 
including the prokaryotic E. coli PNPase, eukaryotic H. sapiens PNPase and an archaeal S. 
solfataricus exosome. This work is described in detail in Chapter 3, along with assessment of 
protein purity and identification of canonical 3’-5’ exoribonuclease activity in vitro, using gel-
based electrophoresis techniques. In Chapter 4, in silico protein sequence alignments and molecular 
docking calculations will be utilised to investigate the conservation of citrate-binding residues 
across evolutionarily distinct PNPase homologs. The effect of citrate on 3’-5’ RNase activity, is 
then examined using in vitro gel-based assays. By combining evidence from in silico and in vitro 
techniques, this work will propose that the attenuation of PNPase activity by citrate is widespread 
across evolution. To investigate the effects of metabolites on PNPase activity, a similar approach of 
combining molecular docking predictions of metabolite-binding with gel-based assays, is applied in 
the subsequent Chapter 5. The given evidence suggests that other metabolites may also play a role 
in affecting RNA turnover. A potential method for improving the kinetic analysis of RNA 
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degradation activity, mediated by PNPase homologs, is explored in Chapter 6. The application of a 
commercially available high-throughput plate reader assay, for determining 3’-5’ RNase activity in 
real-time, is examined so that important kinetic activity parameters can be rapidly and accurately 
calculated. Finally, the data presented within this study will be summarised in Chapter 7 and the 
impact of the proposed communicative link, between metabolites and PNPase homologs, is 
discussed. 
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2 Materials and Methods 
 
2.1 Chapter Aims 
This chapter provides details of the preparation of materials and experimental methods used as 
standard, unless otherwise specified, throughout this thesis. Within the following chapter sub-
sections, in addition to the detailed methods, a basic description of the rationale/theory behind each 
technique is provided if appropriate; for example, if a method/technique is extensively used in 
subsequent chapters.  
 
2.2 Chemical and Biochemical Reagents 
All chemicals and biochemical reagents were provided by Fisher Scientific, except where stated 
otherwise. 
 
2.3 Buffer and Media Recipes 
Solutions, buffers and growth media were prepared with 18.2 Ω deionised water (dH2O) (Purite) 
and filter sterilised using a 0.22 µm filter (Millipore). Non heat-sensitive components were 
autoclaved at 120°C, 15 pound-force per square inch (psi) for 20 minutes, if they were required for 
bacterial growth or for techniques requiring sterile conditions.  
 
2.4 Marker Proteins and Nucleic Acids 
BenchMark™ and Pre-Stained SeeBlue® (Standard and Plus2) protein molecular weight markers 
were supplied by Life Technologies. 100 base pair (bp) DNA ladder, low molecular weight (LMW) 
DNA ladder and Low Range ssRNA Ladder were supplied by New England BioLabs (NEB 
N3231S, N3233S and N0364S respectively). Details of all ladders for gel electrophoresis are 
provided in Appendix 9.2. 
 
2.5 Antibiotics 
Antibiotics were prepared as concentrated stocks (1000 x) and were dissolved in either dH2O or 
100% EtOH, filter sterilised using a 0.22 µm filter and stored at -20°C in 1 ml aliquots, see Table 
2.1 for details. 
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Table 2.1 Antibiotic Preparation 
Antibiotics are listed with the stock concentrations (mg/ml) and dilution factors required to obtain the final 
working concentrations (µg/µl). The solvent in which they were diluted is also provided. 
 
2.6 Antibodies 
Poly-histidine tagged recombinant proteins were probed with either a primary antibody (1° 
antibody): His6-probe polyclonal IgG (G-18) Sc-804 produced in rabbit (Santa Cruz 
Biotechnologies), followed by a secondary antibody (2° antibody): anti-rabbit IgG (whole 
molecule) peroxidase conjugate, produced in goat (Sigma A0545), or directly with a single His6-
probe polyclonal IgG horseradish peroxidase (HRP) conjugate, produced in rabbit (Abcam 
AB1187). Human PNPase was probed with a 1° antibody PNPase polyclonal IgG, produced in 
rabbit (GeneTex, Source Bioscience GTX116542S), and the same anti-rabbit-peroxidase 2° 
antibody mentioned previously (Sigma A0545). 
 
2.7 Nucleic Acids: Deoxyribonucleic acid (DNA) 
DNA stocks were prepared by the variety of methods listed below.  
 
2.7.1 Provided Plasmid DNA 
E. coli PNPase, cloned into an ampicillin resistant pET-Duet-1 vector, was kindly supplied by Prof. 
Ben Luisi (University of Cambridge). The provided plasmid DNA was transformed into bacterial 
cell strains for downstream purification, and subsequent sequencing, as described in Sections 2.9.5, 
2.9.6 and 2.7.4 respectively. 
 
2.7.2 Chemical Synthesis: DNA 
DNA Primers for DNA sequencing were independently designed if Source Bioscience stock 
primers were not available. Using the guidelines provided by Source Bioscience, primers were 
designed to be 18-23 nucleotides (nt) long and bind specifically to the sequence ~ 50 nts upstream 
of region of interest (“Source BioScience,” n.d.). Primers were designed to have no self-
complementarity, a Guanosine/Cytosine (GC) content of ~40-60% (with 2/3 G/Cs at the start of the 
designed primer sequence) and an annealing temperature (TM) of 55-60°C. Mutagenic 
oligonucleotide primers were individually designed for site-directed mutagenesis (SDM) as 
recommended by the QuikChange® XL SDM kit manual (Agilent Technologies, n.d.). All 
oligonucleotides were synthesised by Invitrogen and were diluted with double deionised water 
(ddH2O) to 1 mM and stored at -20°C. Primer sequences are listed in Appendix 9.3.  
Antibiotic
Stock 
Concentration 
(mg/ml)
Solvent
Dilution 
Factor 
Required
Final Working 
Concentration 
(μg/μl)
Chloramphenicol 34 100 % EtOH 1/1000 34
Kanamycin 25 Water 1/1000 25
Ampicillin 100 Water 1/1000 100
Tetracyclin 10 Water 1/1000 10
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2.7.3 DNA Integrity and Concentration 
DNA integrity and size were analysed by agarose gel electrophoresis, as described in Section 
2.10.1 and DNA concentration was determined from the absorbance A260 nm measured using the 
NanoDrop 2000c Spectrophotometer (Thermo Scientific) and the Beer-Lambert equation below. 
 
 
Equation 2.1 Beer-Lambert Law 
The equation describes Absorbance (A) as a function of the concentration (C, ng/μl), path length (l, cm) and 
molar extinction coefficient at 260nm (ε260, ng-cm/μl). The generally accepted extinction coefficients, at a 
wavelength of 260 nm, for double-stranded DNA and single-stranded DNA is 50 and 33 ng-cm/μl respectively. 
When using a NanoDrop 2000c Spectrophotometer (Thermo Scientific), with a path length of 1 cm and when 
A=1, the concentration for double-stranded DNA is 50 ng/μl and single stranded DNA is 33 ng/μl (Thermo 
Scientific, 2009). 
 
2.7.4 DNA Sequencing 
Sanger sequencing (Sanger, Nicklen, & Coulson, 1977) of plasmid DNA constructs was outsourced 
to either Life Technologies (provided with GeneArt synthesis service) or Source Bioscience. DNA 
sequences were then visualised and analysed using FinchTVTM sequencing chromatogram trace 
viewer V1.4, provided by Geospiza® (Geospiza, n.d.).  
 
2.7.5 Site Directed Mutagenesis (SDM) 
In vitro SDM was used to modify plasmid DNA to allow site specific mutation of the nucleotide 
sequence (Hutchison et al., 1978). These mutations consequently change the translated amino acid 
sequence, thus either correcting sequence errors identified through sequencing (Section 2.7.4) or 
introducing point mutations for protein structural and or/ functional analysis. A summary of the 
SDM steps recommended within the QuikChange XL SDM Kit Instruction Manual (Agilent 
Technologies, n.d.) is provided in Figure 2.1 
 
 
 
A=ε260 Cl 
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Figure 2.1 Overview of Site-Directed Mutagenesis (SDM)  
(a) Double stranded DNA plasmid (green and yellow circles), selected for SDM, was denatured and (b) the 
mutagenic primers (pink and blue arrows) with the desired mutation (x) annealed. (c) Primers were extended 
with PfuUltra high fidelity (HF) DNA polymerase, generating a new DNA plasmid (pink and blue circles) 
with the desired mutation (x) within the sequence. (d) The DNA was further amplified by multiple rounds of 
PCR. (e) The parental methylated and hemimethylated DNA was digested with DpnI restriction endonuclease 
enzyme (green and yellow dotted circle) leaving only the intact mutated plasmid, which was transformed into 
competent E. coli cells for nick repair. Image modified from the QuikChange XL SDM Kit Instruction 
Manual (Agilent Technologies, n.d.). 
 
Oligonucleotide primers were individually designed for SDM as described within the guidelines of 
the QuikChange XL SDM kit (Agilent) instruction manual (Agilent Technologies, n.d.). In brief, 
primers were designed to be between 25-45 bases in length, with the mutated nucleotide (s) located 
in the middle; with at least 10-15 bases on each side. Both primers were designed to anneal to the 
same sequence, but on opposite strands of the parental double-stranded DNA vector, with a Tm ≥ 
78°C. Primers also had one or more terminal G/Cs with an overall GC content of 40%. Designed 
oligonucleotide primers were synthesized by Invitrogen™ and were diluted with nuclease-free 
H2O, to a concentration of 50 ng/μl, prior to storage at -20°C. The primer sequences used for SDM 
are listed in the Appendix 9.3.  Mutagenesis reactions were set up, on ice, in 0.5 ml thin-walled 
PCR tubes as described below in Table 2.2. Reagent concentrations and volumes were used as 
recommended in the QuikChange SDM kit protocol and a pWhitescript mutagenesis control was 
used at all times. 
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Table 2.2 In vitro SDM Reaction Preparation 
SDM reagents are listed with the volumes, stock concentrations and the final concentrations for both the (a) 
control and (b) SDM PCR reactions. The deoxynucleotide mix (dNTP), specific primers and proprietary 
SDM kit reagents were added to double stranded (ds) DNA/control plasmid, as recommended in the 
QuikChange XL SDM Kit Instruction Manual (Agilent Technologies, n.d.).  
 
To 50 µl SDM reactions, 1 µl PfuUltra high fidelity (HF) DNA polymerase (2.5 U/µl) was added 
for strand synthesis and the cycling parameters, outlined in Table 2.3, were used for DNA 
amplification in a GeneAmp® PCR System 9700 thermal cycler (Applied Biosystems). Following 
temperature cycling, the reaction tubes were placed on ice for 2 minutes to cool.  SDM DNA 
amplification was confirmed by agarose gel electrophoresis; 10 µl of the SDM product was run on 
a 1% agarose gel as described in Section 2.10.1. As recommended in the manual, even if DNA 
amplification could not be confirmed by gel, the DpnI endonuclease restriction digestion of the 
parental template was still conducted. 
 
 
Reagents
Stock 
Concentration
Volume 
(µl)
Final 
Concentration
Reaction Buffer 10 x 5 1x
pWhitescript 4.5-kb Control 
Plasmid 
5 ng/µl 2 10 ng
Control Primer #1 (34-mer) 100 ng/µl 1.25 125 ng
Control Primer #2 (34-mer) 100 ng/µl 1.25 125 ng
dNTP Mix 1
QuikSolution Reagent 3
ddH2O 36.5
Total 50
Reagents
Stock 
Concentration
Volume 
(µl)
Final 
Concentration
Reaction Buffer 10 x 5 1x
ds DNA Template x ng/µl x 10 ng
Primer #1 x ng/µl x 125 ng
Primer #2 x ng/µl x 125 ng
dNTP mix 1
QuikSolution Reagent 3
ddH2O x
Total 50
(a)
(b)
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Table 2.3 QuikChange ® II XL SDM Cycling Parameters 
The target size of each plasmid DNA was considered (1 minute/ kb of plasmid length) when deciding SDM 
cycling parameters. The other cycling conditions were used, as recommended in the QuikChange XL SDM 
kit instruction manual (Agilent Technologies, n.d.). 
 
To each 51 µl SDM reaction, 1 µl of Dpn I restriction enzyme (10 U/µl) was added and thoroughly 
mixed by gentle pipetting. Reactions were centrifuged briefly for 1 minute in a Thermo Scientific 
Heraeus Fresco 17 benchtop centrifuge, prior to incubating at 37°C for 1 hour in order to digest the 
template DNA (target sequence 5’-Gm6ATC-3’). Post-Dpn I treatment, 2 µl of undigested vector, 
containing the desired mutation, for both the sample and control reactions, were then transformed 
into chemically competent E. coli DH5α cells, alongside a pUC18 transformation control (Section 
2.9.5). Following transformation, appropriate volumes of transformed cells were plated on selective 
LB agar plates as described later in Section 2.9.5; (Table 2.5) and for blue-white colony screening, 
the SDM control reaction was plated on X-Gal/IPTG plates (Section 2.9.1.1). All plates were then 
incubated at 37°C for >16 hrs and mutagenic efficiency was calculated from the number of 
colonies with β-galactosidase activity, as indicated by the presence of a blue colour upon screening. 
After plasmid replication and purification, as described in Section 2.9.6 respectively, all 
recombinant plasmid DNA constructs were sequenced following SDM to confirm the correct 
mutation(s) (Section 2.7.4). 
 
2.8 Nucleic Acids: Ribonucleic acid (RNA) 
RNA stocks were prepared by the variety of methods listed below.  
 
2.8.1 Chemical Synthesis: RNA 
All chemically synthesised, single stranded, RNA molecules were provided by GE healthcare 
(Dharmacon); including the 5’ Fluorescein (Figure 2.2) labelled Poly(A)20 RNA (5’F Poly(A)20mer) 
and unlabelled RNA (Poly(A)20mer), which were utilised in determining RNase 3’-5’ degradation 
activity.  
 
Segment Cycles Temperature (°C) Time
1 1 95 1 minute
95 50 seconds
60 50 seconds
68
1 minute/kb of 
plasmid length
3 1 68 7 minutes
2 18
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Figure 2.2 Fluorescein Structure 
RNA substrates were chemically modified with the addition of a 5’ fluorescein (F) label for detection after 
gel electrophoresis. Fluorescein (MW: 538.47) has an excitation/emission maximum of 494 nm and 525 nm 
respectively and so the Fujifilm FLA-5000 phosphorimager (blue laser/filter) was utilised for visualisation 
(Dharmacon.gelifesciences, n.d.). 
 
2.8.2 RNA Integrity Concentration 
RNA integrity, purity and size was analysed by polyacrylamide gel electrophoresis, as described 
later in Section 2.10.2.2 and RNA concentration was determined from the absorbance A260nm 
measured using the NanoDrop 2000c Spectrophotometer (Thermo Scientific). Absorbance 
measurements were conducted in triplicate and averaged to ensure reproducibility.  
 
2.9 Prokaryote Cell Strains 
The general microbiological techniques used to maintain prokaryotic cell strain stocks are provided 
below. The process of preparing these strains for transformation with recombinant plasmid DNA 
and subsequent DNA replication/purification is also described.  
 
2.9.1 General Microbiological Techniques 
Any media required for bacterial growth was autoclaved at 120°C, 15 psi for 20 minutes as 
standard. Where selective Lysogeny Broth (LB) agar and or liquid media were used for cell strain 
and/or plasmid selection, appropriate antibiotics were added. For antibiotic preparation and 
selection see Section 2.5 and Table 2.4 respectively. 
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Table 2.4 Antibiotic Selection  
Various E. coli cell strains and plasmid DNA types are listed with their respective antibiotic resistances, the 
final working antibiotic concentrations (µg/µl) are also provided. 
 
2.9.1.1  Lysogeny Broth (LB) Agar & Plate Preparation  
In order to make one LB agar plate, typically between 30-40 ml of LB agar (LB Agar, Miller 
components per 1 L: 10 g Tryptone, 5 g Yeast extract, 10 g NaCl2 and 15 g Agar, pH 7 at 25°C) 
was used. The LB agar was prepared as per the manufacturer’s instructions (40 g to be dissolved in 
1 L of dH2O), the volume was adjusted as required and autoclaved as standard. Autoclaved 
selective LB agar was poured into petri dishes using aseptic technique. Agar plates were left to set 
at room temperature (RT) and were subsequently dried upside-down at 65°C for approximately 1 
hour. If plates were not used immediately they were stored at 4°C and then re-dried, as described 
above, prior to use. Additionally, if blue-white colony screening was required, 100 µl of 10 mM 
IPTG (prepared in sterile dH2O and filtered) followed by 100 µl of 2% X-Gal (prepared in 
dimethylformamide (DMF)) was spread on the LB agar. These were added 30 minutes prior to use, 
ensuring they did not mix to avoid precipitation. Depending on the cell culture plated onto the LB 
agar, the appropriate volumes of bacterial cells require to generate individual colonies varied; 
examples of which are listed in Table 2.5. 
 
2.9.1.2 Lysogeny Broth (LB) Liquid Media Preparation 
LB liquid media (LB Broth, Miller components per 1 L: 10 g Tryptone, 5 g Yeast extract, 10 g 
NaCl2, pH 7 at 25°C) was prepared as per the manufacturer’s instructions (25 g to be dissolved in 1 
L of H2O) and autoclaved. 
 
2.9.2 Cell Strains 
The E. coli DH5α cell strain (F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–
, mK+) phoA supE44 λ– thi-1 gyrA96 relA1) was used for plasmid preparation and long term 
plasmid storage. The E. coli BL21(DE3)pLysS ((F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) 
pLysS(cmR)) cell strain was used for protein expression, for more details of cell strain genotypes 
see Appendix 9.4 (“E. coli genotypes,” 2015). Strains were stored at -80°C except when in use, 
where they were kept on ice for the minimal amount of time to avoid thawing. The original DH5α 
Antibiotic  
Resistance
Final Concentration 
(μg/μl)
DH5α None 0
BL21(DE3)pLysS Chloroamphenicol 34
LOBSTR-BL21(DE3) None 0
pET-Duet-1 Ampicillin 100
pET28b Kanamycin 25
pETMCN-EAVNH Ampicillin 100
EcPNPase (pET-Duet-1) Ampicillin 100
hPNPase (pET28b) Kanamycin 25
SsExosome (pETMCN-EAVNH) Ampicillin 100
E. coli  Cell 
Strain
Plasmid 
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and BL21(DE3)pLysS cell strains were kindly provided by Dr James Youell and Dr Luke Evans 
(University of Portsmouth). As discussed in Swords (2003), although a variety of procedures for 
the transformation of E. coli are available; the modified calcium chloride chemical method utilised 
was selected due to ease, relative efficiency, and lack of need for a specialized apparatus such as an 
electroporator. Thus, fresh glycerol stocks of the donated bacterial strains were prepared and then 
made chemically competent for transformation as described in Sections 2.9.3-2.9.4 respectively. 
 
2.9.3 Cell Strain Maintenance 
Frozen E. coli bacterial strains were streaked out on selective LB agar plates. Following streaking, 
agar plates were incubated at 37°C for 12-16 hours. Large, single, well-isolated colonies displaying 
typical morphology were selected and these were used to inoculate 10 ml of selective LB liquid 
media. Bacterial cell cultures were grown at 37°C overnight (O/N) using an Innova 4400 shaking 
incubator at ~220- 225 revolutions per minute (rpm). 1 ml of the O/N culture was aspirated into a 
1.5 ml Eppendorf tube, cells were centrifuged at 3,000 rpm in an Eppendorf Centrifuge 5810 R for 
5 minutes and the supernatant discarded. Cell pellets were re-suspended in 1 ml of 30% (v/v) sterile 
glycerol and these glycerol stocks were stored at -80°C for future use. 
 
2.9.4 Preparation of Chemically Competent E. coli Cell Strains 
A baffled flask containing 250 ml of selective LB liquid media was inoculated with 250 µl of 
relevant O/N bacterial culture (1:1000; standard dilution). Bacterial cells were grown at 37°C in a 
shaking incubator at 220 rpm. The rate of bacterial growth was monitored using a Biowave 
CO8000 cell density meter until an optical density at 600 nm (OD600) of 0.6 was acquired, at which 
point the culture was decanted into a pre-chilled 500 ml flat-bottomed centrifuge bottle. This was 
stored, at all times, on an ice slurry. Cells were harvested by centrifugation at 5,000 rpm at 4°C for 
10 minutes in a Beckman Coulter Allegra 25R refrigerated centrifuge (rotor AT-14-10). The 
resulting supernatant was removed and discarded, and the bacterial cell pellet was gently re-
suspended in 80 ml of ice cold CCMB80 buffer (10 mM KOAc, 80 mM CaCl2.2H2O, 20 mM 
MnCl2.4H2O, 10 mM MgCl2.6H2O, 10% (v/v) glycerol, adjusted to pH 6.4 with 1 mM HCl) and 
incubated on ice for 20 minutes. Bacterial cells were re-centrifuged and the supernatant discarded 
as before. The pellet was once again re-suspended in 10 ml of ice-cold CCMB80 buffer and the cell 
density OD600 was calculated using a 10-fold dilute sample, as the Biowave CO8000 meters error 
increases at OD600 > 1. Additional CCMB80 buffer was added to reach a final OD600 of 1-1.5. For 
long term storage, 250 µl aliquots of each cell strain were stored in 1.5 ml Eppendorf tubes and 
frozen at -80°C.  
 
2.9.5 Transformation of Chemically Competent E. coli Cell Strains with 
Plasmid DNA. 
Chemically competent E. coli cell strains were thawed on ice and 50 µl was decanted into a pre-
chilled 15 ml falcon tube. Typically, recombinant plasmid DNA was prepared as 10 ng/µl stocks 
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and 10 ng (1 µl) of this was added to the competent cells alongside the following two controls; 1) a 
positive plasmid DNA control, which should transform efficiently (10 ng pET-28b) and 2) a dH2O 
negative control. The cell suspension with added plasmid DNA/water was incubated on ice for 30 
minutes. The reactions were then heat-shocked at 42°C for 45 seconds in a water bath and 
immediately cooled on ice for 3 minutes. 900 µl of warm LB liquid media (un-supplemented with 
antibiotics) was added to the transformed cells, incubated at 37°C (225 rpm) for 1 hour to promote 
cell recovery. During this stage cells recover their antibiotic resistance allowing subsequent 
analysis of transformation efficiency on selective LB agar plates. Typically, 200 µl of transformed 
cells were spread and plates were incubated at 37°C O/N. However, some cell strains transformed 
more efficiently with certain selected DNA plasmids and thus a lesser volume was required for 
adequate growth, see Table 2.5 for volumes plated.   
 
 
Table 2.5 Transformation Plates 
Examples of cell culture volumes typically plated on selective LB agar plates are listed for different types of 
transformation reactions. Reactions which usually yield high transformation efficiencies, for example 
transformation controls (pUC18 or pET28b) were diluted prior to spreading, whereas those which typically 
transform poorly were plated directly, e.g. SDM reactions.  
 
A combination of different controls and selective plates were used to determine if the correct cell 
strain had been transformed with the correct plasmid. Essentially, only the cells that had acquired 
the relevant plasmids, containing an antibiotic resistance gene, could grow on these selective plates. 
 
2.9.6 Plasmid DNA Maintenance and Purification 
Following transformation of DH5α cell strains with plasmid DNA, replication and purification of 
plasmids was conducted to generate more plasmid DNA for downstream applications.  
 
For plasmid DNA replication an individual transformed E. coli DH5α colony (containing the 
plasmid of interest) from a freshly streaked selective plate was used to inoculate 10 ml of selective 
LB liquid media. The bacterial culture was grown at 37°C, for 12-16 hours (250 rpm). Following 
growth, 5 ml of the O/N culture was harvested in a 15 ml falcon tube for 3 minutes using a 
Beckman Coulter Allegra 25R (rotor TS-5.1-500) benchtop centrifuge (8,000 rpm).  
 
The plasmid DNA contained within the DH5α host strain was then purified using a modified 
alkaline lysis method (Birnboim & Doly, 1979) as recommended by the QIAprep spin miniprep kit 
protocol (supplied by Qiagen). For reproducible and reliable results Qiagen recommended using 
the DH5α host strain to give high-quality DNA for downstream applications such as DNA 
Reaction Type Volume Plated (μl)
Mutagenesis Control (pWhitescript) 250
Transformation Control (pUC18 or pET28b) 5:200 dilution
Standard Transformation 200
SDM Transformation 250 (2x)
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sequencing, to confirm plasmid DNA sequence identity (Section 2.7.4), and a summary of the 
purification steps is provided in Figure 2.3.  
 
In essence the previously harvested cell pellet, described above, was re-suspended in 250 µl of 
buffer P1 (containing 100 µg/ml RNase A and LyseBlue) and transferred to a microcentrifuge tube. 
250 µl of buffer P2 was added to the pellet suspension and mixed thoroughly by inverting the tube 
4-6 times gently. Once a homogeneously blue coloured suspension was present (< 5 min 
incubation), as visualised by the presence of a LyseBlue colour indicator, 350 µl buffer N3 was 
added and mixed, until the solution was colourless. The lysate was centrifuged for 10 minutes 
(13,000 rpm, Eppendorf Centrifuge 5810 R) in the Eppendorf tube and the supernatant was applied 
directly to a QIAprep spin column. Columns were centrifuged briefly for 30-60 s (13,000 rpm, 
Eppendorf Centrifuge 5810 R) and the flow-through was discarded. Then 0.5 ml buffer PB was 
applied to the column, centrifuged and the flow-through discarded was as before. This method was 
repeated, 0.75 ml buffer PE was added and an additional 60 s spin was conducted to remove all 
residual wash buffers. The plasmid DNA was eluted into a fresh 1.5 ml microcentrifuge tube by 
incubating the column for 60 s in 50 µl buffer EB (10 mM Tris-HCl, pH 8.5) or water and 
centrifuging for 60 s. The resulting plasmid DNA concentration was determined from its A260 nm 
using a Thermo Scientific NanoDrop 2000c, prior to storage at -20°C. 
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Figure 2.3 Plasmid DNA Purification 
Summary figure of plasmid DNA purification using a QIAprep spin miniprep kit (Qiagen). (a) After 
harvesting, pelleted bacteria were re-suspended in buffer P1 which contains RNase A for degradation of 
contaminating RNA and a colour indicator (LyseBlue). In the presence of buffer P2, under alkaline 
conditions, LyseBlue turned blue when cells were successfully lysed. Sodium dodecyl sulphate (SDS) 
detergent in the lysis buffer P2 solubilized the phospholipid and protein components of the cell membrane 
thus leading to lysis and release of cellular contents, while NaOH denatured DNA and proteins. 
Neutralisation of alkaline conditions by buffer N3 was optimal for release of plasmid DNA without 
chromosomal DNA. The solution was adjusted to high-salt binding for efficient DNA adsorption to the 
QIAprep spin column’s silica membrane, which aids further precipitation of unwanted denatured proteins, 
cellular debris and SDS. SDS precipitation was indicated by LyseBlue as a homogeneous colourless solution, 
suggesting successful neutralisation. Following lysate clarification by centrifugation, (b) DNA applied to the 
column was (c) washed with buffers PB and PE to remove endonucleases, ensuring plasmid DNA remained 
intact and salts were removed respectively. (d) Pure plasmid DNA was then eluted in either buffer EB or with 
water pH 7.0-8.5. Image adapted from Qiagen QIAprep spin miniprep kit protocol. 
 
2.10 Gel Electrophoresis 
Following preparation of nucleic acids (DNA and RNA) or proteins, analysis of the size, integrity 
and purity can be conducted using gel electrophoresis (reviewed in Tan & Yiap, 2009). A brief 
description of how different gel electrophoresis techniques were used to separate these 
macromolecules is initially provided, prior to detailed methods.  
 
In principle, macromolecules were separated based on their molecular properties including their 
charge, size and/or shape. Naturally charged molecules, including negatively charged nucleic acids 
or samples with a chemically applied net negative charge, such as proteins coated in SDS 
detergent, were applied to either a native agarose or polyacrylamide gel matrix. Upon application 
of a negatively charged electrical current, these negative molecules were repulsed and migrated 
within the gel matrix towards the positive terminal. In addition to this charge based separation 
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DNA, RNA and proteins were also separated by a sieving action based on their size and shape. The 
smaller/linear molecules or fragments moved through the matrix, consisting of either agarose or 
polyacrylamide gel, faster than larger molecules. In instances where migration of nucleic acids or 
protein samples entirely based on their size was required, denaturing chemical agents such as urea 
or SDS respectively were added and sample structure formation was prevented by heat treatment.  
 
Both these native and denaturing gel electrophoresis techniques were utilised to separate samples 
and estimate the macromolecule’s molecular weight (MW) by comparing the band migration to a 
ladder containing bands of known MW’s. This was useful to determine if the protein or nucleic 
acid’s migration and thus MW, correlated with previous experimental data and/or predicted in 
silico MW values. The purity of samples was also analysed by detecting the presence (or absence) 
of other contaminants upon gel electrophoresis.  
 
For each type of gel electrophoresis utilised within this research detailed methods are outlined in 
the following sub-sections. 
 
2.10.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was conducted using a horizontal gel tank setup and the reagents listed 
in Table 2.6. Agarose powder was dissolved in 1 x Tris-Acetate-EDTA (TAE) (40 mM Tris 
Acetate & 2 mM Na2EDTA, pH 8) (National Diagnostics) by heating in a microwave. The solution 
was allowed to cool slightly before ethidium bromide (0.5 µg/ml) was added, the gel was then cast 
in a 10 x 20 cm gel tank with an appropriate sized comb inserted and allowed to polymerise for at 
least 30 minutes prior to use. Once prepared in 6 x loading dye (3.3 mM Tris-HCl pH 8.0, 2.5% 
Ficoll 400, 11 mM EDTA, 0.017% SDS & 0.015% Bromophenol Blue) to a final 1 x concentration, 
samples were loaded alongside 5 μl of an appropriate molecular weight ladder. This was done in 
order to calibrate the gels; either the low molecular weight DNA ladder (NEB N3233S) or 100 base 
pair ladder (NEB N3231S) were used (see Appendix 9.2 for sizes). Agarose gels were run in 1 x 
TAE (supplemented with 0.5 µg/ml ethidium bromide) for 45 minutes at 120 V and the DNA 
visualised under UV transluminescence using a Syngene G-Box imager and Gene snap software 
(Syngene, n.d.)). 
 
 
Table 2.6 Agarose Gel Preparation  
The mass of each reagent used to prepare 80 ml of 1.2% Agarose gel is provided. 
 
Agarose 0.96 g 
1 x TAE 80 ml
Ethidium Bromide 10 μg/ml
Reagent Amount 
Agarose (1.2 %)
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2.10.2 Polyacrylamide Gel Electrophoresis (PAGE) 
All polyacrylamide gel electrophoresis (PAGE) methods, using a vertical gel tank setup, were 
prepared as described in Sections (2.10.2.1-2.10.2.3) using XCell SureLock™ Mini-Cell gel tanks 
and Novex 1.0 mm plastic gel cassettes (Life Technologies). In addition to specific gel reagents, a 
10% (w/v) stock of ammonium persulfate (APS), N, N, N’, N’-Tetramethylethylenediamine 
(TEMED) and dH2O were used for preparing the gel matrix. Once all gel components were mixed, 
they were poured into a cassette with an appropriate sized comb inserted and allowed to polymerise 
for at least 30 minutes prior to use. Gel reagents, running conditions and molecular visualisation 
methods varied for each type of gel electrophoresis and sample, as highlighted in Sections 2.10.2.1-
2.10.2.3. 
 
2.10.2.1 Native-PAGE 
Native PAGE gels were prepared using AccuGelTM (29% (w/v) Acrylamide and 1% (w/v) Bis-
acrylamide, National Diagnostics EC-852) as outlined in Table 2.7 and samples for loading were 
prepared in an appropriate loading buffer (4x loading dye: 0.25 M Tris HCl pH 6.8, 40% Glycerol 
and 0.02% bromophenol blue). Gels were run in 500 ml of 1 x Tris-Borate-EDTA (TBE) running 
buffer (89 mM Tris Base, 89 mM Boric Acid & 2 mM EDTA pH 8) at 100 V for 1.5 hrs. To detect 
unlabelled RNA, 3 µl SYBR Gold™ (10,000x stock, Invitrogen) was diluted in 30 ml running 
buffer and gels were stained for 5 minutes whilst shaking at room temperature. As recommended in 
the user manual, following staining, gels were visualised near the excitation/emission maxima of 
SYBR gold (~495/537 nm) using the blue laser (473 nm) settings of the Fujifilm FLA-5000 
phosphorimager.  
 
  
Table 2.7 Native-PAGE Preparation 
The volume of each reagent used to prepare one 6% native polyacrylamide gel is provided.  
 
2.10.2.2 Urea-PAGE 
Denaturing urea PAGE gels were prepared using UreaGelTM concentrate (19% (w/v) Acrylamide, 
1% (w/v) Bis-acrylamide, 7.5 M Urea), UreaGelTM diluent (7.5 M Urea) and UreaGelTM buffer 
(0.89 M Tris-Borate pH 8.3, 20 mM EDTA, 7.5 M Urea) (National Diagnostics EC-830) as 
outlined in Table 2.8. Gels were pre-run in 500 ml of 1 x TBE running buffer 200 V for 30 
minutes. Appropriate sample volumes were added to Gel Loading Buffer II (95% Formamide, 
0.025% SDS, 18 mM EDTA, Xylene Cyanol and Bromophenol Blue), heated for 10 minutes at 
95°C, and centrifuged briefly prior to loading. In some instances, a dye-free loading buffer was 
AccuGel™ 1.5 ml
10 x TBE 1 ml
dH2O 7.5 ml
TEMED 8 μl 
10 % (w/v) APS 100 μl
Reagent Volume
AccuGel™ (6 % Native) 
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prepared and used when the dye front migrated at the same location as the RNA band of interest. 
Gels were pre-run at 200 V for 30 minutes, denatured samples were then loaded and run at 200 V 
for 1.5 hrs. Gels were dismantled and visualised using a Fujifilm FLA-5000 phosphorimager. If 
RNA samples were labelled the phosphorimager settings were adjusted to the specific 
excitation/emission maxima of the fluorescent label, unlabelled RNAs were visualised by staining 
for 5 minutes with SYBR Gold™ as described previously.  
 
 
Table 2.8 Denaturing Urea-PAGE Preparation 
The volume of each reagent used to prepare one 20% urea denaturing polyacrylamide gel is provided. 
 
2.10.2.3 SDS-PAGE 
SDS-PAGE gels were prepared using ProtoGelTM 37.5:1 (30% (w/v) Acrylamide, 0.8% (w/v) Bis-
acrylamide), ProtoGelTM Stacking Buffer (0.4% SDS, 0.5 M Tris-HCl pH 8.8) and ProtoGelTM 
Resolving Buffer (0.4% SDS, 1.5 M Tris-HCl pH 8.8) (National Diagnostics EC-890) as outlined 
in Table 2.9. The resolving gel solution was prepared first, poured into the cassette and overlaid 
with 400 µl water-saturated butanol to ensure a flat horizontal gel surface during gel 
polymerisation. Gels were left to polymerise for 30 minutes, the butanol was washed off with dH2O 
prior to adding the stacking gel solution. Gels were again left to polymerise with an appropriate 
sized comb inserted for 30 minutes prior to use.  
 
Samples were prepared for loading by mixing an appropriate sample volume with 2 x reducing 
SDS-PAGE loading dye (0.125 M Tris-HCl pH 6.8, 4% SDS, 0.002% bromophenol blue, 10% β-
mercaptoethanol & 20% Glycerol) (Laemmli, 1970), incubated for 10 minutes at 95 ˚C for 
denaturation, centrifuged briefly and loaded onto a 12% SDS-PAGE gel. When necessary, protein 
samples which were dilute and required concentrating prior to SDS-PAGE analysis, were 
concentrated using StrataClean resin (Agilent). Typically, 250 µl of sample was mixed with 10 µl 
of StrataClean resin, vortexed and centrifuged at 3,000 rpm for 3 minutes in an Eppendorf 
Centrifuge 5810 R. The supernatant was removed and the resin pellet, containing bound protein, 
was retained. 15 µl of 2 x reducing SDS-PAGE loading dye was added, samples were heat 
denatured and loaded as described previously.  
 
Protein samples were loaded alongside 5 μl of a relevant protein ladder in order to calibrate the 
gels; either a BenchMark™ and/or Pre-Stained SeeBlue® (Standard or Plus2) protein molecular 
weight markers (Life Technologies) were used (see Appendix 9.2 for band sizes). The 12% SDS-
UreaGel™ Conc. 8 ml 
UreaGel™ Diluent 1 ml 
UreaGel™ Buffer 1 ml 
TEMED 4 μl
10 % (w/v) APS 80 μl
Reagent Volume
UreaGel™ (20 % Denaturing)
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PAGE gels were run in 500 ml of 1 x Tris-Glycine-SDS (25 mM Tris, 19.2 mM Glycine and 0.1% 
SDS) (National Diagnostics) running buffer at 80 V for 20 minutes into the stacking gel, and then 
150 V for 1 hour 20 minutes into the resolving gel. Gels were then dismantled, stained in 
Coomassie (G-250) with SimplyBlueTM SafeStain (Invitrogen LC6065) and visualised using a 
Syngene G-box UV transilluminator as standard. Gels visualised using SafeStain were rinsed with 
100 ml dH2O, heated for 1 minute in a microwave until almost boiling and placed on a shaker for 1 
minute with gentle mixing. This washing method was repeated 3 times to remove SDS and buffer 
salts as this interferes with the dye binding to the proteins. 20 ml of SafeStain was added, heated 
again as before and shaken for 5 minutes. Once stained, gels were washed to reduce background 
staining in 100 ml of dH2O as before and visualised using a G-Box.  
 
 
Table 2.9 SDS-PAGE Preparation 
The volume of each reagent used to prepare one 12% SDS-polyacrylamide gel is provided; the 12% resolving 
gel was prepared first followed by the 4% stacking gel, which was overlaid on top.  
 
2.11 Western Blot Analysis 
Samples for analysis were initially separated by size using SDS-PAGE, as described in Section 
2.10.2.3, prior to western blot analysis for protein identification. This technique uses labelled 
antibodies, specific to a protein of interest, for protein identification (reviewed in Yang & 
Mahmood, 2012); the methods of which are provided below. 
 
Proteins separated by SDS-PAGE were transferred from the gel onto Amersham Hybond ECL 
Nitrocellulose membrane (GE Healthcare) by applying a 300 mA current for 1 hour 20 minutes in 
gel tank filled with 1 x western transfer buffer (20 mM Tris, 150 mM NaCl and 20% methanol). 
Typically, SeeBlue® Pre-Stained protein standards were loaded onto gels as a quick visual 
indicator of western transfer efficiency.  The membrane was then blocked with 50 ml of 1 x TBST, 
2% Marvel solution (10 mM Tris HCl pH 8, 150 mM NaCl, 0.1% Tween-20 & 2% Marvel) for 3 
hours, at 4°C, on a shaker.  20 ml of the appropriate 1° antibody was then incubated with the 
membrane (1:2000 dilution in 1 x TBST, 2% Marvel solution) O/N at 4°C. Following probing with 
ProtoGel™ 4 ml
Resolving buffer 2.6 ml
dH2O 3.3 ml
TEMED 10 μl
10 % (w/v) APS 100 μl
Stacking solution (4 %) ProtoGel™ 650 μl
Stacking buffer 1.25 ml
dH2O 2.5 ml
TEMED 5 μl
10 % (w/v) APS 25 μl
Reagent Volume
Resolving solution (12 %)
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the 1° antibody, membranes were washed with 20 ml fresh 1 x TBST, 2% Marvel solution three 
times. Depending on the type of 1° antibody used, membranes were either probed with a 2° 
antibody, which was a HRP conjugate or developed directly, if the 1° antibody already contained 
HRP conjugated to it; this HRP conjugate facilitated chemiluminescence detection.  If a 1° 
antibody-HRP wasn’t used, the washed membrane was incubated with 20 ml of the 2° antibody 
(1:2000 dilution in 1 x TBST, 2% Marvel solution) for 2 hours at 4°C. 
Once membranes were probed with relevant 1° and/or 2° antibodies they were washed (as 
described before) with an additional 20 ml wash in 1 x TBST solution (10 mM Tris HCl pH 8, 150 
mM NaCl, 0.1% Tween-20) and the membrane was stored in 20 ml 1 x phosphate buffered saline 
(PBS) until visualised. Visualisation solution 1 (100 μl 250 mM Luminol (prepared in DMSO), 44 
μl 90 mM P-Coumaric acid, 1 ml Tris-HCl pH 8.0 and 8.9 ml dH2O) and solution 2 (6 μl H2O2, 1 
ml Tris-HCl pH 8.0 and 9 ml H2O) were prepared separately prior to mixing together. Membranes 
stored in PBS were rinsed and the final visualisation solution mix was added, incubated for 1 min 
at RT and imaged incrementally at high resolution using an ImageQuant LAS 4010 western camera 
(GE Healthcare) with a minimum exposure of 10 s to detect chemiluminescence. Typically, a 
BenchMark protein ladder was loaded onto SDS-polyacrylamide gels which were probed for the 
presence of His-tagged proteins. Since the ladder is conveniently comprised of recombinant H6-
proteins, it provides not only a size marker but also a visual indicator of western blot efficiency. 
 
2.12 Conclusion 
This Methods Chapter describes the general materials and experimental techniques utilised as 
standard within all chapters of this thesis, whereas subsequent chapters are more specific. 
Accordingly, the following results in Chapter 3 provide all the information regarding the 
preparation of recombinant proteins; including a brief introduction, the specific methods utilised 
and the results obtained.  
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3 Recombinant Protein Preparation 
 
The previous Materials and Methods Chapter provides a repository of common reagents and 
protocols, which were utilised throughout the rest of this thesis. Similarly, this chapter aims to 
provide preparation details for all PNPase and Exosome proteins used, including E. coli and H. 
sapiens PNPase and S. solfataricus exosome (hereafter referred to as EcPNPase, hPNPase and 
SsoExosome respectively).  
 
This chapter will review the applications, methods and limitations of protein-based research. The 
techniques available to produce recombinant proteins in general, alongside the published strategies 
previously employed for relevant PNPase and Exosome proteins will also be addressed. Protocols 
are available for all the proteins listed above and have been applied directly within this research 
where possible. In situations where adaptations to a protocol have been made, an emphasis on the 
reasoning behind these changes has been provided. Details of the methods for cloning, expression 
and purification, followed by protein identification and biological activity analysis, are provided in 
Section 3.2. The outcomes of which are then provided in the following Section 3.3. Important 
conclusions made from this chapter are established in the final Section 3.4, and a summary is 
provided outlining the successful preparation of PNPase and Exosome proteins for downstream 
applications. 
 
3.1 Introduction 
3.1.1 Applications, Methods and Limitations of Protein Research 
From basic life forms including bacteria to more complex beings such as humans, proteins have a 
vital role in all living organisms. Not only are they the basic structural molecule of cells but they 
also regulate a plethora of cellular functions. For this reason, they have been the subject of 
extensive research; understanding the biological activity of an individual protein can potentially 
unveil details of a more complex biological system. Applying this knowledge to manipulate 
individual proteins or biological systems, can result in adaptations which may be beneficial to a 
wide range of areas. This is evident by the extensive use of proteins, typically enzymes, in the food, 
chemical and pharmaceutical industries. Due to the broad use of proteins in both academia and 
industry, protein based research, in either setting, can result in beneficial intellectual and economic 
impact, particularly in cases where large industrial processes are developed for optimal output, as a 
result of a new discovery. 
 
Regardless of the subject matter, research which aims to elucidate the detailed properties of an 
individual protein can be investigated using the following steps. Firstly, the protein of interest can 
be synthesised and then, if necessary, isolated from any contaminant so that only the pure protein 
remains. Secondly, the activity of this pure protein with a known reacting molecule (substrate) can 
be confirmed. This is important so that an understanding of normal functioning is attained, prior to 
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downstream applications, for instance protein interaction research and/or manipulation. Pure and 
active protein is utilised so that researchers can clearly establish if a particular biological activity, 
that may be observed upon testing, resides within the protein specifically and not a contaminant. 
Thus ensures that any information acquired is directly applicable to the purified target protein.  
 
Although cells can naturally synthesise proteins, the high yields required for extensive use in 
industry has promoted advances in developing efficient and cost-effective protein production 
strategies (Adrio & Demain, 2014). These strategies apply the same methods of synthesis utilised 
in nature; most simply, proteins are expressed from the genetic information held within the 
deoxyribonucleic acid (DNA) of the cell. Biochemical techniques have allowed sophisticated 
modifications at each stage of this process and these amendments maximise protein production. 
Such improvements on emerging DNA technologies and expression systems have facilitated not 
only the production of existing proteins but also the discovery of new natural and synthetic proteins 
which can often possess more desirable enzymatic properties than those currently available (Adrio 
& Demain, 2014).  
 
Although significant steps have been made to increase production yields, protein preparation can be 
difficult on both a large and small-scale in industrial manufacturing and academic research. The 
ease of preparation is completely dependent on not only the methodologies utilised but the physical 
properties and functions of the protein. For this reason, if existing methods are available for the 
protein of interest, or homologs they are usually consulted initially and modifications applied to the 
protocol where necessary. With this approach the following Section 3.1.2 provides examples of 
strategies commonly used to produce recombinant proteins in high yields. Attention is then drawn 
to methods previously described in the literature to prepare PNPase and archaeal exosome proteins 
relevant to this research. 
 
3.1.2 Recombinant Protein Technologies 
3.1.2.1 Existing Strategies: Bacterial Expression Systems  
While a gene, encoding a protein of interest, may naturally be present and expressed within a cell, 
additional DNA encoding the protein is often added in the form of a plasmid to maximize protein 
synthesis. This introduced plasmid DNA can either encode a host protein or a heterologous protein 
which is foreign to the expression system. Either way the overexpression of this target gene 
swamps the cell with mRNA so that the cellular translational machinery preferentially synthesises 
the protein of interest. The plasmid DNA which is introduced to an expression system can be 
recombinantly engineered by ligating the gene of interest within a suitable plasmid vector. The 
gene fragment itself can be obtained by direct amplification from the genomic DNA of the species, 
from complementary cDNA libraries or by total gene synthesis (designed in silico). Irrespective of 
the amplification method, genes are typically designed with flanking restriction sites and ligated 
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into a vector using complementary restriction enzymes. Normally, in bacterial expression systems 
this vector also has an antibiotic resistance gene incorporated for selection purposes. 
 
A wide range of plasmid DNA vectors which exhibit controlled gene expression by using an 
inducible promoter are available, these have specific properties aimed at enhancing target gene 
overexpression in various host systems. For example, in bacteria, a commonly used pET vector 
system is available (Broadway, 2012). The pET vectors can be used in conjunction with an E. coli 
λDE3 lysogen expression cell strain. This particular strain contains a phage construct encoding T7 
RNA Polymerase (T7RNAP), which is under the control of a lacUV5 promoter (Studier & Moffatt, 
1986). In normal cellular conditions transcription is silent, until a lactose analogue isopropyl β-D-
1-thiogalactopyranoside (IPTG) is added and this induces T7RNAP expression and thus the target 
gene expression. This is particularly useful for expression of proteins which may be toxic to the 
host cell, allowing maximal growth before expression of the potentially harmful protein (Studier & 
Moffatt, 1986). In this study specifically, this was useful as production of mammalian PNPase has 
been suggested to inhibit growth (Leszczyniecka et al., 2002), hence its overexpression may reduce 
protein yields if the host cells growth is impacted. Additionally, the T7RNAP is very promoter-
specific; only targeting the pET vector T7 promoter which is located upstream of the target gene, 
so that expression can occur directly, and with a low error rate (Mierendorf, Morris, Hammer, & 
Novy, 1998).  
An over-expressed bacterial protein can be extracted from bacterial hosts, however often this is 
simply not feasible and in order to maximise protein synthesis, an expression system different to 
that of the protein host may be selected.  
 
3.1.2.2 Existing Strategies: Other Expression Systems  
A range of expression systems have been established which exploit prokaryotic and eukaryotic 
cellular machinery to synthesise heterologous proteins for study. The optimal expression system 
required depends on the physical attributes of the target protein. Typically, there are four main 
expression systems: bacterial, yeast, insect and mammalian cell culture. They each possess their 
own unique characteristics which can provide both benefits and disadvantages to using the system. 
Bacterial systems allow for rapid cell growth, with low cost and high expression levels; however, 
provide limited post-translational modifications to the protein. Hence, more complex proteins 
requiring glycosylation, phosphorylation, acetylation or other modifications must be synthesised in 
one of the other three systems (yeast, insect and mammalian). Of these systems, yeast is the 
simplest, with rapid cell growth and minimal growth media requirements, like the bacterial system; 
providing a lower cost option than mammalian systems. However, with yeast systems if the protein 
contains disulphide bonds, correct protein refolding may be required, unlike insect and mammalian 
systems, which result in proper folding of proteins. The added complexity of modification provided 
by insect and mammalian systems however results in higher financial costs and lower growth rates, 
[59] 
which are less advantageous. Consequently, the exact system selected needs careful consideration 
to maintain protein preparation efficiency whilst minimising costs.  
 
3.1.2.3 Strategies for Preparing PNPase and Archaeal 
Exosome  
Previous research has reported successful cloning of EcPNPase, hPNPase and SsoExosome into the 
pET vector system and expression of the recombinant proteins for purification in E. coli (Lin et al., 
2012; Lorentzen et al., 2005; Lorentzen, Dziembowski, Lindner, Seraphin, & Conti, 2007; 
Lorentzen & Conti, 2005; Lu, Ding, & Ke, 2010; Nurmohamed, Vaidialingam, Callaghan, & Luisi, 
2009). In this study, EcPNPase plasmid DNA was kindly provided by Prof. Ben Luisi (University 
of Cambridge) and for rapid and cost effective cloning, all other proteins were ligated into relevant 
pET vector following gene synthesis. An additional codon-optimisation step was conducted for the 
eukaryotic hPNPase plasmid DNA in order to prevent codon bias in the bacterial host expression 
strain. This is important as bacterial host systems, lacking eukaryotic tRNAs may lead to enhanced 
mRNA degradation, amino acid incorporation errors and frame shifts; affecting the quantity or 
quality of protein synthesised (Kane, 1995). In situations where codon-optimisation is required, 
alternative methods, which use cell lines containing gene mutations to compensate for tRNA and 
codon preference, can also be selected. For simplicity gene synthesis was conducted and codon 
optimisation was done in silico.  
 
Once the cloning had been conducted, recombinant plasmid DNA must be introduced into an 
appropriate system for protein expression. As PNPase and Exosome proteins require no post-
translational modifications they can be expressed in a simple bacterial expression system following 
DNA transformation using either electroporation or chemical transformation. As the former method 
requires specialist equipment and the latter is relatively simple, the later was employed. When 
considering the bacterial expression systems, multiple strains of bacteria are available, each with 
unique properties optimal for protein expression. More specifically the E. coli BL21(DE3)pLysS 
((F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pLysS(cmR)) cell strain was selected in this study. 
This BL21(DE3)pLysS cell strain contains both the DE3 lysogen (which as explained previously is 
a phage construct that expresses T7RNAP under the control of a lacUV5 promoter) and a pLysS 
plasmid. This additional pLysS plasmid encodes T7 lysozyme which is an inhibitor of T7RNAP 
and can reduce ‘leaky’ background protein expression from the BL21(DE3)pLysS strain. Further 
details of the genotypes for the strain utilised here are provided in Appendix 9.4.   
 
Following cloning, recombinant plasmid DNA can also be routinely stored long-term in bacterial 
cell strains such as the commonly used E. coli DH5α cell strain (F– Φ80lacZΔM15 Δ(lacZYA-
argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1) see Appendix 
for 9.4 details. Utilisation of this DH5α strain increases gene insert stability by the mutation of non-
specific endonucleases including endA1 and protects un-methylated DNA from the EcoKI 
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restriction-modification system. This reduces degradation and consequently improves plasmid 
DNA quality upon preparation and purification.  
 
Once an appropriate vector and expression system, which highly expresses heterologous protein, 
has been chosen the process is expanded to a larger scale to produce enough protein for further 
purification. In some systems, including some types of cell culture, protein expression is automatic. 
However, in the bacterial BL21(DE3) strain utilised within this study, induction is typically 
initiated with IPTG at low temperatures (15–25°C), in rich medium and with good aeration. 
Published protein expression conditions for all PNPase and Exosome proteins were used as an 
initial starting point. Commonly used modifications to improve expression, including lowering the 
IPTG concentration for induction and/or lowering the temperature were applied where necessary. 
 
In any expression system, naturally-produced host cellular macromolecules are present as a by-
product of protein production alongside the recombinant protein of interest. These must be 
removed to leave a pure protein for study; as mentioned previously, in a purified form any 
characteristics observed in vitro, whether they are structural and/or functional, can be attributed to 
the purified protein specifically. Recombinant proteins can be isolated and purified away from 
other host proteins using various experimental techniques. Firstly, once a recombinant protein has 
been successfully expressed, cell lysis must be employed. This can be conducted manually by cell 
homogenisation in a well-buffered solution optimised for cell lysis. Ideally the lysis buffer contains 
ionic strengths equivalent to 300-500 mM of a monovalent salt, such as NaCl (Gräslund et al., 
2008). Alternatively, cells may be disrupted in an appropriate lysis buffer by more forceful 
methods, including sonication and French press. The precise methods are often decided based on 
available equipment and previous methods utilised in the literature. In contrast to previous methods 
which utilise a French press, cell homogenisation and sonication was selected for this work based 
on the equipment available. Irrespective of the lysis method chosen, it is essential to ensure that the 
majority of cells are broken in order to release contained recombinant protein for high-yield protein 
purification. Hence, using SDS-PAGE analysis the effectiveness of the lysis process can be 
determined from the amount of target protein following clarification using centrifugation. Applying 
a strong centrifugal force to total cell lysate effectively separates out the insoluble cellular 
debris/macromolecules from those that are soluble. If the protein is folded correctly and present in 
the soluble supernatant fraction, it can next be isolated for further purification. Alternatively, if the 
protein is denatured or present in inclusion bodies, it may be present in the insoluble cell pellet and 
may require refolding. At various stages of the purification process, the protein’s solubility may be 
taken advantage of to separate the protein of interest based on its individual characteristics, such as 
the protein’s stability at varying pH, temperature or salinity.  Proteins which are known to bind to 
DNA or RNA may also be purified from these contaminants by using enzymes designed to 
specifically degrade such entities. An RNase and/or DNase stage is often employed to improve the 
protein purity.   
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Partially purified proteins may be subject to various chromatography stages in order to purify them 
further. Chromatography is a technique used to separate sample mixtures. It typically works by 
distributing sample components between two phases whilst moving through a column filled with a 
particular medium.  Molecules within the sample, which can interact with the column media, are 
retained within the column and are referred to as being in the stationary phase. In contrast, non-
interacting molecules are not retained and are considered to be in the mobile phase. Depending on 
the type of column media selected and the specific properties of a protein, it may be present in 
either phase. This allows purification of different proteins based on their individual properties. 
Analysis of proteins after chromatography is essential to determine the volume at which a protein 
of interest is eluted. Typically, chromatography is conducted on automated platforms such as the 
AKTA systems. This has many benefits including the measurement of key-variables such as 
temperature, conductivity and buffer component concentrations (if these are being varied). Even 
the absorbance at 280 nm (A280 nm) can be recorded in order to detect proteins. Using the AKTA 
systems, components of a mixture, separated by chromatography, can be collected as individual 
fractions for subsequent analysis and possibly further purification.  
 
In terms of protein purification, the ability to separate proteins, determine the exact volume at 
which they elute by measuring A280 nm and retain the relevant fractions for further use is extremely 
useful. Consequently, chromatography was a vital step used in this work to purify recombinant 
proteins expressed in E. coli cells away from contaminating host proteins. In this instance a variety 
of chromatography methods were employed to purify each protein and the method chosen 
depended on their specific molecular properties including binding affinity, net charge and 
molecular weight (MW). 
 
Recombinant proteins with an affinity tag can be purified away from host proteins by Affinity 
Chromatography (AC); tagged proteins of interest can bind directly to the column media whilst 
others are eluted. A range of tags are available, including the one used specifically within this 
study, which endows proteins with a recombinant poly (6x)-histidine tag (H6) that can be purified 
by Immobilised Metal Affinity Chromatography (IMAC). Essentially a column containing 
immobilised nickel resin binds to histidine; including the H6-tag of the protein and non-binding 
proteins are eluted. In order to elute histidine-rich proteins a buffer containing imidazole can be 
applied to out-compete the binding interaction. This application can be completed using a gradient, 
so that weakly interacting proteins are eluted prior to strongly interacting proteins, providing 
further separation.  
 
Consistent with previous research, hPNPase and SsoExosome constructs encoded proteins with an 
N-terminal H6-tag and EcPNPase was untagged. The affinity tag, present on some of the proteins, 
may be removed to minimize non-native sequences in the recombinant protein and to achieve 
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further purification. This is achieved by using a recombinant, H6-tagged protease and reapplying 
the sample to IMAC column to remove both the protease and any cellular proteins that bind the 
metal affinity resin. Although some literature advises that tags should be removed from proteins 
prior to biochemical testing, a review suggested for a majority of proteins surveyed a H6-tag does 
not have a consistent impact on the N-terminal structure of the target protein (Gräslund et al., 
2008). For consistency with previously published research, the H6-tag of hPNPase and 
SsoExosome was not removed for this study. 
 
In this study, recombinant proteins including EcPNPase without an affinity tag were purified using 
a different means; Ion Exchange Chromatography (IEC). This method works to separate molecules 
based on their net charge. As mentioned before, the individual characteristics of a protein can be 
exploited to present it in either the stationary or mobile phase. If a protein has a net negative 
charge, it can be immobilised by a positively charged resin within the column, this is termed Anion 
Exchange Chromatography (AEC). Contrary to this, if a protein’s net charge is positive, a negative 
resin is used in Cation Exchange Chromatography (CEC). The result of either method ensures 
binding and thus separation of proteins of interest, which can be later eluted using a specific elution 
buffer. Conveniently, due to the nature of proteins, changes in the pH of elution buffers can result 
in modifications to the net charge, thereby eluting bound proteins. In CEC, increasing the pH 
causes the protein to be less protonated and hence, less positively charged. Therefore, it cannot 
form ionic interactions with the negatively charged resin, which ultimately results in the protein 
eluting from the column. AEC is the inverse of this, decreasing the pH causes more protein 
protonation and hence, the more positively charged protein dissociates from the positively charged 
resin. Additionally, the presence of positive Na+ ions and negative Cl- ions, as a result of increasing 
NaCl salt concentrations in the elution buffer, can compete with the protein for binding to the 
charged resin, resulting in protein elution.  
 
The previously mentioned chromatography techniques identify situations where proteins bind to a 
column resin and then have to be eluted in a specific elution buffer. However, another method 
worthy of mention is Size Exclusion Chromatography (SEC). This technique varies compared to 
the other chromatography methods, in that proteins do not necessarily bind to the column, but can 
actually be ‘trapped’ by moving in and out of the resin pores and consequently switching between 
the mobile and stationary phase dependant on their overall size. Smaller molecules are retained 
more within the small pores of the column medium than larger molecules. Molecules with large 
MW can move entirely within the mobile phase (not retained by the column at all) and elute from 
the column in what is termed the void volume, whilst smaller proteins are retained by the media to 
varying degrees and elute later, thus allowing separation by overall size. SEC is a valuable process 
and in the context of this work, consistent with previous research, is the final protein purification 
chromatography stage. Normally protein samples are concentrated to small volumes for SEC. This 
is due to the fact that samples separate by size immediately upon column-loading, as such, larger 
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volumes result in broad A280 nm peaks. Hence small volumes are used in order to improve the 
resolution of sample separation. There are a variety of SEC column media types available. 
Superdex 200 prep grade resin consists of a matrix of dextran covalently attached to highly cross-
linked agarose, aimed at purifying proteins 10-600 kDa in size, hence it was used to purify all 
recombinant proteins in this study.  
 
A relatively simple column calibration can be conducted to determine the molecular weight (MW), 
usually measured in kDa, of any unknown proteins separated on a SEC column. This makes SEC 
not only a helpful separation tool but also an analytical one. A mixture of protein standards with 
known MWs may be applied to the SEC column. If the mixture includes proteins with similar MW, 
which may elute with peaks A280 nm close to one another, the mixture to be loaded onto SEC can 
be split. This would reduce the chance of overlapping A280nm peaks, so that the exact elution volume 
for individual standards can be measured. One typically used standard, Blue Dextran (2,000 kDa), a 
large MW macromolecule is not retained within the column, and can be used to determine the 
specific void volume of a column. The retention volume of smaller protein standards can then be 
calculated as the elution volume minus the void volume. This is a very useful value; if retention 
volumes (ml) are plotted against log MW (kDa) of each protein standard, a calibration curve may 
be produced. With such a calibration curve, the retention volume of unknown proteins in 
subsequent runs can be used to predict their respective MW (kDa).  
 
Production of high-quality, recombinant proteins for further structural and functional biochemical 
studies is essential; however, confirmation of their identity is also vital. Determining the 
identification of any recombinant protein can be conducted using a variety of techniques. Initially 
SDS-PAGE analysis can be conducted to separate protein samples taken throughout the various 
stages of purification. This can be useful to analyse the purity of the protein of interest and predict 
its MW using a protein ladder. If the protein’s size has been previously reported, this known MW 
may be used to predict which band is the target protein. Alternatively, programs such as ProtParam; 
which can predict protein MWs based on amino acid composition, alongside the use of protein 
molecular weight markers, can provide the first indication if a band migrates at a size similar to the 
protein of interest (Wilkins et al., 1999). Additionally, in more analytical methods such as SEC, the 
elution volume may be utilised to predict a MW, or inversely the MW of an unknown protein may 
be used to predict protein elution when using a SEC calibration curve, like the one described 
previously. Following SDS-PAGE, western blot analysis for protein identification can also be 
conducted, this utilises antibodies specific to an affinity tag or directly to the protein of interest, to 
identify the presence of the target protein. Finally, purified protein can be analysed by either 
denaturing or non-denaturing mass spectrometry (MS) to identify the protein of interest.   
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3.1.3 Summary and Aims 
As demonstrated in Section 3.1.2, a range of different methods may be utilised to clone, express 
and purify recombinant proteins from contaminating host proteins and the precise method chosen 
depends on individual characteristics of the protein of interest. Typically, if a method is previously 
well established in the literature it is simplest to reproduce that and amend it where necessary.  
Hence, E. coli and H. sapiens PNPase and S. solfataricus Exosome proteins were prepared with 
this in mind. It is also essential that the final recombinant protein’s purity, identity and activity are 
assessed prior to further structural or functional characterisation.  Henceforth, this chapter describes 
the overall preparation of all recombinant proteins tested.  
 
3.2 Methods 
This methods section describes the techniques used to clone, express and purify each of the 
recombinant proteins EcPNPase, H6-hPNPase and H6-SsoExosome (H6-Rrp4_41_42). It also 
details the subsequent methods used to confirm the identity and activity of each protein. A majority 
of the steps undertaken to purify each recombinant protein are similar, hence methods described 
herein remain non-specific initially, with protein-specific methods indicated later as necessary.  
 
3.2.1 DNA Preparation 
Synthesis and ligation of gene constructs into appropriate DNA vectors were conducted as follows. 
For more detailed sequence information refer to Appendix 9.6. 
 
3.2.1.1 H. sapiens PNPase 
The complete coding sequence for the PNPase open reading frame (ORF) (NCBI accession number 
BC053660.1) from H. sapiens was codon-optimised in silico using proprietary GeneOptimizer® 
software (GeneArt AG, Life Technologies). The subsequent gene sequence was synthesised and 
ligated between restriction sites Nhe1 and Sal1 within the multiple cloning site (MCS) of a pET-
28b vector (Novagen). Thus producing an in-frame, thrombin-cleavable, H6-tag fusion with full-
length hPNPase (H6-hPNPase). The insertion of the H6-hPNPase construct into the pET-28b vector 
was confirmed by DNA sequencing (Life Technologies). 
 
3.2.1.2 S. solfataricus Exosome 
Similarly, to H6-hPNPase, the complete coding sequence for the S. solfataricus archaeal exosome 
(SsoExosome) was codon-optimised in silico using GeneArt technology. Contrastingly the hetero-
trimeric SsoExosome, which is assembled from three individual subunits; Rrp4, Rrp41 and Rrp42 
was cloned as a polycistronic gene. This ensured all three separate gene ORFs were in the same 
order as in the S. solfataricus exosome superoperon (NCBI gene ID Rrp4:1454999, Rrp41:1454998 
and Rrp42:1454997). This approach was taken since previous experimental data indicated that 
cloning a polycistronic Rrp4_41_Rrp42 gene construct led to subsequent co-expression and 
improved complex solubility (Lu et al., 2010). Following synthesis, the SsoExosome gene was 
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ligated between restriction sites NdeI and Xbal of the pETMCN-EAVNH vector kindly provided 
by C. Romier (Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) - Université 
de Strasbourg). This produced a thrombin-cleavable, H6-Rrp4 subunit with which untagged Rrp41 
and Rrp42 can assemble, forming the SsoExosome complex (Lu et al., 2010). As before, the H6-
Rrp4_41_42 (SsoExosome) construct insertion into the pETMCN-EAVNH vector was confirmed 
by DNA sequencing (Life Technologies). 
 
3.2.1.3 E. coli PNPase 
Cloning methods were not required for (untagged) E. coli PNPase as the gene had been previously 
cloned into a pETDuet-1 vector and was kindly supplied by Prof. Ben Luisi (University of 
Cambridge). Nevertheless, to confirm the EcPNPase_ pETDuet-1 plasmid sequence, DNA 
sequencing was conducted as previously described in Section 2.7.4.  
 
3.2.2 DNA Plasmid Transformation 
Following DNA cloning (Section 3.2.1), transformation of plasmid DNA, containing the gene 
construct of interest, into a desired bacterial cell strain was conducted as follows. For more detailed 
methods and bacterial cell strain genotypes see Section 2.9.5 and Appendix 9.4 respectively.  
 
EcPNPase_ pETDuet-1, H6-hPNPase_ pET-28b and H6-Rrp4_41_42_ pETMCN-EAVNH 
recombinant plasmid DNA were all individually transformed into chemically competent E. coli 
DH5α cells for long-term plasmid storage (Section 2.9.5). Transformed DH5α cells were also 
utilised to replicate and purify plasmid DNA in sufficient quantities for DNA sequencing (~100 ng 
required), as it was essential to ensure no base mutations had arisen during synthesis and storage. 
The methods of bacterial growth, lysis and plasmid DNA purification are provided in Section 2.9.6. 
Using the same method, recombinant DNA plasmids listed above were also transformed into 
chemically competent E. coli BL21(DE3) pLysS cell strains for downstream protein expression and 
uptake of antibiotic resistant plasmid DNA was selected for, using LB agar plates supplemented 
with appropriate antibiotics (Section 2.9.5). 
 
3.2.3 Protein Expression: Small-Scale 
Subsequent to transformation into E. coli expression strain BL21(DE3)pLysS (Section 3.2.2), a 
small-scale protein expression trial of EcPNPase, H6-hPNPase and H6-Rrp4_41_42 was conducted. 
Several colonies were selected from a transformation plate and added to individual 30 ml sterilin 
tubes containing 10 ml of selective LB liquid media (Miller). Each 10 ml culture was incubated at 
37°C (250 rpm) overnight and was used as starter cultures for small-scale expression trials. 10 ml 
of fresh selective LB liquid media was inoculated with 10 µl of each starter culture (1:1000). 
Individual cultures were grown at 37°C (250 rpm) for approximately 3 hours or until an OD600 0.4 - 
0.6 was reached. A 1 ml sample (pre-IPTG induction) was taken for each and IPTG was added to 
the remaining culture, resulting in a 1 mM final concentration. Cultures were grown for a further 3 
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hours, a 1 ml (post-IPTG induction) sample was then taken and the OD600 was recorded. At each 
stage, individual samples (pre- and post-IPTG) were centrifuged in 1.5 ml Eppendorf tubes for 5 
minutes (3,000 rpm) in a Thermo Scientific Heraeus Fresco 17 benchtop centrifuge. The pellet was 
retained, 100 µl of 2X SDS-PAGE reducing loading dye was added and samples were boiled at 
95°C for 10 minutes prior to analysis by SDS-PAGE (Section 2.10.2.3). Samples for each colony 
of pre- and post-IPTG induction were loaded, based on comparable cell density. The colony 
displaying high heterologous protein expression was determined by densitometric analysis of the 
SDS-PAGE gel and glycerol stocks were prepared from the relevant starter culture and stored at -
80°C (Section 2.9.3). 
 
3.2.4 Protein Expression: Large-Scale 
Following the small-scale trial (Section 3.2.3), optimisation of EcPNPase, H6-hPNPase and H6-
Rrp4_41_42 protein expression was conducted on a larger scale.  
 
Protein expression was conducted using the E. coli glycerol stock previously shown to display high 
protein expression (Section 3.2.3). An initial 10 ml starter culture of selective LB liquid media was 
inoculated with the relevant glycerol stock and grown at 37°C (250 rpm) O/N. 1 ml of this starter 
culture was added to baffled flasks containing 500 ml of selective LB liquid media. Typically, 3-4 
L of culture was grown at 37°C (250 rpm) until the OD600 optimal for protein-specific expression 
was reached. At this stage protein expression was induced with IPTG and cultures were incubated 
further. Protein-specific conditions for IPTG induction and bacterial growth are listed in Table 3.1. 
Following protein production, cell pellets were harvested in 1 L polypropylene bottles by 
centrifugation at 4°C (7,000 rpm) for 20 minutes in a Beckman Coulter Avanti J-20XP refrigerated 
centrifuge (JLA 8.1000 rotor). The resulting bacterial cell pellets were stored in 50 ml falcon tubes 
at -20°C for subsequent purification. As in the small-scale trial (Section 3.2.3), pre- and post-IPTG 
induction samples were analysed by SDS-PAGE for protein expression. It was critical to ensure 
sufficient quantities of protein had been produced prior to purification.  
 
3.2.5 Protein Purification 
Following large-scale protein expression (Section 3.2.4), EcPNPase, H6-hPNPase and H6-
Rrp4_41_42 purification was conducted. As standard, samples exposed to potential protease 
degradation were purified at 4°C. This was conducted on the AKTA prime platform first, before 
moving to a more automated AKTA express system when these protocols were better established. 
 
If previously published methods were available, recombinant proteins were purified identically, or 
appropriate adaptations were made if necessary. Conveniently, the multi-step purification process 
was similar for each protein, especially H6-tagged proteins. Hence, for simplicity, individual 
purification steps are covered in general in Section 3.2.5, followed by protein-specific methods, 
which outline the precise combination of the steps in more detail in Section 3.2.6. 
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3.2.5.1 E. coli Cell Lysis  
1 L cell pellets, previously prepared and stored at -20°C, were thawed on ice and re-suspended in 
50 ml of appropriate lysis buffer with one cOmplete, EDTA-free Protease Inhibitor Cocktail Tablet 
(Roche Applied Science). If necessary, in order to obtain the uniformly homogenous cell lysate 
required for efficient sonication, cells were physically disrupted using a 30 ml manual 
homogeniser. Bacterial cells, kept on ice, were further disrupted by sonication using a Sonics 
Vibra-cell sonicator. The probe was set to an amplitude of 40%, a maximum temperature of 20°C 
and samples were sonicated for 10 minutes, with a 3.3 second on/ 9.9 second off pulse setting. 
 
3.2.5.2 Isolation of Soluble Proteins 
Soluble proteins were separated from insoluble proteins using centrifugation for 30 minutes 
(18,000 rpm) at 4°C in a Beckman Coulter Avanti JXN-26 Centrifuge (JA25.50 rotor). The cellular 
debris was discarded but the supernatant was retained for further purification. 
 
3.2.5.3 RNase & DNase Treatment 
Protein samples were treated with RNase A (10 µg/ml) and DNase 1 (1 U/ml) by mixing for 30 
minutes at 4°C to remove RNA and DNA contaminants.  
 
3.2.5.4 Heat Step & Centrifugation 
Purification of thermostable proteins utilised heat precipitation; samples were heated at 75°C for 30 
minutes in a water bath. Soluble, heat-stable proteins were clarified from those denatured by 
centrifugation as described Section 3.2.5.2.  
 
3.2.5.5 Ammonium Sulphate Precipitation 
Protein samples were treated with 51.2% (w/v) (NH4)2SO4, by mixing for 1 hour at 4°C. Proteins 
were clarified by centrifugation as described Section 3.2.5.2, however the pellet containing the 
insoluble, salt precipitated, proteins were retained for further analysis.  
 
3.2.5.6 Dialysis  
The pellet from the previous ammonium sulphate step was re-suspended and dialysed O/N. using 
Spectra/Por® dialysis membrane with an appropriate molecular weight cut-off (3.5 kDa MWCO) 
(Spectrum Laboratories, Inc.), and an appropriate buffer.  
 
3.2.5.7 Immobilised Metal Affinity Chromatography 
Using the appropriate AKTA system, a 1 ml HisTrap FF column, pre-packed with Ni Sepharose 6 
Fast Flow resin, was pre-equilibrated in an appropriate binding buffer. The protein solution was 
initially filtered (0.22 µm) and then applied to the column at a flow rate of 1 ml/min. The flow-
through of unbound protein was retained for SDS-PAGE analysis (Section 2.10.2.3) in case the 
protein of interest was not bound to the column. Weakly binding, non-specific proteins were 
[68] 
washed off the column with binding buffer. Once a stable A280 nm baseline was reached, 
recombinant H6-proteins and histidine-rich E. coli host proteins bound to the column were eluted. 
An appropriate elution buffer (supplemented with 500 mM imidazole) was applied from 0-100% 
over a 30 ml gradient at 1 ml/min; 2 ml fractions were collected for SDS-PAGE analysis (Section 
2.10.2.3). Protein-containing fractions were pooled for further purification by other 
chromatography methods. 
 
3.2.5.8 Anion Exchange Chromatography 
Using the appropriate AKTA system, a 5 ml HiTrap Q HP column (High Performance), pre-packed 
with Q Sepharose resin, was pre-equilibrated in an appropriate binding buffer. The protein solution 
was initially filtered (0.22 µm) and then applied to the column at a flow rate of 1 ml/min. The flow-
through of unbound protein was retained for SDS-PAGE analysis (Section 2.10.2.3). Weakly 
binding, non-specific proteins were washed off the column with binding buffer. Once a stable A280 
nm baseline was reached proteins bound to the column were eluted. An appropriate elution buffer 
(supplemented with NaCl) was applied from 0-100% over a 30 ml gradient at 1 ml/min and 1 ml 
fractions were collected for SDS-PAGE analysis (Section 2.10.2.3). Protein-containing fractions 
were pooled for further purification by other chromatography methods. 
 
3.2.5.9 Size Exclusion Calibration  
Using the appropriate AKTA system; the manually re-packed Superdex 200 20/30 column was 
calibrated. Two separate 1 ml protein standard samples were prepared and loaded at 1 ml/min in 20 
mM Tris-HCl pH 8, 150 mM NaCl and 10 mM MgCl2 onto the column. Sample 1 contained Blue 
dextran, Aldolase and Ovalbumin (each 10 mg/ml) and sample 2, Ferritin and Conalbumin (each 10 
mg/ml). The A280 nm (mAU) was recorded and the values plotted against the elution volume. The 
resultant elution volumes were converted into retention volumes using Blue Dextran as an indicator 
of the void volume using the following calculation: Retention volume (ml) = elution volume (ml) – 
void volume (ml). Once the individual retention volumes for each protein standard were calculated, 
they were plotted against the log10 of the known molecular weight (log MW, (kDa)). From the 
resultant graph the equation for the line of best fit was used to predict the MW of any unknown 
proteins with a known elution volume.  
 
3.2.5.10 Protein Concentration 
Depending on the starting volume, samples were concentrated in 20 ml or 2 ml Vivaspin 
concentrators (Sartorius). Concentrators were washed and pre-equilibrated in 5 ml ddH2O and 
appropriate SE buffer respectively for 2 minutes at 3,000 rpm in an Eppendorf 5810 R Centrifuge 
(A-4-62 Rotor). Protein samples were then applied and concentrated by centrifugation at 3,000 rpm 
for various times, dependent on the initial and desired final volume. Protein samples were re-
suspended between spins to avoid precipitation on the concentrator membrane and heat stable 
proteins were concentrated at RT for the same reason. 
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If the protein sample was required for further purification by SEC, it was concentrated to < 1ml. 
The sample was then centrifuged at maximum rpm for 10 minutes in a benchtop Thermo Scientific 
Heraeus Fresco 17 centrifuge to precipitate any insoluble proteins prior to loading. 
 
3.2.5.11 Size Exclusion Chromatography 
Concentrated protein samples (1 ml) for further purification by SEC were loaded at 1 ml/min onto a 
pre-equilibrated Superdex 200 20/30 column in an appropriate SE buffer, as described in Section 
3.2.5.9. Resultant SEC fractions corresponding to A280 nm peaks were analysed by SDS-PAGE. 
Typically, samples were concentrated with strata-clean (Section 2.10.2.3) for analysis. Relevant 
fractions were pooled, concentrated to an appropriate volume/concentration for further use (Section 
3.2.5.10) and stored at -80°C in individual aliquots. 
 
3.2.6 Protein Purification: Protein-Specific  
As outlined in Section 3.2.5, this section describes the protein-specific methods utilised to purify 
recombinant proteins EcPNPase, H6-hPNPase and H6-Rrp4_41_42. 
 
3.2.6.1 hPNPase 
A similar purification method to that conducted in (Lin et al., 2012) was employed. E. coli 1 L cell 
pellets (x 3 L) containing the overexpressed recombinant protein H. sapiens PNPase (hPNPase) 
were lysed in 50 ml lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl and 10 mM imidazole) by 
manual homogenisation and sonication (Section 3.2.5.1). Soluble proteins were then clarified by 
centrifugation (Section 3.2.5.2) and the supernatant retained for RNase and DNase treatment 
(Section 3.2.5.3). Following this, the treated sample was filtered (0.22 µm) and loaded onto a 1 ml 
HisTrap nickel-immobilised metal affinity column (IMAC, 0.3 mPa) pre-equilibrated in lysis 
buffer at 1 ml/min. The column was washed with lysis buffer and proteins were eluted with in a 30 
ml gradient (0-100%) of elution buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, 500 mM 
imidazole). 1 ml fractions were collected, the mAU 280nm was recorded and SDS-PAGE analysis 
was conducted on protein-containing fractions (Section 3.2.5.7). Relevant fractions were pooled 
and concentrated prior to loading onto a Superdex 200 20/30 column (0.5 mPa) pre-equilibrated in 
SE Buffer (20 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM MgCl2) at 1 ml/min (Section 3.2.5.10-
3.2.5.11). SDS-PAGE analysis of strata cleaned fractions was conducted (Section 2.10.2.3) and 
relevant protein-containing fractions were pooled, concentrated and stored at -80°C for future use.  
 
3.2.6.2 EcPNPase 
A similar EcPNPase purification method to that conducted in Nurmohamed et al., 2011 was 
employed. E. coli 1 L cell pellets containing the overexpressed recombinant protein E. coli PNPase 
(EcPNPase) were lysed in 50 ml (20 mM Tris-HCl pH 8.0, 150 mM NaCl and 5 mM MgCl2) by 
manual homogenisation and sonication (Section 3.2.5.1). Soluble proteins were then clarified by 
centrifugation (Section 3.2.5.2) and the supernatant retained for RNase and DNase treatment 
(Section 3.2.5.3). Following this, ammonium sulphate (NH4)2SO4 was added to a final 
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concentration of 51.2% (w/v) and EcPNPase was precipitated by mixing at 4°C for 1 hour (Section 
3.2.5.5). The resultant insoluble proteins were clarified by centrifugation (Section 3.2.5.2) and the 
pellet retained for re-suspension in 20 ml Buffer A (20 mM Tris-HCl pH 8.5, 30 mM NaCl, 5 mM 
MgCl2 and 5 mM DTT). The re-suspended pellet (20 ml) was dialysed in 500 ml Buffer A 
overnight (and placed in fresh Buffer A afterwards) (Section 3.2.5.6). The dialysed sample was 
filtered (0.22 µm) and loaded onto a 5 ml HiTrap Q Sepharose High Performance (HP) anion 
exchange column (AEC, 0.3 mPa) pre-equilibrated in Buffer A at 1 ml/min. The column was 
washed with Buffer A and proteins were eluted with in a 50 ml gradient (0-100%) of Buffer B (20 
mM Tris-HCl pH 8.5, 1 M NaCl, 5 mM MgCl2 and 5 mM DTT). 1 ml fractions were collected, the 
mAU 280nm was recorded and SDS-PAGE analysis was conducted of the protein-containing 
fractions (Section 3.2.5.8). Relevant fractions were pooled and concentrated prior to loading onto a 
Superdex 200 20/30 column (0.5 mPa) pre-equilibrated in SE Buffer (20 mM Tris-HCl pH 8, 150 
mM NaCl & 10 mM MgCl2) at 1 ml/min (Section 3.2.5.10-3.2.5.11). SDS-PAGE analysis of 
fractions was conducted (Section 2.10.2.3) and relevant protein-containing fractions were pooled, 
concentrated and stored at -80°C for future use.  
 
3.2.6.3 SsoExosome 
A similar SsoExosome purification method to that conducted in Lorentzen et al., 2007 was 
employed. E. coli 1 L cell pellets containing the overexpressed recombinant protein SsoExosome 
were lysed in 50 ml lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl and 10 mM imidazole) by 
manual homogenisation and sonication (Section 3.2.5.1) Soluble proteins were then clarified by 
centrifugation (Section 3.2.5.2) and heat treated at 75°C for 30 min (Section 3.2.5.4). Heat-stable 
proteins were isolated from heat-denatured proteins by a second centrifugation step and the 
supernatant was retained for RNase and DNase treatment (Section 3.2.5.3). Following this, the 
treated sample was filtered (0.22 µm) and loaded onto a 1 ml HisTrap nickel IMAC column (0.3 
mPa) pre-equilibrated in lysis buffer at 1 ml/min. The column was washed with lysis buffer and 
proteins were eluted with a 30 ml gradient (0-100%) of elution buffer (50 mM Tris-HCl pH 8, 300 
mM NaCl, 500 mM imidazole). 1 ml fractions were collected, the mAU 280nm was recorded and 
SDS-PAGE analysis was conducted of protein-containing fractions (Section 3.2.5.7). Relevant 
fractions were pooled and concentrated prior to loading onto a Superdex 200 20/30 column (0.5 
mPa) pre-equilibrated in SE Buffer (20 mM Tris-HCl pH 8, 150 mM NaCl & 10 mM MgCl2) at 1 
ml/min (Section 3.2.5.10-3.2.5.11). SDS-PAGE analysis of strata cleaned fractions was conducted 
(Section 2.10.2.3) and relevant protein-containing fractions were pooled, concentrated and stored at 
-80°C for future use.  
 
3.2.7 Protein Identification 
Following protein purification (Section 3.2.6), confirmation of the purified EcPNPase, H6-hPNPase 
and H6-Rrp4_41_42 protein identities was conducted using a variety of techniques. 
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3.2.7.1 SDS-PAGE and Western Blot 
At each stage of protein purification samples were retained for subsequent analysis by SDS-PAGE 
and if necessary western blot analysis was also conducted (Section 2.10.2.3 and 2.11 respectively). 
The aim of this was to determine if the protein of interest had been purified successfully away from 
contaminating E. coli host proteins. Firstly, using predicted MW values from ProtParam (Appendix 
9.6), migration of the protein of interest through the gel was compared to a MW ladder to estimate 
if the purified protein was of the predicted size (Wilkins et al., 1999). Secondly, using antibodies 
specific to the protein itself or its H6-tag, the protein of interest was detected using western blots 
(Section 2.11). 
 
3.2.7.2 Size Exclusion Chromatography 
Not only was SEC utilised to purify the recombinant protein, the elution volume of each 
recombinant protein determined by SEC, in combination with the calibration curve, was used to 
predict the overall size of eluted proteins.  Thus providing an indication of whether the protein was 
in its correct oligomeric state, as described in Section 3.2.5.9.   
 
3.2.7.3 Denaturing Mass Spectrometry (LC-MS/MS) 
Subsequent liquid chromatography tandem mass spectrometry (LC-MS-MS) of relevant proteins 
was performed to confirm protein identity. Samples to be identified were separated by SDS-PAGE 
(5 µg protein loaded) as standard (Section 2.10.2.3). In a laminar flow hood, all equipment required 
for protein band excision was cleaned with 70% EtOH. This reduced the chance of protein 
contaminants that interfere with LC-MS-MS identification. Once the gel band was excised, it was 
placed in a 1.5 mL microcentrifuge tube and covered in 30% ethanol. Samples were analysed by 
the Astbury Centre Mass Spectrometry Facility (University of Leeds) and a full analysis was 
provided including protein identification. 
 
3.2.8 3’-5’ RNA Degradation Activity of Recombinant Proteins  
After establishing the identity of recombinant proteins (Section 3.2.7), a gel electrophoresis-based 
RNA degradation activity assay was conducted for EcPNPase, H6-hPNPase and H6-Rrp4_41_42 to 
confirm 3’-5’ phosphorolytic exoribonuclease activity. Typically experiments which determine a 
particular enzyme’s activity should be conducted in optimal conditions. However, since an initial 
check was required to examine if an intact and active protein was purified, factors including the 
inorganic phosphate (Pi) concentration, magnesium metal cofactor concentration and temperature 
were not optimised. Specific canonical enzyme degradation activity is further characterised in 
Chapter 4. 
 
700 nM of 5’ fluorescein (F) labelled Poly(A) 20mer RNA substrate (5’F Poly(A)20) was incubated 
at 37°C with 240 nM of each protein, in a buffer containing 15 mM Tris pH 8, 112.5 mM NaCl, 
3.75 mM MgCl2, and 0.045 mM Na2PO4. Control experiments were carried out in the absence of 
the relevant recombinant protein (RNA only). The rate of substrate degradation varied for each 
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protein; hence reactions were quenched with 0.1 M EDTA at various times. Degradation products 
of the 5’F Poly(A)20 substrate were separated on a 20% denaturing urea gel at 4°C, visualised using 
a Fujifilm FLA-5000 phosphorimager and quantified by densitometric analysis using Image Gauge 
software (Science Lab Ver. 4.0, Fujifilm) (Section 2.10.2.2). 
 
3.3 Results  
This section describes the results of cloning, expression and purification of the recombinant 
EcPNPase, H6-hPNPase and H6-SsoExosome (H6-Rrp4_41_42) proteins. The majority of results 
from the initial cloning and expression stages have been summarised together for simplicity. 
However, the purification for each individual protein is displayed under separate sub-headings. 
This section also provides the results for the protein identification and 3’-5’ degradation activity 
post-purification. 
 
3.3.1 Recombinant DNA Preparation 
The genes encoding H6-hPNPase, and H6-SsoExosome were successfully synthesised using 
GeneArt Cloning (Section 3.2.1). They were each ligated into their relevant pET vectors; the first 
into pET-28b (kanamycin resistant) and the latter into pETMCN-EAVNH (ampicillin resistant) 
using relevant restriction sites (Nhe1/Sal1 or NdeI/Xbal respectively). For each synthetic construct, 
DNA sequencing identified 100% sequence congruence to the provided template sequence; 
indicating successful cloning by GeneArt (Life Technologies) (data not shown). EcPNPase 
previously cloned into pETDuet-1 vector (ampicillin resistant) was kindly supplied by Prof. Ben 
Luisi (University of Cambridge). 
 
Following successful cloning, transformation of plasmid DNA (containing the gene construct of 
interest) into a desired bacterial cell strain was confirmed using selective LB agar plates (Section 
3.2.2). Using appropriate antibiotics and positive and negative controls pET-28b_H6-hPNPase, 
pETMCN-EAVNH_H6-SsoExosome (H6-Rrp4_41_42) and pETDuet-1_EcPNPase plasmids were 
shown to successfully transform into DH5α cells. Subsequent DNA replication, purification and 
sequencing indicated that all plasmid DNA synthesised by GeneArt had the correct sequence. 
However, sequencing results for the provided full-length EcPNPase plasmid DNA indicated 
multiple nucleotide point mutations within the coding region (data not shown). Ensuring that the 
DNA nucleotide sequence, and thus the encoded protein amino acid sequence was correct was 
crucial. Hence, site-directed mutagenesis was conducted using Agilent Technologies 
QuickChange® II Site-Directed Mutagenesis Kit as described in Section 2.7.5. Re-sequencing 
following multiple rounds of SDM confirmed successful mutagenesis within the coding region. 
 
In summary, results showing colony growth on selective agar plates spread with DH5α cells 
transformed with relevant plasmids (pET-28b_H6-hPNPase, pETMCN-EAVNH_H6-SsoExosome 
(H6-Rrp4_41_42) or pETDuet-1_EcPNPase) indicated successful transformations. The subsequent 
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sequencing results (following SDM for EcPNPase) provided evidence of correct plasmid sequence 
for use in subsequent protein expression and purification. The gene cloning strategy is provided in 
detail in the Appendix (9.6).  
 
3.3.2 Protein Expression 
As before, results showing colony growth on selective agar plates spread with either E. coli 
BL21(DE3)pLysS cells (transformed with pET-28b_H6-hPNPase, pETMCN-EAVNH_H6-
SsoExosome (H6-Rrp4_41_42) or pET-Duet1_EcPNPase) indicated successful transformations into 
a strain viable for protein expression. Colonies from each transformation were screened using a 
small-scale protein expression trial (Section 3.2.3) to check protein production. Typically, all 
colonies tested displayed similar protein expression. Hence, a random individual colony was 
selected for generating glycerol stocks (Section 2.9.3).  
 
Glycerol stocks, shown to express protein in the small-scale expression trial were selected and 
large-scale expression trials were conducted, for each recombinant protein, from their respective 
starter cultures (Section 3.2.4). The conditions optimal for protein expression, as analysed by SDS-
PAGE in Figure 3.1 are listed in Table 3.1. EcPNPase was expressed in the same conditions to 
those previously reported (Figure 3.1 (a)) (Nurmohamed et al., 2011). Detailed conditions for H6-
SsoExosome were not available in the previous literature (Lorentzen, Dziembowski, Lindner, 
Seraphin, & Conti, 2007 or Lu, Ding, & Ke, 2010), hence conditions previously suggested by 
(Bralley & Jones, 2003) to be suitable for PNPases were utilised and protein expression was 
successful in these conditions (Figure 3.1 (c)) (Table 3.1). In order to express hPNPase, conditions 
recommended by Lin et al., 2012 were used initially, however protein expression was sub-optimal 
(data not shown). An expression trial was therefore conducted and the results suggested a lower 
IPTG (0.1 mM) was required to obtain the protein expression shown in Figure 3.1 (b) (Table 3.1). 
 
Analysis of SDS-PAGE large-scale expression results shown in Figure 3.1 provided evidence that 
protein bands corresponding to the sizes expected for EcPNPase, H6-hPNPase, and H6-SsoExosome 
(H6-Rrp4_41_42) proteins were present. Although the ProtParam estimated MW of EcPNPase was 
77 kDa, previous literature has shown the protein to migrate at ~ 84 kDa, consistent with results 
displayed in Figure 3.1 (a) (Soreq, H., Littauer, 1977).  
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Figure 3.1 EcPNPase, hPNPase and SsoExosome Protein Expression Summary 
12% reducing SDS-PAGE analysis of (a) EcPNPase, (b) hPNPase and (c) SsoExosome (Ss) large-scale 
expression alongside the benchmark protein ladder (M). Note some ladder labels are omitted for clarity, see 
Appendix 9.2 for details. Samples of pre and post-IPTG induction at various times (indicated above lane in 
hours (hr)) were loaded and bands corresponding to specific protein monomers are highlighted with blue, red 
or, green asterisk (*) respectively. A single band, which migrates at the size expected for monomeric 
EcPNPase (77 kDa) and hPNPase (83 kDa) was observed. In contrast, due to the nature of SsoExosome 
being a hetero-trimeric of three Rrp4, 41 and 42 monomers (31, 28, and 30 kDa respectively), three bands 
were anticipated. Only two bands were detected as two of the monomers (Rrp4 and 42) migrated at the same 
size, as shown by a double asterisk (**).  
 
In summary, protein expression results justified the progression to protein purification, with the 
aim to remove contaminating E. coli host proteins. 
 
[75] 
 
Table 3.1 Protein-Specific Expression Conditions 
The expression conditions for each recombinant protein are listed with details of the temperature and OD600 nm to which E. coli BL21(DE3)pLysS cell cultures were grown prior to induction 
with IPTG. The concentration of IPTG, temperature and duration of growth following protein expression is also provided (Lin et al., 2012; Nurmohamed et al., 2011). 
 
OD600 nm Temperature (°C) IPTG Concentration (mM) Temperature (°C) Time (Hours)
EcPNPase 0.6 37 0.5 20 20
H6hPNPase 0.6 37 0.1 25 3
H6SsoExosome 0.7 37 1 37 3
Recombinant 
Protein 
Pre-IPTG induction Post-IPTG induction
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3.3.3 Size Exclusion Chromatography Calibration Curve  
Prior to protein purification, a SEC calibration curve was generated from a calibration run using 
protein standards with known molecular weights (MW) (Section 3.2.5.9). For MW standards see 
Table 3.2. The resultant chromatogram showed, as expected, protein standards from individual 
SEC runs 1 and 2 to elute based on their overall size; larger MW proteins eluted earlier than 
smaller MW proteins (Figure 3.2 (a)). Hence both chromatograms were combined in Figure 3.2 (a) 
and elution volumes for protein standards were used to generate a calibration curve in Figure 3.2 
(b). Results demonstrate that as the protein size (Log MW (kDa)) decreased the retention within the 
SEC column increased (Retention Volume (ml)). The data points in Figure 3.2 (b) fit well to the 
straight line equation y = -0.0146x + 3.0456 (where y = log MW (kDa) and x = retention volume 
(ml)). The standard error (+/-) was reasonable for the intercept 3.0456 (+/- 0.0228) and the gradient 
-0.0146 (+/- 0.0003). To further check the accuracy of the equation, elution volumes of protein 
standards were used to re-calculate MW values and these were within <4% (+/-) the actual value, 
as shown in Table 3.2. In summary, the calibration curve equation is suitable for use to predict 
unknown protein MWs, from known elution volumes, following separation by SEC. 
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Figure 3.2 SEC Calibration  
(a) SEC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is shown, with two calibration samples overlaid on one graph (1: Blue dextran 
(2000 kDa), Aldolase (158 kDa) and Ovalbumin (43 kDa) (black line) and 2: Ferritin (440 kDa) and Conalbumin (75 kDa) (grey line)). The elution volume of Blue Dextran (131.07 ml) was 
used as an indicator of the columns void volume. The protein standard Ferritin (□) in sample 2 (grey line) has three peaks; the two labelled (*) are Ferritin oligomers, which elute near the 
void volume, and the peak labelled (□) (159.11 ml) consists of Ferritin monomers. (b) Retention volumes (ml) (elution volume – void volume) for monomeric protein standards were plotted 
against log MW (kDa) to generate a calibration curve and calculate a line of best fit equation: y = -0.0146x + 3.0456 (where y = log MW (kDa) and x = retention volume (ml). The standard 
error of the intercept and gradient was 3.0456 (+/- 0.0228) and -0.0146 (+/- 0.0003) respectively. 
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Table 3.2 SEC Protein Standards 
Protein standards are listed with their molecular weights (MW) and calculated log MW values (both kDa). For each standard, SEC elution volumes (ml) and calculated retention volumes 
(ml) (retention volume = elution volume – void volume) are shown. Protein standard Blue Dextran’s elution volume (131.07 ml) was used as an indicator of this specific SEC column’s 
void volume. The equation of the graph; calculated retention volumes (ml) plotted against log MW (kDa) (Figure 3.2 (b)) was used to recalculate MWs (kDa). Equation: y = -0.0146x + 
3.0456 (where y = log MW (kDa) and x = retention volume (ml). The percentage difference (+/- %) indicated relates to the difference between recalculated and actual MWs. 
 
Protein Standard
MW 
(kDa)
Log MW 
(kDa)
Elution Volume 
(mL)
Retention Volume 
(mL)
Recalculated MW 
(kDa)
Blue Dextran 2000 3.30 131.07 0.00 -
Ferritin 440 2.64 159.11 28.04 432.73 (+1.68%)
Aldolase 158 2.20 187.93 56.86 164.23 (-3.79%)
Conalbumin 75 1.88 212.27 81.20 72.46 (+3.51%)
Ovalbumin 43 1.63 227.62 96.55 43.25 (-0.57%)
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3.3.4 Protein Purification: Protein-Specific 
Results for the purification of individual proteins: EcPNPase, H6-hPNPase and H6-SsoExosome are 
provided.  
 
3.3.4.1 Escherichia coli PNPase 
EcPNPase was purified using a similar method to that conducted in Nurmohamed et al., 2011, see 
methods for details (Section 3.2.6.2). At each stage of the purification process samples were 
retained for SDS-PAGE analysis, see Figure 3.5. Although, for EcPNPase, ProtParam predicts a 
monomeric size of 77 kDa (Appendix 9.6), previous work provided evidence, that upon denaturing 
SDS-PAGE analysis, EcPNPase migrates slightly higher (~85 kDa) than expected when compared 
to a protein molecular weight ladder (Soreq, H., Littauer, 1977). Consequently, the presence of an 
intense band ~ 85 kDa in the lysis, sonication and supernatant purification samples (Figure 3.5) 
provided an initial indication of the successful extraction and clarification of soluble EcPNPase 
recombinant protein from overexpressed E. coli cells. Although the presence of other host proteins 
within these initial stages makes it difficult to confidently assign a visible band to a specific 
protein, over the purification process this becomes easier upon removal of contaminants.  
 
The published purification strategy utilised an ammonium sulphate step to enrich for EcPNPase 
and then dialysis of the sample into an appropriate buffer ready for anion exchange 
chromatography. A band (~85 kDa) indicative of EcPNPase is indicated in the following dialysis 
and pre-HiTrap samples (Figure 3.5). Initial analysis of these lanes suggests little removal of 
contaminants; however, the early samples are normalised for 50 ml of cell lysis whereas the 
dialysis and pre-HiTrap samples are the result of pooling 100 ml soluble protein (supernatant 
samples). Nevertheless, AEC separated EcPNPase further, as highlighted by the presence of the ~ 
85 kDa band in fraction 27 (Figure 3.3 (b), labelled with an asterisk), which related to the 
corresponding protein peak mAU280 nm eluting at ~ 51% Buffer B (Figure 3.3 (a), labelled with an 
asterisk). As indicated in this figure, fraction 27 was retained for further purification by SEC. 
Following SEC, fractions 16-17 were pooled, concentrated and stored at -80°C as standard. This 
was done following the observation of the ~ 85 kDa band (Figure 3.4 (b), labelled with an asterisk) 
within these fractions which corresponded to the protein peak in mAU280 nm recorded at ~162 ml 
(Figure 3.4 (a), labelled with an asterisk). Samples of these chromatography stages (pre and post-
HiTrap or SEC respectively) are also provided in Figure 3.5. These lanes clearly show the removal 
of other contaminants until a pure band of protein migrating at ~85 kDa remains (1 µg).  Using the 
SEC calibration curve elution volumes of 178 ml and 211 ml were predicted for trimeric and 
monomeric EcPNPase respectively, thus suggesting the pooled protein at ~ 166 ml (SEC fractions 
16-17) is more likely to be in the higher oligomeric state (possibly an intact trimer) than 
monomeric form. Further protein identification by mass spectrometry and activity analysis is 
provided in Sections 3.3.5 and 3.3.6 respectively which confirms the purified protein to be 
EcPNPase.  
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Figure 3.3 EcPNPase AEC  
(a) AEC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
Buffer A (20 mM Tris-HCl pH 8.5, 30 mM NaCl, 5 mM MgCl2 and 5 mM DTT) was eluted (black line) with 
a 50 ml gradient (grey dotted line, 0-100%) of elution buffer B (Buffer A with 1 M NaCl). (b) 12% reducing 
SDS-PAGE analysis of pre-HiTrap (AEC), HiTrap flow through (FT) and HiTrap fractions alongside the 
benchmark protein ladder (M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. 
Fractions pooled for further analysis are indicated by label (*). After subsequent analysis (described later) the 
* symbol indicates the peak (a) and fraction (b) containing EcPNPase.  
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Figure 3.4 EcPNPase SEC   
(a) SEC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
SE Buffer (20 mM Tris-HCl pH 8, 150 mM NaCl & 10 mM MgCl2) was also eluted (black line) in SE 
Buffer. (b) 12% reducing SDS-PAGE analysis of pre-SEC sample with various fractions from #6 – 32 
alongside the benchmark protein ladder (M). Note some ladder labels are omitted for clarity, see Appendix 
9.2 for details. The fractions pooled for further analysis are indicated by the bracket. After subsequent 
analysis (described later) the * symbol indicates the peak (a) and fraction (b) containing EcPNPase. 
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Figure 3.5 EcPNPase Purification Stages 
12% reducing SDS-PAGE analysis of EcPNPase purification stages alongside the benchmark protein ladder 
(M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. Initial analysis suggests the 
band present in the final lane (1 µg loaded) may be EcPNPase due to its migration at ~ 80 – 90 kDa, the size 
expected for the monomeric protein. This was confirmed to be EcPNPase after subsequent denaturing mass 
spectrometry analysis (described later).  
 
3.3.4.2 Homo sapiens PNPase  
H6-hPNPase was purified using a similar method to that conducted in Lin et al., 2012, see methods 
for details (Section 3.2.6.1). At each stage of the purification process, samples were retained for 
SDS-PAGE analysis (Figure 3.8). Although ProtParam (Appendix 9.6) predicts a monomeric size 
of 83 kDa for H6-hPNPase, upon denaturing SDS-PAGE analysis, the purified protein migrates 
slightly higher than expected. when compared to a protein molecular weight ladder (Figure 3.8). 
This was similar to EcPNPase, which is also reported to migrates higher than expected (Soreq, H., 
Littauer, 1977). It was difficult to compare the migration of this band to previous hPNPase 
purifications as the sizes of the protein ladder used by Lin et al., 2012 were quite broad (ladder 
bands of 72 kDa and 95 kDa respectively). Either way, the presence of a protein band between 80-
90 kDa was monitored during purification. As with EcPNPase early lysis, sonication and 
supernatant samples were heavily contaminated, providing difficulty in monitoring a specific 
protein band. Following purification via IMAC however, a clear band can be observed in fractions 
15-25 (Figure 3.6 (b), labelled with an asterisk) migrating between 80-90 kDa. Note a spike in 
pressure for the AKTA system was observed in the chromatogram (Figure 3.6 (a) labelled with a 
double asterisk **) and so a broad range of samples were analysed by SDS-PAGE to ensure the 
correct protein-containing fractions were selected (Figure 3.6 (b) labelled with a single asterisk). 
As indicated in this figure, fraction 15-25 was retained for further purification by SEC. Following 
SEC, fractions 18-22 were pooled, concentrated and stored at -80°C as standard. This was done 
following the observation of a band between 80-90 kDa (Figure 3.7 (b), labelled with an asterisk) 
within these fractions which corresponded to the protein peak in mAU280 nm recorded at 180 ml 
(Figure 3.7 (a), labelled with an asterisk). Samples of these chromatography stages (pre- and post-
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HisTrap or SEC respectively) are also provided in Figure 3.8. These lanes clearly show the removal 
of other contaminants until a pure band of protein migrating at ~80-90 kDa remains (0.3 µg). It is 
essential to highlight that 1 ml SEC fractions were concentrated to 10 µl using StrataClean and so 
the samples are heavily overloaded in Figure 3.7 (b) compared to the volume normalised sample 
loaded in Figure 3.8, which suggest that the protein has a similar level of purity compared to other 
proteins prepared within this body of work.  
 
As described previously for EcPNPase, the SEC calibration curve was utilised to predict elution 
volumes of 176 ml and 208 ml, for trimeric (249 kDa) and monomeric (83 kDa) H6-hPNPase 
respectively. This suggests that the pooled protein at ~ 180 ml (SEC fractions 18-22) is more likely 
to be in a higher trimeric than monomeric form. Western blot analysis of this purified protein 
indicated it was a H6-fusion protein and more specifically hPNPase, when using H-tag and Anti-
hPNPase primary antibody probes respectively, Section 2.11. The concentration of hPNPase was 
determined using a Nanodrop 2000 (Desjardins, Hansen, & Allen, 2009); although the yield was 
low (typical yield ~1 mg/ml) the purity was high (>95%) and comparable to the commercially 
available H6-hPNPase (Sigma) which migrated at the same size (not shown). Further protein 
identification by mass spectrometry and activity analysis is provided in Sections 3.3.5 and 3.3.6 
respectively and this confirmed the purified protein to be H6-hPNPase. 
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Figure 3.6 hPNPase IMAC  
(a) IMAC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
lysis buffer (20 mM Tris-HCl pH 8, 300 mM NaCl & 10 mM imidazole) was eluted (black line) with a 30 ml 
gradient (grey dotted line, 0-100%) of elution buffer (lysis buffer with 500 mM imidazole). Note sharp peak 
at ~212 ml was due to a pressure spike detected by the AKTA system (labelled **), hence when compared to 
the chromatogram fraction numbers are slightly out. (b) 12% reducing SDS-PAGE analysis of pre-His 
(IMAC), His flow-through (FT) and His fractions alongside the benchmark protein ladder (M). Note some 
ladder labels are omitted for clarity, see Appendix 9.2 for details. Fractions (15-25) pooled for further 
analysis are indicated by a label (*). After subsequent analysis (described later) the * symbol indicates the 
fractions (b) containing hPNPase.  
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Figure 3.7 hPNPase SEC  
(a) SEC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
SE Buffer (20 mM Tris-HCl pH 8, 150 mM NaCl & 5 mM MgCl2) was eluted (black line) for SEC run. (b) 
12% reducing SDS-PAGE analysis of post-His (pooled IMAC fractions 15-25), pre-SE and Pre-SE FT 
(protein concentrator sample and flow through respectively) with various SEC fractions from #15 – 54 
alongside the benchmark protein ladder (M). Note some ladder labels are omitted for clarity, see Appendix 
9.2 for details. Fractions (18 - 22) used for further analysis are indicated by the bracket, note 1 ml of fractions 
were strata-cleaned, concentrating containing proteins to 10 µl and hence were heavily overloaded. After 
subsequent analysis (described later) the * symbol indicates the peak (b) and fraction (c) containing hPNPase.  
 
[86] 
 
Figure 3.8 hPNPase Purification Stages 
12% reducing SDS-PAGE analysis of hPNPase purification stages alongside the benchmark protein ladder 
(M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. Initial analysis suggests the 
band present in the final post concentration stage (0.3 µg) may be hPNPase due to its migration at ~ 80-90 
kDa, the size expected for the monomeric protein. Additional western blot analysis with a probe for hPNPase 
and H6-tag and the presence of a band in both indicated the presence of H6-hPNPase protein. This was 
confirmed to be hPNPase after subsequent denaturing mass spectrometry analysis (described later).  
 
3.3.4.3 Sulfolobus solfataricus Exosome 
The hetero-trimeric SsoExosome (H6-Rrp4_41_42), was purified using a similar method to that 
conducted in (Lorentzen et al., 2007), see methods for details (Section 3.2.6.3). The three 
individual subunits; Rrp4, Rrp41 and Rrp42 were cloned as a polycistronic gene, since co-
expression has been reported to improve complex solubility (Lu et al., 2010). SDS-PAGE analysis 
of the purification process is provided in Figure 3.11. Although for SsoExosome (H6-Rrp4_41_42) 
ProtParam predicts monomeric sizes of 30.7, 27.6 and 30.2 kDa for subunits H6-Rrp4, Rrp41 and 
Rrp42 respectively (Appendix 9.6). H6-Rrp4 and Rrp41 both migrate at ~ 30 kDa with Rrp42 
migrating higher near 35 kDa. Previous purification shows that the core exosome (H6-Rrp41_42) 
individual subunits migrate at ~ 30 and 35 kDa for H6Rrp41 and Rrp42 respectively (data not 
shown). Hence, when analysing the H6-Rrp4_41_42 complex, reasonable justification can be made 
for the individual Rrp4 subunit, which is visible upon probing for the H6-tag on a western blot, to 
migrate with Rrp41 (unlabelled).  Additionally, this band is more intense than that of Rrp42, 
consisting of only one protein subunit migrating at that position. In summary, the presence of a 
band ~ 35 kDa and a more intense band ~ 30 kDa were monitored during purification. 
 
As in previous purifications the early lysis, sonication and supernatant samples were heavily 
contaminated, providing difficulty in monitoring a specific protein band. Following purification via 
IMAC however, two bands can be observed in fractions 12-19 (Figure 3.9 (a), labelled with an 
asterisk) migrating between 30-35 kDa. As indicated in this figure, fractions 12-19 were retained 
for further purification by SEC. Following SEC, fractions 13-24 were pooled, concentrated and 
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stored at -80°C as standard. This was done following the observation of two bands between 30-4 
kDa (Figure 3.10 (b), labelled with an asterisk) within these fractions which corresponded to the 
protein peak in mAU280 nm recorded at ~172 ml (Figure 3.10 (a), labelled with an asterisk). Samples 
of these chromatography stages (pre- and post-HisTrap or SE respectively) are also provided in 
Figure 3.11. These lanes clearly show the removal of other contaminants until pure bands of 
protein migrating at ~30-35 kDa remains (0.3 µg). As described previously, the SEC calibration 
curve was utilised to predict elution volumes of 238, 241 and 238 ml for individual monomeric 
subunits H6-Rrp4, Rrp41 and Rrp42 respectively and 173.67 ml for trimeric SsoExosome (H6-
Rrp4_41_42). Thus suggesting the pooled protein at ~172 ml (SE fractions 13-24) is more likely to 
be in a higher trimeric than monomeric form. Western blot analysis of this purified protein 
identified it to be a H6-fusion protein when using H-tag antibody probe, Section 2.11.  
 
The oligomeric state could be questioned with the presence of only two bands upon SDS-PAGE; it 
could be suggested that only the Rrp4 and Rrp42 proteins have been purified. Typically, native 
mass spectrometry (MS) can be employed to confirm correct oligomerisation; however, this was 
not possibly due to incompatibility problems with the MS buffer. Nevertheless, as both the Rrp41 
and Rrp42 domains are required to form the catalytically active core structure (Lorentzen et al., 
2005), the 3’-5’ degradation activity confirmation (Sections 3.3.6), supports the successful 
purification of H6-Rrp4_41_42. Additionally, the presence of the Rrp4 domain is anticipated by the 
observed increased degradation activity, when compared to the core H6-Rrp41_42 protein (data not 
shown). 
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Figure 3.9 SsoExosome IMAC  
(a) IMAC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
lysis buffer (20 mM Tris-HCl pH 8, 300 mM NaCl & 10 mM imidazole) was eluted (black line) with a 30 ml 
gradient (grey dotted line, 0-100%) of elution buffer (lysis buffer with 500 mM imidazole). (b) 12% reducing 
SDS-PAGE analysis of pre-His (IMAC), His flow-through (FT) and His fractions alongside the benchmark 
protein ladder (M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. Fractions 
(12-19) pooled for further analysis are indicated by an asterisk. After subsequent analysis (described later) 
the * symbol indicates the fractions (b) containing SsoExosome. 
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Figure 3.10 SsoExosome SEC  
(a) SEC chromatogram; the absorbance units measured at 280 nm (A280 nm (mAU)) over the volume (ml) is 
shown. The fraction number relating to the elution volume is depicted on a second x-axis. Sample loaded in 
SE Buffer (20 mM Tris-HCl pH 8, 150 mM NaCl & 10 mM MgCl2) was eluted (black line) for SEC run. (b) 
12% reducing SDS-PAGE analysis of SEC fractions from #6 – 37 alongside the benchmark protein ladder 
(M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. The Fraction (13 - 24) used 
for further analysis is indicated by the bracket note protein samples were strata cleaned and hence were 
overloaded. After subsequent analysis (described later) the * symbol indicates the peak (b) and fraction (c) 
containing SsoExosome.  
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Figure 3.11 SsoExosome Purification Stages 
12% reducing SDS-PAGE analysis of SsoExosome purification stages alongside the benchmark protein 
ladder (M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for details. Initial analysis 
suggests the band present in the final Post-SE stage (0.3 µg) may be SsoExosome (H6-Rrp4_41_42) due to its 
migration at ~30 and 35 kDa, the size expected for the monomeric protein subunits.  
 
3.3.5 Protein Identification 
The identity of each recombinant protein; EcPNPase, H6-hPNPase and H6-SsoExosome, was 
confirmed by multiple techniques.  
 
3.3.5.1 SDS-PAGE and Western Blot 
As indicated in each protein-specific results sub-section, upon SDS-PAGE analysis, protein 
corresponding to the anticipated size for EcPNPase, H6-hPNPase and H6-SsoExosome were 
observed at > 95% purity. In addition, the presence of a H6-tag, upon western analysis with a 
primary H-tag probe antibody, supports the successful purification of H6-tagged proteins, which are 
likely to be hPNPase and SsoExosome, although more validation was required to confirm these 
protein’s identity. Accordingly, the presence of a protein band upon western analysis, with an 
antibody specific to hPNPase, strongly suggests hPNPase was effectively purified. A summary of 
recombinant protein purification analysis by SDS-PAGE is provided in Figure 3.12. 
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Figure 3.12 Protein Purification Summary 
12% reducing SDS-PAGE analysis of EcPNPase, hPNPase and SsoExosome purification stages alongside 
the benchmark protein ladder (M). Note some ladder labels are omitted for clarity, see Appendix 9.2 for 
details. All recombinant proteins were purified to > 95% purity. 
 
3.3.5.2 Denaturing Mass Spectrometry (LC-MS/MS) 
The identity and monomeric weight of recombinant proteins EcPNPase and hPNPase was 
confirmed by denaturing LC-MS/MS, (Section 3.2.7.3). Analysis of results, provided by the 
Astbury Centre, Mass Spectrometry Facility (University of Leeds), confirmed their identity 
respectively. More specifically, using a peptide digest with trypsin, the percentage coverage for 
EcPNPase and hPNPase were 79% and 54% respectively; with good coverage over both the N-
terminal and C-terminal regions.  
 
The molecular weight of both enzymes were predicted by ProtParam to be ~ 77 and 83 kDa for 
EcPNPase and hPNPase respectively, however both enzymes were found to migrate between 80-90 
kDa, when compared to a protein molecular weight ladder (Figure 3.12). The MW of hPNPase was 
determined by mass spectrometry to be 86 kDa and this aligns well to the enzymes migration in 
Figure 3.12. The MW of EcPNPase, determined by MS, was 77 kDa. Although this was lower than 
the protein migration in Figure 3.12, this was no surprise since EcPNPase is known to migrate 
slightly higher (~85 kDa) than expected upon SDS-PAGE analysis (Soreq, H., Littauer, 1977). 
 
3.3.5.3 Non-Denaturing Mass Spectrometry 
Non-denaturing MS was also performed at the Astbury centre for the SsoExosome (Rrp4_41_42) 
complex; however, results could not be obtained. It was suggested that the protein complex was not 
stable in the mass spectrometry buffer and would require further optimisation. As this was not the 
main focus of the study, and evidence had already been provided that the SsoExosome was intact, 
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as identified by SDS-PAGE analysis of single species from SEC, and formed an oligomeric 
structure of similar MW to the H6-Rrp4_41_42 complex (as shown by SEC analysis), it was 
decided that the 3’-5’ degradation activity would be examined for confirmation of identity.  
 
3.3.6 3’-5’ RNA Degradation Activity of Recombinant Proteins  
The 3’-5’ exoribonuclease degradation activity of each recombinant protein; EcPNPase, H6-
hPNPase and H6-SsoExosome, was confirmed by a gel electrophoresis-based assay (Section 3.2.8). 
Data were normalised, when appropriate, to account for minor differences in enzyme activity 
between protein preparations. Although their activity varied slightly, as indicated by the different 
incubation periods, results from the end-point degradation assay revealed a 3’-5’ processive 
degradation of the 5’FAM Poly(A)20mer RNA substrate by each recombinant protein (Figure 3.13). 
As mentioned previously, assay conditions were not optimised for any protein specifically and this 
allowed the same protocol to be applied, to test quickly whether the enzymes purified exhibited the 
3’-5’ phosphorolytic activity expected. Notably, Chapters 4 and 6 provide details of the gel-based 
degradation assay optimisation and further enzyme characterisation respectively.  
 
 
Figure 3.13 Recombinant Protein Degradation Activity Summary 
20% urea denaturing PAGE loaded with 700 nM 5’FAM pol(A)20mer RNA substrate (R) with or without 240 
nM of relevant RNase (EcPNPase, hPNPase or SsoExosome) (R&P respectively), incubated at 37°C for 
various times (minutes indicated). Samples were separated in 1x TBE buffer at 200 V for 1 hour 30 minutes 
at 4°C. The gels were visualised using the Fujifilm FLA-imaging system (Phosphorimager: Blue filter, Blue 
laser, 473 nm). 
 
3.4 Conclusions 
This chapter describes the successful cloning, expression and purification of the recombinant 
EcPNPase, H6-hPNPase and H6-SsoExosome (H6-Rrp4_41_42) proteins. As supported by the 
variety of experimental evidence provided in the results Section 3.3, the methods utilised (Section 
3.2) to produce each of the recombinant proteins were successful. The majority of methods 
conducted were identical to those previously published in the literature. However, in some cases, 
these published methods were sub-optimal and modifications were applied, as justified in the 
relevant results section. This was conducted to yield enhanced purity.  
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Summary Figure 3.12 and Figure 3.13 show the final purified proteins and their 3’-5’ 
exoribonuclease activity respectively. All recombinant enzymes were purified at > 95% purity with 
a concentration of ~1mg/ml per 2 L of LB media. This yield was not high; however, this may be a 
result of the enzymatic ribonuclease activity within the E. coli expression host. It is well 
established that PNPase knock-outs can affect growth and bulk RNA levels in E. coli (reviewed in 
Arraiano et al., 2010), therefore overexpression of EcPNPase and its homologs, hPNPase and 
SsoExosome, may also have affected the host E. coli expression system. Although the purified 
protein was not prepared in high-yields, it was still sufficient for downstream biochemical testing 
as the subsequent experiments required very little protein. Most importantly, each protein was 
prepared at high enough purity for determining the effect of citrate on PNPase homologs’ activity, 
which is described in the subsequent Chapter 4. 
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4 Inhibition of Homologous Phosphorolytic 
Ribonucleases by Citrate May Represent an 
Evolutionarily Conserved Communicative Link 
between RNA Degradation and Central Metabolism 
 
Chapter 1 has already introduced the current literature and techniques available to study the 
connection between RNA regulation and central metabolism, underlining specific proteins which 
regulate RNA turnover in response to cellular and metabolic flux. Research which lays the 
foundations of this chapter’s work was also covered. In summary, the results described by 
Nurmohamed et al 2011 clearly revealed a communicative link between PNPase and metabolism in 
E. coli. Whether this represents a mechanism that is conserved in other prokaryotes and/or higher 
organisms remains to be identified and was the focus of this chapter.  
 
4.1 Chapter Aims 
The previous Recombinant Protein Preparation Chapter 3 described the successful preparation of 
PNPase and archaeal exosome proteins for use in subsequent experimental chapters. Accordingly, 
this results chapter utilises these enzymes for inhibition studies with the metabolite citrate. 
Unfortunately, the X-ray crystallography of SsoExosome with citrate was not successful within this 
study. Henceforth this chapter describes the various in silico and in vitro techniques used to 
investigate whether this citrate-PNPase link represents a conserved mechanism across the three 
domains of life; utilising representative PNPase homologs from prokaryotes, eukaryotes and 
archaea. Key questions addressed within this work include, whether citrate interacting resides are 
conserved in PNPase homologs and thus is citrate binding predicted to be conserved? Detailed 
methods for protein sequence alignments and predicting citrate-PNPase interactions in silico, using 
molecular modelling and docking tools are provided in Section 4.2. Whether Mg2+ citrate can 
modulate the degradation activity of PNPase homologs is also examined and the methods for in 
vitro gel-based degradation assays are described in Section 4.2. The resulting data are provided in 
the following Section 4.3 and important conclusions regarding the conservation of a citrate-PNPase 
communication link are then summarised in Section 4.4.  
 
4.2 Methods 
The section herein describes the methods that were employed to study citrate-PNPase homolog 
interactions, including bioinformatics studies, in silico molecular docking and trials using X-ray 
crystallography for protein-ligand structure determination. The experimental techniques used to 
assess the effect of Mg2+ citrate on RNase activity in vitro, using gel-based degradation assays, are 
then described. Collectively the methods outlined within this chapter section were used as standard 
in subsequent chapters, unless otherwise specified.  
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4.2.1 Bioinformatics: Protein Sequence Alignments 
Appropriate protein sequences, listed in Table 4.1, were selected and aligned using the default 
parameters of the Clustal Omega progressive alignment tool (McWilliam et al., 2013). Multiple 
protein sequences alignments were then edited and annotated using Jalview software (Waterhouse, 
Procter, Martin, Clamp, & Barton, 2009). 
 
  
Table 4.1 Protein Accession Codes 
The protein accession code for each enzyme used for protein sequence alignments is listed. 
 
A more detailed protein sequence alignment and consensus sequence was then produced. Protein 
sequences from prokaryotic, eukaryotic and archaeal PNPase homolog were extracted from the 
NCBI RefSeq database (Genbank) using polynucleotide phosphorylase and Rrp41/Rrp42 as search 
terms where appropriate (Pruitt, Tatusova, Klimke, & Maglott, 2009). Sequences were not 
extracted directly from BLAST as large numbers of S1 and KH domain homologs were incorrectly 
selected rather than the required PNPase homologs. The protein accession codes used for 
alignments are all provided in Appendix 9.8. The multiple protein sequence alignments, for each 
domain of life, were built using MAFFT vs.7. The G-INS-i iterative refinement strategy was 
selected, along with the default BLOSUM62 and Gap Penalty of 1.53 parameters. (Katoh & 
Standley, 2013). The alignments were then manually curated to remove duplicates and partial 
entries. To filter out redundancy, close homologues, with > 95% sequence identity, were omitted 
from the alignments using Jalview (Waterhouse et al., 2009). The remaining aligned sequences 
were trimmed to the 'core' boundaries using the known E. coli sequence/structure as a guide (e.g. 
EcPNPase residues 1-549, hPNPase 1-601, SsoExosome 1-532). The consensus for the RNA 
Binding Regions 1 and 2, Phosphate Binding Region and Metal Binding Region (RBRI, RBRII, 
PBR and MBR) motifs were identified using these final set of sequences (3509 prokaryote 
sequences, 252 eukaryote sequences and 69 archaeal sequences) and visualised using Weblogo3, 
with the probability score depicted on the y-axis and residues on the x-axis (Schneider & Stephens, 
1990). 
 
Enzyme Protein Accession Code
EcPNPase WP_060707494.1 
hPNPase NP_149100.2
SsoExosome WP_009991308 (Rrp41) WP_009991305.1 (Rrp42)
SspPNPase WP_010871289
CbuPNPase WP_042526278.1
CcrPNPase WP_010917924.1
SanPNPase GI: 75349253
MthExosome WP_010876322.1 (Rrp41) WP_010876321.1 (Rrp42)
AfuExosome WP_010878000.1 (Rrp41) WP_010878001.1 (Rrp42)
PabExosome  WP_010867734.1 (Rrp41) WP_010867735.1 (Rrp42)
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4.2.2 In-Silico Molecular Docking 
All the computational procedures, for each of the PNPase homologs tested, were carried out within 
the molecular docking program MOE (Molecular Operating Environment, 2013), as summarised in 
the flow diagram in Figure 4.1. Details of individual steps are described in Sections 4.2.2.1 to 
4.2.2.3 
 
 
Figure 4.1 MOE Flow Diagram 
Stages of in silico MOE docking (Molecular Operating Environment, 2013), from downloading PDB files to 
preparing heat maps, are illustrated as a flow diagram. Illustration created using GIMP (v2) (GIMP, n.d.). 
 
4.2.2.1 Structure Preparation  
Appropriate X-ray crystal protein structures for EcPNPase, SanPNPase, hPNPase, SsoExosome 
were selected (PDB entry: 3GCM, 1E3P, 3U1K and 4BA1 respectively), downloaded from the 
PDB as text files and opened as biomolecules using MOE. Input structures were checked using 
MOE for additional information within the pdb.txt files, such as extra/non-standard amino acids 
residues/chains, inhibitors and cofactors, and removal of unwanted information was conducted 
where necessary. Individual structures were submitted to a preparation step using the MOE LigX 
interface; assignment of the correct ionization states, geometry optimization, protonation, and 
energy minimization of the protein receptors was conducted. For energy minimization and docking 
in MOE the AMBER12: EHT force field was used, this is recognized to be specifically 
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parameterised for both proteins and small molecules (Scholz, Knorr, Hamacher, & Schmidt, 2015; 
Wang, Wolf, Caldwell, Kollman, & Case, 2004).  
 
Metal ions Mg2+ and/or Mn2+, essential for catalytic activity, were only present in some of the 
PNPase/Exosome crystal structures available on the PDB. Hence EcPNPase, with Mg2+ located in 
its active site, was used as a model for placing Mg2+ in the active sites of those PNPase homologs 
structures lacking this essential ion, as described previously for SsoExosome (Lorentzen & Conti, 
2012). Accordingly, the hPNPase, SanPNPase and SsoExosome enzymes, lacking the presence of 
an Mg2+ co-factor, were aligned against EcPNPase using the MOE superpose panel and the 
EcPNPase Mg2+ cofactor was defined as part of the receptor for the other enzymes. Residues 
known to coordinate Mg2+ within E. coli PNPase were compared to the PNPase homologs to see if 
the corresponding residues, in these enzymes, also coordinated Mg2+; the type of interaction and 
residues involved were checked using the MOE built-in interaction map tool. This ensured that the 
newly placed metal ion was correctly coordinated within the active site; confirming that essential 
contacts and positioning were maintained in this new structure. 
 
Once protein structures were prepared, the MOE Alpha Site Finder panel was used to predict 
putative binding sites from the three-dimensional structure, using a geometric approach. 
Knowledge of active site residues essential for catalytic activity, determined from previous 
publications, was then applied to select the appropriate pocket concavity which represented the 
protein’s active site. More specifically, if multiple residues of the PBR and MBR consensus motifs 
(Figure 1.11) were observed within the Alpha site finder panel, for a particular active site hit, this 
hit was selected. Once selected, the active sites were defined via the placement of dummy atoms at 
the locations of hydrophobic and hydrophilic α-spheres; these spheres represented locations of tight 
packing (Galli et al., 2014). 
 
4.2.2.2 In-Silico Citrate Docking 
The structure of the citrate ion metabolite was obtained from the ZINC database (ZINC00895081); 
downloaded and saved as a MOL2 file in a biologically relevant conformation (Irwin, Sterling, 
Mysinger, Bolstad, & Coleman, 2012). Using the appropriate active site pocket defined previously, 
docking calculations were carried out using the docking module of MOE. The docking parameters 
were selected as recommended for protein-small molecule interactions, including the Amber12: 
EHT force field which suggests ideal parameters for proteins and nucleic acids (Amber ff12) and 
for small molecules (Extended Hueckel Theory) respectively. Enzymes were set as fixed 
‘receptors’ and the ‘ligand’, in this case the citrate ion, was docked into the active site at the 
defined dummy atoms, using the MOE default triangle matcher placement tool and 300 placement 
poses (iterations). This triangle matcher placement methodology is recognised to be the best 
method for standard and well-defined binding sites and it generates poses by superposing triplets of 
ligand atoms and triplets of receptor site points (dummy atoms/ α-spheres centres) (Galli et al., 
2014). Thirty unique receptor-ligand complexes were generated, documented within a database 
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viewer (DBV) and saved as a MOE database (MDB). The accepted ligand poses were scored 
according to the MOE default London dG scoring function, which estimates the binding free 
energy of the ligand from a given pose (Galli et al., 2014). This scoring function contains terms for 
the receptor-ligand interaction, including the loss or gain of translational and rotation entropy, 
energy related to fixing rotatable bonds, hydrogen bond formation, metal ligation and a desolvation 
penalty for removing the ligand from aqueous solution. The more negative the value of this London 
dG score, the higher the affinity of this ligand-receptor complex is predicted to be (Molecular 
Operating Environment, 2013). The 300 docking poses were then subject to a forcefield 
refinement, with no second rescoring, and 30 unique poses for each compound were retained. The 
docking score (S) for these 30 unique receptor ligand complexes were calculated using the 
Generalized Born solvation model (GB/VI).  This calculated the non-bonded interaction energy 
(van der Waals, Coulomb and GB implicit solvent interaction energies) between the receptor and 
the ligand complex whilst excluding the self-energies of the individual receptor and ligand atoms. 
The default rescoring 2 GBVI/WSA dG was not employed; this setting was adjusted to none, as 
recommended by MOE for docking databases (Molecular Operating Environment, 2013). The 
lowest-energy scoring poses for each ligand (citrate ion) were selected and the MOE binding score 
(S) values (kcal/mol) were recorded for each enzyme. The lowest-energy pose with a single citrate 
ion docked was selected and used as the starting structure to dock a second citrate ion.  
 
4.2.2.3 Protein Ligand Interaction Fingerprints (PLIF) and 
Heat Map Generation 
The top 10 lowest-energy scoring poses, with both one and two citrate ions docked, were then 
selected to generate a representation of the three dimensional molecular interactions between the 
docked ligands and protein. This was generated for each enzyme using the MOE Protein Ligand 
Interaction Fingerprints (PLIF) panel (Singh, Deng, Narale, & Chuaqui, 2006). When implemented 
in MOE, PLIF classified interactions between the receptor binding site residues and the ligand, in 
this case citrate, are sorted into various types of weak and strong interactions using the interaction 
assessment function built into the program. There are some variations, but typically an Interaction 
Fingerprint (IF) describes the receptor-ligand intermolecular interactions as a bit string. This bit 
string is defined by the following parameters; whether residues contact the ligand (i), if main chain 
atoms and side chain atoms are involved in binding (ii and iii respectively). The type of interaction 
involved is considered, whether this is a polar interaction (iv), non-polar (v), hydrogen bond 
acceptor(s) (vi) and hydrogen bond donors (vii) (Sato, Honma, & Yokoyama, 2010). The data 
described above generated from the MOE PLIF was exported as bit scores into Microsoft Excel 
(2010). Finally, the frequency with which an interaction was observed between citrate and a 
particular amino acid in the docking calculation was determined from the PLIF bit scores. The 
resulting percentages for docking both one and two citrate ions were presented as heat maps using 
the online Plotly graph software (Plotly Technologies Inc., 2015). 
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4.2.3 X-Ray Crystallography  
A Pre-Crystallization Test (PCTTM, HAMPTON Research) was initially conducted to select the 
appropriate protein concentration for crystallisation screens, as described in the user manual. As 
recommended, the A1/A2 PCT test was conducted first; 0.5 ml of reagents A1 (0.1 M Tris HCl pH 
8.5, 2.0 M (NH4)2SO4) and A2 (0.1 M Tris HCl pH 8.5, 2.0 M MgCl2, 30% (w/v) Polyethylene 
glycol 4,000) were pipetted into the A1 and A2 reservoirs wells of a VDX Plate respectively. To 
the centre of a single glass cover slide 1 µl of protein sample (17.5 µM SsoExosome and 20 mM 
sodium citrate) and 1 µl of A1 reservoir solution was added, without mixing. The slide was then 
inverted over the A1 reservoir and sealed, and the process was repeated for reservoir A2. After 30 
minutes the drops were viewed using a light microscope with a magnification between 20 and 
100x. The results were compared to Figure 4.2 and depending on the results; the process used to 
test reagents A1/A2, was repeated with reagents B1 (0.1 M Tris HCl pH 8.5, 1.0 M (NH4)2SO4) and 
B2 (0.1 M Tris HCl pH 8.5, 2.0 M MgCl2, 15% (w/v) Polyethylene glycol 4,000) as necessary. 
Once the appropriate protein concentration was identified in the PCT test, a crystal screen was 
conducted. 
 
 
Figure 4.2 PCT Recommended Actions 
The recommended steps to take during the PCT Pre-Crystallization test are outline in this figure, which was 
taken directly from the PCTTM, HAMPTON Research user manual. (a) Depending on the precipitate 
observed; either (b) light or (c) heavy amorphous, the recommended actions following the A1/A2 and the 
B1/B2 test are provided. 
 
Following the Pre-Crystallization test a PACT premier™ screen (Molecular Dimensions) was set 
up (Newman et al., 2005), the screen conditions are provided in Appendix 9.7. The screen was 
conducted with 17.5 µM SsoExosome and 20 mM sodium citrate (previously determined optimal 
concentrations in the PCT test), using a honeybee robot (Genomic solutions) at 22°C and 70% 
humidity. A hit was discovered for well D7 (0.2 M NaCl, 0.1 M Tris pH 8 & 20% peg 6,000) after 
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2 weeks at 16°C. Individual crystals were grown for a further 6 months at 16°C prior to being cryo-
protected in 20% glycerol and cryo-cooled in liquid nitrogen. Crystals were analysed at Diamond 
Light Source (remote access) for protein diffraction and data collection and this work was done in 
collaboration with Prof. John McGeehan (University of Portsmouth). 
 
4.2.4 Gel-Based In Vitro RNA Degradation Assays 
Gel-based electrophoresis degradation assays were used to analyse the 3’-5’ phosphorolytic 
exoribonuclease activities of recombinant EcPNPase, hPNPase, SspPNPase and SsoExosome 
proteins canonical activity and in the presence of citrate. 700 nM of 5’ fluorescein amidite (FAM) 
labelled Poly(A)20mer RNA substrate (Dharmacon) was incubated at 37°C with 240 nM of each 
protein, in a buffer containing 15 mM Tris pH 8, 112.5 mM NaCl, 3.75 mM MgCl2, 0.045 mM 
Na2PO4 (+/- 3.75 mM citrate). Control experiments were carried out in the absence of the relevant 
recombinant protein, termed RNA only (+/- 3.75 mM citrate). The rate of substrate degradation 
varied for each protein; hence reactions were quenched with 0.1 M EDTA at various times, details 
of which are provided in the results figure legends respectively. Degradation products of the 
5’FAM Poly(A)20mer RNA substrate were separated on a 20% denaturing urea gel as described in 
Chapter 2, Section 2.10.2.2. Gels were visualised using a Fujifilm FLA-5000 phosphorimager, 
quantified by densitometry using the ImageJ open-source Java-based imaging program (Abràmoff, 
Magalhães, & Ram, 2004) and analysed using GraFit software (Leatherbarrow, 2009). 
 
For consistency all reactions were conducted using identical conditions, although these were 
sometimes sub-optimal for a particular enzyme. Specifically, the RNA substrate was kept 
consistent; a 5’FAM Poly(A)20 mer was used, since PNPases from both prokaryotes and eukaryotes 
and the archaeal exosome have all been shown to process 3’ poly(A) tails. The phosphate 
concentration was particularly low compared to EcPNPase optimum (10-20 mM), since hPNPase 
required less (0.1 mM) for activity and can be inhibited by high concentrations (Portnoy, Palnizky, 
Yehudai-Resheff, Glaser, & Schuster, 2007). Additionally, although the SsoExosome can function 
at temperatures of ~65°C (data not shown), hPNPase and EcPNPase are not tolerant of these 
extreme conditions and so assays were all conducted at 37°C.  In summary, in order to determine if 
citrate affects PNPase homolog activity in vitro, sub-optimal conditions were selected, with the 
main emphasis being on producing comparable data. 
 
4.3 Results  
This section firstly investigates the citrate-PNPase interactions previously documented in the 
literature in further detail, before the results of in silico protein sequence alignments are provided, 
which investigates the conservation of these interactions (Sections 4.3.1-4.3.2 respectively). 
Results from in silico molecular docking are subsequently provided in Section 4.3.3, which initially 
use available EcPNPase and hPNPase structures with citrate bound for validation purposes, prior to 
predicting citrate binding for SanPNPase and SsoExosome homologs. Following predictive tools, 
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the results of a trial of SsoExosome co-crystallisation with citrate are then presented in Section 
4.3.4. Subsequent results from in vitro experiments, investigating the effect of citrate on PNPase 
homologs’ 3’-5’ phosphorolytic degradation activity, are then provided in Section 4.3.5. Finally, a 
more detailed protein sequence bioinformatic analysis is provided in Section 4.3.6 and this focuses 
on the conservation of citrate-binding residues more widely across evolution. 
 
4.3.1 Investigating Citrate-PNPase Interactions 
4.3.1.1 E. coli and H. sapiens Structures 
The first hint that citrate might regulate PNPase came from structural studies of the PNPase PH-
hexamer core from E. coli (Nurmohamed, Vaidialingam, Callaghan, & Luisi, 2009). As mentioned 
in Chapter 1, citrate had been present in the crystallisation buffer and the resulting structure 
revealed up to four molecules of citrate bound per PNPase monomer (Nurmohamed et al., 2009). 
This original paper, describing citrate-PNPase interactions in E. coli, suggested that the citrate 
molecules occupy the proposed location of catalytic intermediates at the catalytic site. They 
suggested that the positions of these molecules would be expected to prevent the formation of the 
Michaelis complex and provide a potential means of enzyme inhibition. Indeed, inhibitory effects 
were seen in vitro for citrate binding within this active site. Interestingly, citrate binding at the 
vestigial site was also shown to modulate PNPase activity, most likely through an allosteric 
mechanism (Nurmohamed et al., 2011). The exact type of interactions between citrate and PNPase 
residues were not discussed at lengths in Nurmohamed et al., 2011, hence more detailed 
information is provided within this section. Understanding these interactions was important before 
comparisons could be made with other PNPase homologs. 
 
Using MOE, an interaction map can be generated which determines the residues and type of 
interaction involved in ligand binding. Simply, the citrate molecules co-crystalised within PNPase 
were selected in turn and using the Ligand Interaction Panel of MOE, the residues and type of 
interaction were computed. Specifically, the interactions of each active site citrate (two citrates per 
monomer) and vestigial site citrates (two citrates in one monomer) of the EcPNPase crystal 
structure (3GCM) were studied (Figure 4.3). The citrate molecule closest to the Mg2+ ion (pdb: Cit 
552, termed citrate 1 herein; Figure 4.3 (a)) was suggested by MOE to contact the metal ion. In one 
monomer, citrate 1 also interacted with G436, S438, S439 residues in the PBR via backbone 
acceptor interactions (blue arrows) and the K494 residue in the MBR via a sidechain acceptor 
(green arrow) as shown in Figure 4.3 (b). The second citrate molecule, furthest from the Mg2+ ion 
(pdb: Cit 551, termed citrate 2 herein; Figure 4.3 (a)), mimicked the position of the scissle 
phopshate in an RNA substrate (Nurmohamed et al., 2011). In one monomer, citrate 2 was 
suggested to interacted with H403 via a sidechain acceptor (green arrow). It also contacted residue 
R93 of RBRI and residues R399 and K494 of RBRII, with residues acting as both an ion contacts 
(purple line) and side chain acceptors (green arrow) (Figure 4.3 (c)).  
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Figure 4.3 EcPNPase Active Site Citrate Interactions  
(a) EcPNPase 3GCM (grey ribbons) with co-crystallised ligands including Mg2+ (purple sphere), citrate 1 and 
2 within the active site (orange sticks). MOE ligand interaction map for (b) citrate 1, (c) citrate 2 and (d) the 
legend. Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) 
(GIMP, n.d.). 
 
The interactions shown in Figure 4.3 highlight those within the active site of one monomer, which 
was later selected for docking. However, upon examination of the active sites in the other two 
monomers, subtle differences in ligand interactions were observed in MOE. This may have been 
due to using a structure generated by X-ray crystallography, which is effectively a snapshot image 
of the fixed protein. In order to generate a summary of interactions which showed the occurrence 
rate of citrate binding residues in all three monomers, a Protein Ligand Interaction Fragment 
(PLIF) was generated (Figure 4.4). The PLIF output, shown in Figure 4.4, clearly illustrated the 
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slight differences in citrate-PNPase interactions for each monomer. For example, interactions of 
residues R399 and H487 with citrate 1 were completely absent in one monomer (monomer 2 and 3 
respectively) and S483 made one more contact in monomer 3 than it did in monomers 1 and 2 
(Figure 4.4 (a)). The types of interactions made for citrate 2 were the most similar, the only residue 
which had a different number of interactions was R399. Only one type of contact was seen in 
monomer 1, three types were made in monomer 3 and four contacts were made in monomer 2. 
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Figure 4.4 EcPNPase Active Site Citrate PLIF  
MOE PLIF for (a) citrate 1 and (b) citrate 2, highlighting individual citrate binding residues for the active site of each monomer (1-3) of the homotrimer EcPNPase 3GCM structure. Black 
bars indicate an individual contact between the citrate (termed the ligand) and the 3GCM active site (termed the receptor). Images generated in MOE (Molecular Operating Environment, 
2013) and prepared in GIMP (v2) (GIMP, n.d.). 
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From the PLIF interaction maps presented in Figure 4.4, a summary of the citrate-PNPase 
interactions for EcPNPase, as a whole protein, were deduced. Eight residues were described to 
interact with citrate including; S437, S438, S439, H487, K494, R93, R399 and H403.  
 
The interactions of the vestigial site citrates were also investigated. The first citrate molecule at the 
vestigial site, closest to active site citrates (VCitrate1) (Figure 4.5 (a)) was suggested to interact 
with R153 and R409 via sidechain acceptors (Figure 4.5 (b)). The vestigial citrate 2 (VCitrate2) 
contacted R372 and K408 via ion/metal contacts, and residues R405 and R409 via sidechain 
acceptor contacts (Figure 4.5 (c)). Since only one monomer contained citrates at the vestigial site, 
the PLIF shown in Figure 4.5 (e) directly represented the interaction maps shown in Figure 4.5 (b-
c). 
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Figure 4.5 EcPNPase Vestigial Site Citrate Interactions  
(a) EcPNPase 3GCM (grey ribbons) with co-crystallised ligands including Mg2+ (purple sphere), citrate 1 and 
2 (Citrate, orange sticks) within the active site and citrate 1 and 2 of the vestigial site (VCitrate, black sticks). 
MOE ligand interaction map for (b) VCitrate 1, (c) VCitrate 2, (d) the legend is shown. (e) MOE PLIF for 
vestigial citrate 1 and 2 is also provided. Images generated in MOE (Molecular Operating Environment, 
2013) and prepared in GIMP (v2) (GIMP, n.d.). 
 
As mentioned in Chapter 1, when the crystal structure of the PNPase core from H. sapiens (3U1K) 
was reported, it too had crystallised in a buffer containing citrate. In this structure, only two 
[107] 
molecules of citrate were observed per PNPase monomer and both were at the active site, there was 
no evidence of citrate binding to a vestigial site (Lin et al., 2012). As conducted for EcPNPase, an 
interaction map was generated in MOE to investigate citrate-hPNPase interactions (Figure 4.6). 
The hPNPase 3U1K pdb file contained only one unique chain, hence when the file was opened in 
MOE, biomolecule symmetry was applied in order to create the homotrimer. As a result, each chain 
and thus the active site citrate-binding interactions were identical for each monomer. This meant 
that the PLIF generated previously wasn’t required; the residues interacting with citrate could be 
determined directly from the interaction maps in Figure 4.6. Accordingly, the residues required for 
citrate 1 interactions were examined, residues S482, S483 and S484 of the PBR interacted via a 
backbone acceptor (blue arrow), and K546 of the MBR bound citrate through a metal/ion contact 
(purple line) (Figure 4.6 (b)). Those residues involved in Citrate 2 interactions included R132 of 
the RBRI via a sidechain acceptor, R446 through a metal/ion contact, and H450 of the RBRII and 
K464 of the MBR via sidechain acceptors (Figure 4.6 (c)).  
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Figure 4.6 hPNPase Active Site Citrate Interactions  
(a) hPNPase 3U1K (grey ribbons) with co-crystallised ligands including citrate 1 and 2 (orange sticks) within 
the active site. MOE ligand interaction map for (b) citrate 1 and (c) citrate 2 and (d) the legend. Images 
generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
 
Comparison of the citrate-EcPNPase and citrate-hPNPase interactions shown in Figure 4.3 and 
Figure 4.6 respectively, revealed that of the 8 citrate-binding residues identified in the EcPNPase 
active site (S437, S438, S439, H487, K494, R93, R399 and H403), 7 are observed to bind citrate in 
hPNPase. Interestingly, the interaction of H487 with citrate 1 in EcPNPase was not present in 
hPNPase and this residue has been substituted for a tyrosine. The PLIF in Figure 4.4 suggests that 
H487 in EcPNPase doesn’t make a contact with citrate in one of its monomers, potentially 
suggesting this is not an essential interaction. Whether this histidine to tyrosine mutation will affect 
the ability of citrate to bind and regulate hPNPase activity is unknown. Lin et al., did not go on to 
[109] 
test the effect of citrate on hPNPase activity and so it remains to be determined whether hPNPase is 
also regulated by this metabolite. However, based on the conservation of citrate-PNPase 
interactions it would be predicted that citrate would inhibit hPNPase similar to EcPNPase.  
 
4.3.1.2 Structural Conservation of PNPase Homologs 
After establishing exactly which residues interact with citrate in both EcPNPase and hPNPase the 
structural conservation of PNPase homologs was investigated. This allowed regions of low and 
high structural conservation to be compared. Comparing PNPase homologs within MOE was 
possible due to the superimpose panel; using this tool, protein structures can be superimposed 
based on the whole protein (in this case the complete homotrimer), individual monomers or even 
specific pocket residues within an active site.  
 
Structural alignments were conducted for all three PNPase homologs; EcPNPase, hPNPase and 
SsoExosome and the results showed that their cores (RNA binding domains absent/removed) were 
structurally very similar (Figure 4.7). Alignment of the EcPNPase Chain_A monomer (blue), with 
the hPNPase Chain_1 monomer (pink) and the SsoExosome Rrp41 Chain_AB monomer (Green) 
was conducted (Figure 4.7 (b)) and all three proteins active sites overlay well (Figure 4.7 (c)). It is 
important to note that the essential magnesium metal ion, required within the active site for 
catalysis, was only present in EcPNPase and was placed within hPNPase and SsoExosome 
structures (Figure 4.7, magenta spheres), as outlined later in Section 4.3.3.2.  
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Figure 4.7 Structural Conservation of PNPase Homologs 
(a) EcPNPase (3GCM), hPNPase (3U1K) and SsoExosome (4BA1) superimposed, a box (red line) highlights 
individual PNPase monomers and the corresponding Rrp41 and Rrp42 archaeal exosome proteins. (b) A 
zoomed in image of these ‘monomers’ are shown in isolation, with chains coloured blue, pink and green for 
EcPNPase (Chain A), hPNPase (Chain 1) and SsoExosome (Chain AA/AB) respectively, a box (red line) 
highlights the location of the active site. (c) Another zoomed in image of the active site shows the structural 
conservation of the three homologs and location of co-crystallised EcPNPase and placed hPNPase and 
SsoExosome Mg2+ ions (pink spheres). Images generated in MOE (Molecular Operating Environment, 2013) 
and prepared in GIMP (v2) (GIMP, n.d.). 
 
The average distance between atoms of these superimposed chains was also calculated (Figure 4.8). 
The measured Root-Mean-Square Deviation (RMSD) values for EcPNPase and hPNPase were 
relatively low (1.25 Å) indicating high structural conservation (Figure 4.8 (b)). The RMSD values 
[111] 
for SsoExosome with either EcPNPase or hPNPase were higher, measuring 2.65 Å and 2.59 Å 
respectively (Figure 4.8 (b)). However, when examining the aligned structures and the RMSD 
values further, peaks in RMSD were observed in discrete regions of the sequence (Figure 4.8 (c)). 
Specifically, when the average RMSD is plotted against the residue number it is clear that a large 
majority of the residues are in similar positions for the superimposed proteins, with variations 
occurring mostly at flanking or loop regions. 
 
 
Figure 4.8 PNPase Homologs PH-1/Rrp41 Domain Conservation 
(a) Structural overlay of the PH-1 domain of EcPNPase (3GCM, blue) and hPNPase (3U1K, pink) and Rrp42 
of SsoExosome (4BA1, green). (b) RMSD values of these proteins superimposed individually (grey-scale 
coloured boxes), the average RMSD was 2.258 Å and a grey-scale RMSD key is included for reference. (c) 
MOE graph representing the average RMSD (Å) plotted against residues. Images generated in MOE 
(Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
 
Mapping these variable RMSD regions onto the catalytically active PH-1/Rrp41 domain structures, 
as shown in Figure 4.9 (two-part figure), highlighted the areas with the largest structural 
differences (red ribbons). For example, the RMSD was higher (> 2 Å) at the start of the graph 
(residues 306-316, Figure 4.9 (b)), where the PNPase helical domain of hPNPase and EcPNPase 
ends and the PH-1 domain starts. This helical domain was not present in SsoExosome and may 
explain the variations in structure. The next region highlighted in Figure 4.9 (c) was between 361-
381 in a loop region, it is well established that structural flexibility is more common in disordered 
regions and more constricted in structured alpha helix or beta sheets regions. Another loop region 
between 396-404 (Figure 4.9 (d)) was structurally variable; this was situated just before the RBRII 
motif, where the RMSD decreases. Three more loop regions, 429-430 (Figure 4.9 (f)), 478-490 
(Figure 4.9 (g)) and 527-530 (Figure 4.9 (h)) showed higher RMSD values, these were all located 
in distinct regions from the active site, either near the top or bottom face of the core protein shown 
in Figure 4.7 (a). The final region shown in Figure 4.9 (j) was located at the end of the PH1/Rrp41 
[112] 
domain, just before the RNA binding domains (~560), which was not solved for EcPNPase, 
partially solved for hPNPase, and both are shown to form a flexible tail. Whereas the equivalent 
Rrp4 domain was solved for SsoExosome and was shown to form a more structured alpha helix. 
 
 
Figure 4.9 PNPase Homologs PH-1/Rrp41 Domain Variations (part 1 of 2) 
(a) Average RMSD (Å) values vs the residues for the superimposed PH-1 domains of EcPNPase (3GCM) 
and hPNPase (3U1K) and Rrp42 of SsoExosome (4BA1). Individual regions of structural variability with an 
RMSD value > 2Å are highlighted (dotted boxes) and mapped on structures (red ribbon) for residues (b) 306-
316, (c) 361-381, (d) 396-404, (f) 429-430, (g) 478-490 and (h) 527-530. Images generated in MOE 
(Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
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Figure 4.9 PNPase Homologs PH-1/Rrp41 Domain Variations (part 2 of 2) 
(a) Average RMSD (Å) values vs the residues for the superimposed PH-1 domains of EcPNPase (3GCM) 
and hPNPase (3U1K) and Rrp42 of SsoExosome (4BA1). Individual regions of structural variability with an 
RMSD value > 2Å are highlighted (dotted boxes) and mapped on structures (red ribbon) for residues (i) 
~560. Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) 
(GIMP, n.d.). 
 
Some of the variable regions, discussed above, appeared to be located near to the active site Mg2+ 
(Figure 4.9 (d and h)). To investigate the structural conservation of the active site, key binding 
motifs important in citrate binding, shown previously in Figure 1.11, were inspected further. 
Accordingly, the RMSD values for residues within the RBRII, PBR and MBR motifs were 
analysed so that the residue flexibility across the PNPase homologs could be determined (Figure 
4.10).  
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Figure 4.10 PNPase Homologs PH-1/Rrp41 Binding Motifs Conservation   
(a) RMSD (Å) values within the RBRII, PBR and MBR motifs of PH-1/Rrp41 were plotted for SsoExosome 
vs hPNPase (dark grey), SsoExosome Vs EcPNPase (light grey) and hPNPase Vs EcPNPase (medium grey). 
Asterisks indicate the areas where the similarity between residues in the PNPases and archaeal exosome 
homologs differ most. (b) Average RMSD values for binding motif residues shown in part (a) were 
calculated for EcPNPase vs hPNPase vs SsoExosome, with error bars depicting the standard deviation. The 
EcPNPase residues for which these relate to are provided on the x axis and a green line cuts the graph at 1 Å 
on the y axis. Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP 
(v2) (GIMP, n.d.). 
 
Upon closer examination of Figure 4.10 (a), a majority of residues in the key citrate-binding motifs 
of PH-1/Rrp41 had low RMSD values, indicating small structural flexibility and thus high 
structural conservation across the three domain models. Looking at individual motifs, the PBR 
motif had the lowest average RMSD values (< 1 Å) for all three alignments; SsoExosome vs 
hPNPase, SsoExosome vs EcPNPase and hPNPase vs EcPNPase, suggesting residues within this 
region were structurally very similar (Figure 4.10 (a)). Residues within the MBR were generally 
very similar, although slight difference were observed between PNPases and the archaeal exosome 
homologs for some residues, and the number of variances increased further in the RBRII motif, 
both highlighted by asterisks in Figure 4.10 (a).  There was a large difference in RMSD between 
[115] 
hPNPase vs SsoExosome and EcPNPase at the start of the RBRII. When the actual residues where 
compared, a leucine was present in this position in hPNPase, however this was a ‘bulky’ proline in 
EcPNPase and SsoExosome, possibly explaining the large variation in RMSD.  
 
The data presented in Figure 4.10 (a) were analysed further. The RMSD values for EcPNPase, 
hPNPase and SsoExosome were averaged, the standard deviation was calculated and the results 
were plotted against EcPNPase sequence, for comparison purposes (Figure 4.10 (b)). Interestingly 
the known metal coordinating aspartate residues within the MBR of PNPases (EcPNPase (D492), 
hPNPase (D544)) were slightly structurally different (> 1 Å) to the archaeal exosome (SsoExosome 
(D188)), when compared to other residues in the motif (Figure 4.10). Remarkably, the RMSD 
values were generally higher for the RBRII residues, with the exception of the known citrate 
binding arginine (EcPNPase (R399), hPNPase (R446)) which was structurally similar (< 1 Å) to 
the equivalent SsoExosome residue (R99). 
 
The data presented within this Section investigated structural similarities of PNPase homologs and 
identified key residues interacting with citrate. In summary, aligning protein structures of 
EcPNPase, hPNPase and SsoExosome revealed a high level of structural conservation within the 
RBRI, RBRII, PBR and MBR active site motifs. 
 
4.3.2 Citrate-PNPase Interactions Are Conserved in all Domains of Life 
Now that the structures of EcPNPase, hPNPase and SsoExosome have been shown to exhibit high 
similarity (Section 4.3.1), the next question addressed within this section, was whether their 
sequences were also highly conserved? More specifically were the residues, identified in Section 
4.3.1 to interact with citrate, conserved more broadly? The in silico protein sequence alignment 
results presented within this section predicted that citrate binding residues are conserved in PNPase 
and archaeal exosome representative homologs, across all domains of life. 
 
4.3.2.1 Active Site Sequence Alignments  
A small collection of previously characterised PNPase homologs, with known structural 
information available, were selected for in silico sequence alignments. This included four bacterial 
PNPases, (E. coli (EcPNPase; Nurmohamed et al., 2009; Shi, Yang, Lin-Chao, Chak, & Yuan, 
2008), Streptomyces antibioticus (SanPNPase; Symmons et al., 2000), Caulobacter crescentus 
(Hardwick, Gubbey, Hug, Jenal, & Luisi, 2012) and Coxiella burnetii (Franklin et al., 2015), Homo 
sapiens PNPase (hPNPase; Lin et al., 2012) and four archaeal exosomes, one from the phylum 
crenarchaeota (Sulfolobus solfataricus (SsoExosome; Lorentzen & Conti, 2005, 2012; Lorentzen et 
al., 2005; Lorentzen, Dziembowski, Lindner, Seraphin, & Conti, 2007; Lu, Ding, & Ke, 2010) and 
three from the phylum euryarchaeota, (Pyrococcus abyssi Navarro, Oliveira, Zanchin, & 
Guimarães, 2008), Archaeoglobus fulgidus (Büttner, Wenig, & Hopfner, 2005; Hartung, 
Niederberger, Hartung, Tresch, & Hopfner, 2010) and Methamothermobacter thermautotrophicus 
[116] 
(MthExosome; Ng et al., 2010). In order to illustrate the level of sequence conservation across 
evolutionally distinct organisms, a simple protein sequence alignment was conducted as per 
Section 4.2.1. A range of key citrate and Mg2+ binding residues, previously identified in EcPNPase 
and hPNPase (Sections 4.3.1), were highlighted so that comparisons between the PNPase homologs 
could be made (Lin et al., 2012; Nurmohamed et al., 2011). The results of this alignment are 
presented within Figure 4.11. 
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Figure 4.11 PNPase Homologs’ Binding Motifs Sequence Conservation  
(a) PNPase and Archaeal Exosome domains are illustrated as a schematic. An important RNA Binding Region (RBRI) in PNPase PH-1 domain and its homologous archaeal exosome Rrp42 
protein are indicated. A helical domain is shown to link the PH-1 and PH-2 domains in PNPase only. A second RNA Binding Region (RBRII), a Phosphate and Metal Ion Binding Region 
(PBR and MBR, respectively) are then indicated within the PNPase PH-2 domain and Rrp41 archaeal exosome homologous protein (Portnoy et al., 2007). The KH and S1 domains in 
PNPase and corresponding protein Rrp4 in archaeal exosome are also shown. (b) Sequence alignments for PNPase and Exosome proteins are provided, key binding regions are indicated, as 
described in (a). Key residues interacting with citrate and metal ions are highlighted, as per the key (Lin et al., 2012; Nurmohamed et al., 2009). The Image was created using a combination 
of GIMP (v2), Jalview and MOE (GIMP, n.d.; Molecular Operating Environment, 2013; Waterhouse et al., 2009) 
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Comparison of the five bacterial PNPase sequences showed that all of the citrate-binding residues 
(Figure 4.11, dark orange arrows) known for EcPNPase were conserved, with the exception of a 
conservative substitution of threonine for serine at the position of EcPNPase S438 in SanPNPase 
(Figure 4.11). Consequently, as citrate binding interactions are already known for EcPNPase, this 
enzyme was selected as a prokaryotic PNPase representative for subsequent in silico molecular 
docking validation. SanPNPase was also selected as a prokaryotic PNPase representative for 
studying the effect of the S438T substitution. In addition to EcPNPase, citrate binding residues in 
hPNPase were also known (Figure 4.11, light orange arrows) and as a result, hPNPase was utilised 
as a eukaryotic PNPase representative for subsequent in silico molecular docking validation. 
Comparison of the four archaeal exosome sequences showed that there was more sequence 
variation amongst the putative citrate-binding residues (Figure 4.11). Only two of the eight citrate-
binding residues identified in EcPNPase were absolutely conserved in the exosome homologs, with 
the greatest sequence variation occurring in the PBR. As the SsoExosome is well characterised, it 
was selected as the archaeal representative for subsequent in silico molecular docking. 
 
In addition to citrate binding residues, key residues previously reported to be involved in 
coordinating the active site Mg2+ metal ions, essential for activity in EcPNPase, were highlighted in 
(Figure 4.11)  (MBR, pink sphere). The two aspartate residues; D492 and D486 in E. coli were 
conserved in all PNPase and archaeal exosome homologs. The lysine residue, which contacts the 
metal ion in EcPNPase, was not conserved in archaeal Exosomes (SsoExosome; P465).  
 
4.3.2.2 Vestigial Site Sequence Alignment 
The ten protein sequences used for the basic alignments in Figure 4.11 were also analysed to 
investigate the conservation of citrate-binding at the EcPNPase vestigial site (Figure 4.12). 
Sequence conservation at this site was found to be much weaker than for the active site; important 
citrate-binding arginine residues in EcPNPase (R153, R372, R405 and R409) were not well 
conserved. Taken together with the absence of citrate at the vestigial site in the hPNPase crystal 
structure (Lin et al., 2012), this suggested that citrate-binding at the vestigial site is highly unlikely 
to be conserved.  
 
 
Figure 4.12 PNPase Vestigial Site Sequence Alignment 
Sequence motifs relating to the four vestigial site arginine’s (orange arrows) identified through mutagenesis 
as being involved in binding citrate in EcPNPase (Nurmohamed et al., 2011). The Image was created using a 
combination of GIMP (v2) and Jalview (GIMP, n.d.; Waterhouse et al., 2009).  
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In summary, aligning protein sequence for well characterised PNPase homologs revealed a high 
level of sequence conservation for the active site citrate binding residues and poor conservation at 
the vestigial site.  
 
4.3.3 Citrate is Predicted to Dock In Silico into Prokaryote, Eukaryote 
and Archaeal PNPase Homologs  
With mounting evidence that citrate-interacting residues are conserved in distantly related PNPase 
homologues (Section 4.3.2), the question then arises whether citrate binding conserved in other 
PNPases. The in silico molecular docking results presented within this section predicts that citrate 
binding is conserved in PNPase and archaeal exosome representative homologs, across all domains 
of life.  
 
4.3.3.1 Candidate Selection for In Silico Docking 
Structure-based molecular docking is a valid computational approach for testing the potential for 
ligand binding in silico, before moving on to more resource-consuming experimental 
methodologies (Galli et al., 2014; Kime et al., 2015). Although the crystal structures of all 9 
PNPase and archaeal exosome homologs aligned in Figure 4.11 were available, and in theory all 
structures could be docked using the methodologies outlined within this section, due to time 
limitations of this PhD project, only a select few structures were chosen for subsequent in silico 
molecular docking calculations. More specifically, EcPNPase (3GCM) and hPNPase (3U1K) were 
initially chosen to validate the in silico molecular docking approach, since they were already 
known to bind citrate. An additional bacterial structure, SanPNPase (1E3P) was also selected to test 
the effect of sequence variation in the S(S/T)S motif within the PBR. Finally, since no information 
was available regarding citrate binding to the archaeal exosome, SsoExosome was chosen as a well 
characterised archaeal model to discover if citrate binding was conserved in this domain. A few 
structures were available for SsoExosome and the structure termed 4BA1, which contained the 
Rrp4 RNA binding domain was selected as it was most similar to PNPase homologs KH and S1 
domains, in contrast to the alternative Csl4-DnaG which has a zinc-ribbon domain (Büttner et al., 
2005). 
 
In summary, at least one structure from each domain was selected for citrate docking studies. 
However, before in silico docking calculations could be conducted, each of these candidate protein 
structures were first prepared for docking, the results of which are described in the subsequent 
Sections 4.3.3.2-4.3.3.3. 
 
4.3.3.2 Protein Structure Preparation: Magnesium Placement  
It was valuable to check that EcPNPase could be used to test the correct placement of Mg2+ ions 
within the active site of PNPase homologs lacking the essential metal ion. To validate this method, 
magnesium was first removed from EcPNPase and then replaced within the enzyme, as outlined 
below. 
[120] 
 
The EcPNPase 3GCM structure was initially downloaded from the PDB and the input file was 
loaded as a biomolecule into MOE. The structure deposited contained three EcPNPase chains A, B, 
C (549 amino acid residues, coloured black, dark grey and light grey) which form the homotrimer, 
donut-like shape, shown previously in Figure 1.10. In order to assess the correct placement of Mg2+ 
ions, all the original Mg2+ ions were removed from the 3GCM file, which was then renamed to 
3GCM_Dock. This 3GCM_Dock file was then superimposed with the original 3GCM file 
(containing Mg2+). The Mg2+ within 3GCM was then successfully transferred across into the new 
3GCM_Dock structure superposed on top and it was defined as part of the structure; effectively 
transferring the metal ion back into EcPNPase. Following removal of 3GCM from the MOE 
window, the new 3GCM_Dock structure was prepared using the MOE LigX built in tool and 
standard LigX protein preparation methods as described in Section 4.2.2.1.  
 
Post protein preparation, the 3GCM and 3GCM_Dock structures were again superimposed in order 
to identify whether the Mg2+ ion was correctly coordinated by the appropriate active site residues, 
results of which are shown in Figure 4.13. As expected, very little overall change was observed 
between the two structures; MOE predicted a root mean square deviation (RMSD) value of 0.248 Å 
for the 3GCM structure vs the 3GCM_Dock (Figure 4.13 (a-b)).  The active site, shown in Figure 
4.13 (c) highlights the similarity between 3GCM (dark grey) and 3GCM_Dock (turquoise). 
Contrastingly and unexpectedly, the newly placed Mg2+ ion appeared to have moved slightly within 
the active site of 3GCM_Dock; as highlighted by the purple (3GCM Mg2+) and pink (3GCM_Dock 
Mg2+) spheres in Figure 4.13 (c). Additionally, as indicated by the MOE interaction map, the active 
site Mg2+ which was originally coordinated by one aspartate residue (D492) in 3GCM (Figure 4.13 
(d)) was now co-ordinated by both D492 and D486 in the new 3GCM_Dock structure (Figure 4.13 
(e)). This observation was seen for each active site Mg2+ ion, in all three monomers, suggesting that 
MOE calculated that both aspartates were involved in coordinating Mg2+, as shown later in Figure 
4.15 (a, c & e).  
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Figure 4.13 EcPNPase Structure Preparation 
(a) EcPNPase 3GCM and 3GCM_Dock overlay of trimeric structure and (b) RMSD value of the protein 
alignment. (c) Active site 3GCM (grey ribbons) and 3GCM_Dock (turquoise ribbons) with the original Mg2+ 
(purple sphere; 3GCM) and the placed Mg2+ (pink sphere; 3GCM_Dock). (d) MOE interaction map 
highlighting Mg2+ coordination in 3GCM only by D492 and (d) in 3GCM_Dock by both D486 and D492. 
Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, 
n.d.). 
 
The publication which originally presented the EcPNPase structure suggested that D486, D492 and 
K494 were all involved in coordinating a Mn2+ ion (Figure 4.14) and that similar interactions 
would be predicted for Mg2+ (Nurmohamed et al., 2009).  Hence the calculations MOE generated, 
predicting that not one but two aspartates were involved in Mg2+ coordination, appeared to align 
[122] 
well to previous publications. However, in the 3GCM MOE interaction map, K494 was not 
suggested to interact with the metal ion, in any of the three monomers.  
 
 
Figure 4.14 EcPNPase Mn2+ Coordination  
(a) Mn2+ (green sphere) coordination by EcPNPase active site residues D486, D492 and K494 (grey sticks). 
Image taken directly from Nurmohamed et al., 2009. 
 
Interestingly if the 3GCM structure, which was originally taken directly from the PDB previously, 
was energy minimised using the built in tools within the MOE program instead, this second 
aspartate contact was made. In this minimised and renamed structure (3GCM_Min), both the D486 
and D492 residues interacted with the Mg2+ ion and this was true for all monomers (Figure 4.15). 
This result suggested that proper minimisation of 3GCM was required to make the same contacts as 
that seen previously published (Figure 4.14) (Nurmohamed et al., 2009).  
[123] 
 
Figure 4.15 EcPNPase Structure Preparation; Mg2+ Placement  
MOE generated interaction maps of Mg2+ interacting with (a) EcPNPase 3GCM pre and post protein 
minimisation for (b-c) black monomer, (d-e) dark grey monomer and (f-g) light grey monomer respectively 
and (h) the legend. Images generated in MOE (Molecular Operating Environment, 2013) and prepared in 
GIMP (v2) (GIMP, n.d.). 
 
In summary EcPNPase can be successfully used as a template for placing Mg2+ in structures lacking 
this essential ion and MOE structure preparation ensured that the correct contacts were made within 
[124] 
the active site. Accordingly, the hPNPase and SsoExosome enzymes, lacking the presence of an 
Mg2+ co-factor, were aligned against EcPNPase using MOE, the EcPNPase Mg2+ cofactor was 
defined as part of the receptor for the other two enzymes and then minimised using LigX. All 
docking structures were superimposed on original PDB structures and the RMSD was calculated to 
be ~ 0.25 Å (Table 4.2). This suggested that the MOE minimisation process had little overall effect 
on the PNPase and archaeal exosome structures. 
 
 
Table 4.2 RMSD Comparison of PDB vs Docking Structure  
The RMSD values (Å) of original PDB structures compared to docking structures are listed for PNPase and 
archaeal exosome homologs.  
 
As before with the placement of Mg2+ within 3GCM_Dock, residues previously suggested to be 
involved in coordinating the metal ion in the active site were investigated to determine if similar 
contacts were made in hPNPase and SsoExosome homologs. As with EcPNPase (D492 and D486), 
key metal-aspartate interactions were sustained in PNPase homologs hPNPase (D538 and D544) 
and SsoExosome (D188) as highlighted in Figure 4.16 (a-c). Interestingly only one aspartate was 
predicted for SsoExosome, as before, this may have been an effect of MOE protein minimisation 
and this was queried further. 
 
Enzyme  RMSD of PBD vs Docking Structures 
EcPNPase 0.248 Å
SanPNPase 0.257 Å
hPNPase 0.247 Å
SsoExosome 0.249 Å
[125] 
 
Figure 4.16 PNPase Homologs Structure Preparation; Mg2+ Placement  
(a) Interaction map and structure for EcPNPase; 3GCM_Dock highlighting D492 and D486 interacting with 
Mg2+ (b) hPNPase; 3U1K_Dock binding Mg2+ via D538 and D544 (c) SsoExosome; 4BA1_Dock only 
interact with Mg2+ through a D188 metal contact and (d) the legend. Images generated in MOE (Molecular 
Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
 
It was observed that the SsoExosome 4BA1 structure, which has a D182A mutation for 
crystallisation purposes, only makes one interaction with Mg2+ upon placement within the active 
site and this was mediated by the D188 residue (Figure 4.17 (a)). In silico mutagenesis of the 
alanine at position 182, back to an aspartate, regained the second interaction with Mg2+ (Figure 
4.17 (b)). However, upon minimisation, this second D182 interaction was again lost (Figure 4.17 
(c)).  
 
[126] 
 
Figure 4.17 SsoExosome Structure Preparation; Mg2+ Placement  
(a) SsoExosome structure and interaction map of 4BA1 interacting (b) with Mg2+ (b) with the crystalised 
alanine mutation (D182A), (c) following in silico MOE mutatgensis back to aspartate (A182D), (d) after 
minimistion of A182D and (e) the legend. Images generated in MOE (Molecular Operating Environment, 
2013) and prepared in GIMP (v2) (GIMP, n.d.). 
 
The observation that following MOE minimisation only one aspartate coordinated the active site 
metal ion Mg2+ conflicted with previous predictions by Lorentzen & Conti, 2012. A possible 
explanation for this may be that Lorentzen and Conti placed Mg2+ in a structure with RNA and Pi 
present, however in the model presented in Figure 4.17 these ligands were absent/removed for the 
purpose of downstream citrate docking. Potentially the lack of these ligands during the 
minimisation processes, may explain why D182 interactions were not observed. Either way, 
whether this prevents citrate docking in silico required further examination and to do this the active 
site needed to be defined so that citrate docking could be conducted. 
 
4.3.3.3 Protein Structure Preparation: Active Site Finder 
Once the essential metal ions had been placed within the PNPase homologs, the MOE Alpha Site 
Finder panel was used to predict a pocket concavity for use in subsequent docking calculations. 
Essentially, MOE uses an input structure to predict pockets that may correspond to an active site. 
Following the MOE site finder calculation, a list of pocket ‘hits’ are suggested. The pocket residues 
are listed and dummy atoms can be placed to signify the locations of tight packing; as represented 
by red hydrophobic and blue hydrophilic spheres. The user can then view these dummy atoms 
[127] 
within the structure and visualise the predicted pocket hits easily. This allows comparison of the 
predicted pocket location, size and residues with a known active site. If the predicted pocket 
residues are the same as known active site residues it helps validate the program; demonstrating 
that MOE can correctly predict the location of an unknown active site.  
 
To validate the site selection, the placement of dummy atoms, which represented the location of the 
predicted pocket and the residues within the predicted pocket were first checked. Accordingly, the 
known active site of EcPNPase, hPNPase, SsoExosome and SanPNPase were shown as ribbons in 
Figure 4.18-Figure 4.21 (a) so that the location of dummy atom placement and therefore the pocket 
location, could be compared in Figure 4.18-Figure 4.21 (b). For all four enzymes, MOE placed 
dummy atoms within the same location as the known active site, this is highlighted in the overlaid 
images in Figure 4.18-Figure 4.21 (c). The dummy spheres, representing the predicted pocket, were 
also placed in the same location as the co-crystallised citrate ligands of EcPNPase and hPNPase 
(Figure 4.18-Figure 4.19 (c)).  
 
More importantly, MOE predicted the correct pocket; the pocket residues listed in Table 4.3 
included the known EcPNPase active site residues (bold red) which interact with citrate and metal 
ions (R93, R399, S437, S438, S439, D486, H487, D492, K494, and H403). The corresponding ten 
residues in hPNPase, SsoExosome and SanPNPase were also identified, although for hPNPase the 
R132 and R446 residues of the RBRI and RBRII motifs respectively were not listed. The hPNPase 
predicted pocket was smaller than the others, with fewer residues and side chain contacts and fewer 
dummy atoms placed. The effect of dummy atom placement within hPNPase, and thus the size of 
the hPNPase pocket was analysed further. The default MOE pocket for hPNPase (small pocket, 
fewer dummy atoms), and the same hPNPase structure with additional EcPNPase dummy atoms 
placed (representing a larger pocket) were compared. These additional dummies were added by 
superimposing the EcPNPase 3GCM_Dock structure and its predicted pocket dummy atoms onto 
the hPNPase 3U1K_Dock structure and transferring the EcPNPase dummy atoms into hPNPase; 
effectively creating a new pocket (3GCM_Dock_EcDummies). Taking into account the default 
small pocket size and a larger pocket size (3GCM_Dock_EcDummies), citrate docking was 
compared and no difference in citrate binding was observed (data not shown). Hence the default 
MOE predicted hPNPase pocket was not limiting and was therefore used for subsequent hPNPase 
docking calculations. This result suggested that the placement of dummy atoms and therefore 
pocket prediction suggested by MOE was valid, further supporting the programs default settings as 
good parameters/methodologies for conducting docking calculations. 
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Figure 4.18 EcPNPase Structure Preparation; Site Finder 
(a) EcPNPase 3GCM (dark grey ribbons) with co-crystallised Mg2+ (purple sphere) and active site citrates 1 
and 2 (black sticks) (b) MOE predicted active site for 3GCM_Dock (blue ribbons), with placed Mg2+ (pink 
sphere) and hydrophobic and hydrophilic dummy atoms (red and blue spheres respectively) representing the 
MOE predicted active site pocket. (c) Superpose of images in (a) and (b). Images generated in MOE 
(Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
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Figure 4.19 hPNPase Structure Preparation; Site Finder 
 (a) hPNPase 3U1K (dark grey ribbons) with active site citrates 1 and 2 (black sticks) (b) MOE predicted 
active site for 3U1K_Dock (blue ribbons), with placed Mg2+ (pink sphere) and dummy atoms (red and blue 
circles) representing the MOE predicted active site pocket. (c) Superpose of images in (a) and (b). Images 
generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
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Figure 4.20 SsoExosome Structure Preparation; Site Finder 
(a) SsoExosome 4BA1 (dark grey ribbons) with two co-crystallised PO43- (grey sticks) (b) MOE predicted 
active site pockets for 4BA1_Dock (blue ribbons), with placed Mg2+ (pink sphere) and dummy atoms (red 
and blue circles) representing the MOE predicted active site pockets. (c) Superpose of images in (a) and (b). 
Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, 
n.d.). 
 
 
Figure 4.21 SanPNPase Structure Preparation; Site Finder and Site Selection Conservation 
(a) SanPNPase 1E3P (cyan ribbons) with placed Mg2+ (pink sphere) and dummy atoms (red and blue circles) 
representing the MOE predicted active site. (b) Superimpose MOE predicted active sites for EcPNPase 
(3GCM_Dock, blue), hPNPase (3U1K_Dock, pink) and SsoExosome (4BA1_Dock, green), highlighting 
placed Mg2+ and dummy atoms (coloured based on ribbons). Images generated in MOE (Molecular 
Operating Environment, 2013) and prepared in GIMP (v2) (GIMP, n.d.). 
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Table 4.3 MOE Site Selection  
MOE predicted pocket for EcPNPase 3GCM_Dock, hPNPase 3U1K_Dock, SsoExosome 4BA1_Dock and SanPNPase 1E3P_Dock are listed; the number of receptor atoms (Size), the 
number of hydrophobic contacts (Hyd), and number of sidechain contacts (Side) are reported. A list of the pocket residues is also provided and those residues highlighted in bold red 
correspond to known active site residues. 
  
EcPNPase Active 163 32 215
(LEU59 THR60 VAL61 ASN62 ALA92 ARG93 ASP96 ARG97 PRO98 ARG100 PRO101 
LEU187 MET188 THR348 TYR380 PHE382 LYS397 ARG398 ARG399 GLU400 HIS403 
LEU406 SER434 ASN435 GLY436 SER437 SER438 SER439 ILE481 LEU482 GLY483 
ASP486 HIS487 ASP492 LYS494 GLN506 ASP508 ILE509 LYS510)(MG552)
hPNPase Active 48 8 74
(LYS306 THR391 TYR427 PHE429 THR434 ARG446 HIS450 VAL476 SER479 ASN480 
GLY481 SER482 SER483 SER484 MET485 LEU534 GLY535 ASP538 TYR539 ASP544 
LYS546)(MG552)
SsoExosome Active 123 24 161
(ARG112 VAL113 ARG116 SER117 ARG119 ASP120 SER228 GLY237 ILE238 
GLN239)(TYR81 MET83 THR88 ARG99 GLU102 LEU103 ALA134 ASP135 ALA136 
GLY137 SER138 ARG139 LEU140 ALA165 GLU179 ASP182 MET183 ASP188 
PRO190 GLN204 LEU205 ASN206)(MG552)
SanPNPase Active 73 22 119
(LYS288 GLU371 TYR404 PHE406 SER410 VAL411 LYS421 ARG423 GLU424 HIS427 
SER458 ASN459 GLY460 SER461 THR462 SER463 ALA489 ILE509 LEU510 GLY511 
ASP514 ASP520 LYS522)(GLN32)(MG556)
Hyd Side Pocket ResiduesEnzyme Site Size
[132] 
In summary, the results so far demonstrated that MOE could be used to prepare PNPase homolog 
structures for docking, including placing essential metal ions and selecting the appropriate pocket 
for subsequent docking calculations. The next validation step aimed to investigate whether MOE 
could also accurately dock citrate ligands within these prepared active site pockets. As before 
EcPNPase and hPNPase were used as models for citrate docking validation purposes; testing 
whether MOE could predict the same citrate binding interactions observed in previously 
crystallised structures. 
 
4.3.3.4 Active Site In-Silico Citrate Docking  
Citrate downloaded from the ZINC database (Figure 4.22) and saved as a MOL2 file in a 
physiologically relevant conformation was docked into 3GCM_Dock using the docking module of 
MOE, using the parameters outlined in Section 4.2.2.2.  Due to limitations of the docking software, 
only a single molecule of citrate could be docked into each structure in in a single docking run, 
hence two separate rounds of docking were required. To achieve this, the lowest-energy structure 
with the first molecule of citrate docked was used as the starting point for a second round of citrate 
docking. The orientations of the top docking hits, for both the first and second round of citrate 
docking calculations for EcPNPase (Figure 4.23 (a)) and hPNPase (Figure 4.23 (b)) are shown. 
 
 
Figure 4.22 Citrate 2D Structure 
Citrate downloaded from ZINC database (ZINC00895081), shown as 2D depiction. Image created in MOE 
(Molecular Operating Environment, 2013). 
 
For both enzymes, in the first round of docking, citrate (Figure 4.23, yellow sticks) was predicted 
to bind at the catalytic active site in the same position as the original co-crystallised Cit 1 (Figure 
4.23, light grey sticks). The lowest-energy docking scores (S values) were -112.3 kcal/mol and -
122.7 kcal/mol for EcPNPase and hPNPase, respectively (Table 4.4). Encouragingly, MOE 
retained 30 unique lowest-energy poses for each docking calculation and they all placed citrate in 
this location, albeit in slightly different orientations. The S values for these are summarised in the 
box plot in Figure 4.24. Furthermore, the number of placement poses (iterations) showed no 
difference in S value between 1,000 and 300 iterations when using the triangle matcher placement 
method. Indicating 300 iterations to be sufficient for determining reliable MOE binding scores in 
the conditions tested (data not shown). Additionally, utilising 300 iterations and retaining 30 results 
[133] 
was adequate, retaining more results was unnecessary and negatively impacted the run times (data 
not shown).  
 
The docking of the citrate from the first round of docking in the same position as Cit 1 in the 
original crystal structures of EcPNPase and hPNPase was a promising result. However, the 
potential for a second citrate molecule binding also needed to be investigated since two molecules 
of citrate were discovered bound to the active site of these enzymes’ solved structures. As 
mentioned above, in order to do this, the lowest-energy pose with one molecule of citrate docked 
was used as the starting point for a second round of docking. Reassuringly, for both EcPNPase 
(Figure 4.23 (a)) and hPNPase (Figure 4.23 (b)) the second citrate molecule (Figure 4.23, orange 
sticks) docked at the equivalent location of Cit 2 observed in the crystal structures (Figure 4.23, 
dark grey sticks), with lowest-energy S values of -63.7 kcal/mol and -58.6 kcal/mol respectively 
(Table 4.4). As before, the orientation of docked citrate varied slightly, but all 30 poses were placed 
in this location (Figure 4.24).  
 
Interestingly, the lowest-energy S values, reported in Table 4.4, proposed that of the two possible 
citrate-binding sites, which were expected based on the crystal structures, citrate binding at the Cit 
1 site was predicted to be stronger than Cit 2. Overall, these results are consistent with the docking 
protocol successfully identifying the citrate-binding sites in both proteins.   
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Figure 4.23 Active Site Citrate Docking  
Co-crystallised citrates (citrate 1; light grey sticks, citrate 2; dark grey sticks) are shown superimposed on 
docking sites for (a) EcPNPase (3GCM_Dock, blue) and (b) hPNPase (3U1K_Dock, pink) with docked 
citrates (citrate 1; yellow sticks, citrate 2; orange sticks). Only the docked citrates are shown for (c) 
SanPNPase (1E3P_Dock, cyan) and (d) SsoExosome (4BA1_Dock, green) since no citrate was found to co-
crystallise. The lowest-energy S values for the first and second round of citrate docking are also provided 
(kcal/mol). Images generated in MOE (Molecular Operating Environment, 2013) and prepared in GIMP (v2) 
(GIMP, n.d.). 
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Figure 4.24 PNPase Homologs Active Site Citrate Docking; All Hits S Values  
The 30 unique, lowest-energy poses docking scores (S values, kcal/mol) are provided for EcPNPase 
(3GCM_Dock), hPNPase (3U1K_Dock), SanPNPase (1E3P_Dock) and SsoExosome (4BA1_Dock) for the 
first and second round of citrate docking (Citrate 1 and 2). Images generated in Minitab (v17).  
 
Having demonstrated the validity of the docking approach, citrate was subsequently docked into 
the structure of a prokaryotic PNPase, that has not previously been shown to bind citrate. As E. 
coli, C. crescentus and C. burnetii all belong to the phylum proteobacteria whereas S. antibioticus 
belongs to the phylum actinobacteria, SanPNPase was selected as the most divergent PNPase 
model, for which structural information was available for subsequent citrate docking. Additionally, 
as nine of the ten residues involved in Mg2+ and citrate-binding in EcPNPase (R93, R399, S437, 
S438, S439, D486, H487, D492, K494, and H403) were found to be conserved in SanPNPase 
(Section 4.3.2.1), with the only difference being a conservative substitution of threonine for serine 
at the equivalent position to EcPNPase S438, SanPNPase was a good example to test the effect of 
the S(S/T)S sequence variation within the PBR (Figure 4.11).  
 
The results shown in Figure 4.23 (c), predicted little effect from the S(S/T)S sequence variation on 
the first round of citrate binding; the top 30 lowest-energy S values obtained for the docking at the 
Cit 1 site were comparable to those obtained for EcPNPase and hPNPase, with a lowest-energy S 
value of -104.6 kcal/mol (Table 4.4). However, for the Cit 2 site, the docking scores obtained were 
significantly smaller than for either of the other PNPases (Figure 4.24); the lowest-energy S value 
was just -27.4 kcal/mol for the Cit 2 site (Table 4.4). 
 
The results obtained so far suggest that citrate-binding could be a common property of PNPases, 
which was not unexpected considering the high level of sequence conservation. The next step was 
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to investigate citrate-binding to the more distantly related archaeal exosome homolog. As for the 
three PNPases, two molecules of citrate were docked into the active site of the SsoExosome (Figure 
4.23 (d)). The docking scores at the Cit 1 site were similar to those obtained for the other three 
PNPases (Figure 4.24); with a lowest-energy S value of -115.4 kcal/mol (Table 4.4). The second 
molecule of citrate docked at the Cit 2 site with a similar S value (-27.4 kcal/mol) to SanPNPase 
(Table 4.4).  
 
 
Table 4.4 PNPase Homologs Active Site Citrate Docking; Top Hits S Value 
The lowest-energy docking score S value (kcal/mol) for the first and second round of citrate docking (Citrate 
1 and 2) with EcPNPase (3GCM_Dock), hPNPase (3U1K_Dock), SanPNPase (1E3P_Dock) and 
SsoExosome (4BA1_Dock). 
 
Overall, these results predicted that citrate may bind and potentially regulate both prokaryotic and 
eukaryotic PNPases and, despite the sequence variation, the archaeal exosome.  Citrate molecules 
also docked in a similar location for all four PNPase homologs tested and this is highlighted in 
Figure 4.25. 
 
 
Figure 4.25 Active Site Citrate Docking Overlay 
Active sites of EcPNPase (3GCM_Dock, blue), hPNPase (3U1K_Dock, pink), SanPNPase (1E3P_Dock, 
cyan) and SsoExosome (4BA1_Dock, green) are shown superimposed with docked citrates (citrate 1; yellow 
sticks, citrate 2; orange sticks). Images generated in MOE (Molecular Operating Environment, 2013) and 
prepared in GIMP (v2) (GIMP, n.d.). 
 
The residues predicted by MOE to be involved in citrate-PNPase binding were analysed further. A 
PLIF was generated for the ten lowest-energy poses, with both one and two molecules of citrate 
docked. This was conducted for each enzyme and the information was summarised as a heat map in 
Figure 4.26. As details of the citrate-EcPNPase/hPNPase ligand-receptor interactions were 
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previously identified for the solved crystal structures (Section 4.3.1), the ligand-receptor 
interactions, identified through in silico docking, were easily compared.  
 
Based on the docking calculations, similar interactions were predicted between citrate and the four 
putative citrate-binding residues (EcPNPase positions R93 in RBRI, R399 in RBRII, and D486 and 
D492, via the Mg2+ ion, in the MBR) that were conserved in EcPNPase, SanPNPase, hPNPase and 
SsoExosome (Figure 4.26, black arrows). The interactions between docked citrate and the two 
amino acids  (EcPNPase positions H403 in RBRII and K494 in the MBR) that were only conserved 
in the three PNPase proteins, were comparable for the PNPases, but there was no equivalent 
interaction evident between citrate and the amino acids that were substituted at these positions in 
SsoExosome (Figure 4.26, L and P, respectively). The EcPNPase H487 residue was not conserved 
in the other PNPase homologs and its interaction with citrate was also not observed in the MBR of 
these homologs (Figure 4.26, black arrow). Within the PBR of EcPNPase interactions were 
frequently observed between citrate and S437 and S438, however interactions between citrate and 
S439 were less common. The amino acid sequence and pattern of interactions within the PBR was 
conserved in hPNPase (Figure 4.26). However, the substitution of threonine for serine (at the 
equivalent position to EcPNPase S438) in SanPNPase appeared to have altered the interactions 
between citrate and the positions equivalent to EcPNPaseS438 and EcPNPase S439. In the 
SsoExosome, EcPNPase positions S437, S438 and S439 were substituted for G, S and R (Figure 
4.11, black arrows). Despite this sequence variation, significant interactions were observed 
between citrate and these three positions in SsoExosome (Figure 4.26, black arrows). 
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Figure 4.26 PNPase Homologs Active Site Citrate Docking; Heat Map 
Heat maps summarising the PLIFs generated for the ten lowest-energy poses obtained when two molecules of citrate (Cit 1 and Cit 2) were docked into the active site EcPNPase, 
SanPNPase, hPNPase and SsoExosome, with an interaction frequency scale (0-100%, coloured bar black to red respectively). Residues involved in citrate and metal coordination are 
indicated (black arrows). Images generated in MOE, Plotly and prepared in GIMP (v2) (GIMP, n.d.; Molecular Operating Environment, 2013; Plotly Technologies Inc., 2015). 
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4.3.4 Crystals Diffract by X-Ray Crystallography and Require Further 
Optimisation 
The structure of the SsoExosome utilised in in silico docking calculations was not co-crystallised 
with citrate bound, unlike the EcPNPase and hPNPase homologs. Following the MOE predictions 
that citrate docks into SsoExosome, interacts with similar residues and produces a similar S value 
to EcPNPase and hPNPase, the possibility of co-crystallising SsoExosome with citrate was 
examined within this section. The concentration of enzyme and citrate appropriate for crystal 
screening was initially determined, and then a small crystallisation trial was conducted as follows.  
 
Initial PCT A1/A2 test results (Figure 4.27) which were used for determining the concentration of 
SsoExosome (+ citrate), showed no precipitate in the A1 well after 30 minutes and a heavy 
amorphous precipitate in A2; hence the B1/B2 test was conducted as recommended in the PCT 
protocol (Figure 4.2). Following this subsequent test, the B1 well was clear of precipitate after 30 
minutes and a light granular precipitate was observed in B2 and this suggested the protein 
concentration was appropriate for setting up crystal screens. 
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Figure 4.27 SsoExosome Crystallisation Trials; PCT Test 
The wells A1-2 and B1-2 for the PCT tests are shown at the start (0 minutes) and end of the reaction (30 
minutes). In the A1/A2 reaction a clear well was observed in well A1and heavy amorphous precipitate in A2 
at the end of the reaction. In the B1/B2 reaction a clear well was observed for B1 and a light granular 
precipitate was seen in B2. Images prepared in GIMP (v2) (GIMP, n.d.). 
 
A subsequent, high-throughput screen using the molecular dimensions PACT premier™ screening 
conditions was used and this identified buffer conditions for crystal growth. Crystals grew in a 
protein sample containing 17.5 µM SsoExosome and 20 mM citrate, in a crystallisation buffer 
[141] 
containing 0.2 M NaCl, 0.1 M Tris pH 8, 20% peg 6,000 (screen #D7) (Figure 4.28). These crystals 
did not grow in the control well containing buffer alone, indicating they were not salt crystals (data 
not shown). 
 
 
Figure 4.28 Crystals of SsoExosome + Citrate  
Crystals forming after (a) 1 week and (b) 3 months with 17.5 µM SsoExosome and 20 mM citrate, in a 
crystallisation buffer containing 0.2 M NaCl, 0.1 M Tris pH 8, 20% peg 6,000 (PACT screen #D7). Images 
prepared in GIMP (v2) (GIMP, n.d.). 
 
The crystals in Figure 4.28 were sent for remote X-ray diffraction at Diamond light source and they 
diffracted. The diffraction pattern indicated protein was present, possibly SsoExosome (Figure 4.29 
(a), green box). However, the diffraction was too weak to solve the structure and to determine 
whether citrate was bound within the active site. For example, the diffraction shown in Figure 4.29 
(a) (green box) for the crystal (~ 40 µm diameter), was less than the example data collected for the 
lysozyme crystal (~ 200 µm diameter) shown in Figure 4.29 (b). However, the conditions used for 
SsoExosome (+citrate) could be optimised in order to grow larger crystals and potentially improve 
the strength of diffraction to help solve the structure. Nevertheless, in silico data predicted citrate 
binding to SsoExosome and the in vitro effects of citrate were therefore investigated within the 
next Section 4.3.5. 
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Figure 4.29 SsoExosome and Lysozyme X-Ray Crystallography Diffraction  
Crystals of (a) SsoExosome + Citrate (~40 µm in diameter) and (b) Lysozyme (~200 µm in diameter) were exposed to an X-ray beam at the Diamond Light Source Synchrotron in Oxford 
(remote access) with a transmission of 100%, a wavelength of 0.9763 Å and an Oscillation of 0.15˚. SsoExosome + Citrate was exposed for 0.200 s to an X-ray beam size of 50 x 20 µm, 
whereas lysozyme was exposed for 0.030 s with a beam size of 80 x 20 µm.  Low resolution diffraction (2.71 Å) was observed for the putative SsoExosome crystal (part a; green box), but 
was high for the lysozyme control; with excellent diffraction at a resolution of 1.5 Å (part b; green box). The putative SsoExosome crystal has large cell axes, indicative that the lattice is 
formed by a macromolecule. Images prepared in GIMP (v2) (GIMP, n.d.). 
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4.3.5 Modulation of PNPase Homologs’ Exoribonuclease Activity by 
Citrate 
The in silico studies described in Section 4.3.3 suggested that citrate-binding at the enzyme’s active 
site may be evolutionarily conserved in bacterial and eukaryotic PNPases and the archaeal 
exosome. For EcPNPase and hPNPase the docking predictions were consistent with the location of 
co-crystallised citrate within the crystal structures (Lin et al., 2012; Nurmohamed et al., 2009). 
Furthermore, for EcPNPase, this binding has been shown to inhibit the exoribonuclease activity 
(Nurmohamed et al., 2011). Whether citrate also inhibits other PNPases and the archaeal exosome 
still remained to be examined.  
 
The EcPNPase, hPNPase and the SsoExosome used in these in vitro experiments were expressed in 
E. coli and purified to homogeneity as described in Chapter 3. A commercially available 
Synechocystis sp. PNPase (SspPNPase) homolog was also utilised for in vitro studies, partly due to 
the ease of availability, but principally because it had the serine/threonine substitution within the 
RBR, similar to SanPNPase, which was of interest to study (Figure 4.11).  
 
The 3’-5’ exoribonuclease activity of PNPase and archaeal exosome homologs on a RNA substrate 
was monitored over time using a gel-based assay in the absence and presence of citrate. The 
percentage of intact fluorescently labelled oligoribonucleotide substrate, separated by denaturing 
PAGE, was calculated and the effect of citrate on PNPase homolog activity was determined.  
 
Initially, a range of concentrations of a 5’FAM labelled Poly(A)20 mer (5’FAM(A)20) RNA 
substrate were tested so that the limit of band detection could be determined. The 20% urea 
denaturing gel shown in (Figure 4.30) suggested that RNA assay concentrations between 560-1120 
nM form a single, intense band that would be sufficient for visualisation and quantification 
purposes. Hence assays were designed with this in mind; 700 nM 5’FAM(A)20 was used as standard 
in all subsequent gel-based degradation assay reactions. 
 
 
Figure 4.30 3’-5’ Degradation Assay; 5’FAM(A)20 RNA Substrate Concentration Range 
A range of 5’FAM Poly(A)20mer RNA substrate concentrations ([RNA (nM)] were run on a 20% urea 
denaturing gel in 1 x TBE ((200 V for 1 hour 30 minutes at 4°C). The gel was visualised using the Fujifilm 
FLA-imaging system (Phosphorimager: Blue filter, Blue laser, 473 nm). An individual band of intact 20 mer 
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RNA is present in each lane, its intensity increased with substrate concentration (size verified by RNA 
ladder, data not shown). The dye front is indicated. Images prepared in GIMP (v2) (GIMP, n.d.). 
 
In order to determine the optimal hPNPase enzyme concentration to use in the assay, a range of 
hPNPase concentrations (4.8, 24, 48, 120 and 240 nM) were subsequently tested with 700 nM 
5’FAM(A)20, as described in Section 4.2.4. As expected, sequential nucleotide removal in the 3’ to 
5’ direction was confirmed for hPNPase against 5’FAM(A)20 RNA substrate (Figure 4.31). A 
concentration of 240 nM hPNPase was selected as the optimal enzyme concentration to degrade 
RNA substrate in a suitable time frame. Thus, for comparison, all subsequent gel-based assays 
within this work contained 240 nM of hPNPase, EcPNPase, SsoExosome or SspPNPase unless 
specified. There was a dye front present in the gel shown in Figure 4.31 and therefore to improve 
the quantification, a ‘dye free’ loading buffer was utilised in subsequent assays.  
 
 
Figure 4.31 3’-5’ Degradation Assay; hPNPase Concentration Range 
A range of hPNPase concentrations (0, 4.8, 24, 48, 120 and 240 nM) were incubated with 700 nM 
5’FAM(A)20 RNA substrate at 37°C for 60 minutes. A no RNA control (120 nM hPNPase) and no protein 
control (0 nM hPNPase) are provided at the start (S) and end (E) of the assay. Samples were run on a 20% 
urea denaturing gel in 1 x TBE (200 V for 1 hour 30 minutes at 4°C) and the degradation of the RNA 
substrate from 20-mer to 2-mer increases with protein concentration. The gel was visualised using the 
Fujifilm FLA-imaging system (Phosphorimager: Blue filter, Blue laser, 473 nm). Images prepared in GIMP 
(v2) (GIMP, n.d.). 
 
Following optimisation of the RNA substrate and enzyme concentration, assays were conducted in 
triplicate, as per Section 4.2.4 in the presence and absence of 3.75 mM citrate (equal molar 
concentrations to Mg2+) and representative gels are shown in Figure 4.32. The pixel intensity of 
RNA bands in Figure 4.32 were quantified using gel densitometry. The percentage of intact RNA 
substrate remaining at the end of the assay was determined for each enzyme, in the absence and 
presence of citrate and the values are provided in Table 4.5. 
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Figure 4.32 3’-5’ Degradation Assay; In Vitro Inhibition of PNPase Homologs by Citrate  
A range of PNPase homologs (240 nM) were incubated with 700 nM 5’FAM(A)20 RNA substrate at 37°C. The no enzyme control, shows intact RNA with (+) and without (-) citrate (3.75 
mM, equal molar to MgCl2+) at the start (S) and end (E, 60 minutes) of the reaction. In these assay conditions, to account for enzymatic efficiency differences, the hPNPase was incubated 
for 60 minutes, the SsoExosome and SspPNPase were incubated for 30 minutes and EcPNPase for 10 minutes. Samples were run on a 20% urea denaturing gel in 1 x TBE and the RNA 
substrate degradation products 2-20 mer are indicated. Images prepared in GIMP (v2) (GIMP, n.d.). 
 
 
No enzyme EcPNPase SspPNPase hPNPase SsoExosome
- + - + - + - + - + Citrate
S E S E S E ESE S S E E S S E E S S E Time point
Figure 4
20-mer
2-mer
10-mer
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Table 4.5  3’-5’ Degradation Assay; Quantifying the in Vitro Inhibition of PNPase Homologs by Citrate 
The percentage of substrate remaining at assay end-point in the absence (-) or presence (+) of citrate are 
listed for PNPase homologs. Values are the mean from at least three experimental repeats and the errors 
reported are the standard deviation.  
 
As previously established in Chapter 3, all three PNPase homologs hPNPase, EcPNPase and 
SsoExosome exhibited 3’-5’ degradation activity, degrading a 20 mer 5’ FAM Poly(A) substrate to 
a 2 mer degradation product. The control assay showed that citrate didn’t affect the RNA integrity 
from the start (S) to the end (E) of the assay; the RNA substrate remained intact in the no enzyme 
control +/- citrate. In the EcPNPase enzyme assay, the RNA was partially degraded within the time 
scale tested, with degradation products spanning from a 20 mer to a 2 mer. EcPNPase activity was 
clearly inhibited by citrate, with 2.5-fold more substrate remaining at the end of the assay in the 
presence of citrate (Figure 4.32; Table 4.5) and this was consistent with previous observations 
(Nurmohamed et al., 2011). The commercially available SspPNPase, which has the same eight 
residues involved in citrate-binding as SanPNPase (Figure 4.11), also showed degradation activity 
and the presence of citrate was inhibitory. Thus suggesting that the serine/threonine mutation in the 
‘SSS’ motif of EcPNPase had no effect on citrate mediated inhibition. These two enzymes 
suggested that citrate-PNPase interactions were conserved in two distinct bacterial species. Citrate 
also inhibited the exoribonuclease activity of hPNPase and SsoExosome to a similar degree as 
EcPNPase (Figure 4.32; Table 4.5). Thus suggesting that citrate regulates these more evolutionarily 
distinct enzymes.  
 
In the presence of citrate, the limit products produced by the SsoExosome were 10-mers rather than 
the 2-mer obtained in the absence of citrate (Figure 4.32). Stalling of the exosome at this position 
was also observed in the absence of citrate and has been previously reported for the A. fulgidus and 
P. abyssi exosomes for short oligoribonucleotides that can no longer be bound at both the active 
site and the entrance to channel (Hartung et al., 2010; Navarro et al., 2008). Supportively, the 
channel size has been shown to accommodate up to ~ 9 nts of substrate (Lorentzen & Conti, 2005). 
Citrate-binding to the active site could occlude the only RNA-binding site possible for short 
oligoribonucleotides and may explain our observation of more of the stalled product. 
 
4.3.6 Sequence Analysis of Citrate Binding Residues 
The results so far strongly suggested that citrate-mediated inhibition of PNPase and exosome 
activity is a commonly exploited regulatory mechanism in all three domains of life. To assess how 
widely this mechanism is conserved, a more detailed bioinformatics sequence analysis compared to 
that previously reported in Section 4.3.2 was undertaken.  
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The conservation of individual residues, within the four main binding motifs (highlighted in Figure 
4.11, were compared across 3,509 prokaryotic PNPase, 252 eukaryotic PNPase and 69 
Rrp41/Rrp42 exosome protein sequences. The resulting sequence logos of active site RBRI, 
RBRII, PBR and MBR motifs are shown in Figure 4.33 and the full consensus sequence list is 
provided in the Appendix 9.8. Of the ten Mg2+ and citrate-binding residues that were originally 
identified in EcPNPase (R93, R399, H403, S437, S438, S439, D486, H487, D492 and K494), eight 
were absolutely conserved in all of the bacteria and eukaryotes examined (Figure 4.33 (a) and (b)). 
Only positions corresponding to EcPNPase S438 in the PBR and H487 in the MBR showed 
variation. There was a conserved serine/threonine substitution at the position of S438 across 
prokaryotes and eukaryotes, only these two residues have been an acceptable mutation over their 
evolution. The number of potential substitutions of H487 increased for prokaryote and eukaryote, 
suggesting that this residue is less evolutionarily conserved. Nevertheless, the docking and activity 
results for EcPNPase, SanPNPase/SspPNPase and hPNPase indicated that the sequence variation at 
these positions was not critical for citrate-binding or citrate-mediated regulation. Therefore, the 
alignments predict that all PNPases may bind and be regulated by citrate.  
 
The sequence logos for the exosomes (Figure 4.33 (c)) confirmed the findings from our initial 
alignment which contained just four exosome sequences (Figure 4.11).  Only four of the Mg2+ and 
citrate-binding residues identified in EcPNPase were absolutely conserved in archaea (R93 in 
RBRI, R399 in RBRII and D486 and D486 in MBR). As for the PNPases, variation was observed 
at the non-critical EcPNPase H487 position in the MBR, in the EcPNPase H403 position in RBRII 
and the EcPNPase K494 position in the MBR. Most strikingly, the S(S/T)S motif in the PBR of 
PNPases appears to have been replaced by a G(T/S)R motif in the archaeal exosomes. 
 
Despite this sequence variation, this study has clearly shown for the SsoExosome that citrate still 
binds to the archaeal exosomes and modulates its activity in vitro. Taken altogether these results 
suggest that all of the PNPases and archaeal exosomes examined may bind to and be regulated by 
citrate.  
 
Protein sequence alignments used for generating sequence logos shown in Figure 4.33 were also 
analysed to investigate the citrate-binding site observed at the vestigial site of EcPNPase and the 
resulting alignment is shown in Figure 4.34. As seen in Section 4.3.2.2, sequence conservation at 
this site was much weaker than for the active site, providing more support for not investigating this 
site further. 
 
In summary sequence analysis of citrate binding residues predicted that the citrate-mediated 
regulation of PNPases and archaeal exosome may represent a common regulatory strategy across 
evolution.  
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Figure 4.33 Conservation of PNPase Homologs Binding Motifs Sequence Logos  
Sequence logos for (a) 3,509 Prokaryote PNPases, (b) 252 eukaryote PNPases and (c) 69 archaeal exosomes sequence are provided, highlighting the protein sequence conservation of the 
RBRI, RBRII, PBR and MBR motifs (x axis) with a probability score (y axis). Uncharged residues are shown in black, with positively and negatively charged residues coloured blue and 
red respectively. Dotted boxes represent residues which are conserved across all three domains. Arrows indicate the residues previously discovered to interact with citrate in EcPNPase in 
(Nurmohamed et al., 2011). Images generated in Weblogo3 and prepared in GIMP (v2) (GIMP, n.d.). 
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Figure 4.34 PNPase Homologs Vestigial Site Sequence Logos  
Sequence logos for (a) 3,509 Prokaryote PNPases, (b) 252 eukaryote PNPases and (c) 69 archaeal exosomes sequence are provided, vestigial site motifs (x axis) were selected to show 
residues around arginines previously shown to bind citrate at the vestigial site (arrows) (Nurmohamed et al., 2011). The probability score is shown for each residue (y axis), with the 
exception of the variable region, where a large number of insertions and deletions are present over evolution of all domains. Uncharged residues are shown in black, with positively and 
negatively charged residues coloured blue and red respectively. Images generated in Weblogo3 and prepared in GIMP (v2) (GIMP, n.d.). 
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4.4 Conclusion 
The results described in Section 4.3.1 firstly investigated in detail the citrate-PNPase interactions 
previously documented in the literature. These results, describing the residues involved in citrate 
binding for EcPNPase were useful since they allowed comparisions to be made between the known 
crystal structures and docking predictions, essentially facilitating validatation of the docking 
process. These citrate-PNPase interactions were then discovered to be conserved across a range of 
PNPase and archaeal exosome homologs, through basic protein sequence alignments in Section 
4.3.2. Results from in silico molecular docking calculations were then presented in Section 4.3.3, 
which initially validate the methodology, using available EcPNPase and hPNPase structures with 
citrate bound, prior to predicting that two citrate molecules dock into SanPNPase and SsoExosome 
homologs active sites. Results of crystal trials of SsoExosome soaked with citrate diffracting X-
Rays was then provided in 4.3.4, although the diffraction was only weak, the results suggested an 
opportunity for optimisation. Subsequently, data obtained from in vitro experiments in Section 
4.3.5 then suggested that citrate inhibits the 3’-5’ phosphorolytic degradation activity of all 
homologs tested (SspPNPase was utilised in place of SanPNPase). Whether one or two citrate 
molecules are required for inhibition remains to be revealed (Nurmohamed et al., 2011). Finally, a 
more detailed sequence analysis, provided in Section 4.3.6, suggested that the citrate binding 
residues are widely conserved and therefore the citrate-mediated regulation of PNPases and 
archaeal exosome reported within this chapter may represent a common regulatory strategy across 
evolution.  
 
In summary, this chapter provides a variety of in silico and in vitro evidence that suggests a 
communicative link may exist between citrate and evolutionarily divergent PNPase homologs. As 
highlighted in Figure 4.35 the interaction between citrate and 3’-5’ exoribonucleases could 
modulate the RNA pool and affect post-transcriptional gene regulation. This supports the model 
where central metabolism acts as another tier in the central dogma flow of cellular information. 
Whether other metabolites can affect PNPase homologs in a similar manner to citrate is 
investigated next in Chapter 5. 
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Figure 4.35 Citrate-PNPase Communication Summary 
The flow of cellular information. The potential interaction of citrate with PNPase homologs is shown, linking 
central metabolism to post-transcriptional gene regulation. Image adapted from Prof. Anastasia Callaghan.  
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5 Metabolites Other Than Citrate May Modulate the 
Phosphorolytic Activity of Polynucleotide 
Phosphorylase from Homo sapiens  
 
The first objective of this PhD study was to explore the conservation of citrate-PNPase interactions. 
Combined evidence from molecular docking calculations, bioinformatics studies and gel-based 
degradation assays supported the hypothesis that attenuation of PNPase activity by citrate may be 
widespread across evolution. More specifically, the use of the docking program MOE, as a tool for 
predicting regulatory molecules, was initially validated. The residues known to be involved in 
citrate-PNPase interactions, were discovered to be highly conserved and, using MOE, citrate was 
predicted to dock into evolutionarily distinct PNPase homologs. Furthermore, citrate was shown to 
affect the 3’-5’ degradation activity of PNPase homologs from all three domains of life, including 
prokaryotes, eukaryotes and archaea. Whether this represented a unique role for citrate, or whether 
other metabolites of the TCA cycle can also interact with PNPase homologs and affect activity, 
remains to be determined. 
 
Accordingly, the second objective of this PhD study, and the focus of this chapter, was to 
investigate whether other metabolites may also play a role in regulating RNA turnover. As 
highlighted in Chapter 1, the pool of available metabolites and the evolution of the TCA cycle 
varies considerably between organisms and this can make comparative studies particularly 
challenging. Since both PNPase and the TCA cycle metabolites are located within the mitochondria 
of H. sapiens the interaction between metabolites and hPNPase was the main focus of this chapter. 
This is potentially important since research suggests that disturbance of RNA turnover within the 
mitochondria is linked to aging, cancer and neurodegenerative diseases in humans (Borowski, 
Szczesny, Brzezniak, & Stepien, 2010). 
 
A similar approach to Chapter 4, of combining in silico molecular docking with in vitro gel-based 
assays, was applied within this chapter. The binding and effect of metabolite-PNPase interactions 
were first predicted using MOE and then quantified using gel-based assays respectively. 
Metabolites which were predicted to bind hPNPase with greater affinity than citrate, and were 
shown to effect hPNPase degradation activity more than citrate, were then examined more closely. 
In order to identify the key functional groups/features of these metabolites, that may be particularly 
important for PNPase regulation, a pharmacophore was generated using MOE. This process 
essentially predicted metabolite (ligand) features, which ensured optimal in silico interactions with 
hPNPase (receptor) (as reviewed in Langer & Wolber, 2004). More specifically, by using MOE, 
‘classical’ pharmacophoric features like H-bond acceptors (Acc) and donors (Don), hydrophobic 
(Hyd) and/or aromatic rings (Aro), together with geometrical constraints like distances, angles, and 
dihedral angles were calculated from a collection of metabolite-hPNPase poses (Molecular 
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Operating Environment, 2013). This set of features, termed the pharmacophoric ‘model’ or 
‘hypothesis’ (Langer & Wolber, 2004), was then used to predict other metabolites which may 
regulate hPNPase activity. To address the question of whether metabolites play a role in regulating 
RNA turnover in humans, a variety of in silico and in vitro experiments were conducted within this 
chapter. 
 
5.1 Chapter Aims 
The previous chapters describe the methods and techniques used to predict the conservation of 
citrate binding residues in silico, and determine the effects of citrate on recombinant PNPase 
homolog activity in vitro. Similarly, this results chapter utilises H. sapiens and E. coli PNPase 
enzyme structures, previously prepared for docking in MOE, for molecular modelling studies 
(Chapter 4), and purified recombinant hPNPase and EcPNPase (Chapter 3) for in vitro gel-based 
assays. As a result, the methods described in Section 5.2 build on those previously provided in 
Chapter 3 and 4.  
 
Key questions addressed within this work examine whether, like citrate, other metabolites of the 
TCA cycle are predicted to bind hPNPase in silico. Additionally, whether these metabolites affect 
hPNPase degradation activity will be determined in vitro. Through generating a pharmacophore 
model, key features of any identified metabolite-PNPase interaction will be examined in more 
detail. Finally, this pharmacophore model will be utilised to predict other metabolites which may 
regulate the activity of hPNPase. The resulting data are provided in Section 5.3 and important 
conclusions regarding a metabolite-PNPase communicative link in the higher eukaryotic organism 
H. sapiens are then summarised in Section 5.4.  
 
5.2 Methods 
Collectively the methods outlined within previous chapters were used as standard, and any 
additional information utilised for this chapter specifically, is detailed below.  
 
5.2.1 In-Silico Molecular Docking 
All the computational procedures, for docking into PNPase from H. sapiens, was carried out using 
MOE as summarised in the flow diagram shown in Chapter 4 (Figure 4.1) (Molecular Operating 
Environment, 2013). Details of individual parameters for docking ‘user defined’ metabolite 
databases, generating PLIFs/heat maps and generating pharmacophore consensus models, are 
described in Sections 5.2.1.1-5.2.1.3 respectively. 
 
5.2.1.1 In-Silico Metabolite Database Docking 
The structures of a selected range of metabolites tested (Appendix 9.9) were downloaded from 
either the ZINC or PubChem database (Table 5.1) and saved as individual MOL2 files in a 
biologically relevant conformation (Irwin, Sterling, Mysinger, Bolstad, & Coleman, 2012). All 
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ligands were then saved in one of two MOE ‘user defined’ database files; allowing them to be 
docked sequentially in larger docking runs (termed TCA_Metabolite.mdb and 
Additional_Metabolites.mdb respectively). These bespoke databases were then docked into the 
appropriate ligand binding site using the MOE docking parameters previously defined (Chapter 4). 
Specifically, the PNPase receptor was set to the prepared hPNPase (3U1K_Dock) active-site 
pocket and the ligand was set as one of the specific databases (mdb file) mentioned above. In 
summary docking calculations were done with Amber12: EHT forcefield, triangle matcher 
placement (with 300 poses), and scored according to the MOE default London dG scoring function. 
The 300 docking poses were then subjected to a forcefield refinement with no second rescoring and 
30 unique poses for each compound were retained. The docking score (S) for each receptor-ligand 
complex was then calculated using the Generalized Born solvation model (GB/VI). The lowest-
energy scoring poses for each ligand were selected and the MOE binding score (S) values 
(kcal/mol) were plotted using the Minitab (v17) Boxplot function (Minitab, 2010).  
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Table 5.1 Metabolite Database Identification Codes  
The Zinc and PubChem database codes for all the metabolites docked in silico into hPNPase are listed (Irwin 
et al., 2012). The metabolites that were used for in vitro gel-based assays are indicated with an asterisk. 
 
5.2.1.2 Protein Ligand Interaction Fingerprints (PLIF) and 
Heat Map Generation 
The top 10 lowest-scoring poses for hPNPase docked with either acetyl-CoA or succinyl-CoA were 
selected. In order to generate a representation of the three-dimensional molecular interactions, 
Protein Ligand Interaction Fingerprints (PLIF) were generated using MOE (Singh, Deng, Narale, & 
Chuaqui, 2006). The resulting PLIF data, for each metabolite, were then exported as bit scores into 
Microsoft Excel (2010). The predicted frequency of acetyl-CoA or succinyl-CoA, interacting with 
Database Compound  Identification Code
Acetyl-CoA ZINC85552088 *
Citrate ZINC00895081 *
Cis-Aconitate ZINC03860972 *
D-Isocitrate ZINC00895176 *
α Ketoglutarate ZINC01532519 *
Succinyl-CoA ZINC96014495 *
Succinate ZINC00895030 *
Fumarate ZINC03860193 *
Pyruvate ZINC01532517 *
D/L-Malate ZINC00895074 *
Oxaloacetate ZINC01532521 *
A ZINC2169830
AMP ZINC3860156
ADP ZINC12360703
ATP ZINC03871615
ppppA ZINC18456332
cAMP ZINC53683809
c-di-AMP PubChem11158091
G ZINC1550030
GMP ZINC2159505
GDP ZINC8215481
GTP ZINC53684323 *
ppppG ZINC30724813 *
ppGpp ZINC30724089 *
pppGpp ZINC83923877
cGMP ZINC13545961
c-di-GMP ZINC33882399
C ZINC2583632
CMP ZINC16546001
CDP ZINC12495268
CTP ZINC19850119
cCMP PubChem19236
U ZINC2583633
UMP ZINC2123545
UDP ZINC12493522
UTP ZINC19796107
cUMP PubChem3081385
CoA ZINC87493113
TCA_Metabolites.mdb 
Additional_Metabolites.mdb
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hPNPase, was then calculated. Finally, the percentages for each ligand were presented as heat maps 
using the online Plotly graph software (Plotly Technologies Inc., 2015). 
 
5.2.1.3 Pharmacophore Generation 
The top 10 lowest-scoring poses for acetyl-CoA and succinyl-CoA were selected and the PLIFs 
generated previously (Section 5.2.1.2) were combined to generate a pharmacophore consensus 
query. The maximum radius of each pharmacophore feature was set to the default size of 3 Å. The 
scheme, which defines the set of attributes used to construct a ligand annotation point, was set to 
default unified scheme; a simple annotation showing Donor (Don), Acceptor (Acc), Hydrophobic 
(Hyd) and Aromatic (Aro) features was selected (Molecular Operating Environment, 2013). In the 
Pharmacophore calculations, MOE used these ‘classical’ features (Langer & Wolber, 2004), 
together with geometrical constraints like distances, angles, and dihedral angles (Molecular 
Operating Environment, 2013), to generate a consensus model for the interactions between acetyl-
CoA/succinyl-CoA and hPNPase. The resulting pharmacophore features were then visually 
represented as mesh spheres within the active site of hPNPase. By comparing the orientation of 
acetyl-CoA and succinyl-CoA poses within the pharmacophore, key functional groups involved in 
hPNPase binding, were predicted. 
 
5.2.2 Gel-Based Degradation Assays 
In order to analyse 3’-5’ phosphorolytic exoribonuclease activities in the presence of metabolites, 
gel electrophoresis degradation assays were conducted as detailed in Chapter 4. The concentrations 
of metabolites used, were the same as citrate (3.75 mM) and were equal molar to the magnesium 
concentration (3.75 mM). This allowed the level of inhibition, for metabolites listed in Table 5.1 
(asterisk) to be compared to citrate. This was important as 3.75 mM citrate had been previously 
suggested to attenuate PNPase activity in Chapter 4.  
 
5.3 Results  
This section firstly provides results from in silico molecular docking calculations which predict that 
TCA metabolites acetyl-CoA and succinyl-CoA bind the active site of PNPase from H. sapiens 
with higher affinity than citrate (Section 5.3.1). Further analysis of in silico data predicted that 
these metabolites also bind hPNPase using the same conserved residues known to be involved in 
citrate binding. The effects of TCA metabolites on hPNPase activity were then investigated using 
in vitro gel-based assays in Sections 5.3.1-5.3.2. The results of which demonstrated that acetyl-
CoA and succinyl-CoA affect hPNPase activity more than citrate. Following the observation that 
these metabolites bind hPNPase using the same highly conserved residues as citrate, the effects of 
these metabolites on the PNPase homolog from E. coli was examined in Section 5.3.4. As acetyl-
CoA and succinyl-CoA were found to affect the activity of both hPNPase and EcPNPase, a 
potential TCA metabolite-PNPase communicative link was proposed. The features that may be 
particularly important in hPNPase regulation were examined further in Section 5.3.5, by generating 
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a pharmacophore model using MOE. The nucleotide part of CoA for both these TCA metabolites 
was predicted to mimic the combined interactions of the two molecules of citrate; essentially 
binding and occluding the hPNPase active site in a similar manner. Following this observation, it 
was predicted that other phosphate containing metabolites including a range of nucleotides and 
signalling molecules, may also dock into the active site of hPNPase and this was investigated in 
Section 5.3.6. Interestingly, phosphate-rich metabolites GTP, ppppG and ppGpp, that were 
predicted to bind to hPNPase in silico with tighter affinity than citrate, were also shown to affect 
both hPNPase and EcPNPase activity in Section 5.3.7. In summary, results presented within this 
section suggest that a metabolite-PNPase communicative link may exists in prokaryotes and 
eukaryotes.  
 
5.3.1 Some TCA Metabolites Are Predicted In Silico to Dock into PNPase 
from H. sapiens 
The TCA cycle metabolites highlighted in bold in Figure 1.12 (Chapter 1) and listed in Table 5.1, 
were docked as a database into the active site of hPNPase (3U1K_Dock), using the docking module 
of MOE and the parameters outlined previously in Section 5.2.1.1. The top 30 lowest-energy poses 
were retained and the S values were presented as box plots in Figure 5.1 (a). The S values 
previously calculated in Chapter 4 for citrate-hPNPase docking were also shown in Figure 5.1 (a) 
(asterisk) for comparative purposes.   
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Figure 5.1 In Silico Docking and In Vitro Degradation Activity of hPNPase with TCA Metabolites 
(a) The 30 unique, lowest-energy poses, docking scores (S values, kcal/mol) are provided for TCA metabolite 
ligands docked into hPNPase (3U1K_Dock), graph generated in Minitab (v17) (Minitab, 2010). For 
comparison, citrate-hPNPase S values (asterisk) are also plotted and the average S value for citrate 1 is 
indicated with a red dotted horizontal line. (b) hPNPase (240 nM) was incubated with 700 nM 5’FAM(A)20 
RNA substrate, in the presence of 3.75 mM of each TCA metabolite, at 37°C. Samples were run on a 20% 
urea denaturing gel in 1 x TBE and the RNA substrate degradation products between 2-20 mer are indicated.  
The samples taken at the start (S, 0 minutes) and end (E, 60 minutes) of each reaction are indicated. A 
representative gel for citrate (asterisk), taken from Chapter 4, is also shown. (c) The no enzyme control, 
shows intact RNA in the presence of 3.75 mM of each metabolite and in the untreated sample. Image 
prepared in GIMP (v2) (GIMP, n.d.). 
 
The range of S values recorded in Figure 5.1 (a), predicted that individual TCA metabolites may 
interact with hPNPase with different binding affinities. For example, the S values for pyruvate, α 
ketoglutarate, succinate, fumarate, malate and oxaloacetate were all higher than the average S value 
calculated for citrate 1 docking (above red line in Figure 5.1 (a)). This suggested that citrate may 
bind the active site of hPNPase with higher affinity than these TCA metabolites. More specifically, 
the average S value of the top 10 metabolite-hPNPase poses for either pyruvate, α-ketoglutarate, 
succinate, fumarate, malate or oxaloacetate were -56, -80, -84, -73, -92 and -83 kcal/mol 
respectively, whereas the average S value for the first round of citrate docking was -112 kcal/mol. 
In contrast, the S values calculated for cis-aconitate (-109 kcal/mol) and isocitrate (-111 kcal/mol) 
were similar to the average S value calculated for one molecule of citrate docked (red line in Figure 
5.1 (a)). Interestingly, only acetyl-CoA and succinyl-CoA were predicted to bind to hPNPase with 
an average S value (both -145 kcal/mol) lower than citrate (below red line in Figure 5.1 (a)). This 
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observation suggested that these two metabolites may bind hPNPase with higher affinity than 
citrate. 
 
In order to understand these TCA metabolite-PNPase interactions further, the lowest-binding 
energy conformation for hPNPase docked with either acetyl-CoA, succinyl-CoA or two molecules 
of citrate were compared. It was clear from the results shown in Figure 5.2 that, like citrate, both 
acetyl-CoA and succinyl-CoA were predicted to bind within the active site of hPNPase. It was 
interesting to note that both TCA metabolites were docked in the location where the magnesium 
metal ion, required for catalysis, is located (Figure 5.2 (b-c). Furthermore, they occupied the same 
Cit 1 and Cit 2 sites where two molecules of citrate are known to bind (Figure 5.2 (a)). 
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Figure 5.2 Lowest Predicted Binding Conformation of Citrate, Acetyl-CoA and Succinyl-CoA in the 
hPNPase Active Site. 
The active site of hPNPase (3U1K_Dock) is coloured blue and red based on their residues positive and 
negative electrostatic charge respectively. The docked metabolites are shown in spheres for (a) two 
molecules of citrate, (b) one acetyl-CoA molecule and (c) one succinyl-CoA molecule, with the top predicted 
S value docking score (kcal/mol). Images generated in MOE and prepared in GIMP (v2) (GIMP, n.d.; 
Molecular Operating Environment, 2013). 
 
In order to predict the residues involved in metabolite binding, the top ten poses for acetyl-CoA 
and succinyl-CoA docked into hPNPase were analysed further. A PLIF was generated for each 
metabolite-hPNPase interaction and the information calculated for the top ten poses were 
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summarised in a heat map. The heat maps for acetyl-CoA and succinyl-CoA interacting with 
hPNPase were shown in Figure 5.3 alongside the results previously determined for citrate (Chapter 
4). For comparative purposes, the interactions predicted for the first and second round of citrate 
docking were combined in one heat map in Figure 5.3. 
 
 
Figure 5.3 Metabolite-hPNPase Heat Map 
A heat maps summarising the PLIF data generated for the ten lowest-energy poses obtained when two 
molecules of citrate (Cit 1 and Cit 2), acetyl-CoA or succinyl-CoA were docked into the active site of 
hPNPase. The interaction frequency (0-100%) was coloured as per the scale bar (from cream to blue 
respectively). Residues involved in citrate and metal ion coordination, within the RNA I (RBRI), RNA II 
(RBRII), Phosphate (PBR) and Metal Binding Regions (MBR) are indicated (black arrows). Images 
generated in MOE, Plotly and prepared in GIMP (v2) (GIMP, n.d.; Molecular Operating Environment, 2013; 
Plotly Technologies Inc., 2015). 
 
The heat maps presented within Figure 5.3 predicted that the residues of hPNPase involved in 
binding all three TCA metabolites were similar. Additionally, the types of interactions were also 
conserved. For example, the ionic and side chain acceptor interactions for R132 within the RNA 
Binding Region I (RBRI), and residues R446 and H450 within the RNA Binding Region II 
(RBRII), were similar for citrate, acetyl-CoA and succinyl-CoA (Figure 5.3, black arrows). 
Furthermore, backbone acceptor interactions of S482 and backbone/sidechain acceptor interactions 
of S483 and S484 within the Phosphate Binding Region (PBR) were present for all three 
metabolites (Figure 5.3, black arrows). The D538 and D544 residues (side chain donors) and K546 
(ionic and sidechain acceptor interactions) within the Metal Binding Region (MBR) also interacted 
with the TCA metabolites in a similar manner (Figure 5.3, black arrows). 
 
In summary, TCA metabolites were predicted to interact with hPNPase with different binding 
affinities and only acetyl-CoA and succinyl-CoA were predicted to bind to hPNPase tighter than 
citrate. The residues involved in binding these two metabolites were predicted to be similar and 
they were suggested to mimick the combined interactions of the two molecules of citrate; 
[162] 
essentially binding and occluding the hPNPase active site. Whether, like citrate, these metabolites 
can also affect hPNPase activity in vitro remains to be discovered and this was the focus of the next 
Section 5.3.2.  
 
5.3.2 Some TCA Metabolites Inhibit H. sapiens PNPase Degradation 
Activity In Vitro 
The effect of each TCA metabolite on recombinant hPNPase 3’-5’ RNA degradation activity was 
examined using the gel-based assays described previously in Chapter 4 and in Section 5.2.2. The 
results of which were shown in Figure 5.1 (Section 5.3.1) alongside the results of docking 
calculations for comparative purposes. It is noteworthy to mention that the control assays, 
containing only the RNA substrate in the presence of each TCA metabolite, confirmed that none of 
the TCA metabolites caused RNA degradation; the RNA substrate remained intact in control lanes 
in Figure 5.1 (c). The results in Figure 5.1 (b) are presented within this section as a larger image 
(Figure 5.4) for easier comparison to the quantification in Table 5.2. 
 
The TCA metabolites, pyruvate, α-ketoglutarate, succinate, fumarate, malate and oxaloacetate were 
not found to affect hPNPase 3’-5’ activity; the percentage of intact RNA at the end of the assay was 
the same as the untreated assay (within error) (Figure 5.4 and Table 5.2). Whether this was a result 
of the reduced binding predicted in silico (Section 5.3.1) could be further examined using other in 
vitro biophysical techniques including X-ray crystallography, surface plasmon resonance (SPR) or 
isothermal titration calorimetry (ITC), however this was not the focus of this study. The in vitro 
data shown in Figure 5.4 and quantification provided in Table 5.2, suggested that isocitrate had no 
effect on hPNPase degradation activity. Additionally, although cis-aconitate appeared to affect 
hPNPase activity (Table 5.2), this metabolite is not thought to be ‘free’ within the cell and so the 
physiological relevance of this interaction is questionable (Lehninger, Nelson, & Cox, 2000). The 
in vitro gel-based degradation assays, shown in Figure 5.4 and quantification in Table 5.2, 
suggested that the presence of either acetyl-CoA or succinyl-CoA affected hPNPase activity more 
than citrate. The presence of succinyl-CoA or acetyl-CoA caused a 4.8 or 7.7-fold increase in the 
percentage of intact 5’ FAM poly(A)20mer RNA respectively.  
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Figure 5.4 In Vitro Degradation Activity of hPNPase with TCA Metabolites 
Image taken from Figure 5.1 (b) and enlarged. hPNPase (240 nM) was incubated with 700 nM 5’FAM(A)20 RNA substrate, in the presence of 3.75 mM of each TCA metabolite, at 37°C. 
Samples were run on a 20% urea denaturing gel in 1 x TBE and the RNA substrate degradation products between 2-20 mer are indicated.  The samples taken at the start (S, 0 minutes) and 
end (E, 60 minutes) of each reaction are indicated. A representative gel for citrate (asterisk), taken from Chapter 4, is also shown. Image prepared in GIMP (v2) (GIMP, n.d.). 
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Table 5.2 Degradation Assay; Quantifying the In Vitro Inhibition of hPNPase by TCA Metabolites 
The percentage of intact RNA substrate remaining at assay end-point, in the absence (-) or presence (+) of 
each metabolite, are listed for hPNPase. Values are the mean from at least three experimental repeats and the 
errors reported are the standard deviation (Std). Percentage values which were lower than citrate are coloured 
red, those equal to citrate (within Std error of the citrate value) were coloured orange, whereas values greater 
than citrate were coloured green. 
 
In summary, the results presented within this section suggested that acetyl-CoA and succinyl-CoA 
affected the activity of hPNPase more than the other TCA metabolites tested within this study, 
including citrate. The following Section 5.3.3, compared the results of previous in silico docking 
calculations (Section 5.3.1) with these in vitro results in more detail. 
 
5.3.3 Correlation of In Silico Docking Calculations and In Vitro 
Degradation Activity 
The data plotted in Figure 5.5 combined evidence from in silico and in vitro techniques; 
specifically, the percentage of intact RNA substrate (5’FAM poly(A)20mer) quantified from gel-
based assays was plotted against the average S value predicted from docking calculations. This 
graph was created to illustrate trends within the data and although there wasn’t a strong linear 
correlation between the docking score and inhibition observed, some of the data could be grouped 
together.  
 
Metabolites with average S values lower than -112 kcal/mol (above red dotted horizontal line in 
Figure 5.5.) were predicted to have weaker binding compared to citrate and were highlighted red in 
Figure 5.5. In contrast Metabolites with S values higher than -112 kcal/mol (below red dotted 
horizontal line in Figure 5.5) were predicted to have stronger binding affinity compared to citrate 
and were highlighted green in Figure 5.5. Metabolites highlighted in red, which were predicted to 
bind hPNPase weaker than citrate, were also observed to have less than 10% of intact substrate 
remaining at the assay end-point (left of red dotted vertical line in Figure 5.5) and therefore 
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exhibited less inhibition than citrate. The only exception was cis-aconitate (highlighted in orange, 
in Figure 5.5) which had 10.1% of substrate remaining at the assay end-point. Both metabolites 
highlighted in green were observed to have more than 10% of substrate remaining at the assay end-
point and therefore exhibited more inhibition than citrate (right of red dotted vertical line in Figure 
5.5).  
 
 
Figure 5.5 In Silico Docking Vs In Vitro Inhibition of hPNPase by TCA Metabolites 
For each TCA metabolite the average S value (kcal/mol) for the top ten poses docked into hPNPase (3U1K) 
were plotted against the percentage of intact RNA at the assay end-point. Metabolites that caused <2.5-fold 
effect on hPNPase 3’-5’ RNase activity are highlighted in red, whereas those which inhibited (>2.5 fold) are 
highlighted green (except cis-aconitate, which inhibited ~ 2.2-fold and is therefore coloured orange). Graph 
generated in Minitab (v17) (Minitab, 2010).  
 
In summary, the TCA metabolites acetyl-CoA and succinyl-CoA affected the in vitro activity of 
hPNPase more than citrate and this aligned to in silico data which predicted these two metabolites 
may bind to hPNPase with a higher affinity. The heat maps presented in Section 5.3.1 predicted 
that the hPNPase residues involved in binding acetyl-CoA and succinyl-CoA, were the same as 
those involved in citrate binding (Figure 5.3). These residues have already been shown to be highly 
conserved across evolution in Chapter 4, and this led to the proposal that acetyl-CoA and succinyl-
CoA may also bind to other PNPase homologs, including PNPase from the prokaryotic E. coli 
model organism. Therefore, whether these two TCA metabolites can also affect the activity of 
EcPNPase was examined in Section 5.3.4. 
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5.3.4 Some TCA Metabolites Inhibit E. coli PNPase Degradation Activity 
In Vitro 
The effect of TCA metabolites, acetyl-CoA and succinyl-CoA, on recombinant EcPNPase 3’-5’ 
RNA degradation activity was examined using the gel-based assays described in Section 5.2.2. The 
results of which were shown in Figure 5.6 alongside the citrate gels taken from Chapter 4. The 
control assays shown previously in Figure 5.1 (c) suggested that RNA integrity was not affected by 
the TCA metabolites. 
 
The in vitro gel-based degradation assays suggested that succinyl-CoA affected EcPNPase activity 
more than citrate. Compared to the untreated assay, the presence of succinyl-CoA, acetyl-CoA or 
citrate caused a 5.0, 2.8 or 2.5-fold increase in the percentage of intact 5’FAM poly(A)20mer RNA 
substrate respectively (Table 5.3). Hence, as predicted, EcPNPase was inhibited by all three TCA 
metabolites. However, unlike hPNPase, succinyl-CoA was the more effective inhibitor of these 
metabolites.  
 
 
Figure 5.6 3’-5’ Degradation Assay; In Vitro Inhibition of EcPNPase Homologs by Citrate, Acetyl-CoA 
and Succinyl-CoA 
EcPNPase (240 nM) was incubated with 700 nM 5’FAM(A)20 RNA substrate, in the presence of 3.75 mM of 
each metabolite, at 37°C. Samples were run on a 20% urea denaturing gel in 1 x TBE and the RNA substrate 
degradation products 2-20 mer are indicated.  The sample taken at the start (S, 0 minutes) and end (E, 10 
minutes) of the reaction are indicated. Image prepared in GIMP (v2) (GIMP, n.d.). 
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Table 5.3 Degradation Assay; Quantifying the In Vitro Inhibition of EcPNPase by Citrate, Acetyl-CoA 
and Succinyl-CoA 
The percentages of intact RNA substrate remaining at assay end-point, in the absence (-) or presence (+) of 
each metabolite are listed for EcPNPase. Values are the mean from at least three experimental repeats and the 
errors reported are the standard deviation. Percentage values which were lower than citrate are coloured red, 
those within the error of citrate were coloured orange, whereas values greater than citrate were coloured 
green. 
 
In summary, the results presented within this section and previously in Section 5.3.2, suggested that 
both acetyl-CoA and succinyl-CoA were good inhibitors of hPNPase and EcPNPase activity. 
Therefore, the purpose of the next section was to analyse the in silico docking results presented 
previously in Section 5.3.1 in more detail, with the aim to identify common features of acetyl-CoA 
and succinyl-CoA that may be involved in regulating PNPase. 
 
5.3.5 Predicting Metabolite Features That May Be Important for 
Interactions with PNPase from H. Sapiens 
The in silico docking results presented previously in Section 5.3.1 predicted that acetyl-CoA and 
succinyl-CoA occupied the active site of hPNPase and mimicked the combined interactions of the 
two molecules of citrate. However, the features of acetyl-CoA and succinyl-CoA that were 
predicted by MOE to be necessary for binding, were not compared with each other. Therefore, in 
order to compare the PLIFS for the top ten acetyl-CoA-hPNPase poses with the equivalent results 
for succinyl-CoA, a pharmacophore consensus model was generated using MOE (Molecular 
Operating Environment, 2013). The results shown in Figure 5.7 suggested that four main features 
(F1-4) were shared between all twenty docking poses.  
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Figure 5.7 hPNPase Pharmacophore Generation 
The active site of hPNPase (3U1K_Dock), with a Mg2+ (magenta sphere) bound, is shown in grey. The position of (a) two docked citrate molecules (top hits) are shown as yellow (Citrate 1) 
and orange sticks (Citrate 2). (b) The consensus pharmacophore (mesh spheres) generated shows the four pharmacophore features (F1-4) with acceptor, hydrophobic, donor and/or aromatic 
labels (Acc, Hyd, Don or Aro respectively). The same pharmacophore is shown with (c) acetyl-CoA and (d) succinyl-CoA bound at the active site. The position of the phosphate, sugar and 
base of the CoA nucleotide head are labelled. Images generated in MOE and prepared in GIMP (v2) (GIMP, n.d.; Molecular Operating Environment, 2013). 
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The first feature (F1) suggested an acceptor, with a radius of 1.31 Å, was present next to the active 
site magnesium ion (magenta, Mg2+) in 100% of the twenty poses (F1, Figure 5.7 (b)). The second 
feature (F2), with a radius of 2.9 Å, overlapped with F1 and suggested that a second acceptor was 
present within this location in 100% of the poses (F2, Figure 5.7 (b)). As shown in Figure 5.7 (a-b), 
both F1 and F2 were in the same location of the hPNPase active site that citrate 1 is known to bind 
and dock. The third feature (F3) suggested that either an acceptor or hydrophobic functional group, 
with a radius of 2.85 Å, was present in 85% of the poses (F3, Figure 5.7 (b)). As shown in Figure 
5.7 (a-b), F3 was in the same location of the hPNPase active site that citrate 2 is known to bind and 
dock. The fourth feature (F4) was found in 65% of poses and had a radius of 2.75 Å. As shown in 
Figure 5.7 (a-b), F4 was situated within the hPNPase active site and was located between the space 
for citrate 1 and 2 binding. The lower percentage (65%) reported for F4 suggested that this feature 
was not as important as F1 and F2, which were present in 100% of the poses respectively. There 
also appeared to be a greater amount of flexibility in the types of functional group permitted within 
this fourth feature; either an aromatic, hydrophobic, acceptor or donor was present within this 
location.  
 
After establishing the location of the four pharmacophore model features shown in Figure 5.7, the 
model was used to predict structural elements which were common to acetyl-CoA and succinyl-
CoA. For both metabolites, the 3’ terminal phosphate of the nucleotide part of CoA appeared to 
located in F1 and F2, whereas the sugar and the base were situated within F3 and F4 respectively 
(Figure 5.7 (c-d)). Essentially, the terminal phosphate of CoA was predicted to act as an acceptor 
and like citrate, interact with the magnesium cation within the Metal Binding Region (MBR), and 
the amino acid residues within the Phosphate Binding Region (PBR) of hPNPase. Whereas the 
nucleoside part of CoA was predicted to bind within the RNA Binding Regions of hPNPase in a 
similar manner to citrate 2; effectively bridging the interactions between these two citrate-binding 
sites. When the terminal phosphate of acetyl-CoA or succinyl-CoA, or the carboxyl group of citrate 
(all bound to hPNPase), were superimposed with the structure of the S. solfataricus archaeal 
exosome (4BA1), the metabolites were all within the equivalent location to the co-crystallised 
phosphate ion of SsoExosome (Figure 5.8). This suggested that the interactions of these TCA 
metabolites may prevent inorganic phosphate binding and therefore may provide an explanation, 
for the reduced phosphorolytic degradation activity, observed for hPNPase in Section 5.3.2. This 
aligned with previous research which proposed that citrate binding inhibited the degradation 
activity of PNPase in E. coli by preventing the formation of the Michaelis complex (Nurmohamed, 
Vaidialingam, Callaghan, & Luisi, 2009). That study suggested that citrate 1 occupied the binding 
site for the orthophosphate substrate whereas the adjacent citrate 2 mimicked the position of the 
scissile phosphate in the backbone of the RNA (Nurmohamed et al., 2009). It was noted that in 
these positions, the two citrate molecules may prevent the binding of inorganic phosphate, which is 
required for catalysis and potentially the RNA substrate itself.  
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Figure 5.8 hPNPase Pharmacophore: Phosphate Positioning  
A small section of the hPNPase (3U1K_Dock) active site (pink ribbons), with Mg2+ (magenta sphere), is 
shown zoomed in. The pharmacophore features 1 and 2 are also shown (blue mesh). The position of citrate 
and the 3’ terminal phosphates from acetyl-CoA, succinyl-CoA are shown alongside the equivalent position 
of co-crystallised phosphate of SsoExosome (4BA1). Images generated in MOE and prepared in GIMP (v2) 
(GIMP, n.d.; Molecular Operating Environment, 2013). 
 
In summary, the results presented within this study proposed that the CoA nucleotide part of acetyl-
CoA and succinyl-CoA may regulate hPNPase in a similar manner to the citrate-mediated 
inhibition mechanism proposed for EcPNPase. The 3’ terminal phosphate of the CoA nucleotide 
may occlude the inorganic phosphate binding region of the hPNPase active site, and the nucleoside 
part of CoA may prevent the binding of the RNA substrate. In combination, these interactions may 
regulate the 3’-5’ RNA degradation of hPNPase by preventing phosphorolytic acid-base catalysis. 
This was interesting as PNPases are known to be regulated by nucleotides in E. coli.  For example, 
EcPNPase was allosterically inhibited by ATP nucleotides (Del Favero et al., 2008) and cyclic di-
GMP secondary messenger molecules in vitro (c-di-GMP; Tuckerman et al., 2011).  
 
Following the prediction that the nucleotide part of CoA was important for regulating PNPase, a 
range of other nucleoside/nucleotide-based metabolites were docked in silico in the following 
Section 5.3.6. The aim of this study was to predict whether other nucleoside/nucleotide containing 
metabolites could bind hPNPase with a similar affinity to either citrate, acetyl-CoA or succinyl-
CoA. 
 
5.3.6 Phosphate-Rich Metabolites Are Predicted to Dock In Silico into 
PNPase from H. Sapiens 
A small bespoke (user defined) database containing a range of nucleosides, mono/di/tri-nucleoside 
phosphates and other phosphate-rich signalling molecules (Additional_Metabolites.mdb, Table 5.1) 
were docked into hPNPase (3U1K_Dock) using the docking module of MOE and the parameters 
outlined in Section 5.2.1.1. The top 30, lowest-energy poses, S values were represented as box 
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plots in Figure 5.9 and the average S value for citrate 1 docking (top ten poses) was shown for 
comparative purposes (red dotted horizontal line in Figure 5.9). 
 
 
Figure 5.9 In Silico Docking of hPNPase with Phosphate-Rich Metabolites 
The docking scores (S value, kcal/mol) predicted by MOE (Molecular Operating Environment, 2013), for the 
30 unique, lowest-energy poses of a range of metabolites bound to hPNPase (3U1K_Dock). Graph was sub-
grouped (grey dotted lines) into results for citrates, nucleosides, cyclic nucleotides, di-cyclic nucleotides, 
mono-phosphate nucleotides, di-phosphate nucleotides, CoA, tri- and tetra-phosphate nucleotides, the 
bacterial stringent response alarmone guanosine tetraphosphate (ppGpp), and its precursor guanosine 
pentaphosphate (pppGpp) respectively. For comparison, the average S value (top ten poses) for citrate 1 was 
indicated with a red dotted horizontal line. Graph generated in Minitab (v17) (Minitab, 2010). 
 
The nucleosides, cyclic nucleotides and di-cyclic nucleotides were all predicted to bind hPNPase 
with S values higher (weaker binding) (Figure 5.9, above red dotted line) than that previously 
determined for citrate 1 (-112 kcal/mol). Looking at the sub-group highlighted in Figure 5.9 in 
more detail (defined by grey dotted vertical lines), the average S value for nucleosides was -38 
kcal/mol (average of the top ten S values, for each metabolite within the subgroup). The cyclic 
nucleotides, which are like other nucleotides except a cyclic bond arrangement occurs between the 
sugar and phosphate groups, had a slightly lower average S value (top ten hits) for adenosine 
(cAMP) and guanosine (cGMP) (67.6 and 76.9 kcal/mol respectively), compared to cytidine 
(cCMP) and uridine (cUMP) which were -24.9 and -26.1 kcal/mol respectively. Interestingly, 
cAMP and cGMP are derivatives of ATP and GTP respectively and both have roles as a second 
messenger molecules, however the roles cCMP and cUMP are poorly understood. Whether these 
docking scores suggest that hPNPase may be able to sense, and thus be regulated by the purine or 
pyrimidine nitrogenous bases differently, requires further research. The di-cyclic nucleotides, 
which have a nitrogenous base linked by a sugar and phosphate, had a lower average S value (-
109.0 kcal/mol) than the cNDPs (Figure 5.9) for the adenosine base, but a similar S value for the 
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guanosine base respectively. It is important to note that structures for both cytidine and uridine di-
cyclic nucleotides were not available within either the Zinc or PubChem databases and so were not 
docked.  
 
When comparing the average S value (average of the top ten values, for each metabolite, within the 
subgroup) for the nucleosides, the mono- (NMP), di- (NDP), tri- (NTP) and tetra-phosphate 
nucleotides (ppppN), a general trend between the number of phosphates and the S value was 
observed (Figure 5.9). Specifically, the addition of one, two, three and four phosphates to 
adenosine, cytidine, guanosine and uridine resulted in an increasingly lower average S value. For 
example, the nucleosides had an average S value of -38 kcal/mol and this decreased to -109.0 
kcal/mol for the mono-phosphate nucleotides. This value reduced further to -127.0 kcal/mol and -
151.1 kcal/mol for NDPs and NTPs respectively and even more to -170.4 for ppppN nucleotides. 
Interestingly, all these average S values were lower than the average S value previously determined 
for citrate 1 docking into the hPNPase active site (-112 kcal/mol, red horizontal dotted line in 
Figure 5.9 ). Thus predicting that NDPs, NTPs and ppppNs may bind hPNPase with tighter affinity 
than citrate. It is important to note that structures for both ppppC and ppppU were not available and 
so were not docked. The average S values calculated for CoA (-140 kcal/mol) was slightly lower 
than NDPs, but slightly higher than NTPs, ppppNs and (p)ppGpp, predicting that phosphate-rich 
nucleotides may bind hPNPase with a higher affinity than CoA. This was an interesting observation 
as the pharmacophore consensus model presented in Section 5.3.5, proposed that the CoA 
nucleotide part of acetyl-CoA and succinyl-CoA was involved in hPNPase interactions.  
 
The metabolites guanosine tetraphosphate (ppGpp), and its precursor guanosine pentaphosphate 
(pppGpp), collectively termed (p)ppGpp, were both predicted to interact with hPNPase with 
average S values (-158.7 and -145.0 kcal/mol respectively) lower than citrate (below red dotted 
horizontal line in Figure 5.9). The cellular levels of these metabolites in H. sapiens mitochondria 
are not currently known. However, they have been shown to inhibit PNPase homologs from 
Nonomuraea sp. and Streptomyces, but not from E. coli (Gatewood & Jones, 2010; Hauryliuk, 
Atkinson, Murakami, Tenson, & Gerdes, 2015; Siculella et al., 2010). Whether these metabolites 
also regulate PNPase activity in humans remains to be revealed.  
It has been shown within this study that metabolites, including acetyl-CoA and succinyl-CoA, with 
S values lower than citrate can affect the activity of hPNPase in vitro. Therefore, it was proposed 
that other metabolites, shown in Figure 5.9 with S values lower than citrate (below the red dotted 
horizontal line), may affect hPNPase activity in a similar way to the TCA cycle metabolites. 
Accordingly, the following Section 5.3.7 describes the investigation of whether phosphate-rich 
nucleotides including GTP, ppppG and ppGpp, which are predicted to bind hPNPase with a lower 
S value than citrate, could also inhibit the enzyme’s activity. 
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5.3.7 Phosphate-Rich Metabolites Inhibit H. sapiens and E. coli PNPase 
Degradation Activity In Vitro 
The effect of phosphate-rich metabolites GTP, ppppG and ppGpp on the 3’-5’ RNA degradation 
activity of recombinant hPNPase and EcPNPase was examined. Gel-based assays were conducted 
as described previously in Chapter 4 and Section 5.2.2, and the results are shown in Figure 5.10. 
The control assays, containing only the RNA substrate in the presence of each metabolite, showed 
that none of the metabolites caused RNA degradation; the RNA substrate remained intact in control 
lanes in Figure 5.10 (c).  
 
The in vitro gel-based degradation assays, shown in Figure 5.10 (a) and quantification in Table 5.4, 
suggested that that GTP, ppppG and ppGpp all affect hPNPase activity. The percentage of intact 
5’FAM poly(A)20mer RNA substrate at the end of the assay, for all three phosphate-rich metabolites, 
increased by ~6.5-fold. These percentages (highlighted in green in Table 5.4) were higher than the 
percentages previously reported for citrate and succinyl-CoA, but were within error of the results 
obtained for acetyl-CoA (Table 5.2). As the average S value of GTP, ppppG and ppGpp (-156.4, -
177.4 and -158.7 kcal/mol respectively) were all lower than citrate (-112 kcal/mol) and following 
the observation that, like acetyl-CoA and succinyl-CoA, they also affect the 3’-5’ degradation 
activity of hPNPase in vitro. This work helped support the proposal made at the end of Section 
5.3.6 that metabolites, predicted to dock into hPNPase with a higher affinity than citrate, may also 
affect the enzymes degradation activity.  
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Figure 5.10 In Vitro Degradation Activity of hPNPase and EcPNPase with Phosphate-Rich Metabolites 
GTP, ppppG and ppGpp 
700 nM 5’FAM(A)20 RNA substrate, in the presence of 3.75 mM of each metabolite (GTP, ppppG and 
ppGpp), at 37°C with either (a) hPNPase, (b) EcPNPase or (c) no enzyme. Samples were run on a 20% urea 
denaturing gel in 1 x TBE and the RNA substrate degradation products 2-20 mer were indicated.  The sample 
taken at the start (S) and end (E) of the reaction are indicated. In these assay conditions, to account for 
enzymatic efficiency differences, the hPNPase and no enzyme control was incubated for 60 minutes and 
EcPNPase for 10 minutes. Image prepared in GIMP (v2) (GIMP, n.d.). 
 
 
Table 5.4 Degradation Assay; Quantifying the In Vitro Inhibition of hPNPase and EcPNPase by 
Phosphate-Rich Metabolites 
The percentage of substrate remaining at assay end-point in the absence (-) or presence (+) of each 
phosphate-rich metabolite are listed for hPNPase and EcPNPase. Values are the mean from at least three 
experimental repeats and the errors reported are the standard deviation. Percentage values lower than citrate 
were coloured black, whereas values greater than citrate were coloured green. 
 
Whether these phosphate-rich metabolites could also inhibit the activity of PNPase from E. coli 
was investigated and the results were shown in Figure 5.10 (b) and Table 5.4. The results suggested 
that in the presence of ppppG, ppGpp or GTP, EcPNPase activity was affected. Additionally, the 
percentage of substrate remaining at assay end-point for all three phosphate-rich metabolites was 
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higher (highlighted in green, Table 5.4)  than the percentage previously reported for citrate (Table 
5.3). The TCA metabolite succinyl-CoA was previously suggested to affect the activity of 
EcPNPase in vitro (Section 5.3.4) and results shown here suggest that ppppG had a similar effect; 
the percentage of intact 5’FAM Poly(A)20mer RNA substrate remaining at the end of each assay was 
11.1% (±0.7%) and 10.7% (±2.0%) respectively. The amount of intact RNA increased to 13.5% 
(±0.8%) and 34.2% (±1.7%) in the presence of ppGpp and GTP respectively. When comparing the 
effect of GTP, ppppG and ppGpp on the activity of EcPNPase, GTP, which is a known inhibitor of 
EcPNPase (Del Favero et al., 2008), affected the enzyme’s activity the most. Interestingly, the 
observation that ppGpp affected EcPNPase activity conflicted with previous literature and this is 
discussed further in Section 5.4 (Gatewood & Jones, 2010).  Nevertheless, the finding that 
phosphate-rich metabolites ppppG, ppGpp and GTP affected the activity of EcPNPase aligned with 
the data presented for hPNPase above. 
 
In summary, the results from this section supported the proposal made in Section 5.3.6, that S 
values calculated for a metabolite docked into the active site of hPNPase, may help predict 
metabolites that are involved in regulating PNPase. Specifically, it was proposed that metabolite-
hPNPase interactions with S values lower than the citrate-hPNPase interaction (-122 kcal/mol) may 
affect the enzymes 3’-5’ degradation activity. The predictions from in silico molecular docking 
calculations in Section 5.3.6 correctly identified phosphate-rich metabolites that could inhibit 
hPNPase activity in vitro. Additionally, these metabolites, namely ppppG, ppGpp and GTP, were 
also shown to inhibit the in vitro degradation activity of the PNPase homolog from E. coli. It was 
observed that these phosphate-rich metabolites had a larger effect on hPNPase activity than on the 
enzyme counterpart in E. coli. This was in agreement with previous research that suggested 
hPNPase was more sensitive to cellular phosphate levels than EcPNPase and is actually inhibited 
by higher phosphate concentrations (Portnoy, Palnizky, Yehudai-Resheff, Glaser, & Schuster, 
2007). Although the levels of metabolite-mediated inhibition appeared to vary between EcPNPase 
and hPNPase, the results still validated the use of the docking program MOE for predicting novel 
metabolite-PNPase interactions across evolutionarily diverse organisms.   
 
5.4 Conclusion 
Recent findings that citrate interacts with PNPase in E. coli (Nurmohamed et al., 2011) and that 
this interaction may represent a conserved communicative link across evolution (Chapter 4), has 
raised the question of whether other metabolites of the TCA cycle, similar to citrate, are involved in 
regulating PNPase homologs. By combining in silico docking calculations and in vitro gel-based 
assay results, the TCA metabolites pyruvate, α ketoglutarate, succinate, fumarate, malate and 
oxaloacetate were predicted to bind hPNPase with a weaker affinity than citrate, and weren’t 
observed to inhibit hPNPase activity. Interestingly, the average S values for citrate, cis-aconitate 
and isocitrate docking into the active site of hPNPase, were all similar. However, unlike citrate and 
cis-aconitate, isocitrate had no effect on hPNPase activity. The difference in inhibition exhibited by 
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isocitrate and cis-aconitate, may be due to their structures; citrate is converted into cis-aconitate 
before isocitrate is formed, hence the structure of cis-aconitate is more similar to citrate (Figure 
1.12, Chapter 1) and may explain its ability to affect hPNPase activity. Although, the physiological 
relevance of cis-aconitate binding and inhibiting hPNPase remains to be determined; it is thought 
that this metabolite is never ‘free’ in the cell, but remains associated with metabolic enzymes (as 
reviewed in Lehninger et al., 2000). The only TCA metabolites which were predicted to bind to 
hPNPase tighter than citrate, were acetyl-CoA and succinyl-CoA. These metabolites were also 
shown to affect hPNPase activity more than citrate. Although, the cellular levels of acetyl-CoA and 
succinyl-CoA in the human mitochondria need to be determined, the physiological relevance of 
these two molecules interacting with hPNPase is interesting as they both have key roles in 
regulating the TCA cycle (as reviewed in Berg, Tymoczko, & Stryer, 2002) and this is discussed 
further in Chapter 7. 
 
The results of in silico docking calculations presented in Section 5.3.1, predicted that acetyl-CoA 
and succinyl-CoA bind and occlude the active site of hPNPase in a similar way to citrate. Similarly, 
in vitro degradation assays presented in Section 5.3.1 and described further in Section 5.3.2 
suggested that only citrate, acetyl-CoA and succinyl-CoA were able to inhibit hPNPase activity 
more than 2.5-fold.  
 
The in silico results presented as heat maps in Figure 5.3 and the pharmacophore consensus model 
provided in Figure 5.7 (b), predicted that the CoA nucleotide part of acetyl-CoA and succinyl-CoA 
was the important structural feature interacting with hPNPase. The residues and types of 
interactions involved in CoA binding were suggested to essentially mimic the combined 
interactions of the two molecules of citrate. Specifically the 3’ terminal phosphate of acetyl-CoA 
and succinyl-CoA and citrate 1, were predicted to bind and occlude the metal and phosphate 
binding region. Whereas the nucleoside part of acetyl-CoA and succinyl-CoA and citrate 2, were 
predicted to bind within the RNA binding regions. In these positions the TCA metabolites may 
prevent the binding of inroganic phosphate which is required for catalysis and prevent the cleavage 
of RNA substrate. Importantly, the hPNPase residues involved in binding acetyl-CoA and succinyl-
CoA were the same as the citrate binding residues which have been shown to be highly conserved 
across evolution (Chapter 4). It was therefore suggested, that like citrate, acetyl-CoA and succinyl-
CoA may also inhibit other PNPase homologs. Accordingly, in vitro gel-based evidence was 
presented that suggested citrate, acetyl-CoA and succinyl-CoA all inhibited EcPNPase 3’-5’ 
degradation activity. Although, the cellular levels of acetyl-CoA and succinyl-CoA in the human 
mitochondria need to be determined, the levels of these metabolites reported in exponentially 
growing E. coli cells, were comparable to the low mM concentrations used within these assays 
(Bennett et al., 2009).  
 
[177] 
When the levels of TCA metabolite-mediated inhibition were compared between hPNPase and 
EcPNPase subtle differences were observed. Whether these differences represented different 
mechanisms of regulating RNA turnover across prokaryotes and eukaryotes, remains to be 
determined. Nevertheless, the results presented so far suggested that the TCA metabolite-mediated 
inhibition of hPNPase and EcPNPase activity could potentially be a commonly exploited regulatory 
mechanism in the two domains of life; eukaryotes and prokaryotes. Additionally, comparisons of 
the in silico data for citrate, acetyl-CoA and succinyl-CoA docking within the active site of 
hPNPase, suggested that hPNPase may interact with other phosphate containing nucleotide-based 
metabolites.  
 
After more in silico docking experiments, phosphate-rich guanosine nucleotides including GTP, 
ppppG and ppGpp, previously implicated in regulating PNPase activity, were predicted to bind 
hPNPase. Although ppppG had a lower average S value than both ppGpp and GTP (-177.4, -158.7 
and -156.4 kcal/mol respectively), all three phosphate-rich metabolites were found to inhibit 
hPNPase. These findings supported the in silico predictions which proposed that metabolites with 
an average S value (top ten docking poses) lower than citrate (-112 kcal/mol), may be able to affect 
hPNPase activity.  
 
The effect of phosphate-rich nucleotides was examined for E. coli PNPase and the results 
suggested that GTP, ppppG and ppGpp also inhibited its 3’-5’ RNA degradation activity. The 
finding that ppGpp could affect the degradation activity of EcPNPase conflicted with previous 
publications. Remarkably, although (p)ppGpp was found to inhibit PNPase from S. antibioticus, it 
was suggested to have no effect on EcPNPase (Gatewood & Jones, 2010), despite the significant 
structural conservation (Nurmohamed et al., 2009; Symmons, Jones, & Luisi, 2000). The 
publication by Gatewood and Jones proposed that ppGpp had no effect on the EcPNPase mediated 
phosphorolysis of an RNA substrate derived from the rpsO-pnp operon of S. coelicolor. They 
suggested that all the products normally observed upon phosphorolysis of the 5601 transcript 
catalysed by EcPNPase, were observed in the presence of ppGpp (Figure 5.11, lanes 6 and 7 
respectively). However, subtle differences were visible; the amount of intact substrate RNA was 
slightly increased (Figure 5.11, lane 7) and the amount of RP2 degradation product (Figure 5.11, 
unlabelled band underneath RP2 in lane 7) appeared to have decreased in the presence of ppGpp 
compared to the untreated sample (Figure 5.11, lane 6). After reviewing differences between the 
methods utilised, the work presented here used an equal molar concentration of 3.75 mM ppGpp to 
3.75 mM magnesium, whereas in previous studies 1 mM ppGpp was not in excess to the 5 mM 
magnesium and potentially this may explain the differences in inhibition level observed. In 
conclusion, the conflicting data presented here may be a result of the exact conditions used and the 
effect of this alarmone in E. coli needs to be examined further. This ppGpp-EcPNPase interaction 
was not the focus of this thesis, but would be of great importance to study since (p)ppGpp has been 
linked to antibiotic production in response to amino acid and energy starvation, and as mentioned 
[178] 
in previous chapters, suggests a potential link between environmental sensing and PNPase activity 
(Bralley & Jones, 2003; Mechold, Cashel, Steiner, Gentry, & Malke, 1996). 
 
 
Figure 5.11 In Vitro Degradation Activity of PNPase Homologs with ppGpp 
Gel electrophoresis of PNPase digests of the 5601 transcript with 32P-labelled 5601 RNA. Gels were 
subjected to autoradiography. Lane 1, undigested 5601 transcript; lanes 2 and 3, digestion with S. antibioticus 
PNPase; lanes 4 and 5, digestion with S. coelicolor PNPase; lanes 6 and 7, digestion with E. coli PNPase. 
The reaction mixtures corresponding to lanes 3, 5, and 7 contained 1 mM ppGpp. The product designations at 
the left and right of the figure relate the bands produced to the 3’ endpoints mapped previously by cDNA 
cloning and sequencing. Figure and legend taken from (Gatewood & Jones, 2010). 
 
Regardless of the conflicting results mentioned above, there was a clear reduction in both hPNPase 
and EcPNPase degradation activity in the presence of phosphate-rich metabolites. Despite the high 
structural and sequence conservation of hPNPase and EcPNPase (Chapter 4), the level of inhibition 
by either GTP, ppppG or ppGpp were greater for hPNPase. Although this finding was supported by 
previous publications reporting different phosphate preferences across diverse organisms (Portnoy 
et al., 2007), the question of how these enzymes are regulated by different cellular phosphate 
levels, remains to be answered and, as discussed in Chapter 7, this would be an interesting avenue 
of study. 
 
In summary, this chapter provided a variety of in silico and in vitro evidence that suggested the 
citrate-PNPase communicative link may extend to include a much wider range of metabolites. The 
detailed sequence analysis provided previously in Chapter 4, suggested that citrate-binding, and 
thus acetyl-CoA and succinyl-CoA binding residues are widely conserved. Therefore, the TCA and 
phosphate-rich metabolites reported to affect H. sapiens and E. coli PNPase activity within this 
chapter, may also inhibit other PNPase homologs. Whether these metabolite-PNPase interactions 
represent a conserved regulatory strategy which is utilised in vivo to control RNA turnover across 
the three domains of life; eukaryotes, prokaryotes and archaea, needs to be determined. 
Additionally, the effects of metabolites on other ribonucleases also needs to be investigated.  
 
[179] 
A better understanding of how RNases can sense different metabolites may explain how PNPase 
homologs are able to regulate RNA turnover in a range of organisms which have a diverse pool of 
metabolites available. The results presented so far within this thesis improve the understanding of 
detailed interactions between metabolites and 3’-5’ PNPase homologs. With further in vivo 
evidence, the overall flow of cellular information may be expanded and the interaction of 
metabolites with 3’-5’ exoribonucleases, may explain how complex organisms are able to fine-tune 
gene expression. 
[180] 
6 Developing a High-Throughput 3’-5’ RNase Kinetic 
Assay  
 
6.1 Introduction 
The previous chapters have described the study of the effects of metabolites on 3’-5’ RNase 
activity using both in silico molecular docking experiments and in vitro gel-based end-point assays. 
These were excellent tools to predict and test whether small molecule metabolites may bind and 
inhibit PNPase and archaeal exosome proteins. Obtaining more detailed enzyme-inhibitor kinetics 
will however be valuable in order to understand how these inhibitors work in more detail. 
Typically, gel-based assays are time-consuming and often limited to short time courses or end-
point assays. In this study, this would limit the number of metabolite-PNPase interactions that 
could be investigated. A more efficient and quantifiable method of characterising metabolite 
interactions with PNPase homologs was therefore required. Real-time enzyme kinetic experiments 
can be conducted in high-throughput, on specialist equipment such as an automated plate reader. 
The ability to obtain enzyme kinetic data in a high-throughput screen (HTS), is extremely 
beneficial for drug/inhibition discovery, as it allows a range of compounds to be screened quickly 
(reviewed in Hughes, Rees, Kalindjian, & Philpott, 2011). This study aimed to develop a high-
throughput plate reader assay which could be later utilised to screen a large range of metabolites 
and quantify quickly and in real-time, their interaction with PNPase homologs. Considering the 
large range of metabolites that are known to exist across prokaryotic, eukaryotic and archaeal 
organisms, this HTS assay would be advantageous to study the conservation of metabolite-PNPase 
interactions. 
 
In this chapter the basics of 3’-5’ RNase catalysis and general enzyme kinetics are initially covered. 
This allows the reader to appreciate the types of variables which must be considered when 
establishing canonical enzyme kinetics and the subsequent effect of inhibitors. The factors which 
must be controlled for studying the kinetics of complex multi-functional/reversible enzymes, 
including PNPase homologs; which can either degrade or polymerise RNA substrates are 
discussed. For example, the HTS assay was optimised to follow only the degradation activity of 
PNPase homologs in real-time and reduce the reverse polymerisation reaction by sequestering the 
ADP product released upon degradation. The methods utilised to develop a high-throughput plate 
assay for testing this 3’-5’ phosphorolytic activity are provided in Section 6.3. The results of the 
plate reader assay development are in Section 6.4; instrument set-up and method optimisation are 
covered before canonical enzyme kinetic analysis is determined. Key conclusions from this chapter 
are then made in Section 6.5, before the thesis Discussion (Chapter 7) reflects on the impact of 
metabolite-RNase communication and the use of a high-throughput assay for further discovery of 
novel interactions.  
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6.1.1 3’-5’ RNase Catalysis 
As described previously in Chapter 1, RNases are the enzymes that control the RNA turnover in all 
domains of life. The mechanism, by which organisms use RNases to regulate RNA turnover can 
vary; some RNA targets may be stabilised, while the same process may lead to RNA degradation in 
a different organism. An example of this is the addition/removal of a poly(A) tail in eukaryotes 
when compared to prokaryotes. In eukaryotes, polyadenylation often results in transcript stability 
and as a signal for further RNA maturation; however, in prokaryotes the same action may recruit 
RNases for targeted degradation (Sarkar, 1997; Wilusz, Wormington, & Peltz, 2001). Since there is 
a large amount of variation in cellular RNA abundance, composition and length of RNA strands 
between organisms, a variety of mechanisms are required to degrade these substrates and this is 
reflected by the large size and functional diversity of the RNase enzyme group (Ibrahim, Wilusz, & 
Wilusz, 2008; Nurmohamed et al., 2011; Zuo & Deutscher, 2001). 
 
The factors affecting the activity of an enzyme are important to understand before conducting 
detailed kinetic studies. Not only can substrate specificity vary for each PNPase homolog, but other 
factors can influence the enzyme’s activity. For example, although prokaryote and eukaryote 
PNPases and the archaeal exosome, all exhibit inorganic phosphate (PO43-) and metal ion (Mg2+ or 
Mn2+) dependent 3’-5’ exoribonuclease activity (reviewed in Zuo & Deutscher, 2001), their 
temperature optimum and preference for essential PO43- concentration varies between enzymes. For 
example, EcPNPase and hPNPase exhibit activity at 37°C, however the thermophile SsoExosome 
can survive at ~ 80°C (Portnoy et al., 2005). Additionally, it has already been reported that 
different PNPase homologs have different phosphate preferences: hPNPase has been shown to have 
a lower phosphate preference than EcPNPase (Portnoy, Palnizky, Yehudai-Resheff, Glaser, & 
Schuster, 2007). It is therefore difficult to select specific reaction conditions for comparative 
enzyme studies which are optimal for the range of enzymes tested, especially if those enzymes span 
a wide range of diverse organisms. Hence, conditions selected within this thesis were not always 
optimal for the specific enzyme, but allowed some comparison to be made across the range of 
species tested. 
 
The next section describes the equations used to calculate general enzyme kinetics parameters and 
how they are used to compare enzyme activity. Where appropriate, a generalised 3’-5’ 
exoribonuclease model is applied, unless a specific enzyme is stated. Moreover, the RNA substrate 
refers to a simple unlabelled 20 mer Poly(A) substrate and therefore the forward reaction is 
degradation and the reverse reaction is polyadenylation. 
 
6.1.2 Enzyme Kinetics Equations 
For a typical enzyme-catalysed reaction, such as the enzymatic degradation of RNA substrates by 
ribonuclease enzymes, the reaction proceeds as follows in Equation 6.1: 
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Equation 6.1 Enzyme Reaction 
The general reaction of enzyme (E) with its substrate (S) produces an enzyme-substrate complex (ES) and 
transition state (ES‡), which is followed by the release of product (P) and enzyme.  
 
Enzyme (E) and substrate (S), both with free translational, rotational and vibrational degrees of 
freedom, must first interact in solution before forming an enzyme-substrate complex (ES). Upon 
binding, a range of events occur involving both the enzyme and substrate, which result in the 
overall change of free energy (∆GB). Firstly, the entropy described above (the freedom of motion of 
molecules in solution, which reduces the possibility they will react) is reduced. The substrate is 
positioned in an orientation which reduces movement and distorts the molecule in order to hold it 
in a position which promotes weak non-covalent interactions; either hydrogen bonds, electrostatic, 
or van der Waals. Secondly, the solvation shell of hydrogen-bonded water that surrounds the 
substrate, which usually stabilises biomolecules in solution, is lost upon entry into the enzyme’s 
active site. This allows hydrogen bonds to be made with the enzyme instead, thus stabilising the 
enzyme-substrate complex. Thirdly, the enzyme itself may need to undergo conformational 
changes to allow proper alignment of catalytic functional groups with the substrate. These 
functional groups may include amino acid sidechains, cofactors or coenzymes. Collectively, the 
energy lost by reducing hydrogen-bonded water interactions and the overall movement and rotation 
of both enzyme and substrate molecules, is compensated for by the binding energy (∆GB) of the ES 
complex. This activation energy acquired is important as it allows the enzyme to reach the 
activated transition state (ES‡). It is within this state that there is equal probability of the forward 
reaction (producing free enzyme (E) and product (P)) or the reverse reaction to occur. The rate of 
reaction can depend on a number of factors including enzyme concentration, temperature, pH and 
substrate concentration [S]. For example, when the [S] is high, the formation of the enzyme-
substrate (ES) transitional intermediate is favourable and follows an energetically downhill 
progression to release product and regenerate enzyme. However, as the [P] increases, the reaction 
rate is reversed. It is therefore important to keep the [S] high in order to promote the forward 
reaction. In the case of 3’-5’ PNPase activity, if the concentration of RNA substrate is high then 
degradation occurs, however if the NDP product concentration is high then the reverse reaction 
occurs and NDPs are added. The reversible action of PNPase is shown in Figure 6.1. 
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Figure 6.1 PNPase Activity 
The reversible action of PNPase on RNA substrates; (a) either degradation in the presence of excess 
inorganic phosphate (PO43-) and a metal ion (e.g. Mg2+) or (b) polyadenylation in the presence of excess 
ADPs (NDP). Figure adapted from (Nurmohamed et al., 2011) using GIMP (v2) (GIMP, n.d.). 
 
Understanding how enzyme reactions occur (Equation 6.1) is important before trying to determine 
the kinetics of a particular enzyme: it’s essential to ensure kinetic parameters are calculated 
correctly using initial rates. The initial rates (Vo) are used since the probability of the enzyme 
encountering a substrate molecule is much higher early in the reaction. More specifically, in order 
to determine the rate of the forward reaction, the [S] must be in excess and the reaction should not 
have proceeded for very long. This ensures that the forward reaction is promoted and that the [S] 
isn’t depleted while the [P] increases, which would effectively reverse the reaction. For example, 
with excess RNA substrate, 3’-5’ PNPase homologs will catalyse substrate degradation and the 
reversible reaction of polyadenylation is minimised. Additionally, in order to prevent the 
accumulation of ADP in the forward degradation reaction, it is suggested that rates are typically 
calculated before <20% of the reaction has proceeded. Alternatively, if the backwards 
polyadenylation reaction requires examining, the [P] must be in excess and in order to prevent the 
accumulation of RNA, rates must be calculated before <20% of the reverse polyadenylation 
reaction has occurred. By using the Vo in substrate excess, the kinetic parameters for the 3’-5’ 
degradation can be calculated, while minimising the reverse reaction rate. As mentioned 
previously, other factors can also affect the rate of reaction and therefore these are kept consistent 
throughout enzyme assays. These include the assay temperature, enzyme concentration, essential 
cofactors (i.e. metal ions) and the pH. 
 
In summary, enzyme assay conditions must be optimised to ensure initial rates (Vo) can be 
calculated correctly. This PhD study has focussed on the degradation activity of PNPase homologs, 
and in order to determine key kinetic parameters for only 3’-5’ RNase degradation, the [RNA] was 
kept in molar excess to the enzyme concentration. All other factors affecting activity were kept 
constant and reaction rates were calculated before <20% of the reaction had proceeded.  
 
Ensuring steady state conditions, described above, means that the Michaelis-Menten kinetic 
equation shown in Equation 6.2, can be utilised to determine key kinetic parameters (reviewed in 
[184] 
Lehninger, Nelson, & Cox, 2000). This is a well-accepted model of enzyme kinetics which relates 
initial reaction rates (Vo) to the [S]. To analyse the kinetic parameters, a range of [S] are titrated 
against a given enzyme concentration and the initial rates (Vo) of reaction can be measured. By 
plotting these Vo values against [S] and fitting the data using Equation 6.2, key enzyme parameters 
can be generated. This includes the maximal velocity (Vmax) and the Michaelis constant (Km), 
which represent the maximum rate at saturating [S] and the substrate concentration at which the 
Vmax is half, respectively. If an enzyme reaction follows Michaelis-Menten kinetics, then the 
calculated parameters can be used to compare enzyme activities. The Vmax and Km can be also used 
to calculate two other useful parameters: The Vmax and total enzyme concentration (ET) provides 
the turnover rate (kcat) (Equation 6.3) and the ratio of kcat/Km provides a good measure of catalytic 
efficiency (Equation 6.4). 
 
 
Equation 6.2 Michaelis-Menten  
The initial rate (Vo) is a function of the extrapolated maximum velocity (Vmax), substrate concentration [S] 
and the Michaelis Constant (Km). 
 
 
Equation 6.3 Turnover Rate 
Turnover rate (kcat) is a ratio of the extrapolated maximum velocity (Vmax) and total enzyme concentration 
(Et). The kcat corresponds to the number of substrate molecules converted per second.  
 
 
Equation 6.4 Catalytic Efficiency 
Catalytic efficiency is a ratio of turnover rate (kcat) and the Michaelis Constant (Km). 
 
Previous chapters and publications have provided information about 3’-5’ RNase activity using gel-
based assays. A real-time plate reader assay could however quickly acquire initial rates, and thus 
catalytic parameters, more easily than the previously established laborious methods. The potential 
to determine enzyme activity is valuable since it may reveal preferred substrate targets or novel 
inhibitors. In addition, conducting this assay in high-throughput would provide an efficient way to 
determine if any other metabolites, in addition to those outlined within this study, have an effect on 
the 3’-5’ activity of PNPase homologs. Therefore, the subsequent Section 6.1.3 describes the steps 
required in order to optimise a commercially available fluorescence-based plate reader assay, for 
collecting 3’-5’ kinetic data for PNPase homologs.  
 
6.1.3 Determining 3’-5’ RNase Kinetics 
A method of real-time (RT) detection of 3’-5’ phosphorolytic RNase activity was developed using 
components of the commercially available Transcreener® ADP2 Fluorescent Intensity (FI) assay 
kit (BellBrook, n.d.). The manual recommended that the assay was compatible with any enzyme 
kcat = Vmax/[Et]   
catalytic efficiency = kcat/Km 
[185] 
class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA 
helicases, carboxylases and glutamine synthetase (BellBrook, n.d.). This FI kit has typically been 
used for determining the kinetics of kinases (Hong, Quinn, & Jia, 2009) and so this study provided 
a novel application for the assay.  
 
This assay provided a means of quantifying ADP production, which when applied in a plate reader 
format allowed high-throughput, sensitive and fast changes in fluorescence intensity to be 
monitored. In summary, when substrate RNA was intact, the ADP Alexa594 Tracer (ADP*) 
fluorescence was quenched by a mouse monoclonal ADP2 Antibody-IRDye® QC-1 (Q-Ab). 
However, upon 3’-5’ RNA degradation, ADP was produced which competed with ADP* for Q-Ab 
binding. An increase in fluorescence was detected when the ADP* was displaced from the Q-Ab 
quencher, see Figure 6.2. As the ADP released from the RNA degradation was sequestered by the 
Q-Ab quencher, it made this assay particularly well suited for studying the degradation activity of 
3’-5’ PNPase homologs, as the reverse polymerisation reaction was reduced. Another great 
advantage of this particular RT assay was the option to use a wide range of unlabelled RNA 
substrates. If the RNA substrate sequence is known to contain adenosines and ADP is released 
upon degradation, it should be suitable for use within this assay. As a result, this allowed the option 
for testing a range of physiologically relevant PNPase or archaeal exosome RNA substrates. 
Moreover, the generation of an ADP standard allowed relative fluorescence units (RFU) values to 
be converted into concentrations of ADP; essentially quantifying the degradation of RNA. Another 
advantage for using this high-throughput design was the possibility for obtaining real-time kinetic 
information during screening for inhibitor compounds.  
 
 
Figure 6.2 ADP Detection Plate Assay 
Substrate RNA with a 3’polyA tail (A(n), green line) is degraded by 3’-5’ RNase using phosphate (PO43-) in 
a sequential manner to produce RNA 3’ A(n-1) (green line), releasing ADP in the process (green circle). The 
fluorescent ADP* (dull red) is initially quenched when bound to Q-Ab. However, upon RNA degradation 
and ADP release, ADP* is displaced and the fluorescence of the non-quenched ADP* increases (bright red). 
Image adapted from Transcreener® ADP2 Fluorescent Intensity (FI) Assay manual (BellBrook, n.d.) and 
created using GIMP (v2) (GIMP, n.d.). 
 
Unfortunately, the ADP* assay component of the Transcreener kit was supplied in a buffer 
containing 0.5 mM KH2PO4 and due to the phosphate sensitivity of PNPase from H. sapiens 
[186] 
(Portnoy et al., 2007) the assay could not be utilised to determine hPNPase enzyme kinetics. 
Therefore, the results presented in Section 6.4 only examine PNPase activity from E. coli and the 
archaeal exosome from S. solfataricus.  
 
6.1.3.1 Plate Reader Set-up and Optimisation 
Although a manual was provided with the Transcreener® ADP2 Fluorescent Intensity (FI) Assay, 
the conditions recommended by Bellbrook were optimal for end-point ADP detection. The manual 
specified that the recommended assays conditions would require further optimisation if used in RT. 
Therefore, each parameter of the assay was checked, including the plate reader set-up and 
ADP*/Q-Ab concentrations, so that the optimal RFU window could be obtained. For example, the 
Transcreener ADP2 FI Assay Alexa594 Tracer (ADP*) had been successfully used at excitations of 
(580-590 nm) and emissions of (610-620 nm) with bandwidths of 10 nm in black 96-well plates, 
for a range of plate readers (BellBrook, n.d.). However, the optimal settings for the H1 Synergy 
BioTek plate reader, utilised in these experiments, had not been previously determined. Hence the 
specific settings for detecting fluorescence intensity (RFU) were determined experimentally by 
conducting an excitation/emission scan, with a set concentration of ADP*, for maximal RFU 
detection. 
 
Once the ideal excitation/emission plate reader settings were determined from initial optimisation 
experiments, it was also important to determine the maximum fluorescence window. The optimal 
gain (sensitivity to FI), plate read height and concentrations of fluorophore (ADP*) and quencher 
(Q-Ab) needed to be established, so that the recommended signal difference of >5 fold, between 
low RFU (quenched ADP* & Q-Ab) and high RFU (ADP* only) could be achieved. Consequently, 
all of these parameters were verified during the optimisation steps outlined in the methods Section 
6.3.1-6.3.2.  
 
6.1.3.2 Optimisation of Assay Conditions 
As mentioned previously, the enzyme concentration and substrate concentration must be optimal; 
[S] must not be limiting and should be present in excess to [ET] to ensure the initial rates 
determined are under steady state conditions, thus Michaelis-Menten kinetics can be correctly 
applied. The conditions of the plate reader were therefore optimised, including [enzyme] and 
[RNA]. An ADP standard curve was also produced so that raw RFU data could be converted into 
the [ADP (nM)].   
 
Initial experiments were conducted in order to determine the optimal enzyme concentration. A 
range of enzyme concentrations were titrated against a constant [RNA], and the lowest enzyme 
concentration that produced a detectable initial rate, was determined. It was useful to select the 
lowest [enzyme] as this not only minimised protein usage, which was cost efficient, but also helped 
ensure that the [RNA] could be in a large excess whilst minimising the use of substrate in each 
reaction. In terms of obtaining a detectable signal, the kit recommended selecting the [ET] which 
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gave rise to a 50-80% change in RFU. These raw RFU data, measured over time, were then 
converted (using the ADP standard curve mentioned previously) into [ADP] (nM). The inverse 
experiment, where [enzyme] was kept constant and [RNA] was titrated, was useful since the 
resulting data helped determine if the enzyme followed typical Michaelis-Menten kinetics. More 
specifically, initial rates (Vo) were plotted against the [S] and if the data followed a typical 
Michaelis-Menten hyperbolic shaped curve, the equation described previously (Equation 6.2) was 
then applied.  
 
6.2 Aims 
As demonstrated in previous chapters, gel-based assays are available for determining the 
degradation activity of PNPase homologs. However detailed kinetics using high-throughput 
techniques are not currently available. Thus, the aim of this study was to repurpose a commercially 
available fluorescence-based high-throughput plate reader assay, typically used to determine end-
point kinase activity, for use in quantifying the activity of PNPase homologs in real-time. Firstly, 
using the modified Transcreener® ADP2 Fluorescent Intensity (FI) (BellBrook, n.d.) assay, the 
study aimed to monitor the release of ADP product from the degradation of an unlabelled 
poly(A)20mer RNA substrate. Secondly, using an ADP standard curve, the study aimed to provide a 
novel way to quantify the RNA degradation kinetics mediated by EcPNPase and SsoExosome. In 
order to meet these two objectives and to develop a quantifiable real-time assay, a range of initial 
method validation steps were required. Key questions addressed within this work will validate the 
plate reader parameters and concentration of reagents, prior to generating a standard curve which 
will allow RFU values to be converted into the [ADP] produced. Whether kinetic information can 
be calculated, including the Vmax and Km, kcat and catalytic efficiency, will also be addressed. The 
resulting data will be provided in Section 6.4 and important conclusions, regarding the benefits and 
limitations of the high-throughput plate reader assay, are then summarised in Section 6.5.  
 
6.3 Methods 
A variety of optimisation experiments were initially conducted for the high-throughput plate reader 
assay, prior to determining protein-specific canonical enzyme kinetics. This included optimising 
instrument set-up, determining the assay RFU window, generating an ADP standard curve and 
conducting an enzyme titration (Sections 6.3.1-6.3.5 respectively). Michaelis-Menten kinetic 
parameters were finally calculated from an RNA titration, as described in Section 6.3.5. 
 
For clarity, concentrations of RNA and ADP corresponded to one poly(A) 20 mer RNA substrate 
(RNA20mer) and twenty ADP molecules (ADP20x); effectively a 2000 nM stock of RNA20mer would 
produce 2000 nM ADP20x. Unless stated otherwise, this method of recording the RNA and ADP 
concentration was used as standard throughout this chapter. The purpose of this was to allow easier 
comparisons to be made between the amount of substrate degraded and product produced, thus all 
kinetic constants were expressed for the polymer. 
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6.3.1 Instrument Set-up  
Transcreener ADP2 FI Assay Alexa594 Tracer (ADP*) (4 nM) was prepared in 100 µl assay buffer 
(20 mM Tris-HCl pH 8, 150 mM NaCl, 10 mM MgCl2, 0.5 mM KH2PO4, 0.05 mM HEPES and 
0.00025% Brij-35), in a sterile black Nunc 96-MicroWell plate (96F) (Fisher # 237107) and a 
range of excitation and emission wavelengths (nm) were scanned at 25°C, ensuring the bandwidth 
was < 10 nm to avoid signal overlap.  The optimal settings, which provided the maximum 
fluorescence intensity (RFU) for the BioTek H1 Synergy plate reader, were determined. 
 
6.3.2 Determining Detection Conditions (Q-Ab & ADP*) 
The kit recommendations for obtaining a maximal signal window between low RFU (quenched 
ADP* & Q-Ab) and high RFU (ADP* only) were only provided for end-point assays. Hence, 
appropriate concentrations of ADP* and Q-Ab, to allow real-time data collection, were confirmed 
experimentally. Using the optimised excitation/emission settings previously established (Section 
6.3.1), a range of Q-Ab concentrations were titrated against 4 nM ADP* in reaction buffer. This 
experiment was then reversed, titrating ADP* against Q-Ab (40 µg/ml) in the same buffer 
conditions used previously. Recorded RFU data at 37°C were collected and analysed to determine 
the total assay window; the concentration of ADP* and Q-Ab, which gave rise to > 5-fold signal 
difference between low and high RFU, was selected. Subsequently, using these ADP* and Q-Ab 
concentrations, the optimal gain and read height settings were also determined.  
 
6.3.3 ADP Standard Curve  
Once the assay conditions and equipment settings were optimised, a range of ADP20x 
concentrations (0, 40, 80, 120, 160, 200, 300, 400, 600, 800, 1200, 2000 nM) were prepared which 
corresponded to a 2000 nM RNA20mer conversion of 0, 2, 4, 8, 10, 15, 20, 30, 40, 60, 100%. A 96-
well plate, containing all the reagents for the reaction, was pre-incubated for 30 minutes at 25°C. 
After this time, the plate was ejected and 10 µl of each ADP20x concentration (10x stock, pre-
incubated in adjacent wells) was added to the relevant 90 µl assay well. A final 100 µl assay with a 
range of ADP20x concentrations (all in 4 nM ADP*, 40 µg/ml Q-Ab and reaction buffer) was 
produced and plates were re-inserted back into the plate reader. The plate reader was set to an 
excitation and emission wavelength of 585 and 616 nm respectively (10 nm bandwidth) and using 
top optics, xenon flash with lamp energy set to high, gain of 150 and a plate read height of 7.75 
mm, the RFU data were recorded.   
 
The RFU data were saved as an Excel file and average RFU values between 30-90 minutes were 
calculated. An ADP standard curve was produced in Minitab (v17) by plotting the average RFU (y 
axis) against ln([L]+1) (x axis), where [L] = [ADP20x (nM)] (Minitab, 2010). The data were then 
fitted using nonlinear regression, as recommended within the assay manual (BellBrook, n.d.). 
Following conversations with Dr David Whitley (Mathematician at the University of Portsmouth) 
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the logistic growth function in Minitab (Figure 6.3 and Equation 6.5) was recommended for fitting 
the standard curve data (Minitab, 2010). Using values from the response curve, (for example the 
maximum RFU (in high [ADP20x], termed Theta1) and the quenched RFU (in low [ADP20x], termed 
Theta2)) as initial estimates for fitting, the equation shown in Equation 6.5 fitted data to a 
sigmoidal shaped curve. This standard curve allowed RFU values (y) to be converted into [ADP] 
by using the re-arranged equation shown in the red box in Equation 6.5. 
 
 
Figure 6.3 Minitab Logistic Growth Function 
The relationship between Theta parameters (Theta 1-4) of the non-linear regression logistic function 
(highlighted blue) are shown in the graph. Snapshot image taken directly from Minitab17 program (Minitab, 
2010). 
 
 
Equation 6.5 Minitab Non-linear Regression Logistic Function 
Relationship of the RFU (y axis) to the concentration of ligand ([L]= ln[ADP20x (nM)] +1) (x axis) for the 
ADP standard curve is shown. The equation from Minitab was rearranged so that RFU values could be 
converted into a [ADP20x (nM)] using Theta values 1-4.  
 
6.3.4 Enzyme Titration  
A 96-well plate, containing all the reagents for the reaction, was pre-incubated for 30 minutes at 
25°C. After this time, the plate was ejected and 10 µl of RNA20mer (10x stock, pre-incubated in 
adjacent wells) was added to the relevant 90 µl assay well (containing each EcPNPase 
concentration) to start the reaction. The consequent 100 µl assay, with a range of EcPNPase 
concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75 and 1 nM), all with 2000 nM RNA20mer, 4 nM ADP*, 
40 µg/ml Q-Ab in reaction buffer was produced. Plates were re-inserted back into the plate reader 
and, using the plate reader settings described in Section 6.3.3, RFU data were collected over 12-
hours. Controls were conducted as standard in every plate, including a buffer blank (No ADP*), 
low RFU (quenched ADP* & Q-Ab only) and high RFU (ADP* only). To determine the assay 
window, a reaction without enzyme was also conducted to ensure RNA integrity; so that enzyme-
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specific degradation could be confirmed. The RFU values from EcPNPase titration were converted 
to ADP20x concentrations (nM) using an ADP standard curve (Section 6.3.3). Resultant [ADP20x] 
(nM) were then plotted against time (minutes). The first 15 minutes of data were removed, as 
recommended by the Kit manual (BellBrook, n.d.); allowing proper ADP*-Q-Ab thermal 
equilibration. The assay conditions were optimised to ensure the initial rates were not affected by 
removing data from between 0-15 minutes. The remaining data were then further processed; only 
values corresponding to less than 5% reaction completion were retained for calculating initial rates. 
These Vo values were then plotted against the [EcPNPase] in GraFit (Leatherbarrow, 2009) and the 
optimal [EcPNPase] (nM) was determined. The same method described for EcPNPase was 
repeated to determine the optimal concentration of SsoExosome, except a final concentration range 
of 0, 1, 2.5, 3, 3.5, 4, 5, 10 nM SsoExosome were titrated against a set concentration of RNA20mer 
(2000 nM). 
 
6.3.5 RNA Substrate Titration  
A range of RNA20mer substrate concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 
1800, 2000 nM) were titrated against the previously determined appropriate concentration of each 
enzyme (Section 6.3.4). A 96-well plate, containing all the reagents for the reaction, was pre-
incubated for 30 minutes at 25°C. After this time, the plate was ejected and 10 µl of each 
[RNA20mer] (10x stock, pre-incubated in the adjacent well) was added to the relevant 90 µl assay 
well, to start the reaction. Final 100 µl assays, with a range of [RNA20mer] and a consistent 
[enzyme] (either 0.5 nM EcPNPase or 4 nM SsoExosome), 4 nM ADP*, 40 µg/ml Q-Ab in 
reaction buffer were produced. Plates were re-inserted back into the plate reader and RFU data 
were recorded as described in Section 6.3.4. The RFU values from the RNA20mer titration were 
converted to ADP20x concentrations (nM) using an ADP standard curve (Section 6.3.3). Resultant 
[ADP20x] (nM) were then plotted against time (minutes) and the first 15 minutes of data were 
removed, as recommended previously. The remaining data were then further processed; only values 
corresponding to less than 10% reaction completion were retained for calculating initial rates. 
These Vo values were then plotted against [RNA20mer] substrate in GraFit and fitted with the 
Michaelis-Menten equation shown in Equation 6.2 (Leatherbarrow, 2009). Data were fitted and 
initial estimates were provided by use of linear fitting using the Lineweaver-Burk rearrangement; 
key parameters including Vmax and Km were determined for each enzyme (Leatherbarrow, 2009). In 
order to determine the optimal concentration of phosphate, the same method described for 
determining EcPNPase kinetics in the standard reaction buffer (20 mM Tris-HCl pH 8, 150 mM 
NaCl, 10 mM MgCl2, 0.5 mM KH2PO4, 0.05 mM HEPES and 0.00025% Brij-35), was conducted 
with higher concentrations of phosphate; in these assays, the reaction buffer instead contained 
either 5 or 10 mM KH2PO4. 
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6.4 Results  
This section firstly provides results from optimisation experiments which determined the optimal 
instrument (Section 6.4.1) and assay conditions for producing a maximal RFU window (Section 
6.4.2-6.4.3). The application of a standard curve to convert RFU values into [ADP20x] and allow 
quantification of ADP production, upon RNA degradation, was examined in Section 6.4.4.  The 
utilisation of the assay, to quantify the RNA degradation activity of the prokaryotic PNPase from 
E. coli, was examined in Section 6.4.5. The optimal concentration of EcPNPase, for determining 
initial rates of RNA20mer degradation, was investigated in Section 6.4.5.2, before the Michaelis-
Menten kinetic parameters were calculated for EcPNPase, in the presence of a range of phosphate 
concentrations (0.5, 10 and 5 mM, Sections 6.4.5.3-6.4.5.5 respectively). Although more repeats 
were required, the high-throughput plate reader assay was successfully used to quantify EcPNPase 
mediated RNA20mer degradation in real-time. Kinetic parameters including Vmax and Km, kcat and 
catalytic efficiency were also determined and this assay validation led to the proposal that other 
PNPase homologs may also be tested. Consequently, the ability to quantify the RNA degradation 
activity of the archaeal exosome from S. solfataricus was examined in Section 6.4.6. As before, the 
optimal concentration of SsoExosome was determined in Section 6.4.6.2, prior to calculating the 
Michaelis-Menten kinetic parameters in Section 6.4.6.3. Unlike Section 6.4.5, only one phosphate 
concentration (0.5 mM) was tested and following the observation that EcPNPase had a phosphate 
preference greater than 5 mM, the effects of higher phosphate levels on SsoExosome activity 
requires investigation. Although the assays for EcPNPase and SsoExosome need to be repeated in 
triplicate, the data provided within this section demonstrate the proof of concept for repurposing 
the Transcreener® ADP2 Fluorescent Intensity (FI) assay kit. In summary, results presented within 
this section suggest that the high-throughput plate reader assay may be used to examine the 
degradation activity of PNPase homologs across evolutionarily diverse organisms; from 
prokaryotes and archaea, in real-time.  
 
6.4.1 Instrument Set-up Optimisation 
The optimal excitation and emission wavelengths of the Transcreener ADP2 FI Assay Alexa594 
Tracer (ADP*) were determined using a BioTek H1 Synergy plate reader as described in Section 
6.3.1. The maximum fluorescence intensity was observed by using top optics (excited and read 
from above) with an excitation and emission wavelength of 585 and 616 nm respectively (10 nm 
bandwidth). This aligned to the recommended excitation (580-590 nm) and emission (610-620 nm) 
settings, which were optimal for other plate readers outlined in the technical manual (BellBrook, 
n.d.). Automatic gain was suggested within the manual, however to avoid plate to plate variations, 
gain was set to 150 for these experiments. These optimised plate reader settings were used as 
standard throughout this chapter.  
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6.4.2 Optimising Q-Ab & ADP* Detection Conditions  
The Transcreener ADP2 FI Assay was developed to follow the progress of any enzyme that 
produces ADP. The examples within the manual (BellBrook, n.d.)  utilised ATP as the substrate for 
the ADP producing reaction; however, in this work RNA20mer was the substrate instead. 
Additionally, the conditions recommended within the Bellbrook manual were optimal for end-point 
ADP detection using a ‘stop’ buffer. It was advised that these conditions may be sub-optimal if the 
assay buffers were changed for real-time ADP detection. With this in mind, the recommendations 
within the Bellbrook kit manual, for end-point ADP detection were first considered in Section 
6.4.2.1, before the assay was modified for real-time ADP detection as described in Section 6.4.2.2.  
 
6.4.2.1 Bellbrook Recommended Conditions for End-Point 
ADP Detection  
The kit provided a Q-Ab antibody with a limited selectivity for adenosine diphosphate (ADP) vs. 
adenosine triphosphate (ATP). With this in mind, Bellbrook suggested that the concentration of Q-
Ab and ADP* determined the total assay window, but the amount of ATP substrate could affect 
this. More specifically, Bellbrook suggested that the relationship between substrate, in their case 
[ATP], and [Q-Ab] was linear between 0.1 µM to 1,000 µM ATP (BellBrook, n.d.). Thus, a 
method for calculating the amount of Q-Ab to use with a known amount of ATP substrate, was also 
provided within their guidelines. Specifically, the technical manual proposed that the amount of Q-
Ab required for enzyme reactions that use ATP, could be determined from y = 0.93x +0.7 where x 
= [ATP µM] and y= [Q-Ab µg/ml]). This equation was used, with a few assumptions, to predict the 
amount of Q-Ab required when instead of ATP, RNA20mer was the substrate used to generate ADP. 
For a basic estimation, it was assumed that 2 µM RNA20mer was equivalent to 40 µM ATP and thus 
[0.93 x 40] + 0.7= 37.9 µg/ml of Q-Ab was recommended. The other assumptions made in this 
calculation were that the assay conditions were similar to those described in the technical manual; 
however, this was not the case. Not only was an RNA20mer substrate used instead of ATP, but the 
assay buffer conditions were modified to allow real-time fluorescence measurements, rather than 
the end-point method previously described in the manual. As a result, the recommended 
concentration of Q-Ab (37.9 µg/ml) was a rough estimation.  
 
It was essential to ensure the amount of Q-Ab used in the 100 µl assay was optimal for generating a 
large RFU window and thus a good ADP detection range. Therefore, titration experiments were 
conducted in the presence of 2 µM RNA20mer substrate, to more accurately determine the amount of 
fluorophore (ADP*) and quencher (Q-Ab) required for detecting ADP production in real-time 
(Section 6.4.2.2). 
 
6.4.2.2 Optimal Conditions for Real-Time ADP Detection  
Titration of ADP* against Q-Ab (40 µg/ml), and the inverse titration of Q-Ab against ADP* (4 
nM) was conducted as described in Section 6.3.2. Following an initial pre-incubation step for 30 
minutes at 37°C, the RFU measured between 30-60 minutes was averaged; this ensured the RFU 
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had time to stabilise. The average RFU was then plotted against the titrant concentration (either 
ADP* or Q-Ab) and data points, which followed a linear trend, were fitted to a linear equation 
using GraFit (Figure 6.4) (Leatherbarrow, 2009). Calculating the concentration of ADP* (x axis) 
that produced an RFU (y axis) equal to zero (no fluorescence), in the presence of 40 µg/ml of Q-
Ab, denoted complete quenching. Consequently, using the linear equation for the data fit in Figure 
6.4 (a) (0 = 679.1429 ([ADP*]) - 1491), it was suggested that ~2.2 nM ADP* will be quenched by 
40 µg/ml Q-Ab (ADP*= 1491/679.1429). Hence a concentration slightly greater than 2.2 nM 
ADP* should be enough to ensure 40 µg/ml of Q-Ab is fully saturated by ADP*. 
 
Analysis of the inverse experiment titrating Q-Ab against ADP* (Figure 6.4 (b), 0 = -161.1571 
([Q-Ab*]) + 7725) correlated well and suggested that 47.9 µg/ml Q-Ab was required to fully 
quench 4 nM ADP* (Q-Ab= -7725/-161.1571). Using a lower concentration of 40 µg/ml Q-Ab 
ensured that 4 nM ADP* was in a slight excess and saturated Q-Ab appropriately.  
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Figure 6.4 Plate Optimisation: ADP* & Q-Ab Concentration Range 
The average RFU (30-60 minutes) for the titration of (a) ADP* against 40 µg/ml Q-Ab and (b) Q-Ab against 4 nM ADP* is shown. The linear equation (y = m*x + c, where y= RFU, m= 
gradient, c = intercept of y axis) was fitted to appropriate linear data points using GraFit. The x axis intercept for (a) y= 679.1*x -1491.0 and (b) y=-161.2*x+7725.5 was calculated and is 
shown in green. Graphs were plotted in GraFit and labelled in GIMP (v2) (GIMP, n.d.; Leatherbarrow, 2009). 
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In summary, results indicated that the ADP* was adequately quenched and Q-Ab was appropriately 
saturated at concentration > 2 nM ADP* and of 40 µg/ml respectively. Therefore, by using 40 
µg/ml Q-Ab to quench a slightly higher concentration of ADP* (> 2 nM), the release of ADP from 
the enzyme reaction could be directly measured since it was not sequestered by free Q-Ab 
(unsaturated with ADP*) but directly competed with ADP* for Q-Ab binding. The resulting 
increase in RFU could therefore be utilised as an indication of the rate of RNA degradation and 
ADP production. Thus, the final plate assay conditions included 4 nM ADP* and 40 µg/ml Q-Ab in 
reaction buffer. 
 
6.4.3 Determining Optimal Plate Parameters 
Once the optimal plate reader settings and ADP* and Q-Ab concentrations had been determined, 
experiments titrating PNPase/archaeal exosome and RNA20mer were conducted at 37°C. 
Unfortunately, assays conducted at this temperature were not very reproducible (data not shown) 
and calculations of enzyme initial rates were not possible due to issues with the RFU stability 
(ADP* quenching by Q-Ab was not stable). Following consultation with the plate assay providers, 
as details of incubation temperatures were not provided in the technical manual, it was suggested 
that the assay temperature may potentially influence the rate of ADP* quenching by Q-Ab. In order 
to investigate this further, the RFU stability of 4 nM ADP* in the presence of 40 µg/ml Q-Ab was 
compared at 37°C and 25°C (Figure 6.5).  
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Figure 6.5 Optimising ADP* Quenching by Q-Ab. 
The effect of assay temperature on ADP* quenching by Q-Ab (A* + Q-Ab) was compared at (a) 37°C and (b) 25°C. Identical assays containing 4 nM ADP* with 40 µg/ml Q-Ab in 
reaction buffer were prepared by either (a) manual pipetting or (b) using multi-pipetting. The RFU values recorded during the plate pre-incubation (heat) step are plotted (red points) against 
time (minutes), for both graphs (a) and (b). Note only the first 15 minutes of the heat run were recorded in (a) whereas data for 30 minutes were recorded in (b). A linear (y=m*x + c) fit 
(red (heat fit) line) is also shown. The RFU values recorded post-incubation, after RNA was added were also plotted (run), data from the first and second 30 minutes (coloured grey and 
black points respectively) were individually fitted to a linear equation (coloured grey and black (run fit) lines respectively). Graphs were plotted in GraFit and labelled in GIMP (v2) (GIMP, 
n.d.; Leatherbarrow, 2009). 
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Both assays shown in Figure 6.5 were set up using a manual pipette, and before the RNA was 
added, the RFU values were recorded during a plate pre-incubation (heat) step (red data points, 
Figure 6.5) at either 25°C or 37°C. The RFU values measured during this heat step increased from 
~ 600 to 1200 at 37°C, whereas RFU values at 25°C remained relatively stable at ~ 700-800. 
Hence, in order to ensure stable RFU in subsequent plate reader assays, all reagents were pre-
warmed at 25°C for 30-minutes prior to adding the RNA substrate and thus initiating the reaction. 
In order to reduce the time that the plate was not kept at constant temperature (25°C) and thus 
avoid any effects of room temperature fluctuations whilst initiating the reactions, a multi-pipette 
was also utilised to add the RNA in subsequent assays. 
 
The assays shown in Figure 6.5 were set up without EcPNPase, hence when the RNA was added 
(dotted vertical line, Figure 6.5) no degradation occurred and the ADP* remained quenched by Q-
Ab. This allowed the stability of ADP* quenching by Q-Ab to be examined following the process 
of RNA addition. The kit recommended that mixing ADP* and Q-Ab required a 15-minute 
equilibration before RFU quenching was stabilised, after which time, data could be collected. 
However, the results shown in Figure 6.5 (a) suggested that after RNA addition (grey dotted 
vertical line), the RFU recorded for the first 30 minutes during the ‘run’ at 37°C (grey data points) 
were still not stable, despite a 30-minute pre-incubation (heat) step. It appeared that the ADP* 
quenching by Q-Ab was still equilibrating for longer than the recommended 15 minutes. In 
contrast, a stable RFU was recorded throughout the first hour at 25°C (grey and black data points, 
Figure 6.5 (b)). Hence, as standard, assays were conducted at 25°C and after starting the enzyme 
reaction, RFU data collected for the first 15 minutes were automatically discarded to allow 
adequate time for ADP* quenching by Q-Ab. It is noteworthy to mention, that enzyme assays were 
optimised to ensure that sufficient data could be collected with this 15-minute pre-equilibration 
period. To achieve this, the enzyme concentration was optimised so that less than 0.1% of the 
initial reaction occurred within the first 15 minutes, thus the initial rates could still be calculated 
before <10% of the reaction had proceeded.  
 
The RFU assay window, for these optimised conditions at 25°C (4 nM ADP* and 40 µg/ml Q-Ab, 
Figure 6.5 (b)), was originally shown in Figure 6.5 (b). However, in order to compare the RFU 
stability over the whole assay duration, RFU values recorded for 12-hours are shown in Figure 6.6. 
The RFU recorded within the maximum ADP* fluorescence well (A* only) was stable at ~ 14,000 
RFU for 12 hours (Figure 6.6 (a), bright red data points). The quenched assay, containing both 
ADP* (A*) and Q-Ab, had an RFU of ~ 800, as shown in Figure 6.6 (a) and in the zoomed in 
image in Figure 6.6 (b) (dark red data points). A blank well containing no sample, and the well 
containing only Q-Ab, both had a background RFU of ~ 200, as shown in Figure 6.6 (a) and in the 
zoomed in image in Figure 6.6 (b) (white and blue coloured data points respectively).  
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Figure 6.6 Assay Window Data 
(a) The stabilities of the maximum RFU signal (unquenched ADP* (A*), bright red data points) and the low 
RFU signal (quenched ADP* and Q-Ab (A*+Q-Ab), dark red data points) were recorded over time at 25°C. 
The first 15 minutes were discarded as standard to allow ADP*+Q-Ab equilibration. Controls containing no 
sample (blank well, white data points) and no fluorescence (Q-Ab only, blue data points) were also plotted to 
show the background RFU. (b) The same graph was also shown zoomed in at (<1,400 RFU) in order to 
visualise the RFU of the quenched A*+Q-Ab reaction (~800) and the RFU of Q-Ab and blank well 
background controls (both ~200 respectively). Graphs were plotted in GraFit and labelled in GIMP (v2) 
(GIMP, n.d.; Leatherbarrow, 2009). 
 
As summarised in Figure 6.7, the low RFU (quenched: 4 nM ADP* & 40 µg/ml Q-Ab) and high 
RFU (unquenched: 4 nM ADP* only) data points over the 12-hour assay (Figure 6.6) fitted to a 
linear equation. Furthermore, the quenched and unquenched RFU values calculated from the y-axis 
intercept, demonstrated that the RFU window (809-14,278 RFU respectively) was greater than that 
recommended within the manual (> 5-fold). As indicated by the gradient of both fitted lines in 
Figure 6.7, the quenched and unquenched signals were also stable over 12 hours, indicating that 
RFU data collected within this time period would not be subject to ADP* fluorescence decrease or 
reduced quenching by Q-Ab over time. This was important to check as any effect on RFU, which 
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was not a result of the PNPase-mediated RNA degradation reaction itself, could influence the 
accuracy of calculating ADP production and thus the enzyme’s activity.  
 
 
Figure 6.7 Assay Window Fit 
A linear (y=b*x + a) fit was applied to the RFU window data (shown in Figure 6.6) to check the stability of 
the maximum RFU signal (unquenched ADP* (A* only, bright red line)) and quenched RFU signal (ADP* 
and Q-Ab (A*+Q-Ab), dark red line) at 25°C. The first 15 minutes were discarded to allow proper ADP*-Q-
Ab equilibration before a linear fit was applied, see table inserts for gradient (b) and y-intercept (a) values. 
The graph was created in GraFit (Leatherbarrow, 2009). 
 
In summary, all plate reader assays were pre-incubated at 25°C for 30 minutes to allow the buffer 
components to reach the correct temperature and to ensure ADP* fluorescence stabilisation. 
Following this plate pre-incubation, the reaction was started by adding RNA using a multi-pipette. 
The data recorded from the first 15 minutes of the actual run were automatically discarded to 
ensure adequate time for ADP* quenching by Q-Ab (pre-equilibration). During these preliminary 
experiments it was also found that the substrate RNA20mer was thermally-stable under the conditions 
tested (30-minute pre-incubation step at 25°C), conversely EcPNPase appeared to lose some 
activity (data not shown) and therefore the RNA20mer was used to start the reactions. After 
optimising the assay conditions to obtain the maximum RFU window and ensure stable signal for 
real-time detection of ADP, an ADP standard curve was generated as described in Section 6.4.4.  
 
6.4.4 ADP Standard Curve 
The ADP standard curve generated within this section was prepared so that the rate of RNA20mer 
substrate degradation, mediated by 3’-5’ PNPase homologs, could be quantified in terms of the 
[ADP20x] produced. A range of ADP20x concentrations (0, 40, 80, 120, 160, 200, 300, 400, 600, 
800, 1200, 2000 nM) were serially diluted and utilised to generate a twelve-point ADP20x standard 
curve. These values corresponded to 0, 2 ,4, 6, 8, 10, 15, 20, 30, 40, 60, and 100% RNA20mer 
conversion when the RNA20mer substrate was 2000 nM. 
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The ADP standard curve was prepared as described in Section 6.3.3. The RFU was recorded (with 
the first 15 minutes discarded to allow ADP* and Q-Ab thermal-equilibration) and was found to 
remain stable over the whole 12-hour assay duration (data not shown). The average RFU values 
between 30-90 minutes, for each [ADP20x], were calculated and these were plotted using Minitab 
(v17) (Minitab, 2010) against the ln([L]+1), where [L] was equivalent to the [ADP20x] (nM) (Figure 
6.8). 
 
 
Figure 6.8 ADP20x Standard Curve  
Average RFU values from 30-90 minutes was plotted against ln([L]+1), where [L] was equivalent to the 
ADP20x concentration (nM). Data were fit using Equation 6.5 (red regression line) and the resulting equation 
was shown above each graph. The 95% confidence and prediction interval (CI and PI respectively) are also 
indicated with a green dashed line and pink dotted line respectively. Graphs were plotted in Minitab (v17) 
and labelled in GIMP (v2) (GIMP, n.d.; Minitab, 2010). 
 
Following consultation with the assay manual (BellBrook, n.d.) and in collaboration with Dr David 
Whitley (Mathematician at the University of Portsmouth), the nonlinear regression, logistic growth 
function in Minitab (Figure 6.3) was utilised to fit the ADP standard curve data shown in Figure 
6.8 (Minitab, 2010). The data points (blue circles) for the ADP20x standard curve were close to the 
regression fit (red line) and the fit was observed to have a small 95% confidence and prediction 
interval (Figure 6.8, dotted green CI line and dotted purple PI line respectively). The displayed 
95% CI represented a range of likely values for the mean response, whereas the PI represented a 
range of likely values for a single new observation. The prediction interval was wider than the 
corresponding confidence interval, as predicting a single response value is typically less certain 
than predicting the mean response value. In summary, data in Figure 6.8 fitted to the regression line 
well. Whether this fit could be used to convert RFU values accurately into the [ADP20x] (nM) was 
then examined below in Table 6.1 
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Table 6.1 ADP20x Standard Accuracy  
(a) The ADP20x standard curve equation parameters Theta 1-4, used to convert RFU values into [ADP20x], are 
provided. (b) The values of average RFU between 30-90 minutes are listed for each [ADP20x (nM)] and these 
RFU values were used within the Equation 6.5 to calculate the [ADP20x (nM)]. The percentage difference 
between calculated and actual [ADP20x(nM)] were determined and values < 10% different were indicated 
with an asterisk. The percentage difference value listed for [0 nM ADP20x] could not be calculated; it 
produced a mathematical error (Err).  
 
In order to determine the accuracy of the standard curve, shown in Figure 6.8, for converting RFU 
values into [ADP20x] (nM), a range of [ADP20x] were calculated from the known RFU and Theta 
values listed in Table 6.1. These calculated [ADP20x] values were compared to known [ADP20x] and 
the percentage difference was typically small (<10%). This was expected since the data points in 
Figure 6.8 fitted to the regression fit well and as mentioned previously, had a small 95% CI and PI. 
The results presented in Table 6.1 validated the conversion of RFU values into [ADP20x] between 
40-800 nM. Hence for an assay containing 400-8000 nM RNA20mer, if 10% of the substrate were 
degraded and converted into product, then 40-800 nM ADP20x would be produced and these values 
would be converted accurately (within 10% error).  
 
In conclusion, the ADP standard shown in Figure 6.8 was suitable for converting RFU values, 
recorded from the initial 10% of 400-8000 nM RNA20mer substrate degradation, into [ADP20x] 
ranging from 40-800 nM. The next Section 6.4.5 focused on using this quantifiable real-time assay 
for determining the Michaelis-Menten kinetics for EcPNPase. 
 
Actual 
[ADP20x (nM)] RFU
Calculated 
[ADP20x (nM)] 
% Difference 
(Calculated/Actual)
2000.00 13200 2891.60 31
1200.00 12888 1054.46 -14 *
800.00 12698 779.85 -3 *
600.00 12536 641.32 6 *
400.00 12003 407.80 2 *
300.00 11446 294.61 -2 *
200.00 10321 183.55 -9 *
160.00 10072 168.26 5 *
120.00 8881 116.04 -3 *
80.00 7842 86.65 8 *
40.00 4979 37.86 -6 *
0.00 1542 0.40 Err
1 13327.9
2 1463.53
3 4.3527
4 0.800887
Theta
  
[202] 
6.4.5 EcPNPase Michaelis-Menten Kinetics 
6.4.5.1 Factors Affecting the EcPNPase RFU Window 
It was important test whether EcPNPase and RNA20mer would affect the maximum ADP* 
fluorescence (when no Q-Ab antibody was present) or quenched fluorescence (when both Q-Ab 
and ADP* were present). The results shown in Figure 6.9 and Table 6.2 suggested that neither the 
ADP* (bright red triangles) fluorescence nor Q-Ab quenching of ADP* (dark red triangles) were 
affected by 0.5 nM EcPNPase (blue circles) or 2000 nM RNA20mer (black triangles).  The average 
RFU between 30-90 minutes, for an assay containing only ADP* was 12,207, with a standard 
deviation of ±532 and when EcPNPase and RNA was added to ADP*, the average RFU was within 
this error (Table 6.2). The average RFU for the quenched A*-Q-Ab assay was 836 ±147 and the 
addition of EcPNPase and RNA, did not affect the RFU, with values of 827 ±127 and 844 ±142 
respectively (Table 6.2).  It is worthwhile noting that the RFU window shown in Figure 6.9 was 
slightly smaller than that observed previously (Figure 6.7); it was possible that the ADP* stock 
may have exhibited reduced fluorescence as a result of storage. However, this was not an issue for 
the high-throughput plate reader assay, as the use of an ADP standard curve accounted for plate to 
plate variations.  
 
It is also valuable to note that the standard deviation for the quenched RFU assays (~140 RFU) was 
lower than the unquenched ADP* assay (532 RFU). The quenching of ADP* by Q-Ab may help 
prevent large fluctuations in fluorescence of the fluorophore. This suggested that high levels of 
ADP production, outcompeting ADP* for Q-Ab quenching, would result in higher fluctuations in 
fluorescence. Calculations of initial rates would avoid the large RFU fluctuations, which were 
observed at higher RFU values when all the ADP* is released from Q-Ab by ADP, and may 
produce more reproducible data.  
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Figure 6.9 RFU Window with EcPNPase Assay Components 
(a) The stability of maximum RFU signal (unquenched 4 nM ADP* (A*, bright red triangle)) and low RFU 
signal (quenched 4 nM ADP* and 40 µg/ml Q-Ab (A*-Q-Ab, dark red triangle)) was recorded over time at 
25°C and the data recorded from 30-90 minutes is shown. The negligible effect of 0.5 nM EcPNPase (Ec) 
and 2000 nM RNA20mer on the maximum RFU (Ec+ RNA (A*), blue circle) is shown. Additionally, their 
individual effect on Q-Ab quenching of ADP* (A*-Q-Ab) is shown for Ec (dark blue circle) and RNA (black 
triangle). A control containing no fluorescence (Q-Ab only, white diamond) was also plotted. (b) The same 
graph is also shown zoomed in at (<1,400 RFU) in order to visualise the RFU of the quenched A*-Q-Ab 
reaction (~800) and the RFU of Q-Ab background controls (~200). Graphs were plotted in GraFit and 
labelled in GIMP (v2) (GIMP, n.d.; Leatherbarrow, 2009). 
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Table 6.2 RFU Window with EcPNPase Assay Components 
The average RFU from 30-90 minutes, for maximum RFU signal (unquenched 4 nM ADP* (A*)) and low 
RFU signal (quenched ADP*-Q-Ab (A*-Q-Ab)), background RFU (40 µg/ml Q-Ab), and the effect of 0.5 
nM EcPNPase (Ec) and 2000 nM RNA20mer (RNA) are listed. The standard deviation (Std) of data points are 
also indicated for each assay.  
 
In summary, both EcPNPase and RNA had no effect on either the unquenched ADP* RFU or 
quenching of ADP* by Q-Ab, and did not affect the assay window. Any changes in RFU measured 
using this high-throughput plate assay would therefore be directly a result of ADP produced from 
RNA degradation mediated by EcPNPase. Additionally, a ADP20x standard curve must be 
conducted in all plate reader experiments to account for plate to plate variations.  
 
6.4.5.2 EcPNPase Titration 
The results presented in Section 6.4.5.1 suggested that none of the assay components effect the 
RFU window; hence the next step was to determine the optimal concentration of EcPNPase. A 
range of EcPNPase enzyme concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75 and 1 nM) were titrated 
against a set concentration of RNA20mer (2000 nM) and the RFU was recorded over time as 
described in Section 6.3.4. The RFU recorded over time increased, in a concentration-dependant 
manner, for all EcPNPase concentrations. However, only EcPNPase concentrations greater than 0.3 
nM exhibited the recommended 50-80% increase in RFU over the assay duration (Figure 6.10). 
Therefore, [EcPNPase] below 0.3 nM were not appropriate for producing the response 
recommended by the Bellbrook manual and were not chosen for subsequent RNA20mer substrate 
titration experiments.  
 
Assay Average RFU Std 
A* 12207 532
Ec+RNA (A*) 12875 532
A*-Q-Ab 836 147
Ec (A*-Q-Ab) 827 127
RNA(A*-Q-Ab) 844 142
Q-Ab 216 72
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Figure 6.10 EcPNPase Titration: RFU vs Time 
The RFU recorded over time (minutes) from (a) repeat 1 and (b) repeat 2 are shown. The maximum RFU 
signal (unquenched (Ec + RNA (A*)), blue circles) and low RFU signal (quenched (A*-Q-Ab), dark red 
triangles)) are indicated alongside a range of EcPNPase concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1 nM) 
which are coloured from light grey to black respectively. Data collected within the first 15-minutes were 
discarded as standard. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
 
The RFU values, shown in Figure 6.10, were converted into ADP20x (nM) concentrations using a 
ADP standard curves as described in Section 6.3.3. The ADP standard used within this assay was 
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suitable (within 10% error) for converting RFU values into [ADP20x] within the range of 16-128 
nM ADP20x. The EcPNPase titration assay contained 2000 nM RNA20mer and therefore the ADP 
standard could be used to convert the initial 5% of ADP20x increase accurately (5% 2000 nM 
RNA20mer substrate degradation produces 100 nM ADP20x). Accordingly, the data from the first 5% 
of the reaction, shown in Figure 6.11, were fit with a linear equation and the resultant rate of 
ADP20x (nM) production over time (minutes) was calculated for each [EcPNPase] (Figure 6.12). 
Only EcPNPase concentrations greater than 0.4 nM reached 5% RNA20mer substrate degradation 
over the duration of the assay (100 nM ADP20x produced). 
 
 
Figure 6.11 EcPNPase Titration: [ADP20x] vs Time 
The [ADP20x (nM)] produced from a range of EcPNPase concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1 nM), 
were plotted over time (minutes) for (a) repeat 1 and (b) repeat 2 (minus 15-minutes equilibration). Graphs 
were plotted in GraFit (Leatherbarrow, 2009). 
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Figure 6.12 EcPNPase Titration: Linear Fit [ADP20x] vs Time 
The [ADP20x (nM)] produced over time (minutes) for a range of EcPNPase concentrations (0, 0.1, 0.2, 0.3, 
0.4, 0.5, 0.75, 1 nM) were fit with the linear equation (y= m*x + c). Results for (a) repeat 1 and (b) repeat 2 
(minus 15-minutes equilibration) are shown with increasing [EcPNPase] coloured from light grey to black 
respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
 
These calculated initial rates were then plotted against the enzyme concentration and a graph, 
showing the average of two repeats, is shown in Figure 6.13, with error bars denoting the standard 
deviation. The enzyme concentrations, for which a linear increase in rate was detected, are shown 
in red (Figure 6.13). Ideally the enzyme concentration, which was within this linear region, should 
be selected for further enzyme kinetics. According to the data shown in Figure 6.13, this included 
EcPNPase concentrations between 0.4-0.75 nM.  
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Figure 6.13 EcPNPase Titration: Rate of ADP20x Production vs [EcPNPase] 
The average rate of [ADP20x (nM)] produced per minute, for a range of EcPNPase concentrations (0, 0.1, 0.2, 
0.3, 0.4, 0.5, 0.75, 1 nM), was plotted (white circles) from duplicate data. The linear equation (y = m*x + c, 
black line) was fitted to appropriate linear data points (red circles) using GraFit and error bars of the standard 
deviation are provided (Leatherbarrow, 2009). 
 
Due to the previously established 15-minute equilibration time for ADP*-Q-Ab quenching at 25°C, 
it was important to select an enzyme concentration with the minimum amount of RNA degradation 
during these first 15-minutes. For this reason, as RNA degradation had already started during this 
equilibration time, neither 0.75 nor 1 nM EcPNPase were selected (Figure 6.12). However, in 
assays containing 0.4-0.5 nM EcPNPase, less than 0.1% (2 nM ADP20x produced) of the RNA 
degradation reaction had occurred within the first 15-minutes of the assay. Hence either 0.4 or 0.5 
nM EcPNPase were suitable for generating a 50-80% RFU signal change in the assay, and ensuring 
the initial rates could be calculated following the 15-minute ADP*-Q-Ab thermal-equilibration. 
Both enzyme concentrations were also low enough to prevent enzyme waste and helped ensure that 
the concentration of RNA20mer substrate would be in excess for determining Michaelis-Menten 
kinetics. So the higher concentration, 0.5 nM EcPNPase, was chosen in order to reduce the assay 
duration. 
 
In summary, following a 15 minute ADP*-Q-Ab equilibration, the degradation of 2000 nM 
RNA20mer by 0.5 nM EcPNPase could be monitored directly in real-time; RFU data were collected 
in high-throughput and the concentration of ADP20x (nM) produced over time was calculated using 
an ADP20x standard curve. The initial rates of RNA degradation, for a range of substrate 
concentrations (in excess), could therefore be quantified and used to calculate Michaelis-Menten 
kinetics. Accordingly, the next Section 6.4.5.3 describes the Michaelis-Menten kinetics calculated 
for 0.5 nM EcPNPase titrated with a range of RNA20mer substrate concentrations. 
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6.4.5.3 EcPNPase Degradation Activity (0.5 mM Phosphate) 
The manual recommended detection of ADP in the presence of excess substrate, assuming initial 
velocity enzyme reaction conditions. In order to determine the canonical EcPNPase RNA 
degradation activity, 0.5 nM EcPNPase (in the presence of 0.5 mM KH2PO4) was incubated at 
25°C, with a range of RNA20mer substrate concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 
1400, 1600, 1800, 2000, 2200, 2400 & 2600 nM), as per Section 6.3.5.  
 
The RFU values recorded over time for each RNA20mer concentration (Figure 6.14) were converted 
into ADP20x (nM) concentrations using a ADP standard curve as described in Section 6.3.3. The 
ADP standard used within this assay was suitable (within 10% error) for converting RFU values 
into [ADP20x] within the range of 16-256 nM ADP20x. Therefore, the ADP standard could be used 
to convert the initial 10% of RNA degradation accurately for substrate concentrations between 160-
2560 nM RNA20mer. Ideally, this ADP standard curve should be expanded to include values at the 
lower range (100 nM [ADP20x]) and this required further optimisation. Nevertheless, the data from 
the initial 10% of the reaction (minus 15-minutes) were plotted against time (Figure 6.15 (a)). The 
data plotted in Figure 6.15 (a), were fitted to a linear equation (Figure 6.15 (b)) and the rate of 
reaction was calculated. These initial rates were then plotted against the concentration of substrate 
to give the Michaelis-Menten curve shown in Figure 6.16. 
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Figure 6.14 RNA20mer Degradation by EcPNPase (0.5 mM Phosphate): RFU vs Time  
The RFU recorded over time (minutes) for the maximum RFU signal (unquenched (A*), bright red circles) and low RFU signal (quenched (A*-Q-Ab), dark red triangles)) are indicated for 
assays containing 0.5 nM EcPNPase (Ec) (+ 0.5 mM phosphate), titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 
2400 and 2600 nM) which are coloured from light grey to black respectively. Data collected within the first 15-minutes were discarded as standard. Graphs were plotted in GraFit 
(Leatherbarrow, 2009). 
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Figure 6.15 RNA20mer Degradation by EcPNPase (0.5 mM Phosphate): [ADP20x (nM)] vs Time 
(a) The [ADP20x (nM)] produced over time (minutes), for an assay containing 0.5 nM EcPNPase (0.5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown (minus 15-minutes equilibration). (b) The data were fit 
with the linear equation (y= m*x + c) and the graph show increasing [EcPNPase] coloured from light grey to 
black respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
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Figure 6.16 RNA20mer Degradation by EcPNPase (0.5 mM Phosphate): Michaelis-Menten  
The rate of [ADP20x (nM)] produced per minute, for an assay containing 0.5 nM EcPNPase (0.5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown. The data were fit using the Michaelis-Menten 
equation shown in Equation 6.2 and the resultant Vmax (nM/Minute) and Km (nM) are indicated with their 
standard deviation (Std) error, red asterisk indicates values with a high error. The graph was plotted and fit 
using GraFit (Leatherbarrow, 2009). 
 
The Michaelis-Menten Curve shown in Figure 6.16 was used to calculate the kinetic parameters 
Vmax and Km for EcPNPase-mediated degradation of RNA20mer substrate in the presence of 0.5 mM 
phosphate. The error calculated for the Km (±409 nM) was high; it was more than 20% of the 
calculated value, and so the assay was optimised further to improve the fit of the curve. The assay 
described within this section contained 0.5 mM phosphate and this was below the optimum 
concentration previously reported for EcPNPase. Hence the experiments presented within the 
following Sections 6.4.5.4, tested a higher concentration of phosphate (10 mM).  
 
6.4.5.4 EcPNPase Degradation Activity (10 mM Phosphate) 
For assays described in subsequent sections a new Transcreener kit was utilised and, due to 
variations between kit stocks, the RFU window was smaller. This was still within the RFU window 
recommended by the kit (>5-fold signal difference). Nevertheless, it is important to note subtle 
variations can occur between kit batches and therefore the use of ADP20x standards is recommended 
on each plate to account for plate to plate variations.  
 
* 
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In order to determine whether increased phosphate would improve the rate of EcPNPase 
degradation, 0.5 nM EcPNPase was incubated at 25°C with a range of RNA20mer substrate 
concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400 & 
2600 nM), as per Section 6.4.5.3, however a higher concentration of phosphate (10 mM KH2PO4) 
was utilised.  
 
The RFU values recorded over time for each RNA20mer concentration (Figure 6.17) were converted 
into [ADP20x] (nM) using a ADP standard curve as described in Section 6.3.3. The ADP standard 
used within this assay was suitable (within 10% error) for converting RFU values into [ADP20x] 
within the range of 40-400 nM ADP20x. Therefore, the ADP standard could be used to convert the 
initial 10% of RNA degradation accurately for substrate concentrations between 400-4000 nM 
RNA20mer. As mentioned previously, ideally, this standard curve should be expanded to include 
values at the lower range (100-200 nM [ADP20x]) and this required further optimisation. 
Nevertheless, the data from the initial 10% of the reaction (minus 15-minutes) were plotted against 
time (Figure 6.18 (a)). The data plotted in Figure 6.18 (a) were fitted to a linear equation (Figure 
6.18 (b)) and the initial rates were plotted against the concentration of substrate to give the 
Michaelis-Menten curve shown in Figure 6.19.  
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Figure 6.17 RNA20mer Degradation by EcPNPase (10 mM Phosphate): RFU vs Time 
The RFU recorded over time (minutes) for the maximum RFU signal (unquenched (A*), bright red circles) and low RFU signal (quenched (A*-Q-Ab), dark red triangles)) are indicated for 
assays containing 0.5 nM EcPNPase (Ec) (+ 10 mM phosphate), titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 
2400 and 2600 nM) which are coloured from light grey to black respectively. Data collected within the first 15-minutes were discarded as standard. Graphs were plotted in GraFit 
(Leatherbarrow, 2009). 
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Figure 6.18 RNA20mer Degradation by EcPNPase (10 mM Phosphate): [ADP20x (nM)] vs Time 
(a) The [ADP20x (nM)] produced over time (minutes), for an assay containing 0.5 nM EcPNPase (10 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown (minus 15-minutes equilibration). (b) The data were fit 
to the linear equation (y= m*x + c) and the graph shows increasing [EcPNPase] coloured from light grey to 
black respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
 
[216] 
 
Figure 6.19 RNA20mer Degradation by EcPNPase (10 mM Phosphate): Michaelis-Menten  
The rate of [ADP20x (nM)] produced per minute, for an assay containing 0.5 nM EcPNPase (10 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 800, 1000, 1200, 1400, 1600, 1800, 
2000, 2200, 2400 and 2600 nM) is shown. The data were fitted using the Michaelis-Menten equation shown 
in Equation 6.2 and the resultant Vmax (nM/Minute) and Km (nM) are indicated with their error of standard 
deviation, red asterisk indicates values with a high error. The graph was plotted and fit using GraFit 
(Leatherbarrow, 2009). 
 
The Michaelis-Menten Curve shown in Figure 6.19 was used to calculate the kinetic parameters 
Vmax and Km for EcPNPase degradation of RNA20mer in the presence of 10 mM phosphate. When 
the phosphate concentration was increased from 0.5 mM (Section 6.4.5.3) to 10 mM, the maximum 
velocity of RNA20mer degradation increased from 0.28 nM Min-1 (Figure 6.16) to 1.44 nM Min-1 
(Figure 6.19). This suggested that the assay, in the presence of 0.5 mM phosphate, was sub-optimal 
and that the higher phosphate concentration increased EcPNPase activity. As the EcPNPase activity 
was higher in 10 mM phosphate, the Vmax was not reached when the same concentration range of 
RNA20mer was used (0-2600 nM); EcPNPase was not completely saturated by the substrate. 
Therefore, the results in Figure 6.19 had fewer data points at Vmax compared to the results in Figure 
6.16 (0.5 mM phosphate) and as a result, the error of the calculated Vmax error was higher. 
Although EcPNPase exhibited higher activity in these conditions, as before (Section 6.4.5.3), the 
error calculated for the Km (±317.5 nM) was still high; it was ~20% of the calculated value. 
Whether a lower phosphate concentration would improve the fitting of kinetics data was thus 
investigated in Section 6.4.5.5 
 
* 
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6.4.5.5 EcPNPase Degradation Activity (5 mM Phosphate) 
In order to determine whether 5 mM phosphate would improve the rate of EcPNPase degradation, 
0.5 nM EcPNPase was incubated at 25°C with a range of RNA20mer substrate concentrations (0, 
100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400 & 2600 nM), as per 
Section 6.4.5.4. However, a lower concentration of phosphate (5 mM KH2PO4) was utilised.  
 
The RFU values recorded over time for each RNA20mer concentration (Figure 6.20) were converted 
into [ADP20x] (nM) using a ADP standard curve as described in Section 6.3.3. The ADP standard 
used within this assay was suitable (within 10% error) for converting RFU values into [ADP20x] 
within the range of 40-1200 nM ADP20x. Therefore, the ADP standard could be used to convert the 
initial 10% of RNA degradation accurately for substrate concentrations between 400 nM-12 µM 
RNA20mer. As mentioned previously, ideally, this standard curve should be expanded to include 
values at the lower range (100-200 nM [ADP20x]) and this required further optimisation. 
Nevertheless, the data from the initial 10% of the reaction (minus 15-minutes) were plotted against 
time (Figure 6.21 (a)). The data plotted in Figure 6.21 (a) were fitted to a linear equation (Figure 
6.21 (b)) and initial rates were plotted against the concentration of substrate to give the Michaelis-
Menten curve shown in Figure 6.22.  
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Figure 6.20 RNA20mer Degradation by EcPNPase (5 mM Phosphate): RFU vs Time  
The RFU recorded over time (minutes) for the maximum RFU signal (unquenched (A*), bright red circles) and low RFU signal (quenched (A*-Q-Ab), dark red triangles)) are indicated for 
assays containing 0.5 nM EcPNPase (Ec) (+5 mM phosphate), titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400 
and 2600 nM) which are coloured from light grey to black respectively. Data collected within the first 15-minutes were discarded as standard. Graphs were plotted in GraFit 
(Leatherbarrow, 2009). 
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Figure 6.21 RNA20mer Degradation by EcPNPase (5 mM Phosphate): [ADP20x (nM)] vs Time  
(a) The [ADP20x (nM)] produced over time (minutes), for an assay containing 0.5 nM EcPNPase (5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown (minus 15-minutes equilibration). (b) The data were 
fitted to a linear equation (y= m*x + c) and the graph shows increasing [EcPNPase] coloured from light grey 
to black respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
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Figure 6.22 RNA20mer Degradation by EcPNPase (5 mM Phosphate): Michaelis-Menten  
The rate of [ADP20x (nM)] produced per minute, for an assay containing 0.5 nM EcPNPase (5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 800, 1000, 1200, 1400, 1600, 2000, 
2200, 2400 and 2600 nM) is shown. The data were fit using the Michaelis-Menten equation shown in 
Equation 6.2 and the resultant Vmax (nM/Minute) and Km (nM) are indicated with their standard deviation 
error. The graph was plotted and fit using GraFit and data from 1800 nM were discarded for better fit error 
(Leatherbarrow, 2009). 
 
In previous experiments using 0.5 nM EcPNPase, in the presence of 0.5 mM phosphate, the 
reaction took around 12 hours to get to 5% RNA20mer substrate degradation and this was too slow 
(Section 6.4.5.3). By increasing the phosphate concentrations from 0.5 mM to 10 mM, the rate of 
substrate degradation was increased; the reaction took ~4 hours to reach 10% RNA20mer substrate 
degradation, however, the Km error remained high (Section 6.4.5.4). When 5 mM phosphate was 
used instead, the initial rates of RNA degradation fitted well to a Michaelis-Menten curve and the 
standard deviation of both the Vmax and Km calculated values improved. Additionally, as the 
reaction in 5 mM phosphate also took ~4 hours to reach 10% RNA20mer substrate degradation, 
reducing the phosphate concentration did not seem to be limiting. The following section compares 
the kinetic parameters for EcPNPase outlined within Section 6.4.5 in more detail. 
 
6.4.5.6 EcPNPase Michaelis-Menten Kinetics Summary  
The kinetic parameters determined for 0.5 nM EcPNPase in either 0.5, 5 or 10 mM phosphate in 
Sections 6.4.5.3-6.4.5.5 are summarised in Table 6.3. For comparative purposes, enzyme 
parameters with a standard error greater than 10% are coloured in red, whereas errors within 10% 
of the calculated value are coloured in green (Table 6.3). It is important to mention that values 
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reported in Table 6.3 were not from triplicate data-sets and care must be taken when comparing 
these kinetic parameters in detail. 
 
 
Table 6.3 EcPNPase Kinetics Summary 
The conditions and kinetic parameter for plate reader assays are listed, including total enzyme concentration 
[Et], maximum velocity (Vmax), Michaelis Constant (Km), turnover number (kcat) and catalytic efficiency. The 
units are provided with the values and the standard deviation error is listed where appropriate. Standard error 
values greater than 10% or less than 10% are highlighted in red or green respectively.   
 
The data for the assay containing 0.5 nM EcPNPase, in the presence of 5 mM phosphate, fitted to 
the Michaelis-Menten hyperbolic curve (Figure 6.22) better than data collected in 0.5 or 10 mM 
phosphate. Therefore, the Km and Vmax values determined for EcPNPase in 5 mM phosphate (green, 
Table 6.3) were more reliable than the results obtained in the presence of 0.5 and 10 mM phosphate 
(red, Table 6.3). In summary, results presented in Table 6.3 suggested that EcPNPase (5 mM 
phosphate), could degrade the RNA poly(A)20mer substrate and release 1.22 ±0.03 nM of ADP20x per 
minute. The kcat, calculated as described previously in Equation 6.3, indicated that 2.45 RNA 
poly(A)20mer substrate molecules were degraded into ADP20x product molecules, for a single 
EcPNPase enzyme per minute. The catalytic efficiency was calculated for EcPNPase, as described 
in Equation 6.4 and suggested that the RNA20mer was degraded by EcPNPase at 43,402 M-1 s-1. 
 
Due to the differences in standard error, caution needs to be made when comparing the enzyme 
parameters in Table 6.3. Nevertheless, EcPNPase activity appears to be reduced in the presence of 
0.5 mM phosphate and increased in 5 and 10 mM phosphate and this correlated with previous 
publications reporting a high phosphate preference for EcPNPase (Portnoy et al., 2007). More 
specifically, the Vmax, kcat and catalytic efficiency appear to increase as the phosphate concentration 
increases, although the assays need to be repeated in order to fully confirm that a trend exists.  
 
In summary, the results in Table 6.3 suggested that the assay containing 0.5 nM EcPNPase, in the 
presence of 5 mM phosphate, could be used to calculate detailed kinetic parameters including the 
Vmax, Km, kcat and catalytic efficiency. Whether the plate reader assay could also be used to 
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determine the activity a PNPase homolog, from the archaeal domain of life, was subsequently 
investigated in Section 6.4.6 using recombinant SsoExosome. 
 
6.4.6 SsoExosome Michaelis-Menten Kinetics 
6.4.6.1 Factors Affecting the SsoExosome RFU Window 
It was important to show that, like EcPNPase (Section 6.4.5.1), the SsoExosome would not affect 
the maximum ADP* fluorescence (when no Q-Ab antibody was present) or quenched fluorescence 
(when both Q-Ab and ADP* were present). The results shown in Figure 6.23 and Table 6.4 
suggested that neither the ADP* (bright red triangles) fluorescence nor Q-Ab quenching of ADP* 
(dark red triangles) were affected by 4 nM SsoExosome (green circles) or 2000 nM RNA20mer 
(black triangles).  The average RFU between 30-90 minutes, for an assay containing only ADP* 
was ~12,200 with a standard deviation of 532, when SsoExosome and RNA was added to ADP*, 
the RFU was within error of this maximum signal (Table 6.4). The average RFU for the quenched 
A*-Q-Ab assay was 836 ±147. The addition of SsoExosome and RNA did not affect the RFU (882 
and 844 respectively); values were within the RFU error of the A*-Q-Ab assay (Table 6.4).  
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Figure 6.23 RFU Window with SsoExosome Assay Components 
(a) The stability of maximum RFU signal (unquenched 4 nM ADP* (A*, bright red triangles)) and low RFU 
signal (quenched 4 nM ADP* and 40 µg/ml Q-Ab (A*-Q-Ab, dark red triangles)) was recorded over time at 
25°C and the data recorded between 30-90 minutes is shown. The negligible effect of 4 nM SsoExosome 
(Sso) and 2000 nM RNA20mer on the maximum RFU (Sso + RNA (A*), green circles) is shown. Additionally, 
their individual effect on Q-Ab quenching of ADP* (A*-Q-Ab) is shown for Sso (dark green circles) and 
RNA (black triangles). A control containing no fluorescence (Q-Ab only, white diamonds) was also plotted. 
(b) The same graph is also shown zoomed in at (<1,400 RFU) in order to visualise the RFU of the quenched 
A*-Q-Ab reaction (~800) and the RFU of Q-Ab background controls (~200). Graphs were plotted in GraFit 
and labelled in GIMP (v2) (GIMP, n.d.; Leatherbarrow, 2009). 
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Table 6.4 RFU Window with SsoExosome Assay Components 
The average RFU between 30-90 minutes, for maximum RFU signal (unquenched 4 nM ADP* (A*)) and 
low RFU signal (quenched ADP*-Q-Ab (A*+Q-Ab)), background RFU (40 µg/ml Q-Ab), and the effect of 4 
nM SsoExosome (Sso) and 2000 nM RNA20mer (RNA) are listed. The standard deviation (Std) of data points 
are also indicated for each assay.  
 
In summary, both SsoExosome and RNA had no effect on either the unquenched ADP* RFU or 
quenching of ADP* by Q-Ab, and did not affect the assay window. Any changes in RFU measured 
using this high-throughput plate assay would therefore be directly a result of ADP produced from 
RNA degradation mediated by SsoExosome.  
 
6.4.6.2 SsoExosome Titration 
The results presented in Section 6.4.6.1 suggested that none of the assay components affect the 
RFU window; hence the next step was to determine the optimal concentration of SsoExosome. A 
range of SsoExosome enzyme concentrations (0, 1, 2.5, 3, 3.5, 4, 5, 10 nM) were titrated against a 
set concentration of RNA20mer (2000 nM) and the RFU was recorded over time as described in 
Section 6.3.4. The concentration range of SsoExosome was higher than those tested for EcPNPase 
(Section 6.4.5.2), as preliminary work suggested that SsoExosome exhibited a lower activity at 
37°C. This may have been a result of using sub-optimal assay temperatures; the thermophile 
SsoExosome can degrade RNA at 65°C. It was therefore expected that the activity would be 
reduced further at 25°C and so a higher range of enzyme concentrations were tested.  
 
The RFU recorded over time increased in a concentration-dependant manner for all SsoExosome 
concentrations. However, only SsoExosome concentrations greater than 3 nM exhibited the 
recommended 50-80% increase in RFU over the assay duration (Figure 6.24). Therefore, 
[SsoExosome] below 3 nM were not appropriate for producing the response recommended by the 
Bellbrook manual and were not chosen for subsequent RNA20mer substrate titration experiments.  
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Figure 6.24 SsoExosome Titration: RFU vs Time 
The RFU recorded over time (minutes) from (a) repeat 1 and (b) repeat 2 are shown. The maximum RFU 
signal (unquenched (Sso + RNA (A*)), green circles) and low RFU signal (quenched (A*-Q-Ab), dark red 
triangles)) are indicated alongside a range of SsoExosome concentrations (0, 1, 2.5, 3, 3.5, 4, 5 and 10 nM) 
which are coloured from light grey to black respectively. Data collected within the first 15-minutes were 
discarded as standard. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
 
The RFU values, shown in Figure 6.24, were converted into [ADP20x] (nM) using an ADP standard 
curve as described in Section 6.3.3. The ADP standard used within this assay was suitable (within 
10% error) for converting RFU values into [ADP20x] within the range of 16-128 nM ADP20x. The 
SsoExosome titration assay contained 2000 nM RNA20mer and therefore the ADP standard could be 
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used to convert the initial 5% of ADP20x increase accurately (5% 2000 nM RNA20mer substrate 
degradation produces 100 nM ADP20x). Accordingly, the data from the first 5% of the reaction, 
shown in Figure 6.25, were fitted to a linear equation and the resultant rate of [ADP20x] (nM) 
production over time (minutes) was calculated for each [SsoExosome] (Figure 6.26). Only 
SsoExosome concentrations greater than 3 nM reached 5% RNA20mer substrate degradation over the 
duration of the assay (100 nM ADP20x produced). 
 
 
Figure 6.25 SsoExosome Titration: Raw Data [ADP20x] vs Time 
The [ADP20x (nM)] produced from a range of SsoExosome concentrations (0, 1, 2.5, 3, 3.5, 4, 5 and 10 nM), 
were plotted over time (minutes) for (a) repeat 1 and (b) repeat 2 (minus 15-minutes equilibration). Graphs 
were plotted in GraFit (Leatherbarrow, 2009). 
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Figure 6.26 SsoExosome Titration: Linear Fit [ADP20x] vs Time 
The [ADP20x] (nM) produced over time (minutes) for a range of SsoExosome concentrations (0, 1, 2.5, 3, 3.5, 
4, 5 and 10 nM) was fitted to the linear equation (y= m*x + c). Results for (a) repeat 1 and (b) repeat 2 
(minus 15-minutes equilibration) are shown with increasing [SsoExosome] coloured from light grey to black 
respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
 
The calculated initial rates were then plotted against the enzyme concentration and a graph, 
showing the average of two repeats, is shown in Figure 6.27, with error bars denoting the standard 
deviation. The enzyme concentrations, for which a linear increase in rate were detected, are shown 
in red (Figure 6.27). Ideally the enzyme concentration, which was within this linear region, should 
be selected for further enzyme kinetics and according to the data shown in Figure 6.27; this 
included [SsoExosome] between 3.5-5 nM.  
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Figure 6.27 SsoExosome Titration: Rate of ADP20x Production vs [SsoExosome] 
The average rate of [ADP20x (nM)] produced per minute, for a range of SsoExosome concentrations (0, 1, 2.5, 
3, 3.5, 4, 5 and 10 nM) was plotted (white circles) from duplicate data. The linear equation (y = m*x + c, 
black line) was fitted to appropriate linear data points (red circles) using GraFit and error bars of the standard 
deviation are provided (Leatherbarrow, 2009). 
 
Due to the previously established 15-minute equilibration time for ADP*-Q-Ab quenching at 25°C, 
it was important to select an enzyme concentration with the minimum amount of RNA degradation 
following 15-minutes. For this reason, since RNA degradation had already started during this 
equilibration time, neither 5 or 10 nM SsoExosome were selected (Figure 6.26). However, in 
assays containing 3.5-4 nM SsoExosome, less than 0.2% (~4 nM ADP20x produced) of the reaction 
had occurred within the first 15-minutes of the assay. Hence either 3.5 or 4 nM SsoExosome were 
suitable for generating a 50-80% RFU signal change in the assay, and ensuring the initial rates 
could be calculated following the 15-minute ADP*-Q-Ab thermal-equilibration. Both enzyme 
concentrations were also low enough to prevent enzyme waste and helped ensure that the 
concentration of RNA20mer substrate would be in excess, for determining Michaelis-Menten 
kinetics. So the higher concentration, 4 nM SsoExosome was chosen in order to reduce the assay 
duration. 
 
In summary, following a 15-minute ADP*-Q-Ab equilibration, the degradation of 2000 nM 
RNA20mer by 4 nM SsoExosome could be monitored directly in real-time; RFU data were collected 
in high-throughput and the concentration of ADP20x (nM) produced over time was calculated using 
an ADP20x standard curve. The concentration of SsoExosome (4 nM) was 8-fold higher than 
EcPNPase (0.5 nM) (Section 6.4.5.2) and this possibly was a result of sub-optimal assay 
temperatures (25°C). Nevertheless, a range of substrate concentrations were titrated against 4 nM 
SsoExosome and the initial rates were used to calculate Michaelis-Menten kinetics. The results of 
which are described below in Section 6.4.6.3. 
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6.4.6.3 SsoExosome Degradation Activity (0.5 mM 
Phosphate)  
In order to determine the canonical SsoExosome RNA degradation activity, 4 nM SsoExosome (in 
0.5 mM phosphate) was incubated at 25°C with a range of RNA20mer substrate concentrations (0, 
100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400 & 2600 nM) as in 
Section 6.3.5. The RFU values recorded over time (Figure 6.28) were converted into [ADP20x] 
(nM) using a ADP standard curve as described in Section 6.3.3. The ADP standard used within this 
assay was suitable (within 10% error) for converting RFU values into [ADP20x] within the range of 
16-256 nM ADP20x. Therefore, the ADP standard could be used to convert the initial 10% of RNA 
degradation accurately for substrate concentrations between 160-2560 nM RNA20mer. Ideally, this 
standard curve should be expanded to include values at the lower range (100 nM [ADP20x]) and this 
required further optimisation. Nevertheless, the data from the initial 10% of the reaction (minus 15-
minutes) were plotted against time (Figure 6.29 (a)). The data plotted in Figure 6.29 (a) were fitted 
to a linear equation (Figure 6.29 (b)) and the rate of reaction was calculated. These initial rates 
were then plotted against the concentration of substrate to give the Michaelis-Menten curve shown 
in Figure 6.30.  
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Figure 6.28 RNA20mer Degradation by SsoExosome (0.5 mM Phosphate): [ADP20x (nM)] vs Time  
The RFU recorded over time (minutes) for the maximum RFU signal (unquenched (A*), bright red circles) and low RFU signal (quenched (A*-Q-Ab), dark red triangles)) are indicated for 
assays containing 4 nM SsoExosome (Sso) (+ 0.5 mM phosphate), titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 
2400 and 2600 nM) which are coloured from light grey to black respectively. Data collected within the first 15-minutes were discarded as standard. Graphs were plotted in GraFit 
(Leatherbarrow, 2009). 
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Figure 6.29 RNA20mer Degradation by SsoExosome (0.5 mM Phosphate): [ADP20x (nM)] vs Time  
(a) The [ADP20x (nM)] produced over time (minutes), for an assay containing 4 nM SsoExosome (0.5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown (minus 15-minutes equilibration). (b) The data were 
fitted to a linear equation (y= m*x + c) and the graph shows increasing [SsoExosome] coloured from light 
grey to black respectively. Graphs were plotted in GraFit (Leatherbarrow, 2009). 
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Figure 6.30 RNA20mer Degradation by SsoExosome (0.5 mM Phosphate): Michaelis-Menten  
The rate of [ADP20x (nM)] produced per minute, for an assay containing 4 nM SsoExosome (0.5 mM 
phosphate) titrated with a range of RNA20mer concentrations (0, 100, 200, 400, 600, 800, 1000, 1200, 1400, 
1600, 1800, 2000, 2200, 2400 and 2600 nM) is shown. The data were fit using the Michaelis-Menten 
equation shown in Equation 6.2 and the resultant Vmax (nM/Minute) and Km (nM) are indicated with their 
error of standard deviation. The graph was plotted and fit using GraFit (Leatherbarrow, 2009) 
 
The data plotted in Figure 6.30 indicated that SsoExosome, in the presence of 0.5 mM phosphate, 
reached a Vmax of 0.69 nM/Minute and had a Km of 334 nM. The kcat and catalytic efficiency were 
also calculated using Equation 6.3 and Equation 6.4 respectively and the results were shown in 
Table 6.5. Although the error calculated for the Vmax was quite reasonable (<10%), the Michaelis-
Menten curve shown in Figure 6.30, reached the Vmax relatively quickly compared to EcPNPase 
(Section 6.4.5.5) and the Km error was ~14%. Therefore, it would be worthwhile to optimise this 
assay; obtaining more initial rate data points at lower [RNA20mer], before the SsoExosome reaches 
maximum velocity, may improve the Km error. 
 
 
Table 6.5 SsoExosome Kinetic Parameters 
The conditions and kinetic parameter for the plate assay are listed, including total enzyme concentration [Et], 
maximum velocity (Vmax), Michaelis Constant (Km), turnover number (kcat) and catalytic efficiency. The units 
are provided with the values and a standard deviation error is listed where appropriate. 
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In summary, the assay used to determine SsoExosome kinetic parameters requires further 
optimisation. In order to examine, if like EcPNPase, SsoExosome has a higher phosphate 
preference, more experiments are required and these are part of ongoing work within our group. 
Nevertheless, the information presented within this section provided proof of concept results and 
demonstrated that the plate assay developed was suitable to test the 3’-5’ degradation activity of 
SsoExosome. The application of this real-time assay can therefore be used to quantify the 
degradation activity of PNPase homologs across the two domains of life, prokaryotes and archaea. 
Although kinetic parameters determined for SsoExosome were not obtained from triplicate data-
sets, the results supported the use of the high-throughput assay for determining SsoExosome 
kinetics in real-time. 
 
6.5 Conclusions 
This chapter described the successful development of a real-time high-throughput plate reader 
assay for quantifying PNPase-mediated degradation activity on a poly(A)20mer RNA substrate. The 
methods used to modify the currently available Transcreener® ADP2 Fluorescent Intensity (FI) 
assay, which was optimised for end-point ADP detection (Bellbrook), to be used for real-time 
studies instead, were provided in Section 6.3. The results provided in Section 6.4, validate the assay 
parameters and conditions, prior to determining enzyme kinetics. 
 
The results presented within this chapter consisted mainly of proof of concept/preliminary data; 
more optimisation is required and the assays need to be conducted in triplicate. However, the data 
in this chapter clearly demonstrated a novel application of the high-throughput assay to determine 
kinetic parameters, for a range of 3’-5’ PNPase homologs, in real-time. For example, both 
EcPNPase and SsoExosome were suitable for generating data which fitted to a Michaelis-Menten 
curve and could be utilised for calculating detailed kinetic parameters including the Vmax, Km, kcat 
and catalytic efficiency. Also by using an ADP standard curve within this assay, the degradation of 
RNA substrates mediated by PNPase homologs was not just reported as changes in RFU over time, 
but could be more relevantly quantified in terms of [ADP] produced. A basic summary of the 
kinetic parameters for EcPNPase and SsoExosome are provided in Table 6.6 
 
 
Table 6.6 PNPase Homologs Kinetics Summary 
The conditions and kinetic parameter for plate reader assays are listed, including the enzyme, phosphate 
concentration, total enzyme concentration [Et], maximum velocity (Vmax) and turnover number (kcat). The 
units are provided with the values and a standard deviation error is listed where appropriate.   
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As reviewed in Godefroy-Colburn & Grunberg-Manago, 1975, kinetic studies of PNPases have 
been conducted using various synthetic poly(A) substrates. Since values reported in Table 6.3 were 
not from triplicate data-sets, care must be taken when comparing these kinetic constants in detail. 
Nevertheless, although the focus of this work was not to compare kinetic parameters 
comprehensively, it was important to demonstrate that EcPNPase kinetic values, calculated within 
this study, aligned with previously published data.  
 
It has been reported by multiple publications that the Km values decrease with increasing RNA 
chain length. For example, the Km values of Micrococcus luteus PNPase were reported to decrease 
from 2.5 to 0.033 mM as the chain length (n) of (Ap)nA increased from 2 to 8 nucleotides (Chou & 
Singer, 1970b). Similarly, the Km values of M. luteus PNPase decreased from 0.067 to 0.033 mM as 
the chain length of (Ap)nA increased from 4 to 5 nucleotides (Chou & Singer, 1970a). Additionally, 
Km values of E. coli PNPase were reported to be within the order of 0.1 mM for (pA)4. While the 
Km for poly(A)500 chain was in the low nM range (as reviewed in Godefroy-Colburn & Grunberg-
Manago, 1975); with Km values of 3 and 4 nM for E. coli PNPase (Godefroy, Cohn, & Grunberg-
Manago, 1970) and M. luteus PNPase  respectively (Chou, Singer, & McPhie, 1975). The Km value 
reported within this study, for the E. coli PNPase-mediated degradation of a Poly(A)20mer RNA 
substrate was 940 nM ±66 nM and this was as expected, lower than the values previously reported 
above for an 8-nucleotide substrate but higher than those calculated for a Poly(A)500mer. 
 
Additionally, although the results listed in Table 6.3 were not conducted in duplicate. The Km and 
kcat values for EcPNPase degrading a Poly(A)20mer, correlated well with values previously reported 
for EcPNPase degrading 5601 and 5660 substrates, derived from the rpsO-pnp operon of S. 
coelicolor (Chang, Cozad, Mackie, & Jones, 2008). The Km values published by Chang and 
colleagues were calculated from a range of 5601 and 5660 RNA concentrations (200-3300 nM and 
200-2000 nM respectively) similar to the [Poly(A)20mer] used within this study (100-2600 nM). The 
Km calculated for the 5601 transcript (780 nM ±20 nM) was slightly lower than the Km of the 
Poly(A)20mer substrate (940 nM ±66 nM) whereas the Km for the 5660 transcript was higher (6330 
nM ±440 nM) than both values. This suggested that more Poly(A)20mer RNA substrate was needed 
to reach half Vmax compared to the 5601 transcript, but less was needed compared to the 5660 
transcript. The turnover rate (kcat) of EcPNPase for the 5601 and 5660 transcript were higher (11.2 
±0.2 Min-1 and 5.55 ±0.34 Min-1 respectively), than the Poly(A)20mer RNA substrate (2.45 Min-1); 
suggesting that within the conditions tested, EcPNPase degraded more 5601 and 5660 transcripts 
per minute than the Poly(A)20mer. Even though the kcat for the 5660 transcript was high, because the 
Km was also high, the catalytic efficiency of EcPNPase degrading the 5660 transcript was ~ 3-fold 
lower (14,607 M-1s-1) than the enzyme degrading the poly(A)20mer substrate (43,402 M-1s-1). In 
contrast, the high kcat and low Km of EcPNPase for the 5601 transcript, meant that the catalytic 
efficiency was 5-fold higher (239,316 M-1s-1) than the poly(A)20mer substrate. The publication by 
Chang and colleagues suggested that the phosphate concentration used was not limiting (1 mM), 
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and therefore the differences in these kinetic values may be due to substrate preference. In 
conclusion, for the EcPNPase-mediated degradation of Poly(A)20mer RNA substrate, the kinetic 
values calculated within this chapter were similar to those previously published. This supported the 
use of the high-throughput assay for determining EcPNPase kinetics in real-time.  
 
Comparing the Vmax values for SsoExosome with EcPNPase would not be appropriate as an 8-fold 
higher concentration of SsoExosome was utilised (4 and 0.5 nM respectively). However, the 
turnover number (kcat) could be compared as it was the ratio of Vmax to [Et]. The kcat of 
SsoExosome, in the presence of 0.5 mM phosphate, was lower than EcPNPase in 5 mM phosphate 
(0.17 and 2.45 RNA20mer/Minute respectively). These results suggested that the amount of RNA20mer 
degraded per minute, by one enzyme molecule, was less for SsoExosome. This reduced turnover 
rate may have been a result of the sub-optimal temperature; the archaeal exosome from the 
thermophile S. solfataricus is known to exhibit activity at high temperatures. Unfortunately, this 
variable could not be adjusted due to the issue, mentioned previously in Section 6.4.3, of the 
thermal-equilibration between ADP* and Q-Ab at higher temperatures. Alternatively, the lower kcat 
calculated for SsoExosome may have been due to sub-optimal phosphate concentrations. Perhaps, 
like EcPNPase, SsoExosome may exhibit optimal enzyme activity in higher phosphate 
concentrations. Due to time limitations, this was not conducted and therefore is currently the 
subject of following investigations within our group.  
Once the real-time plate reader assay has been fully optimised and canonical enzyme kinetic 
information is available, in triplicate, high-throughput data collection should be possible. These 
data could then be utilised to calculate kinetic parameters, for comparing the turnover rate (kcat) and 
catalytic efficiency of individual PNPase homologs, in a range of conditions. For example, as long 
the sequence is known and a detectable amount of ADP is released from RNA substrate 
degradation, a range of different physiologically relevant substrates may be tested. Additionally, 
the effects of inhibitors may also be studied, including the effects of citrate and other metabolites 
on 3’-5’ PNPase homolog activity. Data collection using this method would be more time-effective 
than previously available gel-based methods, which is economically beneficial. The impact and the 
possible applications of this assay are discussed further in Chapter 7. 
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7 Discussion and Future Perspectives 
 
To maintain cellular homeostasis a repertoire of intricate systems must be able to respond to 
internal changes and environmental stimuli. For example, central metabolism can meet the needs of 
a cell by providing the specific building blocks and energy required for normal cell growth. 
However, in situations where a cell experiences either internal or external changes, metabolism can 
be adjusted for cell survival (Nielsen, 2003). As reviewed in Wegner, Meiser, & Weindl, 2015, 
these adaptations may occur at many different levels. Modification may occur at the gene level by 
encoding different enzyme isoforms, or at the transcriptional level by regulating which genes are 
expressed. Factors such as alternative splicing, mRNA stability, translation, and protein 
degradation, which can all control the abundance of enzymes, may also allow long-term 
adaptations. Alternatively, these adaptations may provide short-term regulation of pathways that 
need to be constitutively active. For example, metabolic fluxes may fine tune the activity of 
enzymes already present within the cell (Wegner et al., 2015).  
 
It is considered that a metabolite has a role in regulating cellular metabolism if its concentration 
fluctuates in response to cellular changes and if the activity of one or more specific enzymes is 
changed in response (Wegner et al., 2015). There are a wide range of metabolites which fulfil these 
requirements and regulate cellular metabolism, at both the transcriptional and translational level. 
An excellent example of a major cellular adaptation at the transcriptional level is the metabolite-
mediated reprogramming that is required by a cell to survive in situations of oxygen or nutrient 
depletion. In these circumstances, metabolites are known to interact with transcription factors and 
drive large rearrangements of metabolic processes. For example, the processes controlling 
anaerobic or aerobic cellular respiration involve a number of regulatory steps, and metabolites are 
reported to be essential for adapting the cells metabolism to enable survival in environments where 
oxygen levels may fluctuate (Wegner et al., 2015). Additionally, in a number of organisms, 
metabolites can regulate adaptations at the translational level, by directly binding to riboswitches 
and inducing a conformation change in the target mRNA to either activate or inactive translation 
(Li & Breaker, 2013). It has also been reported that metabolite fluxes may regulate cellular 
metabolism in a feedback loop in stem cells. More specifically, an unsaturated fatty acid was found 
to bind to a translational activator in stem cells and induce a conformational change, which 
prevented the binding and translation of a fatty acid desaturase (stearoyl-CoA desaturase-1 
(SCD1)) mRNA (Clingman et al., 2014).  
 
In conclusion, cellular metabolite levels are known to fluctuate in a range of conditions and can 
directly or indirectly affect gene transcription and protein translation. However, their indirect effect 
on regulating RNA turnover, via interactions with ribonucleases, is poorly understood. 
Consequently, this study initially reviewed the recurrent evolution of a physical association 
between the enzymes of RNA degradation and central metabolism, prior to exploring the concept 
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that a conserved communicative link may exist between RNA turnover and central metabolism. 
The key results of this study are discussed in the following Section 7.1 before future perspectives 
are addressed in Section 7.2. 
 
7.1 Regulating RNA Turnover in Response to Cellular 
Metabolism 
There is a growing body of evidence which suggests that small molecule metabolites link the 
cellular metabolic status of a cell and RNase activity in bacteria. A physical association between 
metabolic enzymes and RNases, in a range of organisms, has been documented over the last two 
decades. For example, the glycolytic enzymes enolase and aconitase are canonical components of 
the E. coli and C. crescentus degradosome respectively (Hardwick, Chan, Broadhurst, & Luisi, 
2011; Miczak, Kaberdin, Wei, & Lin-Chao, 1996; Py, Higgins, Krisch, & Carpousis, 1996). 
Furthermore, degradosome-like complexes containing two glycolytic enzymes (enolase and 
phosphofructokinase), four RNases (RNase Y, RNase J1, RNase J2 and PNPase) and a helicase 
(CshA) appear to be present in Bacillus subtilis (Commichau et al., 2009; Lehnik-Habrink et al., 
2010) and Staphylococcus aureus (Roux, DeMuth, & Dunman, 2011). Not only has the physical 
association of metabolic enzymes with RNA degradation machinery been discovered, but small 
molecules, including ATP (Del Favero et al., 2008), c-di-GMP (Tuckerman, Gonzalez, & Gilles-
Gonzalez, 2011) and citrate (Nurmohamed et al., 2011), have been found to modulate the RNase 
activity of E. coli PNPase. The signalling molecule/alarmone (p)ppGpp has also been shown to 
modulate PNPase activity in Streptomyces (Gatewood & Jones, 2010) and Nonomuraea sp. 
(Siculella et al., 2010). The results presented in this thesis suggest that the modulation of RNase 
activity by small molecules, may be more widespread than previously thought and may represent 
an evolutionarily conserved communication mechanism.  
 
7.1.1 Interactions Between Citrate and Homologous 3’-5’ Phosphorolytic 
Ribonucleases   
The first indication that the interaction of small molecule metabolites with RNases may be 
conserved, came upon studying the detailed interactions of citrate co-crystallised within the 
PNPase enzymes of E. coli and H. sapiens (Lin et al., 2012; Nurmohamed, Vaidialingam, 
Callaghan, & Luisi, 2009). When the citrate and Mg2+ binding residues of these two enzymes were 
compared with a small group of other PNPase homologs (for which either sequence or structural 
information was available), they were discovered to be highly conserved. This result promoted 
more detailed bioinformatics analysis; protein sequence comparisons of PNPase from 3509 
prokaryotic and 252 eukaryotic species with that of the archaeal exosome from 69 archaeal species, 
suggested that citrate-binding residues were highly conserved across evolution. The observation 
that these residues were conserved across all three domains of life showed that citrate-binding may 
exist in evolutionarily diverse PNPase homologs. Unfortunately, conclusive evidence of citrate 
binding to the archaeal exosome from S. solfataricus could not be obtained during this study, since 
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only weak X-ray diffraction was recorded for crystals containing the SsoExosome soaked with 
citrate. Therefore, an alternative in silico molecular docking approach was utilised to explore 
citrate binding.  
 
The in silico molecular docking validation, described in Chapter 4, suggested that MOE was a 
suitable program for predicting citrate-PNPase interactions. In summary, through in silico 
molecular docking calculations, two citrate molecules were shown to interact with the catalytic 
centre and the neighbouring RNA-binding regions in the same way as previously identified in the 
co-crystallised structures of EcPNPase and hPNPase (Lin et al., 2012; Nurmohamed et al., 2009). 
Therefore, in silico docking was applied to predict citrate interactions with other PNPase 
homologs, for which no binding information was currently available. Consequently, subsequent 
docking calculations predicted that two citrate molecules could also bind within the active site of 
SsoExosome and a bacterial PNPase homolog from S. antibioticus, and that the residues and types 
of interactions were conserved. These results were particularly interesting since the sequence 
conservation of both the active site, and consequently the putative citrate-binding residues, was 
much weaker in the more distantly related archaeal exosomes. In particular, the PBR S(S/T)S 
motif, that is required for phosphate-binding in PNPase (Nurmohamed et al., 2009), has been 
replaced by an G(T/S)R motif in the archaeal exosomes. Despite the sequence variation, this motif 
has been shown to bind phosphate (Hartung, Niederberger, Hartung, Tresch, & Hopfner, 2010; 
Navarro, Oliveira, Zanchin, & Guimarães, 2008) and in silico data presented here suggest that two 
molecules of citrate can dock into the SsoExosome. Furthermore, regardless of the sequence 
variation, the S value for citrate binding at the Cit 1 site of all four PNPase homologs (EcPNPase, 
hPNPase, SsoExosome and SanPNPase) was similar. By contrast, the sequence variation of the 
PBR motif may affect the second citrate binding event. The docking scores for the Cit 2 site for 
SsoExosome (GSR motif) and SanPNPase (STS motif) were significantly higher than for 
EcPNPase and hPNPase, which both have the SSS motif. The physiological relevance of these 
different S values remains to be determined, especially since it is currently unknown whether one 
or two citrate molecules are required to inhibit PNPase activity.  
 
Previous reports highlighted that, at physiological concentrations of citrate, attenuation of 
EcPNPase activity rather than complete inhibition is likely to occur in vivo (Nurmohamed et al., 
2011). The in vitro results presented within this work, suggested that PNPase from another 
bacterial species Synechocystis sp may also be susceptible to inhibition/attenuation by citrate and 
that this attenuation may be commonplace among prokaryotes. Furthermore, the 3’-5’ degradation 
activity of both eukaryotic PNPase from human mitochondria and the archaeal exosome complex 
from S. solfataricus, was similarly reduced in the presence of citrate. The level of citrate-mediated 
EcPNPase inhibition previously published by Nurmohamed and colleagues was similar to the 
effects observed for all the PNPase homologs tested within this study. This suggests a conserved 
role for citrate in attenuating the function of PNPase homologs. It remains to be demonstrated 
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whether or not the citrate-mediated attenuation of exoribonuclease activity demonstrated in vitro is 
utilised as a regulatory strategy in vivo. Nevertheless, the reoccurring interaction between citrate 
and PNPase homologs across all three domains of life, may represent an ancient and evolutionarily 
conserved mechanism of regulating RNA turnover. 
As mentioned previously, for a metabolite such as citrate to act as a regulator, the intracellular 
concentration of the metabolite must vary under different physiological conditions and the response 
elicited must be dose-dependent within this concentration range. Intracellular citrate concentrations 
in E. coli depend upon the carbon source and have been reported to range between 2 mM for 
growth on glucose or glycerol, and 20 mM for growth on acetate (Bennett et al., 2009). 
Furthermore, the level of inhibition of EcPNPase by citrate observed in vitro correlated well with 
citrate concentrations in this range (Nurmohamed et al., 2011). Therefore, for EcPNPase, there was 
evidence to support citrate-mediated regulation. However, the situation for other organisms is less 
clear. There is a lack of metabolomics data reporting normal intracellular citrate concentration(s); 
this information appears to be non-trivial to obtain.  
High levels of citrate have been shown to lead to apoptotic cell death in H. sapiens and citrate has 
therefore been proposed for use in anticancer therapeutics (Icard et al., 2012; Lu et al., 2011; Sun 
et al., 2010; Usenik & Legis, 2010). With this in mind, the significance of a citrate-PNPase 
interaction in human cells needs to be investigated further, especially as hPNPase has been shown 
to localise to the mitochondria, the location of citrate synthesis (Piwowarski et al., 2003). 
Furthermore, in human melanoma cells induced to terminally differentiate and human progeria 
cells, which exhibit increased cellular senescence, the gene encoding hPNPase was identified to be 
upregulated. Since hPNPase has been linked to terminal differentiation and cellular senescence, 
understanding its activity and mechanisms of inhibition may therefore be of interest to cell renewal 
and research into ageing (Leszczyniecka et al., 2002; Sarkar et al., 2004). 
7.1.2 Interactions Between TCA Metabolites and 3’-5’ Phosphorolytic 
Ribonucleases 
Following the observation that a conserved communicative link may exist between citrate and 
PNPase homologs, other TCA metabolites similar to citrate were also considered as potential 
inhibitors. The in silico molecular docking results suggested that the only two TCA metabolites 
predicted to bind to hPNPase more tightly than citrate were acetyl-CoA and succinyl-CoA. During 
in vitro studies these metabolites were also shown to affect hPNPase and EcPNPase activity more 
than citrate. Although the role of hPNPase within the mitochondria, which is also the location of 
the TCA cycle, is not fully understood, the physiological relevance of these two molecules 
interacting with hPNPase was interesting since they both have key roles in regulating the TCA 
cycle. Essentially, entry into the TCA cycle is controlled by acetyl-CoA, ATP and NADH; 
increasing the NADH/NAD+, acetyl-CoA/CoA, or ATP/ADP ratio promotes phosphorylation of the 
[240] 
pyruvate dehydrogenase complex. This prevents the conversion of pyruvate to acetyl-CoA, 
therefore inhibiting entry into the TCA cycle. Additionally, although the TCA cycle is primarily 
regulated by ATP and NADH concentrations, succinyl-CoA regulates the enzyme α-ketoglutarate 
dehydrogenase, which is one of the other control points of this metabolic process (reviewed in 
Berg, Tymoczko, & Stryer, 2002). Thus, when energy charge is high and biosynthetic 
intermediates acetyl-CoA and succinyl-CoA are in excess, entry and progression through the TCA 
cycle is inhibited (pink negative sign, Figure 7.1). By contrast, in low energy charge states when 
ADP is high, key enzymes regulating the TCA cycle are activated (green positive sign, Figure 7.1).  
 
When the TCA cycle control checkpoints described above and shown in Figure 7.1, were compared 
to the in vitro gel-based assay results in Chapter 5, similarities were observed. More specifically, 
key metabolites involved in the TCA cycle entry and progression also affect the degradation 
activity of PNPase. For example the metabolites ATP and citrate, known to inhibit EcPNPase 
activity (Del Favero et al., 2008; Nurmohamed et al., 2011) (Figure 7.1, orange bolts) and the 
metabolites citrate, acetyl-CoA and succinyl-CoA, found within this study to affect both EcPNPase 
and hPNPase activity (Figure 7.1, yellow bolts); all have regulatory roles in the TCA cycle.  
 
 
Figure 7.1 Control Points and Metabolites Regulating The TCA Cycle  
The TCA cycle is primarily regulated by the concentration of ATP and NADH; high cellular concentrations 
prevent entry and regulation through the cycle (pink, negative sign). High cellular levels of acetyl-CoA also 
reduce entry into the TCA cycle. The key control points are the enzymes isocitrate dehydrogenase and α-
ketoglutarate dehydrogenase. High cellular levels of ADP stimulate isocitrate dehydrogenase, whereas 
succinyl-CoA prevents the activity of α-ketoglutarate dehydrogenase; positively and negatively regulating the 
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metabolic pathway respectively. The orange coloured bolts highlight known inhibitors of PNPase activity in 
E. coli (Del Favero et al., 2008). Whereas the yellow bolts indicate metabolites which were found in this 
study, to affect both EcPNPase and hPNPase degradation activity in vitro. Figure and legend adapted from 
(Berg et al., 2002). 
 
As highlighted in Figure 7.1, the TCA cycle involves a number of metabolites and research 
previously conducted by Huynen, Dandekar, & Bork, 1999 has demonstrated that TCA evolution, 
across all three domains of life, is incredibly complex. Recent publications have highlighted that 
progress still needs to be made to elucidate the nature of this cycle in some organisms. For 
example, it was commonly thought that the TCA cycle was incomplete in cyanobacteria, because 
the enzyme 2-oxoglutarate dehydrogenase was absent. This misunderstanding was overturned 
when a study discovered that two alternative enzymes could complete the cycle and as a result a 
decades-old belief was discarded (Steinhauser, Fernie, & Araújo, 2012).  
 
There has been some controversy over the completeness of the TCA cycle in archaeal species. 
Nevertheless, whether like EcPNPase and hPNPase, archaeal exosome homologs are affected by 
TCA metabolites needs to be determined. It would interesting to compare the effects of metabolite 
based PNPase inhibition between the archaeal exosomes from S. solfataricus and 
Methanothermobacter thermautotrophicus, since they represent species with a proposed complete 
and incomplete TCA cycle respectively (Huynen et al., 1999). Furthermore, these species provide 
an excellent example for investigating archaeal exosome evolution since they represent members of 
the Euryarchaeota and Crenarchaeota phyla respectively. The structure of SsoExosome (Lorentzen 
& Conti, 2012) and M. thermautotrophicus exosome are both available (Ng, Waterman, Antson, & 
Ortiz-Lombardia, 2010), therefore similar in silico studies conducted within this work could be 
undertaken to predict metabolite interactions. Despite the diversity of the TCA pathway within 
archaea, any information gained from comparative studies may provide insight into whether TCA 
metabolites commonly modulate exosome activity. The question of whether a widely conserved 
communicative link exists between TCA metabolites and PNPase homologs, may then be 
addressed.  
 
7.1.3 Interactions Between Phosphate-Rich Metabolites and 3’-5’ 
Phosphorolytic Ribonucleases   
The TCA metabolite-PNPase interaction study described here highlighted some other interesting 
avenues to investigate further. It was noticed that the CoA nucleotide part of acetyl-CoA and 
succinyl-CoA were predicted to interact with known, highly-conserved, citrate-binding residues 
within the catalytic centre and the neighbouring RNA-binding regions of hPNPase in silico. Thus, 
it was proposed that the nucleotide CoA group potentially binds and occludes the active site in a 
similar way to citrate, suggesting a potential phosphate recognition role, that may be widely 
conserved across PNPase homologs. The proposed interaction between CoA with PNPase 
homologs was very interesting because, as reviewed in Tahiliani & Beinlich, 1991, altered CoA 
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metabolism has been observed in diverse disease states including starvation, diabetes, vitamin B12 
deficiency and certain tumours; signifying its importance in a wide range of biological systems.  
 
The prediction that the nucleotide part of CoA may be important for regulating PNPase, directed 
the study to examine other nucleoside/nucleotide containing metabolites that may affect activity. 
Following more in silico docking calculations and in vitro gel-based assays, phosphate-rich 
nucleotides including GTP, ppppG and ppGpp were shown to affect the 3’-5’ degradation activity 
of hPNPase and EcPNPase in vitro. When comparing the levels of inhibition between PNPase 
homologs, despite the sequence and structural similarities of the binding pockets in the presence of 
phosphate-rich metabolites, attenuation of hPNPase activity was greater than EcPNPase. This 
aligned with previous research that suggested hPNPase was more sensitive to cellular phosphate 
levels than EcPNPase, and was actually inhibited by high phosphate concentrations (Portnoy, 
Palnizky, Yehudai-Resheff, Glaser, & Schuster, 2007). How hPNPase can ‘sense’ higher phosphate 
levels is currently unknown. In order to determine whether subtle differences in the architecture of 
the binding pockets may exist/facilitate these phosphate-binding preferences, the exact residues of 
hPNPase involved and their types of interactions with phosphate-rich metabolites need to be 
compared with EcPNPase.  
 
The observation that GTP inhibited both hPNPase and EcPNPase was unsurprising since this 
energy-containing molecule has been previously implicated in regulating EcPNPase activity (Del 
Favero et al., 2008). However, the finding that ppGpp inhibited the activity of EcPNPase was 
interesting as it conflicted with previous publications suggesting that the alarmone affected PNPase 
activity in Streptomyces but not in E. coli  (Gatewood & Jones, 2010). As mentioned in Chapter 5, 
this conflicting data may have been a result of different assay conditions, and so the effect of this 
alarmone in E. coli needs to be examined further. This is especially important as (p)ppGpp has 
been shown to regulate a wide range of cellular processes. More specifically, upon exposure to 
stresses including heat shock and nutrient deprivation, the cellular concentration of (p)ppGpp 
increases and many important processes are reprogrammed. These processes include DNA 
replication, transcription and quorum sensing; collectively these modifications are referred to as the 
stringent response (reviewed in Dalebroux, Svensson, Gaynor, & Swanson, 2010; Hauryliuk, 
Atkinson, Murakami, Tenson, & Gerdes, 2015). (p)ppGpp has also been linked to bacterial 
persistence and antibiotic production in response to amino acid/energy starvation (Hauryliuk et al., 
2015). The interaction between (p)ppGpp and bacterial PNPase homologs are important to study as 
it may suggest a potential link between environmental sensing and RNA turnover. 
 
As shown in Figure 7.2, the RelA-SpoT homologue (RSH) family are key for both synthesis and/or 
degradation of (p)ppGpp. Although long multi-domain RSH enzymes have not yet been identified 
in humans (Dalebroux et al., 2010), a small alarmone hydrolases (SAH), which is a short, single-
domain, mono-functional RSH, has been identified in humans and Drosophila melanogaster 
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(termed Mesh1) (D. Sun et al., 2010). In this study, a D. melanogaster Mesh1 null mutant showed 
retarded body growth and impaired starvation response, suggesting that this enzyme may function 
in a similar manner to RSH enzymes. The publication also noted that Mesh1 has diverged greatly 
from SpoT during the evolution of animals and therefore it is possible that other enzymes have 
evolved to function as ppGpp synthetase (D. Sun et al., 2010). However, given the absence of 
detectable (p)ppGpp levels in animals (Thammana, Buerk, & Gordon, 1976), the role of Mesh1 is 
currently unknown. Therefore, more research is required before a physiological relevance of the 
ppGpp-mediated attenuation of hPNPase activity can be deduced.  
 
 
Figure 7.2 (p)ppGpp Metabolism in E. coli 
(a) Guanosine diphosphate (GDP) or guanosine triphosphate (GTP) is converted into guanosine 
tetraphosphate (ppGpp) or guanosine pentaphosphate (pppGpp) respectively (γ-phosphate moiety of GTP and 
pppGpp highlighted in red). The addition of pyrophosphate from adenosine triphosphate (ATP) to the 3’OH 
of GDP/GTP is catalysed by RelA-SpoT homolog proteins (RSH) and adenosine monophosphate (AMP) is 
released as a by-product. (b) (p)ppGpp metabolism, as described in (a) ATP is used by RSH proteins RelA 
and SpoT to generate (p)ppGpp from GDP/GTP releasing AMP as a product. In addition, the conversion of 
pppGpp to ppGpp by (p)ppGpp phosphatase (GppA) and GTPases, releasing inorganic phosphate (Pi). SpoT 
catalyses the conversion of (p)ppGpp to GDP/GTP (solid line) and ppGpp to GDP (dotted line) releasing 
pyrophosphate (PPi) in the process. GDP can be further converted to GTP by nucleoside diphosphate kinase 
(Ndk) and nucleoside triphosphates (NTP), resulting in nucleoside diphosphate (NDP) production. Image 
taken directly from (Hauryliuk et al., 2015). 
 
The list of metabolites which may affect the activity of PNPase homologs is clearly expanding and 
this study proposes that this may represent an ancient and evolutionarily conserved communicative 
link between central metabolism and RNA turnover. Although many conclusions can be made from 
this work and the potential physiological meaning of these findings can be discussed, more 
research is required before a comprehensive understanding of how metabolites potentially regulate 
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RNA turnover can be acquired. The use of in silico molecular docking calculations and a novel in 
vitro high-throughput plate reader assays, for predicting metabolite-PNPase interactions and 
quantifying the 3’-5’ degradation activity of PNPase homologs respectively, were validated within 
this work. The following Section 7.2 discusses how combining these in silico and in vitro 
techniques may facilitate the discovery of novel metabolite-RNase interactions. 
 
7.2 Future Perspectives 
7.2.1 Discovering Novel Metabolite-RNase Interactions 
A large range of metabolites and different PNPase homologs are known to exist across prokaryotic, 
eukaryotic and archaeal organisms. A more efficient method of predicting metabolites which may 
bind PNPase homologs and then quantifying the metabolites’ effect on 3’-5’ degradation activity is 
required to understand the regulatory interactions involved. It is possible that a similar method, of 
high-throughput in silico and in vitro screening of ligand-receptor interactions, that is routinely 
employed in drug discovery, could be applied for addressing this issue (reviewed in Hughes, Rees, 
Kalindjian, & Philpott, 2011). More specifically, by using the molecular docking program MOE a 
larger range of metabolites could be screened for binding to PNPase homologs in silico (Molecular 
Operating Environment, 2013). Additionally, by utilising the high-throughput fluorescence-based 
plate reader assay (BellBrook, n.d.), any potential interactions could be investigated further in vitro.  
 
The method described above for discovering novel metabolite-PNPase interactions using a plate 
reader, provides a significant advantage to the currently available gel-based assays since detailed 
kinetic information can be acquired in real-time. Moreover, although the assay was developed for a 
96-well format, this could be further expanded to a 384-well format, thus allowing a wide range of 
metabolite-PNPase homolog interactions to be studied. An ADP standard curve can be conducted 
for each assay, and rather than reporting RFU changes, the degradation of RNA by PNPase 
homologs could be quantified in terms of the concentration of ADP release. The plate reader assay 
has been validated for determining important kinetic information, the effects of metabolites on 
PNPase homologs could be tested by titrating a range of inhibitor concentrations and IC50 values 
(i.e. the concentration of inhibitor which reduces the response of the enzyme by a half) could be 
determined. Alternatively, more detailed kinetic parameters of canonical enzyme activity including 
Km, Vmax kcat and catalytic efficiency, could be compared to those obtained in the presence of an 
inhibitor.  
 
Another great advantage of this particular real-time assay is the option to use a wide range of 
unlabelled and physiologically relevant RNA substrates. If the RNA substrate sequence is known to 
contain adenosines and ADP is released upon degradation, it should be suitable for use within this 
assay. This would allow the option for testing a range of physiologically relative PNPase or 
archaeal exosome RNA substrates.  
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The assay could also be used to screen protein mutants, possibly identifying amino acid mutations 
essential for activity. Alternatively, other 3’-5’ RNases, such as RNase PH, could be examined. 
The effect of 3’-5’ RNases acting independently or as part of a multi-protein complex may also be 
compared. For example, the activity of PNPase or PNPase as part of the degradosome in E. coli 
could be examined.  
 
In summary, the methods used within this PhD study could be applied to investigate a wide range 
of metabolite-RNase interactions. This may help improve our understanding of how RNA turnover 
is regulated in evolutionarily distinct organisms.  
 
7.2.2 Examining Metabolite-RNase Interactions In Vivo 
Although this study describes a wide range of in silico and in vitro data which supports the 
proposed communicative link between metabolism and RNA turnover, this needs to be further 
validated in vivo. 
 
In terms of investigating the interactions of key metabolites with PNPase in bacteria, a number of 
E. coli cell strains are available and have been successfully used to examine the effect of 
intracellular citrate concentrations on PNPase activity (Nurmohamed et al., 2011). The effect of 
other metabolites on PNPase activity could be established by applying a similar approach. More 
specifically, in the presence of a metabolite, the growth of a (RNase II-/R-) mutant strain, which is 
known to be dependent on PNPase for viability (Cheng & Deutscher, 2003; Donovan & Kushner, 
1986), could be compared to a wild-type strain. Furthermore, using these strains, the effects of 
metabolites on the cellular transcript levels could then be studied using RT-PCR and/or microarray, 
as described in Nurmohamed et al., 2011, or RNA-sequencing could be utilised. In the microarray 
analysis conducted by Nurmohamed and colleagues, a PNPase-mediated response to citrate was 
revealed by comparing a PNPase null mutant +/- citrate, against a WT strain +/- citrate. Genes 
generally affected by PNPase and those displaying a PNPase-mediated response to citrate were 
then compared. The results suggested that the PNPase-mediated citrate response broadly affected 
genes involved in cellular metabolic processes including cellular amino acid and derivative 
metabolic processes, and cellular biosynthetic and organic acid metabolic processes (Nurmohamed 
et al., 2011). The effects of citrate on specific mRNA transcripts, including cirA and fkpA, known 
to be regulated by PNPase, was also investigated using RT-PCR. Collectively, results from RT-
PCR and microarray analysis showed that not only were specific transcripts affected in a PNPase-
dependent response to citrate, but RNA metabolism was also broadly altered in vivo (Nurmohamed 
et al., 2011). Using similar experimental and analysis methods, the levels of transcripts affected in 
a PNPase-dependent response to other metabolites, could be investigated. More specifically, 
bacterial cell strains could be grown in the presence of metabolites such as acetyl-CoA, succinyl-
CoA and (p)ppGpp, alternatively the intracellular levels of a particular metabolite could be 
modified by artificially blocking or activating the enzymes involved in their synthesis and break-
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down. Transcriptomic and bacterial growth studies could then be applied to study the effect of 
individual metabolites on PNPase-mediated RNA regulation.  
 
In the study conducted by Nurmohamed and colleagues, PNPase has already been shown to affect 
cellular metabolism by using 1H NMR spectroscopy and gas chromatography mass spectrometry. 
Many metabolites were affected by PNPase loss, when comparing the null strain with the WT 
(Nurmohamed et al., 2011). Whether these same metabolites are affected by metabolite-mediated 
inhibition of PNPase activity, could be examined using similar techniques. This may shed light on 
whether metabolite levels can affect PNPase-mediated RNA turnover in vivo in a feedback loop. 
 
In terms of investigating the interactions of key metabolites with PNPase in higher organisms, a 
number of methods are available for extracting mitochondria from human cell lines and studying 
their function in isolation (Azimzadeh, Aghdaei, Tarban, & Akhondi, 2016; Lanza & Sreekumaran 
Nair, 2009). Whether TCA metabolites can effect PNPase activity and thus mitochondrial RNA 
levels needs to be determined and would be an interesting area to study. It is known that metabolic 
flux can be modified using blockers and as mentioned previously, RNA levels could be examined 
using RNA-sequencing. For example, a previous study added the blocker maleate to isolated rat 
heart mitochondria since it can convert CoA into a stable thioester which is metabolically inert 
(Pacanis, Strzelecki, & Rogulski, 1981). This rapidly reduced the CoA levels and a range of 
biological systems were found to be effected. For example, the oxidation of CoA-dependent 
substrates (i.e. α-ketoglutarate and pyruvate), oxygen uptake and oxidative phosphorylation were 
all inhibited (Pacanis et al., 1981; Tahiliani & Beinlich, 1991). Potentially, a similar technique 
could be applied to investigate the effect of cellular metabolic fluxes on transcript levels in wild-
type and PNPase mutant cell lines. 
 
Whether metabolites effect PNPase activity in vivo also need to be explored in higher model 
organisms. Since the early development of Xenopus embryos can be studied, it would be interesting 
to examine whether PNPase has a role within these early stages. Preliminary experiments, using a 
cross-reacting hPNPase antibody, suggested that the PNPase protein was present in the early stages 
of Xenopus laevis development and was also expressed maternally in the fertilised egg (data not 
shown). In order to determine whether PNPase is essential for embryo development, knock out 
studies could be conducted and the physiological effect on growth could be monitored. The first 
step could involve using antisense morpholino oligonucleotides to determine whether the mRNA 
can be depleted in the oocyte (as reviewed in Hulstrand, Schneider, & Houston, 2011). If 
unsuccessful, more drastic measures involving genome editing in the parent could be conducted (as 
reviewed in Tandon, Conlon, Furlow, & Horb, 2016). During these studies, if PNPase is non-
essential and embryos survive, then transcriptomics may be utilised to compare RNA levels in 
wild-type and PNPase KO strains, in the presence and absence of a metabolite; the levels of which 
could be manipulated by microinjection. This could identify a PNPase-dependent response to a 
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particular metabolite and reveal whether specific mRNA substrates are differentially 
regulated/stabilised in vivo as a result. 
 
The in vivo research proposed above requires a significant amount of work and unfortunately was 
not possible during the duration of this PhD, but could be the focus of following work.  
 
7.3 Summary 
In summary, the data provided within this thesis are of importance to the field of post-
transcriptional gene regulation research. A greater understanding of the intricate network of 
interactions occurring in cells is invaluable for developing novel medical and biotechnological 
applications. The in silico and in vitro work conducted requires validation in vivo and the effect of 
metabolites on other RNases and multi-protein RNA degrading machines remains to be discovered. 
Nevertheless, the study presented here supports the existence of an ancient and evolutionarily 
conserved interaction between key metabolites and the enzymes involved in regulating RNA 
turnover. Furthermore, development of a real-time, high-throughput assay could help determine, in 
more detail, the effect of potential PNPase inhibitors investigated within this thesis and previously 
suggested in the literature. As 3’-5’ RNases could be studied more efficiently than gel-based assays 
using this method, this would be beneficial to the RNA field. The plate reader assay may also 
facilitate the screening of small molecules with metabolite-RNase interactions for potential medical 
and/or biotechnological applications.  
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9 Appendix 
 
9.1 Certificate of Ethics Review 
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9.2 Gel Electrophoresis Ladders 
 
Figure 9.1 100 bp DNA Ladder 
100 Base pair (bp) DNA ladder is a set of 12 DNA molecules which provide markers in the range 100 – 
1,517 bp. Ladder sizes (bp) and mass (ng) are indicated and the increased intensity of the 500 b and 1, 000 
bands serve as reference bands. (Information provided by NEB N3231S). 
(https://www.neb.com/products/n3231-100-bp-dna-ladder) 
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Figure 9.2 Low Molecular Weight (LMW) DNA Ladder  
Low molecular weight DNA ladder is a set of 11 DNA molecules which provide markers in the range 25 – 
766 base pairs (bp). Ladder sizes (bp) and mass (ng) are indicated and the increased intensity of the 200 bp 
band serves as a reference band. (Information provided by NEB N3233S).  
(https://www.neb.com/products/n3233-low-molecular-weight-dna-ladder) 
 
 
Figure 9.3 Low Range ssRNA Ladder 
Low range single stranded (ss) RNA ladder is a set of 6 RNA molecules which provide markers in the range 
50 – 1,000 bases. Ladder sizes are indicated and the doubled intensity of the 300 bases band serves as a 
reference band. (Information provided by NEB N0364S). (https://www.neb.com/products/n0364-low-range-
ssrna-ladder) 
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Figure 9.4 SeeBlue® Pre-Stained Standard Protein Molecular Weight Ladder 
The SeeBlue® Pre-Stained Standard is a set of 9 polypeptides that resolve into sharp, tight blue bands in the 
range of 4–250 kDa which can be used for various SDS-PAGE systems as molecular weight size markers 
(approximate MW depending upon the buffer system). Information provided by Thermo Fisher (LC5625) 
(https://www.thermofisher.com/order/catalog/product/LC5625) 
 
 
Figure 9.5 SeeBlue® Plus2 Pre-Stained Standard Protein Molecular Weight Ladder 
The SeeBlue® Plus2 Pre-Stained Standard is a set of 10 polypeptides that resolve into sharp, tight bands; 8 
blue and 2 contrasting coloured bands in the range of 4–250 kDa which can be used for various SDS-PAGE 
systems as molecular weight size markers (approximate MW depending upon the buffer system). Information 
provided by Thermo Fisher (LC5925) (https://www.thermofisher.com/order/catalog/product/LC5925). 
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Figure 9.6 BenchMark™ Standard Protein Ladder 
The BenchMark™ Standard Protein Ladder is a set of 15 recombinant H6-proteins that resolve into sharp, 
tight blue bands in the range of 10–220 kDa which can be used for various SDS-PAGE systems as molecular 
weight size markers. Ladder sizes are indicated and the increased intensity of the 20 and 50 kDa bands serve 
as reference points. (approximate MW depending upon the buffer system). Information provided by Thermo 
Fisher (10747-012) (https://www.thermofisher.com/order/catalog/product/10747012). 
 
9.3 Primer Sequences 
All primer sequences utilised for site directed mutagenesis and DNA sequencing are listed.  
 
9.3.1 Mutagenesis Primers 
E. coli Core 
Sense: 5'-cgatgcttaccgcatcaccgacaaacaagagcg-3' 
Anti-Sense: 5'-cgctcttgtttgtcggtgatgcggtaagcatcg-3' 
 
E. coli Full length and vestigial mutant (remove additional Valine)  
Sense: 5'-ctttaagaaggagatataccatgcttaatccgatcgttcgtaaatt-3' 
Anti-Sense: 5'-aatttacgaacgatcggattaagcatggtatatctccttcttaaag-3' 
 
E. coli vestigial mutant (Change T->A, ACT->GCT)  
Sense: 5'-caacgctgggtactgctcgtgacgcgcag-3' 
Anti-Sense: 5'-ctgcgcgtcacgagcagtacccagcgttg-3' 
 
E. coli vestigial mutant (Change C->R, TGT->CGT)  
Sense: 5'-ggcaggcgaaccgcgtatcgacggtcg-3' 
[265] 
Anti-Sense: 5'-cgaccgtcgatacgcggttcgcctgcc-3' 
 
E. coli Full length (Change G->A) 
Use E. coli vestigial mutant (Change T->A, ACT->GCT) primers  
 
E. coli Full length (Change P->A) 
Sense: 5'-ggtactggtcgtgacgcgcaggttcttgatg-3'  
Anti-Sense: 5'-catcaagaacctgcgcgtcacgaccagtacc-3' 
 
9.3.2 Sequencing Primers  
Source Bioscience Stock Primers  
Forward primer pET upstream: 5'-atgcgtccggcgtaga-3   
Reverse primer Duet Down 1: 5’-gattatgcggccgtgtacaa-3’ 
The sequence coverage was low using these primers so designed new primers were designed for 
sequencing the start and middle of the PNPase sequence: 
 
For sequencing the start of the E. coli PNPase gene inserted between the Nco1 and Not1 
restriction sites of the pETDuet-1 vector MCS1 
Forward primer:  5’-ccgatcgttcgtaaattcca-3’  
Reverse primer: 5’-cgcttactcgccctgttcag-3’ 
 
For sequencing the middle region of the E. coli PNPase gene inserted between the Nco1 and 
Not1 restriction sites of the pETDuet-1 vector MCS1 
Forward primer: 5’-cgtactcacggttctgcgct-3’ 
Reverse primer: 5’-cggagggaagttgtagtgga-3’ 
 
9.4 Cell Strain Genotypes 
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Figure 9.7 E. coli Cell Strain Genotype.  
Information provided within this table was adapted from (“E. coli genotypes,” 2015) in Excel.  
Effects of Mutation
F-  Deletion Fertility (F) plasmid Preventing homologous recombination into bacterial chromosomes
ompT Mutation in outer membrane protein protease VII Reducing proteolysis of expressed proteins
gal Deficient in galactose metabolism Blocks galactose utilization
dcm
DNA cytosine methylase mutation; methylation at second C of 
CCWGG sites exist (where W= Aor T) Makes DNA susceptible to cleavage by certain restriction enzymes
lon deletion of the lon Serine protease Reducing proteolysis of expressed proteins
hsdSB(rB-mB-)
Host DNA restriction modification system mutation; E.coli B strain, 
minus restriction system (inactivation of EcoK1 endonuclease), minus 
methylation system (r- m-)
Mutations allow E. coli to recognize DNA as foreign,  eliminating restriction of unmethylated EcoK I 
sites of foreign DNA, thus allowing efficient transformation
λDE3 Lysogen that encodes T7 RNA polymerase. Used to induce protein expression of sequences under T7 RNA polymerase promoter 
pLysS
Includes pLysS plasmid carrying chloramphenicol resistance and phage 
T7 lysozyme
 T7 lysozyme inhibits activity of T7 RNA polymerase, lowering basal protein expression of sequences 
under T7 RNA polymerase promoter 
cmR Chloramphenicol antibiotic resistance a selection marker of pLysS plasmid
F-  Deletion Fertility (F) plasmid Preventing homologous recombination into bacterial chromosomes.
Φ80lacZΔM15
Element required for β-galactosidase complementation when plated on 
X-gal; carried on the lambdoid prophage φ80 Allows blue/white screening of recombinants for use as a reporter marker
Δ(lacZYA-argF)U169 Ornithine carbamoyltransferase mutation Ability to use arginine blocked and resistance to high levels of hydrogen peroxide increased
recA1 
Mutation in a gene responsible for general repair and recombination of 
DNA Prevents repair of cloned genes with direct repeats
endA1 Mutation in the non-specific Endonuclease AI Eliminates non-specific endonuclease activity, resulting in improved plasmid preps 
hsdR17 (rK–, mK+)
Host DNA restriction modification system mutation; E.coli K strain, 
minus restriction system (inactivation of EcoK1 endonuclease), with 
active methylation system (r- m+)
Mutations allow E. coli to recognize DNA as foreign,  eliminating restriction of unmethylated EcoK I 
sites of foreign DNA, thus allowing efficient transformation
phoA Mutation in alkaline phosphatase Blocks phosphate utilization; used for PhoA-based reporter systems
supE44 Glutamine tRNA mutation (glutamine anticodon GUC -> AUC) 
Supresses the nonsense mutation (insertion of a stop codon) UAG (Amber), which would otherwise 
stop translation. 
λ-thi-1 Mutation in thiamine metabolism Mutants require thiamine for growth in minimal media
gyrA96 DNA gyrase mutant  Produces resistance to nalidixic acid 
relA1 Relaxed phenotype, ppGpp synthetase I mutation.
ppGpp synthetase can detect uncharged tRNA (sign of amino acid starvation), deletion allows RNA 
synthesis in absence of protein synthesis. Changes in membrane composition increases fragility with 
respect to sonication and osmotic shock, whilst preventing protein leakage thus aiding purification
E. coli  BL21(DE3)pLysS (F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pLysS(cmR)) 
E. coli  DH5α (F– Φ80lac ZΔM15 Δ(lac ZYA-arg F) U169 rec A1 end A1 hsd R17 (rK–, mK+) pho A sup E44 λ– thi -1 gyr A96 rel A1) 
Description
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9.5 Vector Maps 
The DNA vectors used for recombinant DNA plasmids cloning are provided as vector maps within 
this section and as DNA sequences in Appendix 9.6. 
 
 
Figure 9.8 pET-28a-c (+) Vector Map 
A schematic of the Pet-28a-c (+) vector map is shown, important restriction enzyme sites are indicated and 
labelled with their positions. The sequence is numbered so that the T7 expression region is reversed on the 
circular map. 
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Figure 9.9 pETMCN-EAVNH Vector Map 
A schematic of the pETMCN-EAVNH vector map is shown, important restriction enzyme sites are indicated 
and labelled with their positions.  
 
 
Figure 9.10 pETDuet-1 Vector Map 
A schematic of the pETDuet-1 vector map is shown, important restriction enzyme sites are indicated and 
labelled with their positions.  
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9.6 Gene Cloning Strategy 
9.6.1 Vector Sequence: pET-28b (+) (Reverse Complement) 
 (5368 base pairs) Sequence from: http://www.addgene.org 
 
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTAC
GCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCC
CTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCT
TTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTG
ATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAG
TCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTC
GGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATG
AGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCA
GGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACA
TTCAAATATGTATCCGCTCATGAATTAATTCTTAGAAAAACTCATCGAGCATCAAATG
AAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCT
GTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATC
GGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAA
ATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGC
AAAAGTTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATC
AAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGA
AATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGC
AGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATA
CCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGT
ACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTG
ACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTC
TGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTAT
CGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCT
AGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGT
AAGCAGACAGTTTTATTGTTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTG
AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGC
GTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGG
ATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACC
AAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCA
CCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAA
GTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCG
GGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAA
CTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAG
GCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTT
CCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGA
[270] 
GCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAAC
GCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCG
TTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCG
CCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCT
GATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCAC
TCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCT
ACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGA
CGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCT
GCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAAAG
CTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCT
CGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAG
GGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGG
GGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATG
AACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGC
GGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAG
GTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCA
GGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCAT
GTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTAT
CGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAAC
GACAGGAGCACGATCATGCGCACCCGTGGGGCCGCCATGCCGGCGATAATGGCCTGC
TTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGTGC
AAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCGG
TCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAA
AGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCGCGCCCACCGGAAGGAGC
TGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAGATCCCGGTGCCTAATGAGTGAG
CTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGT
GCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGC
GCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGC
CTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCAGGCGAAA
ATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCGTCGT
ATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCAT
TGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCA
TTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTC
CGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGA
CGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATG
CGACCAGATGCTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTT
GATGGGTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCAGGCAGC
TTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACG
CGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTAC
[271] 
CATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACA
ATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGAC
TGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGC
CGCTTCCACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGG
AAACGGTCTGATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTT
CACATTCACCACCCTGAATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAG
GTTTTGCGCCATTCGATGGTGTCCGGGATCTCGACGCTCTCCCTTATGCGACTCCTGCA
TTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATG
GTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCATAC
CCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGT
GATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCAC
GATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTA
TAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAG
AAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTG
CCGCGCGGCAGCCATATGG/CTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCCG
AATTCGAGCTCCG/TCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACT
GAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG
AGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCT
GAAAGGAGGAACTATATCCGGAT 
 
Key sequences highlighted: T7 Promoter Sequence (Grey-25%), Ribosome Binding Site (RBS) 
(Dark Yellow), Start Codon ATG (Teal), (6x) Histidine-Tag (H6-Tag) (Turquoise), Thrombin 
cleavage site (Bright Green), Restriction site Nhe1 (Red) & cut site (/), Sequence between Nhe1 
and Sall restriction sites to be replaced by gene insert (Grey-50%) and Restriction site Sall (Violet) 
& cut site (/). 
 
9.6.2 Vector Sequence: pET-MCN-EAVNH 
(5766 base pairs) Sequence from 
(http://archive.igbmc.fr/recherche/Sup_papers/Cavarelli/pET-MCN/pET-MCN.html) 
 
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAA
TAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTAT
TTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGAT
AAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGC
CCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGT
GAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGA
 
Nhe1 Restriction cut site (                                            ) 
Sall Restriction cut site (                                            ) 
[272] 
TCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATG
AGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAG
AGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGT
CACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCAT
AACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGG
GAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCA
GCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCC
GGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTC
GGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCT
CGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCT
ACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAG
GTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAG
ATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA
TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAG
AAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAA
ACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTC
TTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGT
GTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTT
GGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTC
GTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCG
TGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGT
AAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCT
GGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGAT
GCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTT
CCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGT
GGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACC
GAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTC
CTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGC
TCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCAT
GGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTC
CCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGT
TTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTC
GTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCA
GAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGT
TTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGAT
GAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACT
GGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAAT
[273] 
CACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGC
CAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCG
TTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGC
AGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCT
AACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCA
TGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGATGCGCCGCGTGCGGCTGCTGGA
GATGGCGGACGCGATGGATATGTTCTGCCAAGGGTTGGTTTGCGCATTCACAGTTCTC
CGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATCCGTTAGCGAGGTGCCGCC
GGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGCGGGGAG
GCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTTCCATGTGCTCGCC
GAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAGTGATCGAAGTTAGGCTGGTA
AGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCATCTACCTGCCTGGACA
GCATGGCCTGCAACGCGGGCATCCCGATGCCGCCGGAAGCGAGAAGAATCATAATGG
GGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTCGG
CCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGT
GACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGAT
CATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGC
ACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCA
TGCCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCG
AGATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCC
GCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGG
GGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGG
GCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCAC
GCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAA
CATGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCA
GCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAG
CATCGCAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGAC
ATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATA
TTTATGCCAGCCAGCCAGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAA
CAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCCCAGTCGCGTACCG
TCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAATA
ACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGG
ATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTA
CAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTGAT
CGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGG
AGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTT
GGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTTTCCCGCGTTTTCGCAGAAA
CGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCGGCATACTC
TGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCTCTTCCG
[274] 
GGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGGATCTC
GACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCC
GTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCC
CCCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAA
GTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCA
CCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGA
TCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCA
CTAGTAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCAT
CATCATCATCACAGCAGCGGTACCGGCAGCGGCGAAAACCTTTACTTCCAGGGCCATA
TGCTCGAGCTTAAGCAATTGGGATCCTAATAGTCTAGAGCTAGCCCTAGGAGATCCGG
CTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACT
AGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGA
ACTATATCCGGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAAGCCTATGCC
TACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATA
CACGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTAT
CGATGATAAGCTGTCAAACATGAGAA 
 
Key sequences highlighted: T7 Promoter Sequence (Grey-25%), Ribosome Binding Site (RBS) 
(Dark Yellow), Start Codon ATG (Teal), (6x) Histidine-Tag (H6-Tag) (Turquoise), TEV cleavage 
site (Bright Green), Restriction site Nde1 (Green) & cut site (/), Sequence between Nde1 and Xba1 
restriction sites to be replaced by gene insert (Grey-50%) and Restriction site Xba1 (Pink) & cut 
site (/).  
 
9.6.3 Homo sapiens Polynucleotide Phosphorylase (hPNPase) 
9.6.3.1 Amino Acid Sequence: hPNPase 
 Homo sapiens Polynucleotide Phosphorylase (hPNPase) (Gene: PNPT1_HUMAN, GenBank: 
BC053660.1 UniProt: Q8TCS8) amino acid sequence. Web Resources:  
(http://www.ncbi.nlm.nih.gov/nucleotide/31657165) 
(http://www.uniprot.org/uniprot/Q8TCS8) 
The actual sequence inserted into pET-28b Vector (using I natural variant from UniProt Q8TCS8 
sequence and not the V natural variant present in the PDB 3U1K) did not include 5’ mitochondrial 
peptide signal (Yellow): 
 
MAACRYCCSCLRLRPLSDGPFLLPRRDRALTQLQVRALWSSAGSRAVAVDLGNRKLEISS
GKLARFADGSAVVQSGDTAVMVTAVSKTKPSPSQFMPLVVDYRQKAAAAGRIPTNYLRR
 
Nde1 Restriction cut site     (                                         ) 
Xbal Restriction cut site      (                                         ) 
[275] 
EIGTSDKEILTSRIIDRSIRPLFPAGYFYDTQVLCNLLAVDGVNEPDVLAINGASVALSLSDIP
WNGPVGAVRIGIIDGEYVVNPTRKEMSSSTLNLVVAGAPKSQIVMLEASAENILQQDFCHA
IKVGVKYTQQIIQGIQQLVKETGVTKRTPQKLFTPSPEIVKYTHKLAMERLYAVFTDYEHD
KVSRDEAVNKIRLDTEEQLKEKFPEADPYEIIESFNVVAKEVFRSIVLNEYKRCDGRDLTSL
RNVSCEVDMFKTLHGSALFQRGQTQVLCTVTFDSLESGIKSDQVITAINGIKDKNFMLHYE
FPPYATNEIGKVTGLNRRELGHGALAEKALYPVIPRDFPFTIRVTSEVLESNGSSSMASACG
GSLALMDSGVPISSAVAGVAIGLVTKTDPEKGEIEDYRLLTDILGIEDYNGDMDFKIAGTN
KGITALQADIKLPGIPIKIVMEAIQQASVAKKEILQIMNKTISKPRASRKENGPVVETVQVPL
SKRAKFVGPGGYNLKKLQAETGVTISQVDEETFSVFAPTPSAMHEARDFITEICKDDQEQQ
LEFGAVYTATITEIRDTGVMVKLYPNMTAVLLHNTQLDQRKIKHPTALGLEVGQEIQVKY
FGRDPADGRMRLSRKVLQSPATTVVRTLNDRSSIVMGEPISQSSSNSQ 
 
9.6.3.2 pET-28b [hPNPase] Transcript 
Transcribed sequence from pET28-b (+) with hPNPase coding nucleotide sequence (Orange) 
ligated between Nhe1 and Sall restriction sites. (Sequence transcribed from start codon ATG (Teal) 
to stop codon TAA (Blue). 
 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCC
ATATGGCTAGCGCAGTTGCAGTTGATCTGGGTAATCGTAAACTGGAAATTAGCAGCGG
TAAACTGGCACGTTTTGCAGATGGTAGCGCAGTGGTTCAGAGCGGTGATACCGCAGTT
ATGGTTACCGCAGTGAGCAAAACCAAACCGAGCCCGAGCCAGTTTATGCCGCTGGTTG
TTGATTATCGTCAGAAAGCAGCAGCAGCCGGTCGTATTCCGACCAATTATCTGCGTCG
TGAAGTTGGCACCAGCGATAAAGAAATTCTGACCAGCCGTATTATTGATCGTAGCATT
CGTCCGCTGTTTCCGGCAGGTTATTTCTATGATACCCAGGTTCTGTGTAATCTGCTGGC
AGTTGATGGTGTTAATGAACCGGATGTTCTGGCAATTAATGGTGCAAGCGTTGCACTG
AGCCTGAGCGATATTCCGTGGAATGGTCCGGTTGGTGCAGTTCGTATTGGCATTATTGA
TGGTGAATATGTTGTTAACCCGACCCGTAAAGAAATGAGCAGCAGTACCCTGAATCTG
GTGGTTGCGGGTGCACCGAAAAGCCAGATTGTTATGCTGGAAGCAAGCGCAGAAAAC
ATTCTGCAGCAGGATTTTTGTCATGCCATTAAAGTGGGTGTGAAATATACCCAGCAGA
TCATTCAGGGCATTCAGCAGCTGGTTAAAGAAACCGGTGTTACCAAACGTACACCGCA
GAAACTGTTTACCCCGAGTCCGGAAATTGTTAAATACACCCACAAACTGGCAATGGAA
CGTCTGTATGCAGTTTTTACCGATTATGAGCATGATAAAGTGAGCCGTGATGAAGCCG
TTAACAAAATTCGTCTGGATACCGAAGAACAGCTGAAAGAAAAATTTCCTGAAGCCG
ATCCGTATGAAATCATCGAAAGCTTTAATGTGGTTGCCAAAGAAGTGTTTCGCAGCAT
TGTTCTGAATGAGTATAAACGTTGTGATGGTCGTGATCTGACCAGTCTGCGTAATGTTA
GCTGTGAAGTGGATATGTTTAAAACCCTGCATGGTAGTGCACTGTTTCAGCGTGGTCA
GACACAGGTGCTGTGTACCGTTACCTTTGATAGCCTGGAAAGCGGTATTAAAAGCGAT
CAGGTTATTACCGCCATTAACGGCATCAAAGACAAAAACTTTATGCTGCACTATGAGT
TTCCGCCTTATGCCACCAATGAAATTGGTAAAGTTACCGGTCTGAATCGTCGTGAACT
[276] 
GGGTCATGGTGCACTGGCAGAAAAAGCACTGTATCCGGTTATTCCGCGTGATTTTCCG
TTTACCATTCGTGTTACCAGCGAAGTTCTGGAAAGCAATGGTAGCAGCTCAATGGCAA
GCGCATGTGGTGGTAGCCTGGCACTGATGGATAGCGGTGTTCCGATTAGCAGTGCAGT
TGCCGGTGTTGCAATTGGTCTGGTTACCAAAACCGATCCGGAAAAAGGTGAAATTGAA
GATTATCGCCTGCTGACCGATATTCTGGGTATCGAAGATTATAATGGCGATATGGACTT
TAAAATCGCAGGCACCAATAAAGGTATTACCGCACTGCAGGCAGATATTAAACTGCCT
GGTATTCCGATTAAAATCGTGATGGAAGCAATTCAGCAGGCCAGCGTTGCAAAAAAA
GAAATCCTGCAGATTATGAACAAAACCATCAGCAAACCGCGTGCAAGCCGCAAAGAA
AATGGTCCTGTTGTTGAAACCGTTCAGGTTCCGCTGAGCAAACGTGCAAAATTTGTTG
GTCCGGGTGGTTACAATCTGAAAAAACTGCAGGCCGAAACAGGTGTGACCATTAGCC
AGGTTGATGAAGAAACCTTTAGCGTTTTTGCACCGACCCCGAGCGCAATGCATGAAGC
ACGTGATTTTATCACCGAAATCTGCAAAGATGATCAAGAGCAGCAACTGGAATTTGGT
GCCGTTTATACCGCAACCATTACCGAAATTCGTGATACCGGTGTGATGGTTAAACTGT
ATCCTAATATGACCGCAGTGCTGCTGCATAATACCCAGCTGGATCAGCGCAAAATCAA
ACATCCGACCGCACTGGGTCTGGAAGTTGGTCAAGAAATTCAGGTTAAATACTTTGGT
CGCGATCCGGCAGATGGTCGTATGCGTCTGAGCCGTAAAGTTCTGCAGAGTCCGGCAA
CCACCGTTGTTCGTACACTGAACGATCGTAGCTCAATTGTTATGGGTGAACCGATTAG
CCAGAGTAGCAGCAATAGCCAGTAA 
 
9.6.3.3 pET-28b [hPNPase] Plasmid Map 
Cloning-GeneArt (Life Technologies) confirmed that the requested pET-28b [hPNPase] was 
successfully synthesised and cloned. Full length sequencing showed 100% identity and the 
resultant vector map is provided (Figure 9.11). 
 
 
Figure 9.11 hPNPase Plasmid Map 
The synthetic gene pET28b_hPNPT1 was assembled from synthetic oligonucleotides. The fragment was 
cloned into pET28b_M712 using NheI and SalI cloning sites. The final construct was verified by sequencing. 
The sequence congruence within the used restriction sites was 100%. Image provided by GeneArt AG, Life 
Technologies. 
[277] 
 
9.6.3.4 pET-28b [hPNPase] Translation 
Translated sequence from pET28-b with hPNPase ligated between Nhe1 and Sall restriction using 
Expasy Translate Program (Frame1- H6-hPNPase, V-I natural variant (V in Red)). When the 
sequence was transcribed from the start codon ATG (M) to the stop codon TAA, extra amino acids 
(underlined), not part of the hPNPase protein, are included at the 5’ end. This includes GSS, 6x 
Histidine’s (His-tag), SSGLVPR/GS HMAS (where (/) is the thrombin cleavage site). 
MGSSHHHHHHSSGLVPR/GSHMASAVAVDLGNRKLEISSGKLARFADGSAVVQSGDTAV
MVTAVSKTKPSPSQFMPLVVDYRQKAAAAGRIPTNYLRREVGTSDKEILTSRIIDRSIRPLF
PAGYFYDTQVLCNLLAVDGVNEPDVLAINGASVALSLSDIPWNGPVGAVRIGIIDGEYVVN
PTRKEMSSSTLNLVVAGAPKSQIVMLEASAENILQQDFCHAIKVGVKYTQQIIQGIQQLVK
ETGVTKRTPQKLFTPSPEIVKYTHKLAMERLYAVFTDYEHDKVSRDEAVNKIRLDTEEQL
KEKFPEADPYEIIESFNVVAKEVFRSIVLNEYKRCDGRDLTSLRNVSCEVDMFKTLHGSALF
QRGQTQVLCTVTFDSLESGIKSDQVITAINGIKDKNFMLHYEFPPYATNEIGKVTGLNRREL
GHGALAEKALYPVIPRDFPFTIRVTSEVLESNGSSSMASACGGSLALMDSGVPISSAVAGV
AIGLVTKTDPEKGEIEDYRLLTDILGIEDYNGDMDFKIAGTNKGITALQADIKLPGIPIKIVM
EAIQQASVAKKEILQIMNKTISKPRASRKENGPVVETVQVPLSKRAKFVGPGGYNLKKLQA
ETGVTISQVDEETFSVFAPTPSAMHEARDFITEICKDDQEQQLEFGAVYTATITEIRDTGVM
VKLYPNMTAVLLHNTQLDQRKIKHPTALGLEVGQEIQVKYFGRDPADGRMRLSRKVLQS
PATTVVRTLNDRSSIVMGEPISQSSSNSQ 
 
9.6.3.5 ProtParam Output: H6-hPNPase 
Number of amino acids: 761 
Molecular weight: 83311.2  
Theoretical pI: 6.63 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    35675 
Abs 0.1% (=1 g/l)   0.428, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    35300 
Abs 0.1% (=1 g/l)   0.424, assuming all Cys residues are reduced 
 
9.6.4 Sulfolobus solfataricus Exosome (SsoExo4_41_42)  
9.6.4.1 Amino Acid Sequence: SsoExo4_41_42 
Sulfolobus solfataricus Exosome subunits Rrp4, Rrp41 & Rrp42 (SsoExoRrp4_41_42) (Gene ID: 
Rrp4:1454999, Rrp41:1454998 and Rrp42:1454997, UniProt: Q9UXC4, Q9UXC2, Q9UXC0) 
amino acid sequences: 
 
SsoExoRrp4 
MNMSQSQKIVLQPRSIVVPGELLAEGEFQIPWSPYILKINSKYYSTVVGLFDVKDTQFEVIP
LEGSFYYPKINDIVIGLVEDVEIYGWVVDIKAPYKAYLPASNLLGRSINVGEDLRRYLDVG
[278] 
DYVIARIENFDRSIDPVLSVKGKDLGRVSNGIVIDIMPVKVPRVIGKNKSMYETLTSKSGCSI
FVANNGRIWATCPSRFSEEILIEAIRKIENESHIKGLTDRIKQFIEEKLGERNASSGETKTNS 
 
SsoExoRrp41 
MREMLQVERPKLILDDGKRTDGRKPDELRSIKIELGVLKNADGSAIFEMGNTKAIAAVYGP
KEMHPRHLSLPDRAVLRVRYHMTPFSTDERKNPAPSRREIELSKVIREALESAVLVELFPRT
AIDVFTEILQADAGSRLVSLMAASLALADAGIPMRDLIAGVAVGKADGVIILDLNETEDM
WGEADMPIAMMPSLNQVTLFQLNGSMTPDEFRQAFDLAVKGINIIYNLEREALKSKYVEF
KEEGV 
 
SsoExoRrp42 
MSSTPSNQNIIPIIKKESIVSLFEKGIRQDGRKLTDYRPLSITLDYAKKADGSALVKLGTTMV
LAGTKLEIDKPYEDTPNQGNLIVNVELLPLAYETFEPGPPDENAIELARVVDRSLRDSKALD
LTKLVIEPGKSVWTVWLDVYVLDYGGNVLDACTLASVAALYNTKVYKVEQHSNGISVNK
NEVVGKLPLNYPVVTISVAKVDKYLVVDPDLDEESIMDAKISFSYTPDLKIVGIQKSGKGS
MSLQDIDQAENTARSTAVKLLEELKKHLGI 
 
9.6.4.2 pET-MCN-EAVNH [SsoExo4_41_42] Transcript 
Transcribed sequence from pET-MCN-EAVNH vector with Sulfolobus solfataricus Exosome 
(SsoExo) Rrp4, Rrp41 and Rrp42 coding nucleotide sequences (Orange) inserted between Nde1 
and Xba1 restriction sites. (The Three Rrp4, Rrp41 and Rrp42 sequences each transcribed from 
start codon ATG (Teal) to stop codons TAA (Blue). 
 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGTACCGGCAGCGGCGAAAAC
CTTTACTTCCAGGGCCATATGAATATGAGCCAGAGCCAGAAAATTGTTCTGCAGCCTC
GTAGCATTGTTGTTCCGGGTGAACTGCTGGCAGAAGGTGAATTTCAGATTCCGTGGTC
ACCGTATATTCTGAAAATCAACAGCAAATACTATAGCACCGTTGTGGGTCTGTTTGAT
GTTAAAGATACCCAGTTTGAAGTGATTCCGCTGGAAGGTAGCTTCTATTATCCGAAAA
TTAACGACATTGTGATCGGCCTGGTTGAAGATGTTGAAATTTATGGTTGGGTGGTGGA
TATCAAAGCACCGTATAAAGCATATCTGCCTGCAAGCAATCTGCTGGGTCGTAGTATT
AATGTTGGTGAAGATCTGCGTCGTTATCTGGATGTGGGTGATTATGTTATTGCCCGTAT
CGAAAATTTTGATCGCAGCATTGATCCGGTTCTGAGCGTTAAAGGTAAAGATCTGGGT
CGCGTTAGCAATGGTATTGTGATTGATATTATGCCGGTTAAAGTTCCGCGTGTGATTGG
TAAAAACAAAAGCATGTATGAAACCCTGACCAGCAAAAGCGGTTGCAGCATTTTTGTT
GCAAATAATGGTCGTATTTGGGCAACCTGTCCGAGCCGTTTTAGCGAAGAAATTCTGA
TTGAAGCCATCCGCAAAATCGAAAACGAAAGCCATATTAAAGGTCTGACCGATCGCAT
TAAACAGTTTATCGAAGAAAAACTGGGTGAACGTAATGCAAGCAGCGGTGAAACCAA
AACCAATAGCTAACTCGAGCTTAAGCAATTGGGATCCCGATCCCGCGAAATTAATACG
ACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCACTAGTAATAATTTTGTTTA
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ACTTTAAGAAGGAGATATAGCACCGATGCGTGAAATGCTGCAGGTTGAACGTCCGAA
ACTGATTCTGGATGATGGTAAACGTACCGATGGTCGTAAACCGGATGAACTGCGTAGC
ATTAAAATCGAACTGGGTGTTCTGAAAAATGCAGATGGTAGCGCAATTTTTGAAATGG
GTAATACCAAAGCAATCGCAGCAGTTTATGGTCCGAAAGAAATGCATCCGCGTCATCT
GAGCCTGCCGGATCGTGCAGTTCTGCGTGTTCGTTATCACATGACCCCGTTTAGCACCG
ATGAACGTAAAAATCCGGCACCGAGCCGTCGTGAAATTGAACTGAGCAAAGTTATTCG
TGAAGCACTGGAAAGCGCAGTTCTGGTTGAACTGTTTCCGCGTACCGCAATTGATGTT
TTTACCGAAATTCTGCAGGCAGATGCAGGTAGCCGTCTGGTTAGCCTGATGGCAGCAA
GCCTGGCACTGGCCGATGCCGGTATTCCGATGCGTGATCTGATTGCCGGTGTTGCAGTT
GGTAAAGCAGATGGTGTTATTATTCTGGATCTGAACGAAACCGAAGATATGTGGGGTG
AAGCAGATATGCCGATTGCAATGATGCCGAGCCTGAATCAGGTTACCCTGTTCCAGCT
GAATGGTAGCATGACTCCGGATGAATTTCGTCAGGCATTTGATCTGGCAGTGAAAGGC
ATTAACATCATCTATAATCTGGAACGCGAAGCCCTGAAAAGCAAATATGTGGAATTTA
AAGAAGAAGGCGTTTAACTCGAGCTTAAGCAATTGGGATCCCGATCCCGCGAAATTAA
TACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCACTAGTAATAATTTT
GTTTAACTTTAAGAAGGAGATATAGCACCGATGAGCAGCACCCCGAGCAATCAGAAC
ATTATTCCGATCATCAAAAAAGAAAGCATCGTGAGCCTGTTTGAAAAAGGTATTCGTC
AGGATGGTCGCAAACTGACCGATTATCGTCCGCTGAGCATTACCCTGGATTATGCAAA
AAAAGCCGATGGTAGTGCACTGGTTAAACTGGGCACCACCATGGTTCTGGCAGGCACC
AAACTGGAAATTGATAAACCGTATGAAGATACCCCGAATCAGGGCAATCTGATTGTTA
ATGTTGAACTGCTGCCGCTGGCCTATGAAACCTTTGAACCGGGTCCGCCTGATGAAAA
TGCCATTGAACTGGCACGTGTTGTTGATCGTAGCCTGCGTGATAGCAAAGCCCTGGAC
CTGACAAAACTGGTTATCGAACCGGGTAAAAGCGTTTGGACCGTTTGGCTGGATGTTT
ATGTTCTGGATTACGGTGGTAATGTGCTGGATGCATGTACCCTGGCAAGCGTTGCAGC
ACTGTATAATACAAAAGTGTACAAAGTGGAACAGCACAGCAATGGTATTAGCGTGAA
TAAAAACGAAGTGGTTGGTAAACTGCCGCTGAATTATCCGGTTGTTACCATTAGCGTT
GCCAAAGTGGATAAATATCTGGTTGTGGATCCGGACCTGGATGAAGAAAGTATTATGG
ATGCCAAAATCAGCTTCAGCTATACACCGGATCTGAAAATTGTGGGTATTCAGAAAAG
CGGTAAAGGTAGCATGTCACTGCAGGATATTGATCAGGCAGAAAACACCGCACGTAG
CACCGCAGTGAAACTGCTGGAAGAACTGAAAAAACATCTGGGCATCTAA 
 
9.6.4.3 pET-MCN-EAVNH [SsoExo4_41_42] Plasmid Map 
Cloning-GeneArt (Life Technologies) confirmed that the requested pET-MCN-EAVNH 
[SsoExo4_41_42] was successfully synthesised and cloned. Full length sequencing showed 100% 
identity and the resultant vector map is provided (Figure 9.12) 
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Figure 9.12 SsoExosome Plasmid Map 
The synthetic gene SsoExo4_41_42 was assembled from synthetic oligonucleotides. The fragment was 
cloned into pET-MCN-EAVNH vector using NdeI and Xba1 cloning sites. The final construct was verified 
by sequencing. The sequence congruence within the used restriction sites was 100%. (Cloning-GeneArt AG, 
Life Technologies). Image provided by GeneArt AG, Life Technologies. 
 
9.6.4.4 pET-MCN-EAVNH [SsoExo4_41_42] Translation 
Translated sequence from pET-MCN-EAVNH with SsoExo4_41_42 ligated between Nde1 and 
Xba1 restriction sites using Expasy Translate Program (Frame1- H6-SsoExoRrp4, Rrp41 and 
Rrp42). When the sequence was transcribed from the start codons ATG (M) to the stop codons 
TAA, extra amino acids (underlined) not part of the H6- SsoExoRrp4 protein are included at the 5’ 
end. This includes MGSS, 6x Histidine’s (His-tag), SSGTGSGENLYFQ/GH (where (/) is the TEV 
cleavage site). 
 
H6- SsoExoRrp4 
MGSSHHHHHHSSGTGSGENLYFQGHMNMSQSQKIVLQPRSIVVPGELLAEGEFQIPWSPYI
LKINSKYYSTVVGLFDVKDTQFEVIPLEGSFYYPKINDIVIGLVEDVEIYGWVVDIKAPYKA
YLPASNLLGRSINVGEDLRRYLDVGDYVIARIENFDRSIDPVLSVKGKDLGRVSNGIVIDIM
PVKVPRVIGKNKSMYETLTSKSGCSIFVANNGRIWATCPSRFSEEILIEAIRKIENESHIKGLT
DRIKQFIEEKLGERNASSGETKTNS 
 
SsoExoRrp41 
MREMLQVERPKLILDDGKRTDGRKPDELRSIKIELGVLKNADGSAIFEMGNTKAIAAVYGP
KEMHPRHLSLPDRAVLRVRYHMTPFSTDERKNPAPSRREIELSKVIREALESAVLVELFPRT
AIDVFTEILQADAGSRLVSLMAASLALADAGIPMRDLIAGVAVGKADGVIILDLNETEDM
WGEADMPIAMMPSLNQVTLFQLNGSMTPDEFRQAFDLAVKGINIIYNLEREALKSKYVEF
KEEGV 
 
SsoExoRrp42 
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MSSTPSNQNIIPIIKKESIVSLFEKGIRQDGRKLTDYRPLSITLDYAKKADGSALVKLGTTMV
LAGTKLEIDKPYEDTPNQGNLIVNVELLPLAYETFEPGPPDENAIELARVVDRSLRDSKALD
LTKLVIEPGKSVWTVWLDVYVLDYGGNVLDACTLASVAALYNTKVYKVEQHSNGISVNK
NEVVGKLPLNYPVVTISVAKVDKYLVVDPDLDEESIMDAKISFSYTPDLKIVGIQKSGKGS
MSLQDIDQAENTARSTAVKLLEELKKHLGI 
 
9.6.4.5 ProtParam Output: H6-SsoExo4 
H6- SsoExoRrp4 
Number of amino acids: 274 
Molecular weight: 30706.0 
Theoretical pI: 6.46 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    34505 
Abs 0.1% (=1 g/l)   1.124, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    34380 
Abs 0.1% (=1 g/l)   1.120, assuming all Cys residues are reduced 
 
9.6.4.6 ProtParam Output: SsoExo41 
SsoExoRrp41 
Number of amino acids: 248 
Molecular weight: 27577.9 
Theoretical pI: 5.20 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    11460 
Abs 0.1% (=1 g/l)   0.416 
 
9.6.4.7 ProtParam Output: SsoExo42 
SsoExoRrp42 
Number of amino acids: 275 
Molecular weight: 30193.6 
Theoretical pI: 5.16 
 
Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    27390 
Abs 0.1% (=1 g/l)   0.907, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    27390 
Abs 0.1% (=1 g/l)   0.907, assuming all Cys residues are reduced 
 
9.6.4.8 ProtParam Output: H6- SsoExo4_41_42 
H6- SsoExoRrp4_4_41_42 
Number of amino acids: 2391 
Molecular weight: 265288.7 
Theoretical pI: 5.57 
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Extinction coefficients: 
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient   220190 
Abs 0.1% (=1 g/l)   0.830, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient   219690 
Abs 0.1% (=1 g/l)   0.828, assuming all Cys residues are reduced 
 
9.6.5 E. coli Polynucleotide Phosphorylase (EcPNPase) 
9.6.5.1 Amino Acid Sequence: EcPNPase 
E. coli Polynucleotide Phosphorylase (EcPNPase) (Gene: PNP_ECOLI, UniProt: P05055, 
(http://www.uniprot.org/uniprot/P05055) was cloned into a pETDuet-1 vector and kindly 
supplied by Prof. Ben Luisi (University of Cambridge)  
 
9.6.5.2 ProtParam Output: EcPNPase  
User-provided sequence: 
        10         20         30         40         50         60  
MLNPIVRKFQ YGQHTVTLET GMMARQATAA VMVSMDDTAV FVTVVGQKKA KPGQDFFPLT  
 
        70         80         90        100        110        120  
VNYQERTYAA GRIPGSFFRR EGRPSEGETL IARLIDRPIR PLFPEGFVNE VQVIATVVSV  
 
       130        140        150        160        170        180  
NPQVNPDIVA MIGASAALSL SGIPFNGPIG AARVGYINDQ YVLNPTQDEL KESKLDLVVA  
 
       190        200        210        220        230        240  
GTEAAVLMVE SEAQLLSEDQ MLGAVVFGHE QQQVVIQNIN ELVKEAGKPR WDWQPEPVNE  
 
       250        260        270        280        290        300  
ALNARVAALA EARLSDAYRI TDKQERYAQV DVIKSETIAT LLAEDETLDE NELGEILHAI  
 
       310        320        330        340        350        360  
EKNVVRSRVL AGEPRIDGRE KDMIRGLDVR TGVLPRTHGS ALFTRGETQA LVTATLGTAR  
 
       370        380        390        400        410        420  
DAQVLDELMG ERTDTFLFHY NFPPYSVGET GMVGSPKRRE IGHGRLAKRG VLAVMPDMDK  
 
       430        440        450        460        470        480  
FPYTVRVVSE ITESNGSSSM ASVCGASLAL MDAGVPIKAA VAGIAMGLVK EGDNYVVLSD  
 
       490        500        510        520        530        540  
ILGDEDHLGD MDFKVAGSRD GISALQMDIK IEGITKEIMQ VALNQAKGAR LHILGVMEQA  
 
       550        560        570        580        590        600  
INAPRGDISE FAPRIHTIKI NPDKIKDVIG KGGSVIRALT EETGTTIEIE DDGTVKIAAT  
 
       610        620        630        640        650        660  
DGEKAKHAIR RIEEITAEIE VGRVYTGKVT RIVDFGAFVA IGGGKEGLVH ISQIADKRVE  
 
       670        680        690        700        710  
KVTDYLQMGQ EVPVKVLEVD RQGRIRLSIK EATEQSQPAA APEAPAAEQG E 
 
Number of amino acids: 711 
Molecular weight: 77100.9 
Theoretical pI: 5.10 
 
Extinction coefficients: 
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Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    30370 
Abs 0.1% (=1 g/l)   0.394, assuming all pairs of Cys residues form cystines 
 
Ext. coefficient    30370 
Abs 0.1% (=1 g/l)   0.394, assuming all Cys residues are reduced 
 
9.7 PACT Premier™ Crystallography Screen  
The PACT premier™ screen (Molecular Dimensions) conditions are listed in Table 9.1 (Newman 
et al., 2005). 
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Table 9.1 PACT Premier™ Crystallography Screen 
Conditions for the PACT Premier™ screen from Molecular Dimensions (Newman et al., 2005). 
 
Tube # Conc1 Units1 Salt 1 Conc2 Units2 Buffer2 pH Conc3 Units3 Precipitant3
1-1 0.1 M SPG 4 25 % w/v PEG 1500
1-2 0.1 M SPG 5 25 % w/v PEG 1500
1-3 0.1 M SPG 6 25 % w/v PEG 1500
1-4 0.1 M SPG 7 25 % w/v PEG 1500
1-5 0.1 M SPG 8 25 % w/v PEG 1500
1-6 0.1 M SPG 9 25 % w/v PEG 1500
1-7 0.2 M Sodium chloride 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-8 0.2 M Ammonium chloride 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-9 0.2 M Lithium chloride 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-10 0.2 M Magnesium chloride hexahydrate 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-11 0.2 M Calcium chloride dihydrate 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-12 0.01 M Zinc chloride 0.1 M Sodium acetate 5 20 % w/v PEG 6000
1-13 0.1 M MIB 4 25 % w/v PEG 1500
1-14 0.1 M MIB 5 25 % w/v PEG 1500
1-15 0.1 M MIB 6 25 % w/v PEG 1500
1-16 0.1 M MIB 7 25 % w/v PEG 1500
1-17 0.1 M MIB 8 25 % w/v PEG 1500
1-18 0.1 M MIB 9 25 % w/v PEG 1500
1-19 0.2 M Sodium chloride 0.1 M MES 6 20 % w/v PEG 6000
1-20 0.2 M Ammonium chloride 0.1 M MES 6 20 % w/v PEG 6000
1-21 0.2 M Lithium chloride 0.1 M MES 6 20 % w/v PEG 6000
1-22 0.2 M Magnesium chloride hexahydrate 0.1 M MES 6 20 % w/v PEG 6000
1-23 0.2 M Calcium chloride dihydrate 0.1 M MES 6 20 % w/v PEG 6000
1-24 0.01 M Zinc chloride 0.1 M MES 6 20 % w/v PEG 6000
1-25 0.1 M PCTP 4 25 % w/v PEG 1500
1-26 0.1 M PCTP 5 25 % w/v PEG 1500
1-27 0.1 M PCTP 6 25 % w/v PEG 1500
1-28 0.1 M PCTP 7 25 % w/v PEG 1500
1-29 0.1 M PCTP 8 25 % w/v PEG 1500
1-30 0.1 M PCTP 9 25 % w/v PEG 1500
1-31 0.2 M Sodium chloride 0.1 M HEPES 7 20 % w/v PEG 6000
1-32 0.2 M Ammonium chloride 0.1 M HEPES 7 20 % w/v PEG 6000
1-33 0.2 M Lithium chloride 0.1 M HEPES 7 20 % w/v PEG 6000
1-34 0.2 M Magnesium chloride hexahydrate 0.1 M HEPES 7 20 % w/v PEG 6000
1-35 0.2 M Calcium chloride hexahydrate 0.1 M HEPES 7 20 % w/v PEG 6000
1-36 0.01 M Zinc chloride 0.1 M HEPES 7 20 % w/v PEG 6000
1-37 0.1 M MMT 4 25 % w/v PEG 1500
1-38 0.1 M MMT 5 25 % w/v PEG 1500
1-39 0.1 M MMT 6 25 % w/v PEG 1500
1-40 0.1 M MMT 7 25 % w/v PEG 1500
1-41 0.1 M MMT 8 25 % w/v PEG 1500
1-42 0.1 M MMT 9 25 % w/v PEG 1500
1-43 0.2 M Sodium chloride 0.1 M Tris 8 20 % w/v PEG 6000
1-44 0.2 M Ammonium chloride 0.1 M Tris 8 20 % w/v PEG 6000
1-45 0.2 M Lithium chloride 0.1 M Tris 8 20 % w/v PEG 6000
1-46 0.2 M Magnesium chloride hexahydrate 0.1 M Tris 8 20 % w/v PEG 6000
1-47 0.2 M Calcium chloride dihydrate 0.1 M Tris 8 20 % w/v PEG 6000
1-48 0.002 M Zinc chloride 0.1 M Tris 8 20 % w/v PEG 6000
2-1 0.2 M Sodium fluoride 20 % w/v PEG 3350
2-2 0.2 M Sodium bromide 20 % w/v PEG 3350
2-3 0.2 M Sodium iodide 20 % w/v PEG 3350
2-4 0.2 M Potassium thiocyanate 20 % w/v PEG 3350
2-5 0.2 M Sodium nitrate 20 % w/v PEG 3350
2-6 0.2 M Sodium formate 20 % w/v PEG 3350
2-7 0.2 M Sodium acetate trihydrate 20 % w/v PEG 3350
2-8 0.2 M Sodium sulfate 20 % w/v PEG 3350
2-9 0.2 M Potassium sodium tartrate tetrahydrate 20 % w/v PEG 3350
2-10 0.02 M Sodium/potassium phosphate 20 % w/v PEG 3350
2-11 0.2 M Sodium citrate tribasic dihydrate 20 % w/v PEG 3350
2-12 0.2 M Sodium malonate dibasic monohydrate 20 % w/v PEG 3350
2-13 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-14 0.2 M Sodium bromide 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-15 0.2 M Sodium iodide 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-16 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-17 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-18 0.2 M Sodium formate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-19 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-20 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-21 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-22 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-23 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-24 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 6.5 20 % w/v PEG 3350
2-25 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-26 0.2 M Sodium bromide 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-27 0.2 M Sodium iodide 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-28 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-29 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-30 0.2 M Sodium formate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-31 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-32 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-33 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-34 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-35 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-36 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 7.5 20 % w/v PEG 3350
2-37 0.2 M Sodium fluoride 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-38 0.2 M Sodium bromide 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-39 0.2 M Sodium iodide 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-40 0.2 M Potassium thiocyanate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-41 0.2 M Sodium nitrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-42 0.2 M Sodium formate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-43 0.2 M Sodium acetate trihydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-44 0.2 M Sodium sulfate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-45 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-46 0.02 M Sodium/potassium phosphate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-47 0.2 M Sodium citrate tribasic dihydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
2-48 0.2 M Sodium malonate dibasic monohydrate 0.1 M Bis-Tris propane 8.5 20 % w/v PEG 3350
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9.8 Protein Accession Codes 
Protein Accession codes for all sequences utilised for basic bioinformatics studies are listed in 
Table 9.2. Sequences used for generating sequence logos are provided as supplementary data in an 
excel file (CD). 
 
 
Table 9.2 Protein Accession Codes 
The accession numbers for each organism utilised in basic bioinformatics alignments are provided.  
 
9.9 Metabolite Structures 
The 2D structures of the metabolites utilised for docking calculations in MOE (Molecular 
Operating Environment, 2013) are provided in Figure 9.13-Figure 9.14. 
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Figure 9.13 Metabolite 2D Structures  
The 2D structures of the metabolites utilised for docking calculations in MOE (Molecular Operating 
Environment, 2013). 
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Figure 9.14 Metabolite 2D Structures Continued 
The 2D structures of the metabolites utilised for docking calculations in MOE (Molecular Operating 
Environment, 2013) 
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